SEARCH
検索詳細
小松 嘉人 (コマツ ヨシト)
| 北海道大学病院 腫瘍センター | 准教授 |
各種企業治験、医師主導治験にも精力的に参加し活動しています。地元北海道においても臨床試験グループを立ち上げ、新規消化器癌薬物療法の開発を中心にこの分野での研究を中心に活動しています。抗がん療法の開発のみならず、支持療法や緩和ケアなど、幅広く包括的にOncologyに携わっております。
研究者基本情報
■ 学位■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID■ 研究キーワード・分野
研究キーワード研究分野■ 担当教育組織
経歴
■ 経歴経歴
- 2018年10月 - 現在
北海道大学病院腫瘍センター, 化学療法部・CancerBoard部, 部長・診療教授 - 2011年04月 - 現在
北海道大学病院腫瘍センター, 化学療法部, 副センター長・部長・診療教授 - 2008年01月 - 2011年03月
北海道大学病院腫瘍センター, 化学療法部, 副センター長・部長・准教授 - 2007年12月 - 2008年01月
北海道大学病院外来治療センター, 化学療法部, センター長・准教授 - 2008年
- 腫瘍センター 准教授 - 2006年 - 2007年
地域医療連携センター 講師 - 2006年 - 2007年
Lecturer,Community Service Network Center - 2007年
外来治療センター 准教授 - 2004年 - 2006年
北大癌診断治療学講座 腫瘍内科 助手 助手 - 2004年 - 2006年
Research Associate - 2001年 - 2004年
北大病態内科学講座 第三内科 助手 助手 - 2001年 - 2004年
Research Associate - 1998年 - 2001年
第三内科 研究員 - 1998年 - 2001年
Researcher - 1993年 - 1996年
国立がんセンター 中央病院 薬物療法部 職員(医療系)
- 2001年06月 - 現在, 北海道大学大学院医学研究科博士号取得, Graduate School of Medicine
- 1989年03月 - 現在, 東京医科大学卒業
- 1989年04月 - 2001年05月, 北海道大学, 医学部, 第三内科研究生
研究活動情報
■ 受賞■ 論文
- RAS/BRAF wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and BRAF V600E mutant: a translational research.
Shonosuke Wakayama; Shin Takahashi; Kota Ouchi; Yasuhiro Sakamoto; Tadamichi Denda; Atsuo Takashima; Yoshito Komatsu; Masato Nakamura; Hisatsugu Ohori; Tatsuro Yamaguchi; Yoshimitsu Kobayashi; Hideo Baba; Masanori Kotake; Kenji Amagai; Hitoshi Kondo; Ken Shimada; Yasuhide Yamada; Atsushi Sato; Satoshi Yuki; Akira Okita; Keigo Komine; Mika Watanabe; Satoshi Morita; Chikashi Ishioka
Scientific reports, 2026年03月08日, [国際誌]
英語, 研究論文(学術雑誌) - Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.
Yuqing Duan; Tadayoshi Hashimoto; Taro Shibuki; Hiroya Taniguchi; Yu Sunakawa; Yoshito Komatsu; Naoki Takahashi; Yuta Sato; Kensei Yamaguchi; Tomohiro Nishina; Tomonori Nakanoko; Shogen Boku; Taroh Satoh; Hisateru Yasui; Taito Esaki; Mitsuho Imai; Takao Fujisawa; Yoshiaki Nakamura; Hideaki Bando; Takayuki Yoshino
JCO precision oncology, 10, 3, e2500971, 2026年03月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Advanced esophageal squamous cell carcinoma (ESCC) has a poor prognosis, and current treatments provide limited survival benefits. This study aimed to identify prognostic biomarkers and therapeutic targets by genomic profiling of advanced ESCC using circulating tumor DNA (ctDNA). METHODS: The SCRUM-MONSTAR GOZILA study is a nationwide, plasma-based molecular profiling project using Guardant360, involving 31 core cancer institutions in Japan. We evaluated the genomic landscape of advanced ESCC and investigated associations between specific alterations and overall survival (OS). The correlation between blood tumor mutation burden (bTMB) and clinical outcomes in patients with PD-1 inhibitors was also assessed using multiple cutoff values (2, 4, 6, 8, and 10 mutations/Mb). RESULTS: Among 313 patients, alterations predominantly consisted of single nucleotide variants (SNVs, 68.9%) and copy number alterations (20.7%). TP53 was the most frequent alterations (88.5%), followed by PIK3CA (36.4%), NFE2L2 (24.3%), CCND1 (22.4%), and EGFR (20.1%). Amplifications in PIK3CA, FGFR1, CCND1, and EGFR, as well as mutations in NFE2L2, FGFR1, and RB1 were associated with worse OS (any P < .05). Multivariable analysis confirmed mutations in NFE2L2 or FGFR1 and amplifications in EGFR or PIK3CA as independent poor prognostic factors (all P < .05). In 142 patients treated with PD-1 inhibitors, no significant differences in objective response rate or progression-free survival were observed at different bTMB cutoff values (all P > .1). CONCLUSION: ctDNA analysis identified key genomic alterations linked to poor outcomes in advanced ESCC, revealing potential prognostic biomarkers and therapeutic targets. In contrast, bTMB did not show predictive value for the efficacy of PD-1 inhibitors in this study. - Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201).
Kazuaki Harada; Shinya Kajiura; Kentaro Sawada; Kazuteru Hatanaka; Atsushi Sato; Ken Ito; Hotaka Tamura; Ayako Doi; Takayuki Ando; Michio Nakamura; Hiroshi Nakatsumi; Tetsuhito Muranaka; Susumu Sogabe; Takahiro Ishii; Shintaro Nakano; Masayoshi Dazai; Yusuke Sasaki; Yasuyuki Kawamoto; Satoshi Yuki; Yuh Sakata; Yoshito Komatsu
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 34, 3, 221, 221, 2026年02月19日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Anamorelin hydrochloride (ANAM), used to treat cancer cachexia, is often discontinued early in clinical practice. Herein, we explored the clinical factors associated with the early discontinuation (Ed) of ANAM and examined its effect on treatment outcomes. METHODS: Clinical data of patients with gastrointestinal cancers who were administered ANAM between April and November 2021 from 16 institutions were retrospectively collected. Ed was defined as ANAM discontinuation within 4 weeks of initiation. ANAM efficacy was compared between the continuation (Co) and Ed groups. RESULTS: Of the 123 patients, 50 had an Ed of ANAM. The most common reasons were cancer progression (36%), adverse events (30%), and insufficient efficacy (22%). Age ≥ 75 years (odds ratio [OR] 4.11, 95% confidence interval [CI] 1.418-11.952, p = 0.009), no concomitant anticancer chemotherapy (OR 8.84, 95% CI 1.900-41.151, p = 0.006), and modified Glasgow prognostic score 2 (OR 2.65, 95% CI 1.065-6.604, p = 0.036) were significant risk factors for Ed. At 3 ± 1 weeks after ANAM initiation, the number of patients with increased appetite (Co 50.8% vs Ed 14.3%, p = 0.012) and food intake (Co 59.2% vs Ed 20.0%, p = 0.002) were significantly higher in the Co group than in the Ed group. CONCLUSION: Initiating ANAM while patients can still receive concurrent chemotherapy may help prevent Ed and achieve better therapeutic benefit. Trial registration The registration number in the UMIN Clinical Trial Registry is UMIN000051550. The date of registration is July 7, 2023. - Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A).
Yusuke Sano; Riku Kajikawa; Junki Mizusawa; Tatsuya Ioka; Masato Ozaka; Satoaki Nakamura; Yoshinori Ito; Junji Furuse; Satoshi Kobayashi; Haruhiko Fukuda; Takuji Okusaka; Masafumi Ikeda; Haruo Miwa; Naoki Sasahira; Fumio Nagashima; Kazuyoshi Ohkawa; Kentaro Yamazaki; Masashi Kanai; Taro Yamashita; Kazuo Hara; Yukiko Takayama; Yoshito Komatsu; Nao Fujimori; Naoki Hama; Ken Kamata; Terumasa Hisano; Satoshi Shimizu; Kazutoshi Tobimatsu; Shin Maeda; Makoto Ueno
BMC cancer, 26, 1, 2026年02月10日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Two main therapeutic approaches are currently used for locally advanced pancreatic cancer (LAPC): chemoradiotherapy and systemic chemotherapy. It remains unclear which approach may be more promising, or whether these strategies should be considered alternative or complementary therapeutic options in the management of LAPC. Clinical outcomes and safety were assessed for S-1 plus concurrent radiotherapy (S-1 + RT) and gemcitabine plus nab-paclitaxel (GnP) in patients with LAPC. METHODS: We conducted a pooled exploratory analysis of individual patient data derived from two multi-institutional randomized phase II trials conducted by the Japan Clinical Oncology Group (JCOG1106 and JCOG1407). JCOG1106 evaluated S-1 + RT with or without induction chemotherapy. JCOG1407 compared GnP with modified FOLFIRINOX. Based on the results of these trials, S-1 + RT and GnP were selected as promising regimens for chemoradiotherapy and systemic chemotherapy, respectively. The primary endpoint of this study was progression-free survival (PFS). Inverse probability of treatment weighting (IPTW) with stabilized weights was applied based on the propensity score to account for baseline imbalances between the two groups. RESULTS: A total of 113 patients were included. After adjustment for patient characteristics, Kaplan–Meier curves showed median PFS, overall survival (OS), and distant metastasis-free survival (DMFS) of 10.2 vs. 9.3 (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.60–1.30), 19.1 vs. 21.2 (HR, 0.73; 95% CI, 0.48–1.11), and 11.5 vs. 13.1 months (HR, 0.73; 95% CI, 0.49–1.08) for S-1 + RT and GnP, respectively. Treatment received after protocol therapy differed substantially: 77.5% in the S-1 + RT group received single-agent chemotherapy, whereas 50.0% in the GnP group, received more intensive regimens, including multi-agent chemotherapy or chemoradiotherapy. CONCLUSIONS: GnP may offer advantages in suppressing micrometastatic disease, whereas S-1 + RT may provide benefits in local disease control. These findings suggest that both approaches represent important and complementary therapeutic options for LAPC. Prospective randomized studies are warranted to determine the optimal initial strategy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-026-15699-8. - HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry.
Michiko Nagamine; Takao Fujisawa; Naoya Sakamoto; Yoshiaki Nakamura; Shigenori Kadowaki; Makoto Ueno; Shogen Boku; Yoshito Komatsu; Eiji Oki; Akitaka Makiyama; Norio Nonomura; Chigusa Morizane; Hidemichi Watari; Susumu Okano; Hiroji Iwata; Kenjiro Namikawa; Yutaka Hatanaka; Kanako C Hatanaka; Kenichi Taguchi; David Spetzler; Milan Radovich; Daniel Magee; Takayuki Yoshino; Matthew Oberley; Takeshi Kuwata
JCO precision oncology, 10, e2500413, 2026年01月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: The tumor-agnostic approach has been increasingly adopted in precision oncology. Immunohistochemistry (IHC) is the standard biomarker testing for human epidermal growth factor receptor 2 (HER2)-targeted therapies, whereas next-generation sequencing (NGS) has been widely incorporated in routine clinical practices. Here, we investigated the concordance between NGS-based assays and IHC in HER2 testing. Interfering factors leading to discordant results between the assays were also studied. MATERIALS AND METHODS: Over 78,000 solid tumors across various types from two independent cohorts in the United States and Japan were investigated for HER2 DNA copy number, mRNA expression, and protein overexpression by whole-exome sequencing (WES), whole-transcriptome sequencing (WTS), and IHC, respectively. RESULTS: In the US cohort (n = 77,267), HER2 DNA amplification, mRNA overexpression, and IHC-positive (IHC-P) were detected in 4.9%, 10.1%, and 4.7% of the tumors, respectively. Positive results in at least one of the three assays were observed in 10.7% of tumors, while 3.9% were positive for all three assays. Using IHC as a comparator, WTS showed better sensitivity than WES but a lower positive predictive value. These results were consistent in the Japanese cohort (n = 1,225). Although the overall HER2 RNA expression level correlated well with IHC score and DNA copy number, the degree of correlation varied among tumor types. Heterogeneous distribution of IHC-P tumor cells was associated with discordant results between NGS-based assays and IHC. CONCLUSION: HER2-positive status in protein, mRNA, and DNA showed concordance in general but varied among tumor types. NGS-based assays, especially WTS, could be a useful predictive tool for HER2 testing in tumor-agnostic settings. Intratumor heterogeneity in HER2 protein expression should be considered when bringing bulk sequencing tests into clinical settings. - Successful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report.
Ryota Kanno; Yoshitaka Saito; Yoh Takekuma; Kazuaki Harada; Yoshito Komatsu; Mitsuru Sugawara
Journal of pharmaceutical health care and sciences, 11, 1, 110, 110, 2025年12月22日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Nano-liposomal irinotecan (nal-IRI) combined with 5-fluorouracil (5-FU) and levofolinate has been reported to extend the survival of patients with pancreatic cancer and represents an effective second-line treatment. Nal-IRI encapsulates IRI in liposomes modified with polyethylene glycol (PEGylation), which can lead to infusion reactions. Hypersensitivity reactions (HSR) to chemotherapeutic agents include both allergic and infusion reactions, which are difficult to distinguish. Severe HSR can be fatal; however, discontinuation of the suspected drug directly affects the treatment strategy. We report a case of severe HSR during the first nal-IRI administration, in which treatment was successfully continued with supportive management. CASE PRESENTATION: A woman in her early 80s with metastatic pancreatic cancer received nal-IRI + 5-FU + levofolinate as second-line treatment. Five minutes after the initiation of the first nal-IRI infusion, the patient developed a tightening sensation in the head, respiratory distress, convulsions, and loss of consciousness, with percutaneous oxygen saturation dropping to the 80% range. The nal-IRI infusion was immediately discontinued, and emergency management was initiated with intravenous infusion of hydrocortisone, famotidine, d-chlorpheniramine maleate, and oxygen administration, resulting in symptom improvement. Given the limited treatment options for metastatic pancreatic cancer and the patient's strong desire to continue therapy, we decided to re-administer the regimen with intensified management, increasing dexamethasone to 19.8 mg and adding famotidine 20 mg and d-chlorpheniramine maleate 5 mg. Furthermore, we adopted a three-step dose-escalation method. The infusion was started at one-third of the standard rate, increased to two-thirds after 30 min, and finally adjusted to the full rate after another 30 min, after confirming the absence of HSR symptoms. Consequently, the patient did not exhibit any signs of HSR, and the same administration method was continued for 11 cycles until disease progression. CONCLUSIONS: The novelty of this report lies in presenting, for the first time, the detailed course and process by which treatment was successfully continued in a patient experiencing severe HSR upon initial nal-IRI administration, through enhanced supportive care tailored to the characteristics of the drug and stepwise dose adjustment. - Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B).
Satoshi Kobayashi; Kohei Nakachi; Kouji Yamamoto; Makoto Ueno; Yuta Maruki; Kenji Ikezawa; Takeshi Terashima; Satoshi Shimizu; Kotoe Oshima; Kunihiro Tsuji; Yoshiharu Masaki; Hidetaka Tsumura; Taro Shibuki; Masato Ozaka; Naohiro Okano; Yukiyasu Okamura; Kumiko Umemoto; Tatsunori Satoh; Yasushi Kojima; Kazuhiko Shioji; Hiroko Nebiki; Toshifumi Doi; Atsushi Naganuma; Shigeki Kataoka; Emiri Kita; Hiroyuki Asama; Kaoru Tsuchiya; Michiaki Unno; Reiko Ashida; Kazuyuki Matsumoto; Izumi Ohno; Takao Itoi; Yuji Negoro; Yasunari Sakamoto; Shiho Arima; Akinori Asagi; Hiroyuki Okuyama; Yoshito Komatsu; Noritoshi Kobayashi; Hiroaki Nagano; Junji Furuse
Journal of gastroenterology, 60, 12, 1584, 1595, 2025年12月, [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: Systemic chemotherapy with gemcitabine plus S-1 (GEM + S-1), GEM + CDDP plus S-1 (GEM + CDDP + S-1), or gemcitabine plus cisplatin (GEM + CDDP) is standard treatment for advanced biliary tract cancer (aBTC). We aimed to evaluate the efficacy and safety of combination chemotherapy in older patients with aBTC. METHODS: This multicenter prospective observational study (JON2104-B, UMIN000045156) included patients aged ≥ 70 years with aBTC. Inverse-probability weighting propensity-score analyses (IPW) were used to compare overall survival (OS) as the primary endpoint and progression-free survival (PFS) across treatment groups. RESULTS: This study included 305 patients between August 2021 and January 2023. Of them, 75, 131, 26, 52, and 10 received GEM + CDDP + S-1, GEM + CDDP, GEM + S-1, gemcitabine, and S-1; their median ages were 74, 75, 77.5, 80, and 80 years, and approximately 24%, 16.8%, 23.1%, 9.6%, and 0% had G-8 scores of > 14, respectively. GEM + CDDP had a safety profile comparable to that of GEM + CDDP + S-1 but was more toxic than gemcitabine. Per IPW, the hazard ratio (HR) for GEM + CDDP + S-1 versus GEM + CDDP was 0.80 for OS (95% confidence interval [CI], 0.55-1.17) and 0.55 for PFS (95% CI 0.38-0.80). The HR for GEM + CDDP versus gemcitabine was 0.74 for OS (95% CI 0.42-1.29) and 0.79 for PFS (95% CI 0.42-1.49). CONCLUSIONS: GEM + CDDP + S-1 was associated with longer PFS without additional toxicity than GEM + CDDP for fit older patients. However, the OS for both were not statistically different. The efficacies of GEM + CDDP and gemcitabine for vulnerable older patients did not also differ significantly. These findings highlight the importance of vulnerability in patients with aBTC. - Evaluation of factors associated with drug fever following gemcitabine and nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 11, 1006, 1006, 2025年11月01日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Gemcitabine (GEM) + nanoparticle albumin-bound paclitaxel (nab-PTX) is an effective treatment for advanced pancreatic cancer. However, drug fever is a frequently observed adverse effect of GEM, and PTX can also induce symptoms. This study aimed to identify factors for drug fever in the real-world treatment of pancreatic cancer with GEM + nab-PTX. METHODS: We retrospectively assessed patients with pancreatic cancer who received GEM + nab-PTX (n = 386). The primary endpoint was the identification of factor(s) associated with the incidence of drug fever following the first administration. We also assessed symptoms between specific patient groups. RESULTS: The incidence of drug fever following the first GEM + nab-PTX treatment was 12.7%. The median onset time was day 3 (range: 1-4) with a symptom duration of 1 (1-6) day. Unresectable setting (adjusted odds ratio [95% confidence interval]: 3.35 [1.35-8.32], P = 0.009) and elevated baseline C-reactive protein (CRP) levels (≥ 1.0 mg/dL) (3.55 [1.80-6.98], P = 0.0002) were identified as risk factors using the multivariable logistic regression analysis. Patients receiving regular antipyretic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen had a lower risk (0.42 [0.20-0.87], P = 0.02). No difference was observed in the impact of the type of antipyretics on drug fever between NSAIDs and acetaminophen. CONCLUSION: An unresectable disease status and high baseline CRP levels are risk factors for drug-induced fever, while patients receiving regular antipyretics are at lower risk of developing these symptoms during real-world treatment of pancreatic cancer with GEM + nab-PTX. - Baseline hypoalbuminemia enhances regorafenib-induced problematic fatigue development in real-world metastatic colorectal cancer treatment.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 11, 990, 990, 2025年10月29日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Regorafenib, a multikinase inhibitor for treating metastatic colorectal cancer (mCRC), induces fatigue in 40-50% of administered patients, including approximately 10% of grade ≥ 3 cases. Additionally, hypoalbuminemia is associated with cancer- and chemotherapy-induced fatigue and frequently observed in patients with advanced cancers. This study aimed to assess the impact of baseline hypoalbuminemia on the development of clinically problematic fatigue in a real-world regorafenib treatment for mCRC. METHODS: Patients with mCRC who underwent regorafenib (n = 102) were divided into the control (baseline serum albumin levels ≥ 3.5 g/dL) and hypoalbuminemia (baseline serum albumin levels < 3.5 g/dL) groups, and retrospectively evaluated. The primary endpoint was comparison of grade ≥ 2 fatigue incidence during all treatment cycles. We also assessed the impact of grade ≥ 2 symptoms on the treatment efficacy. RESULTS: Incidence of grade ≥ 2 fatigue in all treatment cycles in the hypoalbuminemia group was 41.7%, which was significantly higher than that in the control group (14.1%, P = 0.008). In addition, grade ≥ 2 fatigue within the first cycle was significantly more confirmed in the hypoalbuminemia group than in the control group (37.5% vs. 11.5%, P = 0.01). Additionally, patients with early grade ≥ 2 fatigue within 14 days from treatment initiation had a significantly shorter time to treatment failure or overall survival than those without the symptoms. CONCLUSION: Patients with baseline hypoalbuminemia developed clinically problematic fatigue after regorafenib monotherapy for mCRC. Because regorafenib is a later-line mCRC treatment, successful management of emerging fatigue is crucial and requires further evaluation. - Factors associated with taxane-associated acute pain syndrome in pancreatic cancer patients receiving gemcitabine and nab-paclitaxel.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Discover oncology, 16, 1, 1967, 1967, 2025年10月27日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Taxane-associated acute pain syndrome (T-APS) is a common adverse event in patients treated with gemcitabine (GEM) + nanoparticle albumin-bound paclitaxel (nab-PTX) for pancreatic cancer. As several T-APS risk factors, such as age, cancer type, and taxane dose or formulation, differ between pancreatic cancer and other malignancies in previous studies, we aimed to identify factors associated with T-APS in a real-world setting of GEM + nab-PTX treatment for pancreatic cancer. METHODS: We retrospectively analyzed 394 patients with pancreatic cancer receiving GEM + nab-PTX. The primary endpoint was the identification of factors associated with all-grade T-APS. Symptom incidence was also compared across specific patient groups. RESULTS: T-APS occurred in 26.1% of patients after the first GEM + nab-PTX administration (grade 1: 21.6%; grade 2: 4.6%). Among patients with T-APS, 39.8% received medication, with more than two-thirds reporting symptom relief. Multivariable logistic regression analyses identified body mass index (BMI) ≥ 25 kg/m2 as a risk factor and baseline use of mild analgesics (non-steroidal anti-inflammatory drugs [NSAIDs] and/or acetaminophen) as a preventive factor (adjusted odds ratio, 2.98; 95% confidence interval, 1.68-5.31; P = 0.0002 for BMI, 0.48; 0.26-0.89; P = 0.02 for mild analgesics). A subgroup analysis comparing baseline NSAIDs and acetaminophen in patients receiving mild analgesic monotherapy showed no significant difference (P = 0.49). CONCLUSION: Our study identified BMI ≥ 25 kg/m2 as a risk factor and baseline use of mild analgesics as a preventive factor for T-APS development in a real-world GEM + nab-PTX regimen for pancreatic cancer. - Impact of baseline hypoalbuminemia on peripheral edema induced by gemcitabine and nab-paclitaxel for pancreatic cancer treatment.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 11, 938, 938, 2025年10月13日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Gemcitabine (GEM) + nanoparticle albumin-bound paclitaxel (nab-PTX), which is effective in treating pancreatic cancer, frequently induces peripheral edema. Hypoalbuminemia causes generalized peripheral edema and occasionally occurs in patients with cancer, but reports evaluating its interaction with chemotherapy-induced symptoms are lacking. Therefore, we aimed to assess the effect of baseline hypoalbuminemia on peripheral edema following real-world GEM + nab-PTX therapy. METHODS: Patients with pancreatic cancer receiving GEM + nab-PTX (n = 212) were divided into a hypoalbuminemia group (serum albumin levels < 3.5 g/dL), and a control group without hypoalbuminemia, and retrospectively evaluated. The primary endpoint was the incidence of grade ≥ 2 peripheral edema within 6 months of treatment initiation. RESULTS: The incidence of grade ≥ 2 peripheral edema within 6 months was 5.7% in the control group and 22.6% in the hypoalbuminemia group, with a significant difference (P = 0.0009), meeting the primary endpoint. The onset time of grade ≥ 2 peripheral edema was significantly earlier in the hypoalbuminemia group than in the control group (P = 0.0003). In contrast, the incidence of all-grade symptoms was 20.1% in the control group and 30.2% in the hypoalbuminemia group, which was not significantly different (P = 0.13). These results were confirmed in the propensity score-matched population. Multivariate Cox proportional hazard regression analyses showed that baseline hypoalbuminemia was a significant risk factor for grade ≥ 2 peripheral edema (adjusted hazard ratio, 3.84; 95% confidence interval, 1.60-9.23; P = 0.003). CONCLUSION: Our study revealed that patients with baseline hypoalbuminemia who received GEM + nab-PTX therapy for pancreatic cancer developed problematic peripheral edema. - A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701).
T Masuishi; H Taniguchi; D Kotani; H Bando; Y Komatsu; E Shinozaki; Y Sunakawa; T Satoh; T Nishina; T Esaki; M Wakabayashi; S Nomura; K Takahashi; H Ono; N Hirano; N Fujishiro; N Fuse; A Sato; Y Sakamoto; N Kuramoto; I Miki; H Ichiki; Y Nakamura; G Sharma; S Skrzypczak; E Schultz; C Kingsford; A Ohtsu; T Yoshino
ESMO open, 10, 11, 105839, 105839, 2025年10月09日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Based on the reported antitumor effects of microtubule inhibitors in xenograft models of BRAF V600E mutant colorectal cancer, this multicenter phase II study aimed to evaluate the efficacy and safety of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Patients with BRAF V600E mutant mCRC who received at least one prior regimen were administered intravenous eribulin. The primary endpoint was the objective response rate (ORR). Biomarker analyses were carried out using tumor and serial blood samples. Patients with reduced tumor size and/or progression-free survival (PFS) of >6 months were classified into the good response group, and the remaining patients were classified into the poor response group. RESULTS: Among the 27 patients enrolled, the ORR was 0% (95% confidence interval 0.0% to 12.8%), the disease control rate was 41%, the median PFS was 1.4 months, and the median survival time was 5.3 months (median follow-up, 5.3 months). Of 26 patients for whom tumors for RNA sequencing were available, all four patients in the good response group had the BRAF mutant (BM)2 subtype on gene expression analysis of BM subtype, whereas 22 patients in the poor response group had the BM1 (n = 8) or BM2 (n = 14) subtypes (P = 0.07). The proportion of patients with decreasing BRAF V600E relative clonality at the start of the second cycle was 75% and 11% in the good response and poor response groups, respectively (P = 0.02). Grade 3 and 4 adverse events included neutropenia (63%) and febrile neutropenia (22%). CONCLUSIONS: This phase II study of eribulin for patients with BRAF V600E mutant mCRC did not meet the primary endpoint. Although BM2 on gene expression analysis of BM subtype may be a predictive marker of eribulin efficacy, further studies are required to validate this hypothesis. - Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan.
Daisuke Kotani; Takayuki Yoshino; Toshiki Masuishi; Yu Sunakawa; Atsuo Takashima; Kentaro Yamazaki; Hisato Kawakami; Tomohiro Nishina; Yoshito Komatsu; Taito Esaki; Cathy Eng; Stacey Ukrainskyj; Rajash Pallai; Shivani Nanda; Zhao Yang; William Schelman; Marek Kania; Taroh Satoh
International journal of clinical oncology, 30, 10, 2043, 2052, 2025年10月, [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: In the phase 3 FRESCO-2 study, fruquintinib plus best supportive care (BSC) significantly improved overall survival (OS) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). We present the results of a FRESCO-2 post hoc subgroup analysis evaluating outcomes of patients enrolled in Japan. METHODS: In FRESCO-2, patients had previously received all standard chemotherapies, anti-VEGF and anti-EGFR therapies if indicated, and had progressed on, or were intolerant to trifluridine-tipiracil and/or regorafenib. Patients were randomized 2:1 to receive fruquintinib 5 mg or matching placebo by mouth once daily on days 1-21 in 28-day cycles, plus BSC. The primary endpoint was OS; secondary endpoints included progression-free survival (PFS) and safety. RESULTS: Of the 56 patients enrolled in Japan, 40 (71.4%) and 16 (28.6%) were randomized to fruquintinib and placebo, respectively. OS was improved with fruquintinib versus placebo (median 6.9 vs. 5.6 months; hazard ratio [HR], 0.42; 95% confidence interval [CI] 0.19 - 0.92). PFS was also improved with fruquintinib versus placebo (median 3.6 vs. 1.8 months; HR, 0.27; 95% CI 0.13 - 0.56). The incidence of grade ≥ 3 treatment-emergent adverse events (TEAEs) with fruquintinib versus placebo was 71.8% versus 29.4%; the most common grade ≥ 3 TEAEs with fruquintinib were hypertension (23.1%) and palmar-plantar erythrodysesthesia (17.9%). CONCLUSIONS: Fruquintinib improved OS and PFS versus placebo in FRESCO-2 patients enrolled in Japan and demonstrated a manageable safety profile. Results from the Japan subgroup were consistent with the global FRESCO-2 population, thus supporting fruquintinib as a novel treatment option for patients in Japan with refractory mCRC. CLINICAL TRIAL DETAILS: ClinicalTrials.gov; NCT04322539. - Urinary Titin as a Non-Invasive Biomarker for Sarcopenia Sex Differences in Unresectable Digestive Malignancies: A Retrospective Cohort Study.
Shiho Kaneko; Kazuaki Harada; Masatsugu Ohara; Shintaro Sawaguchi; Tatsuya Yokoyama; Koichi Ishida; Yasuyuki Kawamoto; Satoshi Yuki; Yoshito Komatsu; Naoya Sakamoto
International journal of molecular sciences, 26, 14, 2025年07月15日, [国際誌]
英語, 研究論文(学術雑誌), The prognosis of sarcopenia is poor in cancer patients. Recently, urinary titin, a biomarker of muscle damage, has been suggested as a potential marker for sarcopenia. However, its utility in patients with unresectable digestive malignancies remains unclear. In addition, sex differences have been reported in the association between sarcopenia and urinary titin levels. This study aimed to evaluate urinary titin as a diagnostic marker for unresectable digestive malignancies, focusing on sex differences. This retrospective study enrolled 96 patients (58 males, 38 females; median age 70), and urinary titin was evaluated as a diagnostic biomarker in relation to clinical factors (e.g., age, Eastern Cooperative Oncology Group performance status [ECOG PS], albumin [Alb]) and muscle indicators (e.g., psoas muscle index [PMI], handgrip strength). In male patients, urinary titin levels were significantly higher in the sarcopenia subgroup (5.78 vs. 2.79 pmol/mgCr, p = 0.008), and multivariate analyses identified urinary titin as an independent predictor of sarcopenia (odds ratio 13.4, p = 0.028). The receiver operating characteristic (ROC) analysis demonstrated fair diagnostic performance (area under the curve [AUC] 0.729), with an optimal cutoff value of 3.676 pmol/mgCr. Urinary titin may serve as a useful non-invasive diagnostic biomarker for sarcopenia in patients with unresectable digestive malignancies, particularly in males. These findings suggest that sex-specific approaches are required for sarcopenia assessment with urinary titin. - Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
Hisato Kawakami; Shigenori Kadowaki; Akitaka Makiyama; Masahiro Tsuda; Kenro Hirata; Naotoshi Sugimoto; Nozomu Machida; Hiroki Hara; Hidekazu Hirano; Taito Esaki; Yoshito Komatsu; Shuichi Hironaka; Yukari Kobayashi; Kazuhiro Kakimi; Yasutaka Chiba; Narikazu Boku; Ichinosuke Hyodo; Kei Muro
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43, 19, 2184, 2195, 2025年07月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Microsatellite instability-high (MSI-H) advanced gastric or esophagogastric junction cancer (AGC), accounting for 5%-6% of all AGC cases, has shown an enhanced responsiveness to immunotherapy. We performed a single-arm phase II study to evaluate the combination of nivolumab (NIVO) and low-dose (LD) ipilimumab (IPI) for first-line treatment of MSI-H AGC. PATIENTS AND METHODS: Patients with MSI-H AGC received NIVO (240 mg once every 2 weeks) and IPI (1 mg/kg once every 6 weeks). The primary end point was overall response rate (ORR) assessed by blinded independent central review. Secondary end points included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), safety, and biomarker analysis. MSI-H status was confirmed with an MSI-IVD Kit (Falco). RESULTS: Twenty-nine patients were enrolled. The ORR was 62.1% (95% CI, 42.3 to 79.3), with a complete response rate of 10.3%. The DCR was 79.3% (95% CI, 60.3 to 92.0). Treatment-related adverse events (TRAEs) of any grade occurred in 93.1% of patients, with those of grade ≥3 manifesting in 37.9% of patients. At the data cutoff (median follow-up of 9.0 months), treatment had been discontinued in 21 patients, with such discontinuation being due to TRAEs in 12 (41.4%) patients. However, after exclusion of one patient with progressive disease, the remaining 11 patients showed long-term antitumor efficacy after treatment discontinuation (range of response duration, 0.9+ to 15.6+ months). The median PFS was 13.8 months (95% CI, 13.7 months to not reached [NR]) and the median OS was NR (95% CI, 13.7 months to NR), with a 12-month OS rate of 79.5%. CONCLUSION: NIVO plus LD-IPI showed robust and durable antitumor efficacy as a first-line treatment for MSI-H AGC. Although TRAEs often led to treatment discontinuation, treatment efficacy was subsequently sustained in most patients. - Landscape Analysis of
CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights FromMONSTAR ‐SCREEN ‐2 Study
Tadayoshi Hashimoto; Naoko Iida; Yoshiaki Nakamura; Norio Nonomura; Chigusa Morizane; Hiroji Iwata; Susumu Okano; Wataru Yamagami; Naoya Yamazaki; Shigenori Kadowaki; Makoto Ueno; Shogen Boku; Eiji Oki; Yoshito Komatsu; Satoshi Yuki; Akitaka Makiyama; Takatsugu Ogata; Naoki Takahashi; Naohiro Okano; Tomohiro Nishina; Naoya Sakamoto; Takeshi Kuwata; Riu Yamashita; Taro Shibuki; Mitsuho Imai; Takao Fujisawa; Hideaki Bando; Kohei Shitara; Takayuki Yoshino
Cancer Science, 116, 8, 2218, 2231, Wiley, 2025年06月02日
研究論文(学術雑誌), ABSTRACT
Claudin 18.2 (CLDN18.2), a tight junction protein isoform, is an emerging therapeutic target in oncology. CLDN18 is well‐characterized in gastric cancer, but its pan‐cancer expression profiles and isoform distributions are poorly documented. In the present study, we analyzed CLDN18 expression in patients with solid tumors enrolled in the MONSTAR‐SCREEN‐2 study using immunohistochemistry (IHC, n = 349) and whole‐transcriptome sequencing (WTS, n = 2191). A splice junction analysis algorithm characterized isoform distribution patterns in WTS data and evaluated temporal changes using paired pre‐ and postchemotherapy specimens. IHC detected CLDN18.2 (≥ 40% of tumor cells showing any staining intensity) in 16.3% of patients, with highest prevalence in gastric (54.5%), biliary tract (21.7%), pancreatic (20.7%), and small intestinal (18.2%) cancers. WTS and IHC findings were significantly correlated (p < 0.001). WTS analysis with optimized transcript thresholds (n = 2191) demonstrated the CLDN18‐high population to be 13.8%, with highest proportions in gastric (64.5%), small intestinal (40.0%), pancreatic (37.8%), and biliary tract (20.0%) cancers. Isoform analysis of 364 patients revealed CLDN18.2 predominance (mean 18.2/18.1 proportion 0.945), with CLDN18.1 predominance observed in only 4.9% of patients. Longitudinal analysis of 27 paired gastric cancer samples revealed a significant reduction in CLDN18 expression and a nonsignificant decrease in the CLDN18.2 proportion following chemotherapy. This analysis validates WTS as a complementary approach to IHC for CLDN18 assessment and demonstrates significant CLDN18 expression across multiple cancer types. The predominance of CLDN18.2 supports the expansion of targeted therapeutic approaches beyond gastric cancer and indicates the potential of RNA‐based screening. - Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma
Takeaki Nakamura; Kanako C. Hatanaka; Yasuyuki Kawamoto; Shiho Kaneko; Koichi Ishida; Kazuaki Harada; Satoshi Yuki; Yoshito Komatsu; Yutaka Hatanaka; Naoya Sakamoto
Journal of Cancer Research and Clinical Oncology, 151, 5, Springer Science and Business Media LLC, 2025年05月10日
研究論文(学術雑誌) - Impact of baseline proteinuria on progression-free survival after regorafenib treatment for metastatic colorectal cancer.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 5, 443, 443, 2025年05月02日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Regorafenib improves the survival of patients with metastatic colorectal cancer (mCRC). However, proteinuria frequently occurs in regorafenib treatment, and development of severe hypertension, which is closely related to proteinuria, is associated with better treatment outcomes. We previously reported that patients with baseline proteinuria exhibit regorafenib-induced problematic symptoms. In this study, we aimed to assess the effect of baseline proteinuria on the treatment efficacy of regorafenib for mCRC. METHODS: Patients with mCRC receiving regorafenib (n = 100) were categorized into control (without baseline proteinuria) and pre-existing proteinuria (baseline grades 1-2) groups and retrospectively evaluated. The primary endpoint was the progression-free survival (PFS). RESULTS: Patients in the pre-existing proteinuria group exhibited significantly worse PFS than those in the control group (median with 95% confidence interval [CI] = 51 (46-56) and 56 (49-81) days, respectively; P = 0.04). Overall survival and disease control rate were lower in the pre-existing proteinuria group than in the control group although the difference was not statistically significant (P = 0.11 and 0.10, respectively). Similar results were obtained in the propensity score-matched population. Multivariate Cox hazard regression analyses revealed that baseline pre-existing proteinuria was associated with poor PFS (adjusted hazard ratio = 1.67; 95% CI = 1.03-2.72; P = 0.04). Additionally, ratio of drug suspension duration during all treatment cycles was higher in patients with pre-existing proteinuria than those without symptoms. CONCLUSION: Our results suggest that patients with baseline proteinuria experience poor PFS following regorafenib treatment for mCRC, although we should consider the clinical significance of the difference. - イリノテカン誘発性コリン症状に対する抗コリン薬単回予防投与の症状コントロール不良因子の探索
渡辺 拓也; 齋藤 佳敬; 武隈 洋; 清水 康; 木下 一郎; 小松 嘉人; 菅原 満
日本臨床腫瘍薬学会雑誌, 41, 137, 137, (一社)日本臨床腫瘍薬学会, 2025年05月
日本語 - Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.
Kentaro Sawada; Riu Yamashita; Shunsuke A Sakai; Satoshi Horasawa; Ayumu Yoshikawa; Takao Fujisawa; Shigenori Kadowaki; Ken Kato; Makoto Ueno; Eiji Oki; Yoshito Komatsu; Tatsuyuki Chiyoda; Yosuke Horita; Hisateru Yasui; Tadamichi Denda; Hironaga Satake; Taito Esaki; Taroh Satoh; Naoki Takahashi; Kentaro Yamazaki; Nobuhisa Matsuhashi; Tomohiro Nishina; Hiroyuki Takeda; Koushiro Ohtsubo; Takashi Ohta; Akihito Tsuji; Masahiro Goto; Takeshi Kato; Hideaki Bando; Katsuya Tsuchihara; Yoshiaki Nakamura; Takayuki Yoshino
Cancer research communications, 5, 5, 857, 870, 2025年05月01日, [国際誌]
英語, 研究論文(学術雑誌), UNLABELLED: Although the gut microbiome is associated with cancer development and progression, little is known about the effects of the gut microbiome landscape and the efficacy of immune checkpoint inhibitors (ICI) across cancer types. We investigated the association between the microbiome, clinical features, and ICI efficacy across cancer types in a large nationwide screening project for solid tumors. Among 2,180 patients with advanced solid tumors enrolled in the SCRUM-Japan MONSTAR-SCREEN between October 2019 and September 2021, in the chemotherapy-naïve cohort (n = 817), a high prevalence of oral bacteria was observed in patients using proton pump inhibitors (PPI) and those with upper gastrointestinal cancers, particularly postoperative patients with gastric or pancreatic cancer. Among patients treated with ICIs (n = 333), a high abundance of sequence variants in the gut microbiome was not significantly associated with ICI efficacy across cancer types (HR = 0.94; 95% confidence interval, 0.73-1.21). However, high oral bacteria in feces significantly correlated with a shorter progression-free survival compared with low oral bacteria (median, 4.34 vs. 6.97 months; HR = 1.38; 95% confidence interval, 1.07-1.78). Notably, in patients using PPIs, a higher proportion of oral bacteria influenced progression-free survival outcomes of ICI treatment (median, 3.15 vs. 2.04 months; P = 0.08), unlike in PPI nonusers (median, 7.13 vs. 5.55 months; P = 0.74). This study of the gut microbiome has unveiled significant insights into its landscape and potential impact on ICI efficacy. It highlights that the abundance of oral bacteria in feces may play a critical role in diminishing ICI efficacy among patients using PPIs. SIGNIFICANCE: As part of the MONSTAR-SCREEN, a prospective nationwide project for patients with solid tumors, we found that although gut microbiome diversity does not consistently predict ICI efficacy across cancer types, a high level of oral bacteria in the gut is linked to reduced ICI effectiveness, especially in patients using PPIs. These findings highlight the potential clinical impact of microbiome variations on cancer treatment outcomes. - Evaluation of nausea induced by trifluridine/tipiracil in metastatic colorectal cancer treatment.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Journal of chemotherapy (Florence, Italy), 1, 8, 2025年03月20日, [国際誌]
英語, 研究論文(学術雑誌), Trifluridine/tipiracil (FTD/TPI) frequently induces chemotherapy-induced nausea and vomiting (CINV). As evidence of factors associated with CINV in oral chemotherapeutic agents is limited, we aimed to assess factors for nausea development in a real-world FTD/TPI-containing treatment for metastatic colorectal cancer (mCRC). Patients with mCRC receiving FTD/TPI with or without bevacizumab (n = 104) were retrospectively evaluated. Nausea occurred in 40.4% of the patients, and the severity was grade 1 for 23.1%, grade 2 for 15.4%, and grade 3 for 1.9%. Multivariable logistic regression analysis suggested that female sex (adjusted odds ratio 2.74, 95% confidence interval 1.02-7.33, p = 0.045) and concomitant bevacizumab (2.68, 1.13-6.37, p = 0.03) were independent risk factors for all-grade nausea during the first cycle as a primary endpoint. Particularly, among patients with FTD/TPI monotherapy, females significantly exhibited nausea compared to males. Our study revealed that concomitant bevacizumab and female sex are independent risk factors for nausea in FTD/TPI-containing treatment for mCRC. - Identification of risk factors related to problematic peripheral neuropathy development in gemcitabine and nab-paclitaxel treatment for pancreatic cancer.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 4, 263, 263, 2025年03月10日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect in patients treated with gemcitabine (GEM) and nanoparticle albumin-bound paclitaxel (nab-PTX) for pancreatic cancer, negatively impacting their quality of life. This study aimed to identify risk factors for significant CIPN development in a real-world setting of GEM + nab-PTX treatment to inform effective management strategies. METHODS: Patients with unresectable pancreatic cancer who received GEM + nab-PTX (n = 140) were retrospectively assessed. The primary endpoint was to identify the risk factor(s) associated with the development of problematic grade ≥ 2 CIPN within six months of treatment initiation. We also evaluated factors associated with all-grade CIPN and compared CIPN incidence across specific patient groups. RESULTS: The incidence of grade ≥ 2 CIPN was 35.0%, with 63.6% of patients experiencing symptoms of any grade. Multivariate Cox proportional hazard regression analysis identified baseline preexisting neuropathy as an independent risk factor for developing grade ≥ 2 CIPN (adjusted hazard ratio 4.03, 95% confidence interval 1.82-8.96, P = 0.0006). Conversely, dose modification of nab-PTX at or within 4 weeks of treatment initiation emerged as a protective factor (0.45, 0.22-0.91, P = 0.03). Additionally, the cumulative incidence of grade ≥ 2 CIPN was significantly lower and delayed in patients who underwent dose modification within 4 weeks compared to those who did not in the population with preexisting neuropathy (P = 0.01). CONCLUSION: Baseline preexisting neuropathy significantly increases the risk, while early dose modification of nab-PTX serves as a protective factor against developing grade ≥ 2 CIPN in patients receiving GEM + nab-PTX treatment for pancreatic cancer. - ゾルベツキシマブ投与中に腹部超音波検査で胃壁構造変化を認めた胃癌の1例
石田 浩一; 原田 一顕; 横山 達也; 金子 志帆; 中村 赳晶; 川本 泰之; 結城 敏志; 小松 嘉人; 西田 睦; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 136回・130回, 45, 45, 日本消化器病学会-北海道支部, 2025年03月
日本語 - 進行/再発胃癌に対するFTD/TPI+RAM療法の多施設共同後方視的観察研究(HGCSG2302)
中村 赳晶; 澤田 憲太郎; 川本 泰之; 石黒 敦; 元尾 伊織; 園田 悠紀; 吉河 歩; 鈴木 一広; 中積 宏之; 細川 歩; 石井 貴大; 畑中 一映; 中村 路夫; 中野 真太郎; 村中 徹人; 太宰 昌佳; 生本 太郎; 佐藤 温; 結城 敏志; 坂本 直哉; 小松 嘉人
日本胃癌学会総会記事, 97回, 249, 249, (一社)日本胃癌学会, 2025年03月
日本語 - 転移性結腸直腸癌におけるレゴラフェニブ減量開始の有用性を検討する多施設共同後方視的解析
原田 一顕; 川上 武志; 伏木 邦博; 山崎 健太郎; 舛石 俊樹; 谷口 浩也; 室 圭; 胡 慶江; 安藤 幸滋; 沖 英次; 小松 嘉人; 坂本 直哉; 結城 敏志
日本大腸肛門病学会雑誌, 78, 2, 86, 86, (一社)日本大腸肛門病学会, 2025年02月
日本語 - Ultrasound-detected gastric changes related to zolbetuximab-induced emesis: a case series.
Kazuaki Harada; Koichi Ishida; Shiho Kaneko; Tatsuya Yokoyama; Shintaro Sawaguchi; Takeaki Nakamura; Yasuyuki Kawamoto; Satoshi Yuki; Mutsumi Nishida; Naoya Sakamoto; Yoshito Komatsu
Frontiers in oncology, 15, 1686245, 1686245, 2025年, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Zolbetuximab prolongs survival in patients with claudin18.2 (CLDN18.2)-positive gastric cancer (GC) and gastroesophageal junction cancer. However, it is associated with an increased risk of emesis, and its underlying mechanism remains unclear. CASE PRESENTATION: This report presents three cases of advanced GC that underwent abdominal ultrasonography (US) during zolbetuximab administration. In two patients with primary gastric lesions, severe nausea occurred during the first treatment cycle. US findings revealed increased echogenicity of the submucosal layer, enhanced layer stratification, and increased blood flow signals, which improved as the emesis subsided. During the second cycle, emesis was milder, and US findings revealed only slight changes. In the third patient who underwent total gastrectomy, no nausea or abnormal US findings were observed. CONCLUSION: These US findings indicate gastric tumor tissue injury due to zolbetuximab, which is associated with emesis. US is a valuable tool for further elucidating the mechanisms underlying zolbetuximab-induced emesis and may also contribute to the prediction and prevention of this adverse event. STATEMENT: Zolbetuximab treatment has been reported to improve survival in patients with HER2-negative, CLDN18.2-positive advanced, unresectable, or recurrent gastric and gastroesophageal junction cancers. However, it is associated with a high incidence of nausea, particularly during the first infusion, and the underlying mechanism remains unclear. We present three cases of advanced or recurrent gastric cancer treated with zolbetuximab, during which abdominal ultrasonography (US) was performed. In two cases with primary gastric tumors, US revealed characteristic changes in the gastric wall at the onset of nausea, suggestive of edema and inflammation. These changes appeared prior to the symptoms and resolved as nausea improved. Nausea during the second infusion was milder, with less pronounced US changes. The third case includes a patient who had undergone total gastrectomy; the patient did not experience nausea, and no gastrointestinal changes were observed on US. This is the first report to describe US findings associated with zolbetuximab-induced nausea. These observations suggest that gastric wall changes detectable using US are closely linked to nausea and may reflect underlying gastric injury. This report also highlights the potential of bedside US monitoring to help predict and prevent nausea during zolbetuximab therapy. - 高齢者における消化管癌の薬物療法の現状 進行再発結腸直腸癌に対するIRIS/Bevの多施設共同後方視的観察研究(HGCSG1901) 高齢者の治療成績
原田 一顕; 伊藤 憲; 結城 敏志; 川本 泰之; 吉河 歩; 澤田 憲太郎; 石黒 敦; 武藤 理; 畑中 一映; 奥田 博介; 佐藤 温; 笹木 有佑; 中村 路夫; 目黒 高志; 植田 亮; 坂本 直哉; 坂田 優; 小松 嘉人
日本消化管学会雑誌, 9, Suppl., 204, 204, (一社)日本消化管学会, 2025年01月
日本語 - Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors.
Yoshiaki Nakamura; Hiroshi Ozaki; Makoto Ueno; Yoshito Komatsu; Satoshi Yuki; Taito Esaki; Hiroya Taniguchi; Yu Sunakawa; Kensei Yamaguchi; Ken Kato; Tadamichi Denda; Tomohiro Nishina; Naoki Takahashi; Taroh Satoh; Hisateru Yasui; Hironaga Satake; Eiji Oki; Takeshi Kato; Takashi Ohta; Nobuhisa Matsuhashi; Masahiro Goto; Naohiro Okano; Koushiro Ohtsubo; Kentaro Yamazaki; Riu Yamashita; Naoko Iida; Mihoko Yuasa; Hideaki Bando; Takayuki Yoshino
Nature medicine, 31, 1, 165, 175, 2025年01月, [国際誌]
英語, 研究論文(学術雑誌), Although comprehensive genomic profiling has become standard in oncology for advanced solid tumors, the full potential of circulating tumor DNA (ctDNA)-based profiling in capturing tumor heterogeneity and guiding therapy selection remains underexploited, marked by a scarcity of evidence on its clinical impact and the assessment of intratumoral heterogeneity. The GOZILA study, a nationwide, prospective observational ctDNA profiling study, previously demonstrated higher clinical trial enrollment rates using liquid biopsy compared with tissue screening. This updated analysis of 4,037 patients further delineates the clinical utility of ctDNA profiling in advanced solid tumors, showcasing a significant enhancement in patient outcomes with a 24% match rate for targeted therapy. Patients treated with matched targeted therapy based on ctDNA profiling demonstrated significantly improved overall survival compared with those receiving unmatched therapy (hazard ratio, 0.54). Notably, biomarker clonality and adjusted plasma copy number were identified as predictors of therapeutic efficacy, reinforcing the value of ctDNA in reflecting tumor heterogeneity for precise treatment decisions. These new insights into the relationship between ctDNA characteristics and treatment outcomes advance our understanding beyond the initial enrollment benefits. Our findings advocate for the broader adoption of ctDNA-guided treatment, signifying an advancement in precision oncology and improving survival outcomes in advanced solid tumors. - Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial.
Mitsuho Imai; Yoshiaki Nakamura; Sangwon Shin; Wataru Okamoto; Takeshi Kato; Taito Esaki; Ken Kato; Yoshito Komatsu; Satoshi Yuki; Toshiki Masuishi; Tomohiro Nishina; Kentaro Sawada; Akihiro Sato; Takeshi Kuwata; Riu Yamashita; Takao Fujisawa; Hideaki Bando; Chan-Young Ock; Satoshi Fujii; Takayuki Yoshino
JCO precision oncology, 9, e2400385, 2025年01月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise in treating HER2-amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores the potential of artificial intelligence (AI) in predicting treatment responses to trastuzumab plus pertuzumab (TP) in patients with HER2-amplified mCRC from the phase II TRIUMPH trial. MATERIALS AND METHODS: AI-powered HER2 quantification continuous score (QCS) and tumor microenvironment (TME) analysis were applied to the prescreening cohort (n = 143) and the TRIUMPH cohort (n = 30). AI analyzers determined the proportions of tumor cells (TCs) with HER2 staining intensity and the densities of various cells in TME, examining their associations with clinical outcomes of TP. RESULTS: The AI-powered HER2 QCS for HER2 immunohistochemistry (IHC) achieved an accuracy of 86.7% against pathologist evaluations, with a 100% accuracy for HER2 IHC 3+ patients. Patients with ≥50% of TCs showing HER2 3+ staining intensity (AI-H3-high) exhibited significantly prolonged progression-free survival (PFS; median PFS, 4.4 v 1.4 months; hazard ratio [HR], 0.12 [95% CI, 0.04 to 0.38]) and overall survival (OS; median OS, 16.5 v 4.1 months; HR, 0.13 [95% CI, 0.05 to 0.38]) compared with the AI-H3-low (<50% group). Stratification among patients with AI-H3-high included TME-high (all lymphocyte, fibroblast, and macrophage densities in the cancer stroma above the median) and TME-low (anything below the median), showing a median PFS of 1.3 and 5.6 months for TME-high and TME-low respectively, with an HR of 0.04 (95% CI, 0.01 to 0.19) for AI-H3-high with TME-low compared with AI-H3-low. CONCLUSION: AI-powered HER2 QCS and TME analysis demonstrated potential in enhancing treatment response predictions in patients with HER2-amplified mCRC undergoing TP therapy. - Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.
Masataka Yagisawa; Hiroya Taniguchi; Taroh Satoh; Shigenori Kadowaki; Yu Sunakawa; Tomohiro Nishina; Yoshito Komatsu; Taito Esaki; Daisuke Sakai; Ayako Doi; Takeshi Kajiwara; Hiromi Ono; Masatoshi Asano; Nami Hirano; Justin Odegaard; Satoshi Fujii; Shogo Nomura; Hideaki Bando; Akihiro Sato; Takayuki Yoshino; Yoshiaki Nakamura
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42, 32, 3817, 3825, 2024年11月10日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: HERALD/EPOC1806 was conducted as a multicenter phase II trial assessing trastuzumab deruxtecan (T-DXd) therapy for patients with human epidermal growth factor receptor 2 (HER2)-amplified progressive stage solid tumors detected by cell-free DNA (cfDNA) testing. PATIENTS AND METHODS: Patients exhibited advanced solid tumors with HER2 amplification that was identified via next-generation sequencing of cfDNA testing, without the requirement for immunohistochemical HER2 testing. The studied group was administered T-DXd at 5.4 mg/kg once every 3 weeks until onset of disease progression or intolerable toxicity. RESULTS: Overall, 4,734 patients underwent cfDNA testing from December 2019 to January 2022, and 252 demonstrated HER2 amplification. Finally, the study included 62 patients with 16 cancer types with a median baseline plasma HER2 copy number (CN) of 8.55 (range, 2.4-73.9). Confirmed overall response rate (ORR) by investigator assessment was 56.5% (95% CI, 43.3 to 69.0), thus showing a value beyond the 5% threshold. Responses were evaluated for 13 cancer types, including KRAS-mutant colorectal (1/3), PIK3CA-mutant endometrial (5/6), and tissue HER2-negative gastric (1/2) cancers. Plasma HER2 CN above versus below the baseline median value did not differ for impact response; however, clearance of HER2 amplification in cfDNA on cycle 2 day 1 had higher response values compared with persistence. Median progression-free survival and response duration were 7.0 (95% CI, 4.9 to 9.7) and 8.8 (95% CI, 5.8 to 11.2) months, respectively, with the majority of complications being mild to moderate. Interstitial lung diseases were identified in 16 (26%) patients, including 14 patients with grade 1 disease, one patient with grade 2 disease, and one patient with grade 3 disease. CONCLUSION: T-DXd treatment demonstrated high ORR with durable response in patients with advanced HER2-amplified solid tumors determined with cfDNA testing. - Impact of renal impairment on early development of severe neutropenia with trifluridine/tipiracil treatment for metastatic colorectal cancer.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Scientific reports, 14, 1, 26990, 26990, 2024年11月06日, [国際誌]
英語, 研究論文(学術雑誌), Trifluridine/tipiracil (FTD/TPI) with or without bevacizumab is an effective treatment for metastatic colorectal cancer (mCRC). As this agent is mainly excreted via the kidney, we aimed to evaluate the impact of renal impairment (RI) on the early development of severe neutropenia, a dose-limiting toxicity and whose development reflects better treatment outcomes, in patients with mCRC treated with FTD/TPI. Patients with mCRC receiving FTD/TPI ± bevacizumab (n = 100) were divided into the RI group (creatinine clearance [CCr] < 90 mL/min) or control group (CCr ≥ 90 mL/min), and retrospectively evaluated. Severe neutropenia during the first two cycles occurred in 57.6% and 34.2% of patients in the RI and control groups, respectively, which was significantly different (P = 0.03) and met our primary endpoint. Furthermore, the incidence during the first cycle also differed significantly (52.5% in the RI group and 17.1% in the control group, P = 0.0004). Multivariate logistic regression analysis suggested that baseline RI and neutropenia were significant risk factors for early severe neutropenia (adjusted odds ratio and 95% confidence interval: 3.07, 1.24-7.59, P = 0.02 for RI, and 9.76, 1.08-88.11, P = 0.04 for neutropenia). In conclusion, our study suggested that patients with RI can exhibit early severe neutropenia during real-world FTD/TPI treatment for mCRC. - The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.
Tadayoshi Hashimoto; Yoshiaki Nakamura; Takao Fujisawa; Mitsuho Imai; Taro Shibuki; Naoko Iida; Hiroshi Ozaki; Norio Nonomura; Chigusa Morizane; Hiroji Iwata; Susumu Okano; Wataru Yamagami; Naoya Yamazaki; Shigenori Kadowaki; Hiroya Taniguchi; Makoto Ueno; Shogen Boku; Eiji Oki; Yoshito Komatsu; Satoshi Yuki; Akitaka Makiyama; Tomoyuki Otsuka; Hiroki Hara; Naohiro Okano; Tomohiro Nishina; Yasutoshi Sakamoto; Izumi Miki; Shin Kobayashi; Junichiro Yuda; Shun-Ichiro Kageyama; Michiko Nagamine; Shingo Sakashita; Naoya Sakamoto; Riu Yamashita; Yoshikatsu Koga; Hideaki Bando; Genichiro Ishii; Takeshi Kuwata; Woong-Yang Park; Atsushi Ohtsu; Takayuki Yoshino
Cancer discovery, 14, 11, 2243, 2261, 2024年11月01日, [国際誌]
英語, 研究論文(学術雑誌), The SCRUM-Japan MONSTAR-SCREEN consortium is a nationwide molecular profiling project employing artificial intelligence-driven multiomics analyses for patients with advanced malignancies, aiming to develop novel therapeutics and diagnostics and deliver effective drugs to patients. Concurrently, studies assessing molecular residual disease-based precision medicine for resectable solid tumors, including CIRCULATE-Japan, are ongoing. The substantial data generated by these platforms are stored within a state-of-the-art supercomputing infrastructure, VAPOR CONE. Since 2015, our project has registered over 24,000 patients as of December 2023. Among 16,144 patients with advanced solid tumors enrolled in MONSTAR-SCREEN projects, 5.0% have participated in matched clinical trials, demonstrating a 29.2% objective response rate and 14.8-month median survival (95% CI, 13.4-16.3) for patients treated in the matched clinical trials. Notably, patients who received matched therapy demonstrated significantly prolonged overall survival compared with those who did not (hazard ratio 0.77; 95% confidence interval, 0.71-0.83). Significance: Our nationwide molecular profiling initiative played pivotal roles in facilitating the enrollment of patients with advanced solid tumors into matched clinical trials and highlighted the substantial survival benefits of patients treated with matched therapy. We aim to facilitate an industry-academia data-sharing infrastructure ecosystem, fostering new drug discovery paradigms and precision medicine. - 消化器癌に対するS-1を含む全身化学療法による眼障害に関する前向き観察研究
八木澤 允貴; 中村 路夫; 澤田 憲太郎; 川本 泰之; 村中 徹人; 中積 宏之; 太宰 昌佳; 辻 靖; 進藤 吉明; 中野 真太郎; 上林 実; 渡邉 桃子; 原田 一顕; 結城 敏志; 小松 嘉人
日本癌治療学会学術集会抄録集, 62回, P62, 3, (一社)日本癌治療学会, 2024年10月
英語 - 消化器癌に対するS-1を含む全身化学療法による眼障害に関する前向き観察研究
八木澤 允貴; 中村 路夫; 澤田 憲太郎; 川本 泰之; 村中 徹人; 中積 宏之; 太宰 昌佳; 辻 靖; 進藤 吉明; 中野 真太郎; 上林 実; 渡邉 桃子; 原田 一顕; 結城 敏志; 小松 嘉人
日本癌治療学会学術集会抄録集, 62回, P62, 3, (一社)日本癌治療学会, 2024年10月
英語 - がん悪液質に対するアナモレリン塩酸塩の早期中止と関連する因子の検討(HGCSG2201)
原田 一顕; 梶浦 新也; 澤田 憲太郎; 畑中 一映; 佐藤 温; 伊藤 憲; 田村 穂高; 土井 綾子; 安藤 孝将; 中村 路夫; 中積 宏之; 村中 徹人; 小松 嘉人
日本癌治療学会学術集会抄録集, 62回, EN3, 6, (一社)日本癌治療学会, 2024年10月
英語 - がん悪液質患者におけるアナモレリン塩酸塩の治療効果に関連する因子(HGCSG2201)
畑中 一映; 原田 一顕; 梶浦 新也; 澤田 憲太郎; 佐藤 温; 伊藤 憲; 田村 穂高; 土井 綾子; 安藤 孝将; 中村 路夫; 中積 宏之; 村中 徹人; 曽我部 進; 石井 貴大; 小松 嘉人
日本癌治療学会学術集会抄録集, 62回, O68, 4, (一社)日本癌治療学会, 2024年10月
英語 - Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
Kanwal Raghav; Salvatore Siena; Atsuo Takashima; Takeshi Kato; Marc Van den Eynde; Filippo Pietrantonio; Yoshito Komatsu; Hisato Kawakami; Marc Peeters; Thierry Andre; Sara Lonardi; Kensei Yamaguchi; Jeanne Tie; Cristina Gravalos Castro; Hung-Chih Hsu; John H Strickler; Tae-You Kim; Yongjun Cha; Daniel Barrios; Qi Yan; Takahiro Kamio; Kojiro Kobayashi; Aislyn Boran; Makito Koga; John D Allard; Takayuki Yoshino
The Lancet. Oncology, 25, 9, 1147, 1162, 2024年09月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Trastuzumab deruxtecan has shown encouraging activity in patients with treatment-refractory HER2-positive, RAS wild-type and BRAF wild-type metastatic colorectal cancer. Dose optimisation and further antitumour assessments in patients with RAS mutations and those with previous anti-HER2 therapy are warranted. We aimed to evaluate two doses of trastuzumab deruxtecan (5·4 mg/kg and 6·4 mg/kg) to establish the recommended dose in patients with pretreated HER2-positive, RAS wild-type or mutant metastatic colorectal cancer. METHODS: DESTINY-CRC02 was a multicentre, randomised, two-stage, two-arm, phase 2 study done in 53 research hospitals and medical centres in Australia, Belgium, France, Italy, Japan, South Korea, Spain, Taiwan, the UK, and the USA. Eligible patients were aged 18 years and older or 20 years and older (depending on region) with pretreated pathologically documented, unresectable, recurrent, or metastatic HER2-positive, and RAS wild-type or mutant colorectal cancer. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and have received previous chemotherapy, and anti-EGFR, anti-VEGF, or anti-PD-L1 therapy, if clinically indicated. In stage 1, patients were randomly assigned (1:1), via a secure interactive response technology system, to receive 5·4 mg/kg or 6·4 mg/kg trastuzumab deruxtecan administered intravenously every 21 days. Stratification factors were ECOG performance status, HER2 status, and RAS status. In stage 2, patients were assigned into the 5·4 mg/kg treatment group only. The primary endpoint was confirmed objective response rate by blinded independent central review, assessed in all patients for whom treatment was assigned (full analysis set). Safety was assessed in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT04744831, and is ongoing (not recruiting). FINDINGS: Between March 5, 2021, and March 29, 2022, 135 patients were centrally screened, 122 of whom were enrolled. In stage 1, 40 patients each were randomly assigned to receive trastuzumab deruxtecan 5·4 mg/kg and 6·4 mg/kg. In stage 2, an additional 42 patients were enrolled in the 5·4 mg/kg group. 64 (52%) participants were male and 58 (48%) were female. The median duration of follow-up was 8·9 months (IQR 6·7-10·5) in the 5·4 mg/kg group and 10·3 months (5·9-12·7) in the 6·4 mg/kg group. The confirmed objective response rate by blinded independent central review was 37·8% (31/82 [95% CI 27·3-49·2]) in the 5·4 mg/kg group and 27·5% (11/40 [14·6-43·9]) in the 6·4 mg/kg group. 34 (41%) of 83 patients in the 5·4 mg/kg group and 19 (49%) of 39 in the 6·4 mg/kg group had grade 3 or worse drug-related treatment-emergent adverse events. The most common grade 3 or worse drug-related treatment-emergent adverse events were neutrophil count decreased (13 [16%] of 83 patients), anaemia (six [7%]), nausea (six [7%]), and white blood cell count decreased (five [6%]) in the 5·4 mg/kg group; and were neutrophil count decreased (10 [26%] of 39 patients), anaemia (eight [21%]), platelet count decreased (four [10%]), and white blood cell count decreased (four [10%]) in the 6·4 mg/kg group. Drug-related serious adverse events occurred in 11 (13%) of 83 patients in the 5·4 mg/kg group and six (15%) of 39 patients in the 6·4 mg/kg group; the most common in the 5·4 mg/kg group was nausea (three [4%] patients) and the most common in the 6·4 mg/kg group were fatigue (two [5%] patients), neutropenia (two [5%]), and thrombocytopenia (two [5%]). A drug-related treatment-emergent adverse event related to death occurred in one (1%) patient in the 5·4 mg/kg group (due to hepatic failure). Adjudicated drug-related interstitial lung disease or pneumonitis events were observed in seven (8%) patients in the 5·4 mg/kg group (all grade 1 or 2) and in five (13%) patients in the 6·4 mg/kg group (four grade 1 or 2; one grade 5). INTERPRETATION: The promising antitumour activity and favourable safety profile support trastuzumab deruxtecan 5·4 mg/kg as the optimal single-agent dose for patients with pretreated HER2-positive metastatic colorectal cancer, including those with RAS mutations, previous anti-HER2 therapy, or both. FUNDING: Daiichi Sankyo and AstraZeneca. - Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series.
Yuta Toji; Shintaro Takeuchi; Yuma Ebihara; Yo Kurashima; Kazuaki Harada; Mariko Hayashi; Hirotake Abe; Hideyuki Wada; Satoko Yorinaga; Toshiaki Shichinohe; Utano Tomaru; Yoshito Komatsu; Satoshi Hirano
Surgical case reports, 10, 1, 200, 200, 2024年08月28日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Nivolumab with chemotherapy has been transformative for metastatic gastric cancer (GC). The potential of this regimen for local tumor control could be utilized for perioperative chemotherapy in locally advanced GC with bulky tumors or lymph node metastasis involving other organs. CASE PRESENTATION: Five patients with HER2-negative advanced GC were treated with nivolumab and oxaliplatin-based chemotherapy. All patients presented with clinical stage III or IVA GC with tumors in contact with either the pancreas or liver. Following chemotherapy, all tumors demonstrated shrinkage, allowing successful radical gastrectomies including four minimally invasive approach without postoperative complications. Four patients avoided combined resection of other organs. CONCLUSIONS: Perioperative chemotherapy with nivolumab was effective for local disease control in this case series. This regimen could be a promising treatment approach for locally advanced GC; however, its survival benefits should be evaluated in clinical trials. - Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.
Naoko Iida; Mitsuho Imai; Wataru Okamoto; Takeshi Kato; Taito Esaki; Ken Kato; Yoshito Komatsu; Satoshi Yuki; Toshiki Masuishi; Tomohiro Nishina; Hiromichi Ebi; Hiroya Taniguchi; Norio Nonomura; Yu Sunakawa; Manabu Shiozawa; Kentaro Yamazaki; Shogen Boku; Hideaki Bando; Yuichi Shiraishi; Maki Kobayashi; Hiroki Goto; Akihiro Sato; Satoshi Fujii; Takayuki Yoshino; Yoshiaki Nakamura
Clinical cancer research : an official journal of the American Association for Cancer Research, OF1-OF12, 2024年08月20日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: HER2-targeted therapies in ERBB2-amplified metastatic colorectal cancer (mCRC) are effective; however, a notable portion of patients do not respond to treatment, and secondary resistance occurs in most patients receiving these treatments. The purpose of this study was to investigate determinants of treatment efficacy and resistance in patients with ERBB2-amplified mCRC who received HER2-targeted therapy by analyzing multiomics data. EXPERIMENTAL DESIGN: We investigated genomic data from a nationwide large cancer genomic screening project, the SCRUM-Japan project. We analyzed paired genome and transcriptome data of tissue and genomic data of ctDNA collected pre- and postprogression in patients enrolled in the related trial, TRIUMPH, in ERBB2-amplified mCRC. RESULTS: In 155 patients with ERBB2-amplified solid tumors who received HER2-targeted therapy based on the SCRUM-Japan project, the objective response rate was 50%, 51%, and 35% in ERBB2 wild-type, variant of unknown significance, and pathogenic variant groups, respectively. In the paired genome and transcriptome data analyses in TRIUMPH, we identified the novel splicing-associated variant c.644-66_-2del in one of the 11 patients with paired whole-exome sequencing and whole-transcriptome sequencing data sets, which lacks the binding domain of pertuzumab, in progressed metastatic tumor as a variant with potential pathogenicity. The time-course ctDNA analysis detected c.644-66_-2del as an acquired variant. CONCLUSIONS: This study highlighted the importance of ERBB2 genomic status when evaluating the efficacy of HER2-targeted therapies in ERBB2-amplified mCRC. The identification of a novel splicing-associated variant may provide insights into potential mechanisms of treatment resistance. Furthermore, we demonstrated the utility of ctDNA to follow the acquired genomic status of mCRC tumors. - A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801.
Hiroshi Nakatsumi; Yoshito Komatsu; Kazuaki Harada; Yasuyuki Kawamoto; Satoshi Yuki; Kentaro Sawada; Atsushi Ishiguro; Susumu Sogabe; Takayuki Ando; Yusuke Sasaki; Ayumu Yoshikawa; Michio Nakamura; Masayoshi Dazai; Miki Tateyama; Osamu Muto; Masahito Kotaka; Tamotsu Sagawa; Tetsuhito Muranaka; Kazuteru Hatanaka; Ryo Takagi; Yu Sakata
International journal of cancer, 2024年08月14日, [国際誌]
英語, 研究論文(学術雑誌), Aflibercept (AFL) plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer (mCRC). However, there is limited evidence on the efficacy and safety of AFL plus FOLFIRI previously treated with anti-epidermal growth factor receptor (EGFR) agents. Therefore, we conducted a prospective open-label phase II trial evaluating the efficacy and safety of AFL plus FOLFIRI in Japanese patients with mCRC failing a prior oxaliplatin-based chemotherapy plus an anti-EGFR agent. AFL (4 mg/kg iv) followed by FOLFIRI (irinotecan 180 mg/m2, leucovorin 200 mg/m2 iv, bolus 5-fluorouracil [5-FU] 400 mg/m2, and infusional 5-FU 2400 mg/m2/46 h) was given every 2 weeks until progression or unacceptable toxicities. The primary endpoint was progression-free survival (PFS) rate at 6 months. Forty three patients were enrolled between November 2019 and October 2022. The primary endpoint was met: 6-month PFS rate was 58.8% (90% confidence interval [CI], 45.7%-72.0%). Median PFS and OS were 7.3 months (95% CI, 5.5-11.0 months) and 18.8 months (95% CI, 12.9-26.6 months), respectively. The overall response rate was 20.9% (95% CI, 10.0-36.0%) and disease control rate was 88.4% (95% CI, 74.9-96.1%). The main grade ≥3 adverse events included hypertension (62.8%), neutropenia (55.8%), leukopenia (25.6%), febrile neutropenia (11.6%), fatigue (9.3%), anorexia (9.3%), proteinuria (9.3%), and diarrhea (7.0%). No deaths and no new safety signals with a causal relation to the study treatment were observed. This study suggests that AFL plus FOLFIRI shows a high response rate and a manageable safety profile in Japanese patients with mCRC who failed prior oxaliplatin-based chemotherapy plus an anti-EGFR agent. - Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial.
Akihiro Ohba; Chigusa Morizane; Yasuyuki Kawamoto; Yoshito Komatsu; Makoto Ueno; Satoshi Kobayashi; Masafumi Ikeda; Mitsuhito Sasaki; Junji Furuse; Naohiro Okano; Nobuyoshi Hiraoka; Hiroshi Yoshida; Aya Kuchiba; Ryo Sadachi; Kenichi Nakamura; Naoko Matsui; Yoshiaki Nakamura; Wataru Okamoto; Takayuki Yoshino; Takuji Okusaka
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2302010, 2024年08月05日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Treatment options for patients with unresectable or recurrent biliary tract cancer (BTC) who progress on a gemcitabine-containing regimen are limited. In addition, the significance of anti-human epidermal growth factor receptor 2 (HER2) therapy in HER2-expressing BTC has not been sufficiently investigated. METHODS: In this phase II trial, participants from five institutions in Japan were enrolled. Eligible patients had pathologically confirmed unresectable or recurrent BTC with centrally confirmed HER2-positive (immunohistochemistry [IHC]3+ or IHC2+ and in situ hybridization [ISH]+) or HER2-low (IHC2+ and ISH-, IHC1+, and IHC0 and ISH+) and were refractory or intolerant to a gemcitabine-containing regimen. The patients received 5.4 mg/kg trastuzumab deruxtecan (T-DXd) once every 3 weeks until disease progression or unacceptable toxicity. The primary end point was the confirmed objective response rate (ORR) in HER2-positive BTC by an independent central review (threshold ORR, 15%; expected ORR, 40%). RESULTS: A total of 32 patients were enrolled and treated. Among these patients, 22 with HER2-positive disease comprised the primary efficacy population and had a confirmed ORR of 36.4% (90% CI, 19.6 to 56.1; P = .01), meeting the primary end point. Eight with HER2-low disease comprised the exploratory population and had a confirmed ORR of 12.5%. The most common ≥grade 3 treatment-related adverse events were anemia (53.1%) and neutropenia (31.3%). Eight patients (25.0%) had interstitial lung disease (ILD), including two grade 5 events. CONCLUSION: T-DXd showed promising activity in patients with HER2-positive BTC and a signal of efficacy in patients with HER2-low BTC. Although the safety profile was generally manageable, ILD requires careful monitoring and early intervention. - 当院における切除不能胆道癌に対するゲムシタビン+シスプラチン+デュルバルマブ療法の使用経験
横山 達也; 川本 泰之; 原田 一顕; 中村 赳晶; 石田 浩一; 金子 志帆; 結城 敏志; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 135回・129回, 47, 47, 日本消化器病学会-北海道支部, 2024年08月
日本語 - Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors.
Tadayoshi Hashimoto; Yoshiaki Nakamura; Yoshito Komatsu; Satoshi Yuki; Naoki Takahashi; Naohiro Okano; Hidekazu Hirano; Koushiro Ohtsubo; Takashi Ohta; Eiji Oki; Tomohiro Nishina; Hisateru Yasui; Hisato Kawakami; Taito Esaki; Nozomu Machida; Ayako Doi; Shogen Boku; Toshihiro Kudo; Yoshiyuki Yamamoto; Akiyoshi Kanazawa; Tadamichi Denda; Masahiro Goto; Naoko Iida; Hiroshi Ozaki; Taro Shibuki; Mitsuho Imai; Takao Fujisawa; Hideaki Bando; Yoichi Naito; Takayuki Yoshino
BJC reports, 2, 1, 54, 54, 2024年07月25日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: While advanced gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs), acquired resistance from specific mutations in KIT or PDGFRA frequently occurs. We aimed to assess the utility of circulating tumor DNA (ctDNA) as a modality of therapeutic decision-making in advanced GIST. METHODS: We conducted a pooled analysis of SCRUM-Japan studies for advanced GIST patients. We compared patient characteristics analyzed with tissue and blood samples, assessed gene alteration profiles, and evaluated prognostic implications from ctDNA status. RESULTS: In 133 patients, tissue and blood samples were analyzed for 89 and 44 patients, respectively. ctDNA was detected in 72.7% of cases; no prior treatment or progressive disease was significantly associated with ctDNA-positivity. ctDNA-positive patients had significantly shorter progression-free survival compared with ctDNA-negative patients (hazard ratio = 3.92; P = 0.007). ctDNA genotyping revealed a complex landscape of gene alterations, characterized by multi-exonic mutations in KIT, compared with tissue-based analysis. Patients who received TKIs matched to the identified KIT mutation in ctDNA demonstrated significantly longer PFS than those with unmatched treatment (median, 8.23 vs. 2.43 months; P < 0.001). CONCLUSIONS: ctDNA-based analysis facilitates assessment of disease status and genomic profiles, thus potentially assisting in identifying optimal therapeutic strategies for advanced GIST patients. - Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.
Hiroki Osumi; Eiji Shinozaki; Yoshiaki Nakamura; Taito Esaki; Hisateru Yasui; Hiroya Taniguchi; Hironaga Satake; Yu Sunakawa; Yoshito Komatsu; Yoshinori Kagawa; Tadamichi Denda; Manabu Shiozawa; Taroh Satoh; Tomohiro Nishina; Masahiro Goto; Naoki Takahashi; Takeshi Kato; Hideaki Bando; Kensei Yamaguchi; Takayuki Yoshino
Nature communications, 15, 1, 5885, 5885, 2024年07月13日, [国際誌]
英語, 研究論文(学術雑誌), "NeoRAS WT" refers to the loss of RAS mutations (MTs) following first-line treatment in metastatic colorectal cancer (mCRC). We evaluate the incidence and clinicopathological characteristics of NeoRAS WT mCRC using next-generation sequencing of plasma circulating tumor DNA. Patients with mCRC enrolled in the GOZILA study initially diagnosed with tissue RAS MT mCRC and received subsequent systemic therapy are eligible. NeoRAS WT is defined as the absence of detectable RAS MT in plasma and assessed in all eligible patients (Group A) and in a subgroup with at least one somatic alteration detected in plasma (Group B). Overall, 478 patients are included. NeoRAS WT prevalence is 19.0% (91/478) in Group A and 9.8% (42/429) in Group B. Absence of liver or lymph node metastasis and tissue RAS MTs other than KRAS exon 2 MTs are significantly associated with NeoRAS WT emergence. Overall, 1/6 and 2/6 patients with NeoRAS WT treated with anti-EGFR monoclonal antibodies (mAbs) show partial response and stable disease for ≥6 months, respectively. NeoRAS WT mCRC is observed at a meaningful prevalence, and anti-EGFR mAb-based therapy may be effective. - HGCSG1803 進行膵癌オキサリプラチン・イリノテカン・S-1(OX-IRIS療法)の第II相試験
川本 泰之; 中野 真太郎; 澤田 憲太郎; 宮城島 拓人; 曽我部 進; 陳 豫; 佐藤 温; 太宰 昌佳; 伊藤 憲; 結城 敏志; 横田 勲; 坂本 直哉; 小松 嘉人
膵臓, 39, 3, A463, A463, (一社)日本膵臓学会, 2024年07月
日本語 - QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC.
Hideaki Bando; Daisuke Kotani; Hironaga Satake; Tetsuya Hamaguchi; Manabu Shiozawa; Masahito Kotaka; Toshiki Masuishi; Hisateru Yasui; Yoshinori Kagawa; Yoshito Komatsu; Eiji Oki; Yoshiyuki Yamamoto; Hisato Kawakami; Toshihiro Misumi; Hiroya Taniguchi; Kentaro Yamazaki; Kei Muro; Takayuki Yoshino; Takeshi Kato; Akihito Tsuji
Med (New York, N.Y.), 2024年06月14日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: The QUATTRO-II trial examined the efficacy and safety of capecitabine+oxaliplatin+irinotecan (CAPOXIRI)+bevacizumab (BEV) vs. 5-fluorouracil+folinic acid+oxaliplatin+irinotecan (FOLFOXIRI)+BEV in metastatic colorectal cancer (mCRC). METHODS: In this phase II study (ClinicalTrials.gov: NCT04097444; jRCTs041190072), patients were randomized (1:1) to FOLFOXIRI+BEV or CAPOXIRI+BEV. The induction treatment in the FOLFOXIRI+BEV/CAPOXIRI+BEV arms was continued for 8/6 cycles (maximum 12/8 cycles if feasible), and the maintenance treatment was 5-fluorouracil/leucovorin+BEV or capecitabine+BEV at the investigators' discretion. The primary endpoint was progression-free survival (PFS), with the two arms deemed equivalent if the hazard ratio (HR) of the point estimate was 0.80 < HR < 1.25. Secondary endpoints were overall response rate (ORR), overall survival (OS), incidence of adverse events (AEs), and patient-reported outcomes. FINDINGS: Overall, 51 and 52 patients were randomized to FOLFOXIRI+BEV and CAPOXIRI+BEV, respectively. The study met its primary endpoint; PFS at median follow-up of 23.7 months was 10.6 months (95% confidence interval [CI], 7.7-13.3) in the FOLFOXIRI+BEV arm vs. 10.9 months (95% CI, 9.3-14.3) in the CAPOXIRI+BEV arm (HR 1.114 [0.80 < HR < 1.25], p = 0.654). In the FOLFOXIRI+BEV vs. CAPOXIRI+BEV arms, the 2-year OS rate (95% CI) was 65.5% (49.5%-77.6%) vs. 74.3% (59.8%-84.2%), and the ORR (95% CI) was 76.5% (62.5%-87.2%) vs. 84.6% (71.9%-93.1%). Major (grade ≥3) AEs in the FOLFOXIRI+BEV vs. CAPOXIRI+BEV arms were neutropenia (68.6% vs. 40.4%), febrile neutropenia (9.8% vs. 11.5%), diarrhea (7.8% vs. 17.3%), and appetite loss (7.8% vs. 17.3%). CONCLUSION: CAPOXIRI+BEV was well tolerated with reduced hematological toxicity and efficacy comparable to those of FOLFOXIRI+BEV, providing a potentially convenient first-line treatment alternative to FOLFOXIRI+BEV in patients with mCRC. FUNDING: Chugai Pharmaceutical Co., Ltd. - English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology.
Seiichi Hirota; Ukihide Tateishi; Yuji Nakamoto; Hidetaka Yamamoto; Shinji Sakurai; Hirotoshi Kikuchi; Tatsuo Kanda; Yukinori Kurokawa; Haruhiko Cho; Toshirou Nishida; Akira Sawaki; Masato Ozaka; Yoshito Komatsu; Yoichi Naito; Yoshitaka Honma; Fumiaki Takahashi; Hironobu Hashimoto; Midori Udo; Minako Araki; Sumito Nishidate
International journal of clinical oncology, 29, 6, 647, 680, 2024年06月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), The Japan Society of Clinical Oncology Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) have been published in accordance with the Minds Manual for Guideline Development 2014 and 2017. A specialized team independent of the working group for the revision performed a systematic review. Since GIST is a rare type of tumor, clinical evidence is not sufficient to answer several clinical and background questions. Thus, in these guidelines, we considered that consensus among the experts who manage GIST, the balance between benefits and harms, patients' wishes, medical economic perspective, etc. are important considerations in addition to the evidence. Although guidelines for the treatment of GIST have also been published by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), there are some differences between the treatments proposed in those guidelines and the treatments in the present guidelines because of the differences in health insurance systems among countries. - ナノリポソーマルイリノテカンとレボホリナートの並列投与における有効性、安全性の評価
坂本 達彦; 齋藤 佳敬; 渡辺 拓也; 内山 数貴; 武隈 洋; 小松 嘉人; 菅原 満
日本臨床腫瘍薬学会雑誌, 36, 191, 191, (一社)日本臨床腫瘍薬学会, 2024年05月
日本語 - Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.
Yasuyuki Kawamoto; Chigusa Morizane; Yoshito Komatsu; Shunsuke Kondo; Makoto Ueno; Satoshi Kobayashi; Masayuki Furukawa; Lingaku Lee; Taroh Satoh; Daisuke Sakai; Masafumi Ikeda; Hiroshi Imaoka; Arisa Miura; Yutaka Hatanaka; Isao Yokota; Yoshiaki Nakamura; Takayuki Yoshino
Future oncology (London, England), 1, 7, 2024年04月17日, [国際誌]
英語, 研究論文(学術雑誌), Due to the widespread use of cancer genetic testing in gastrointestinal cancer, the BRCA1/2 genetic mutation has been identified in biliary tract cancer as well as pancreatic cancer. Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor, and PARP inhibitors exert their cytotoxicity against cancer cells in the context of homologous recombination deficiency, such as BRCA mutations, via the mechanism of synthetic lethality. The aim of this phase II NIR-B trial is to evaluate the efficacy and safety of niraparib for patients with unresectable advanced or recurrent biliary tract cancer, pancreatic cancer or other gastrointestinal cancers with germline or somatic BRCA1/2 mutations revealed by genetic testing. The primary end point is an investigator-assessed objective response rate in each cohort.Clinical Trial Registration: jRCT2011200023 (ClinicalTrials.gov). - Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program.
Daisuke Kotani; Atsuo Takashima; Takeshi Kato; Taroh Satoh; Toshiki Masuishi; Yoshito Komatsu; Manabu Shiozawa; Taito Esaki; Naoki Izawa; Shinji Takeuchi; Hideaki Bando; Satoru Iwasa; Hiroko Hasegawa; Toshifumi Yamaguchi; Hiroya Taniguchi; Yasunori Ushida; Toshiya Oizaki; Chiaki Inoue; Takayuki Yoshino
Clinical colorectal cancer, 2024年03月09日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: The phase 3 BEACON CRC study demonstrated the survival benefits of encorafenib and cetuximab, with or without binimetinib (the BEACON triplet or doublet regimen), for BRAFV600E-mutant metastatic colorectal cancer (mCRC). This expanded access program (EAP) and subsequent follow-up study assessed the efficacy and safety of the BEACON triplet regimen in Japanese patients with BRAFV600E-mutant mCRC. MATERIALS AND METHODS: The EAP was an open-label, single-arm study including Japanese patients with BRAFV600E-mutant mCRC whose disease progressed after 1 to 2 prior regimens. The patients received the BEACON triplet regimen with 28-day cycles. The subsequent follow-up study assessed the survival outcomes following EAP completion. Safety was assessed only during the EAP. RESULTS: Among the 86 enrolled patients, 81 received the BEACON triplet regimen. The objective response rate and median progression-free survival were 27.6% (95% confidence interval [CI], 18.0%-39.1%) and 5.26 (95% CI, 4.14-5.52) months, respectively. Grade 3 to 4 adverse events and treatment-related adverse events occurred in 43.2% and 28.4% of patients, respectively. No new safety signals were observed during the EAP. Among 58 patients with confirmed survival at EAP completion, 57 were included in the follow-up study. With a median observation period of 9.17 months through the EAP and follow-up study, the median overall survival was 10.38 (95% CI, 9.00-16.16) months. CONCLUSION: The efficacy and safety of the BEACON triplet regimen in Japanese patients with BRAFV600E-mutant mCRC were consistent with those reported in the BEACON CRC trial, supporting its use as a standard treatment for pretreated patients with BRAFV600E-mutant mCRC. - Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms.
Takuya Watanabe; Yoshitaka Saito; Yoh Takekuma; Yasushi Shimizu; Ichiro Kinoshita; Yoshito Komatsu; Mitsuru Sugawara
International journal of clinical pharmacology and therapeutics, 2024年03月03日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: Irinotecan (IRI) is an anticancer drug that is frequently used to treat colorectal, gastric, and pancreatic cancers. Its side effects include cholinergic symptoms, such as diarrhea, abdominal pain, nausea, and hyperhidrosis. Anticholinergic medicines are frequently used for treatment or prophylaxis; however, the risk factors for the failure of a single prophylactic anticholinergic administration remain unclear. Moreover, an appropriate anticholinergic drug for prophylaxis remains unknown. Thus, we aimed to identify the risk factors associated with the failure of a single prophylactic dose of anticholinergic drugs for IRI-induced cholinergic symptoms and to evaluate the usefulness of multiple prophylactic doses of anticholinergic drugs. MATERIALS AND METHODS: Patients who underwent IRI treatment for colorectal, gastric, or pancreatic cancer and received prophylactic anticholinergic drugs for IRI-induced cholinergic symptoms (n = 135) were retrospectively evaluated. Univariate and multivariate logistic regression analyses were performed to identify the risk factors for failure of a single prophylactic dose of anticholinergic drugs. We also evaluated the efficacy of multiple prophylactic anticholinergic drug administration. RESULTS: Based on univariate and multivariate analyses, colorectal cancer, female sex, and prophylactic use of scopolamine butyl bromide were identified as risk factors for failure of a single prophylactic dose of anticholinergic drugs. The efficacy of multiple prophylactic doses was confirmed to be 95% of the patients who had a single prophylactic failure due to temporary effect but symptom appearance after a certain period of time (wearing-off). CONCLUSION: We determined that colorectal cancer, female sex, and prophylactic use of scopolamine butyl bromide were risk factors associated with the failure of a single prophylactic dose of anticholinergic drugs, and that multiple prophylactic doses for wearing-off can be a promising method. - Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Scientific reports, 14, 1, 5153, 5153, 2024年03月02日, [国際誌]
英語, 研究論文(学術雑誌), Regorafenib is the first multikinase inhibitor for treating metastatic colorectal cancer (mCRC). Proteinuria is a frequently encountered adverse effect, regardless of prior administration of vascular endothelial growth factor inhibitors. Herein, we aimed to assess the impact of baseline preexisting proteinuria on regorafenib-induced problematic proteinuria during real-world mCRC therapy. Patients with mCRC receiving regorafenib (n = 100) were retrospectively assessed and divided into control and preexisting proteinuria (baseline grade of 1-2) groups. The primary endpoint was the development of grade ≥ 2 (grade ≥ 3 in case of baseline grade 2 patients) proteinuria. Propensity score-matching was performed to confirm the robustness of primary analyses. Defined proteinuria occurred in 30.7 and 57.9% of patients in the control and preexisting proteinuria groups, respectively, with significant differences in the all-patient population (P = 0.01). The preexisting proteinuria group exhibited significant defined proteinuria development within 7 days of regorafenib initiation, grade ≥ 3 symptoms, and treatment suspension owing to proteinuria. Similar results were obtained in the propensity score-matched population. According to multivariate logistic regression analysis, baseline proteinuria was a singular risk factor for defined proteinuria development (adjusted odds ratio; 3.76, 95% confidence interval; 1.45-9.75, P = 0.007). Collectively, our study revealed that patients with preexisting proteinuria develop regorafenib-induced proteinuria degradation. - Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
Kohei Shitara; Kei Muro; Jun Watanabe; Kentaro Yamazaki; Hisatsugu Ohori; Manabu Shiozawa; Atsuo Takashima; Mitsuru Yokota; Akitaka Makiyama; Naoya Akazawa; Hitoshi Ojima; Yasuhiro Yuasa; Keisuke Miwa; Hirofumi Yasui; Eiji Oki; Takeo Sato; Takeshi Naitoh; Yoshito Komatsu; Takeshi Kato; Ikuo Mori; Kazunori Yamanaka; Masamitsu Hihara; Junpei Soeda; Toshihiro Misumi; Kouji Yamamoto; Riu Yamashita; Kiwamu Akagi; Atsushi Ochiai; Hiroyuki Uetake; Katsuya Tsuchihara; Takayuki Yoshino
Nature medicine, 30, 3, 730, 739, 2024年03月, [国際誌]
英語, 研究論文(学術雑誌), Certain genetic alterations and right-sided primary tumor location are associated with resistance to anti-epidermal growth factor (EGFR) treatment in metastatic colorectal cancer (mCRC). The phase 3 PARADIGM trial (n = 802) demonstrated longer overall survival with first-line anti-EGFR (panitumumab) versus antivascular endothelial growth factor (bevacizumab) plus modified FOLFOX6 in patients with RAS wild-type mCRC with left-sided primary tumors. This prespecified exploratory biomarker analysis of PARADIGM (n = 733) evaluated the association between circulating tumor DNA (ctDNA) gene alterations and efficacy outcomes, focusing on a broad panel of gene alterations associated with resistance to EGFR inhibition, including KRAS, NRAS, PTEN and extracellular domain EGFR mutations, HER2 and MET amplifications, and ALK, RET and NTRK1 fusions. Overall survival was prolonged with panitumumab plus modified FOLFOX6 versus bevacizumab plus modified FOLFOX6 in patients with ctDNA that lacked gene alterations in the panel (that is, negative hyperselected; median in the overall population: 40.7 versus 34.4 months; hazard ratio, 0.76; 95% confidence interval, 0.62-0.92) but was similar or inferior with panitumumab in patients with ctDNA that contained any gene alteration in the panel (19.2 versus 22.2 months; hazard ratio, 1.13; 95% confidence interval, 0.83-1.53), regardless of tumor sidedness. Negative hyperselection using ctDNA may guide optimal treatment selection in patients with mCRC. ClinicalTrials.gov registrations: NCT02394834 and NCT02394795 . - 消化器癌患者における鉄欠乏性貧血に対するカルボキシマルトース第二鉄の有用性の検討
川本 泰之; 原田 一顕; 金子 志帆; 石田 浩一; 中村 赳晶; 結城 敏志; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 134回・128回, 75, 75, 日本消化器病学会-北海道支部, 2024年03月
日本語 - 切除不能進行再発大腸癌の治療戦略 転移性結腸直腸癌におけるレゴラフェニブ減量開始の有用性を検討する多施設共同後方視的解析
結城 敏志; 原田 一顕; 小松 嘉人; 坂本 直哉; 川上 武志; 山崎 健太郎; 舛石 俊樹; 谷口 浩也; 胡 慶江; 沖 英次
日本消化器病学会雑誌, 121, 臨増総会, A73, A73, (一財)日本消化器病学会, 2024年03月
日本語 - VOLTAGE-2: multicenter phase II study of nivolumab monotherapy in patients with mismatch repair-deficient resectable locally advanced rectal cancer
H. Bando; Y. Tsukada; S. Kumagai; Y. Miyashita; A. Taketomi; S. Yuki; Y. Komatsu; T. Akiyoshi; E. Shinozaki; Y. Kanemitsu; A. Takashima; M. Shiozawa; A. Shiomi; K. Yamazaki; N. Matsuhashi; H. Hasegawa; T. Kato; E. Oki; M. Fukui; M. Wakabayashi; N. Fuse; H. Nishikawa; M. Ito; T. Yoshino
ESMO Gastrointestinal Oncology, 3, 100031, 100031, Elsevier BV, 2024年03月
研究論文(学術雑誌) - CA125 Kinetics as a Potential Biomarker for Peritoneal Metastasis Progression following Taxane-Plus-Ramucirumab Administration in Patients with Advanced Gastric Cancer
Akira Ueda; Satoshi Yuki; Takayuki Ando; Ayumu Hosokawa; Naokatsu Nakada; Yosuke Kito; Iori Motoo; Ken Ito; Miho Sakumura; Yurika Nakayama; Yuko Ueda; Shinya Kajiura; Koji Nakashima; Kazuaki Harada; Yasuyuki Kawamoto; Yoshito Komatsu; Ichiro Yasuda
Cancers, 16, 5, 2024年03月
研究論文(学術雑誌) - CA125 Kinetics as a Potential Biomarker for Peritoneal Metastasis Progression following Taxane-Plus-Ramucirumab Administration in Patients with Advanced Gastric Cancer.
Akira Ueda; Satoshi Yuki; Takayuki Ando; Ayumu Hosokawa; Naokatsu Nakada; Yosuke Kito; Iori Motoo; Ken Ito; Miho Sakumura; Yurika Nakayama; Yuko Ueda; Shinya Kajiura; Koji Nakashima; Kazuaki Harada; Yasuyuki Kawamoto; Yoshito Komatsu; Ichiro Yasuda
Cancers, 16, 5, 2024年02月22日, [国際誌]
英語, 研究論文(学術雑誌), Currently, no established marker exists for predicting peritoneal metastasis progression during chemotherapy, although they are major interruptive factors in sequential chemotherapy in patients with advanced gastric cancer (AGC). This multicenter retrospective study was conducted from June 2015 to July 2019, analyzing 73 patients with AGC who underwent taxane-plus-ramucirumab (TAX/RAM) therapy and had their serum carbohydrate antigen 125 (CA125) concentrations measured. Of 31 patients with elevated CA125 levels above a cutoff of 35 U/mL, 25 (80.6%) had peritoneal metastasis. The CA125 concentrations before TAX/RAM treatment were associated with ascites burden. The overall survival was significantly shorter in the CA125-elevated group. CA125 kinetics, measured at a median of 28 days after chemotherapy, were associated with the ascites response (complete or partial response: -1.86%/day; stable disease: 0.28%/day; progressive disease: 2.33%/day). Progression-free survival in the CA125-increased group, defined by an increase of 0.0067%/day using receiver operating characteristic curve analysis, was significantly poorer among patients with peritoneal metastases. In conclusion, this study highlights that CA125 kinetics can serve as an early predictor for the progression of peritoneal metastasis during TAX/RAM treatment. - Risk Factor Analysis for Anti-epidermal Growth Factor Receptor Monoclonal Antibody-induced Problematic Skin Toxicities in Patients With Liver Metastatic Colorectal Cancer.
Yoshitaka Saito; Kazuki Uchiyama; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
In vivo (Athens, Greece), 38, 5, 2390, 2398, 2024年, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND/AIM: We previously reported that patients with metastatic colorectal cancer (mCRC) and baseline liver metastasis are at a higher risk of developing grade ≥2 overall skin toxicities when treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibody. This study aimed to identify additional factors associated with skin toxicities induced by anti-EGFR treatment in patients with liver metastatic CRC. PATIENTS AND METHODS: Patients with liver metastatic CRC who initially received anti-EGFR monoclonal antibody-containing treatment (n=77) were retrospectively assessed. The primary endpoint was to identify the factor(s) responsible for the development of grade ≥2 overall skin toxicities. Additionally, factors for grade ≥2 rash and paronychia were evaluated. RESULTS: The incidence of grade ≥2 overall skin symptoms, rash, and paronychia was 62.3%, 31.2%, and 28.6%, respectively. Multivariate Cox proportional hazard regression analyses revealed that age <65 years and anemia were independent baseline risk factors for grade ≥2 overall skin toxicities (adjusted hazard ratio 2.09, 95% confidence interval=1.10-3.97, p=0.02 for age; 2.36, 1.20-4.61, p=0.01 for anemia). In contrast, combination prophylaxis using systemic minocycline and corticosteroid ointment was a preventive factor (0.47, 0.25-0.88, p=0.02). Males and age <65 years were baseline risk factors for grade ≥2 rash, and combination prophylaxis was identified as a preventive factor. No factors were identified for paronychia. CONCLUSION: Age <65 years and anemia were identified as independent baseline risk factors. Additionally, combination prophylaxis was found to be a preventive factor against anti-EGFR monoclonal antibody-induced grade ≥2 overall skin toxicities in patients with liver metastatic CRC. - Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatment.
Yoshitaka Saito; Kazuki Uchiyama; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 32, 1, 8, 8, 2023年12月06日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Anti-epidermal growth factor receptor (EGFR) antibodies often cause skin toxicities. Preemptive skin treatments using systemic antibiotics with or without topical steroid are reportedly effective although the most suitable method remains unclear. This study aimed to determine whether combination prophylaxis using systemic minocycline and topical steroid is superior to minocycline alone in a real-world metastatic colorectal cancer (mCRC) treatment. METHODS: Patients with mCRC (n = 87) who received anti-EGFR monoclonal antibodies were retrospectively assessed. The primary objective was to compare the incidence of grade ≥ 2 overall skin toxicities during all treatment periods between the control group receiving prophylactic minocycline 100 mg/day, and the combination prophylaxis group receiving minocycline 100 mg/day + topical steroid. The incidence of each skin symptom was also evaluated. RESULTS: The incidence of grade ≥ 2 overall skin toxicities was 63.6% in the control and 56.9% in the combination groups, with no significant difference (P = 0.63). Similarly, the incidence of grade ≥ 2 dry skin, fissures, paronychia, and pruritus did not significantly differ. In addition, incidence of all-grade skin toxicities was not different. However, the incidence of grade ≥ 2 papulopustular rashes was significantly lower in the combination group (23.1% vs. 50.0%, P = 0.03). Propensity score-matched analysis supported these results. Multivariate logistic regression analysis showed no significant association between combination prophylaxis and grade ≥ 2 overall skin toxicities, but it did show a reduction in grade ≥ 2 papulopustular rashes. CONCLUSION: Adding topical steroids to systemic minocycline did not mitigate grade ≥ 2 overall skin toxicities induced by anti-EGFR antibodies; however, it significantly improved papulopustular rashes. - Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis
M. Imai; Y. Nakamura; T. Denda; Y. Komatsu; S. Yuki; T. Nishina; Y. Hamamoto; H. Hara; T. Esaki; H. Kawakami; K. Kato; T. Satoh; N. Okano; Y. Sunakawa; H. Taniguchi; K. Yamaguchi; T. Yamada; I. Miki; M. Wakabayashi; T. Kuwata; K. Shitara; T. Yoshino
ESMO Gastrointestinal Oncology, 2, 100008, 100008, Elsevier BV, 2023年12月
研究論文(学術雑誌) - 胸部食道がん化学放射線療法における重症放射線食道炎に関する後方視的研究
原田 一顕; 中村 赳晶; 渡辺 亮介; 山村 貴洋; 結城 敏志; 坂本 直哉; 川本 泰之; 小松 嘉人; 打浪 雄介; 田口 大志; 加藤 徳雄; 青山 英史
北海道医学雑誌, 98, 2, 139, 140, 北海道医学会, 2023年11月
日本語 - Re-appraisal of the universal definition of tumor rupture among patients with high-risk gastrointestinal stromal tumors.
Naoto Gotohda; Toshirou Nishida; Shinsuke Sato; Masato Ozaka; Yujiro Nakahara; Yoshito Komatsu; Masato Kondo; Haruhiko Cho; Yukinori Kurokawa; Yuko Kitagawa
Annals of gastroenterological surgery, 7, 6, 1021, 1031, 2023年11月, [国内誌]
英語, 研究論文(学術雑誌), AIM: Tumor rupture has been indicated as a risk factor for recurrence of gastrointestinal stromal tumors (GISTs). The universal definition of tumor rupture was proposed. This study evaluated whether the universal definition was more accurate in identification of GISTs with high recurrent risk than subjective judgment. METHODS: The study included 507 patients with high-risk GISTs who underwent complete resection between December 2012 and December 2015. We conducted a questionnaire survey in participating institutes to re-diagnose tumor rupture based on the universal definition according to their surgical and pathological findings. We compared the clinical outcomes of tumor rupture based on the definition to those based on the surgeon's judgment and clarified the clinical importance of the rupture. RESULTS: Sixty-four patients were initially registered to have tumor rupture by surgeon's judgment, and it became 90 patients who had tumor rupture after reevaluation. Although there were significant differences in recurrence-free survival (RFS) between no rupture and rupture for both initial registration and reevaluation (p = 0.002, <0.001, respectively), a significant difference in overall survival was only observed after reevaluation (p = 0.011). Tumor rupture was significantly associated with large tumor size, mixed cell type in histology, R1 resection, frequent adjuvant therapy and recurrence, but not with location, mitosis, and genotype. Adjuvant therapy more than 3 years improved RFS of patients with tumor rupture. CONCLUSION: This study suggested that tumor rupture based on the universal definition more accurately identified GISTs with poor prognostic outcomes than the subjective judgment. - 胸部食道がん化学放射線療法における重症放射線食道炎に関する後方視的研究
原田 一顕; 中村 赳晶; 渡辺 亮介; 山村 貴洋; 結城 敏志; 坂本 直哉; 川本 泰之; 小松 嘉人; 打浪 雄介; 田口 大志; 加藤 徳雄; 青山 英史
北海道医学雑誌, 98, 2, 139, 140, 北海道医学会, 2023年11月
日本語 - Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas.
Bennett A Caughey; Kumiko Umemoto; Michelle F Green; Masafumi Ikeda; Melissa E Lowe; Makoto Ueno; Donna Niedzwiecki; Hiroya Taniguchi; Daniel J Walden; Yoshito Komatsu; Rachel D'Anna; Taito Esaki; Tadamichi Denda; Michael B Datto; Hideaki Bando; Tanios Bekaii-Saab; Takayuki Yoshino; John H Strickler; Yoshiaki Nakamura
Journal of gastrointestinal oncology, 14, 5, 2083, 2096, 2023年10月31日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Evaluation for activating mutations in KRAS, NRAS, and BRAF in colorectal cancer (CRC) and in KRAS in pancreatic ductal adenocarcinoma (PDAC) is essential for clinical care. Plasma cell-free DNA (cfDNA) next-generation sequencing (NGS) allows convenient assessment of a tumor's molecular profile, however low tumor DNA shedding limits sensitivity. We investigated mutant allele frequency (MAF) of other oncogenic dominant genes to identify a threshold for accurate detection of KRAS, NRAS, and BRAF (RAS/RAF) mutations in cfDNA. METHODS: Molecular and clinical data were obtained from the Duke Molecular Registry of Tumors and the SCRUM-Japan GOZILA study. Patients with CRC or PDAC and a KRAS, NRAS, or BRAF activating single nucleotide variant (SNV) present on tissue NGS and with available cfDNA assays were included. Recursive partitioning and Wilcoxon-rank statistics methods identified potential cut-points for discriminative MAF values. RESULTS: One hundred and thirty-five CRC and 30 PDAC cases with 198 total cfDNA assays met criteria. Greatest non-RAS/RAF dominant gene MAF of 0.34% provided maximum discrimination for predicting RAS/RAF SNV detection. Sensitivity for RAS/RAF SNVs increased with dominant gene MAF, with MAF ≥1% predicting sensitivity >98%, MAF between 0.34 and 1% predicting sensitivity of 84.0%, and MAF £0.34% predicting sensitivity of 50%. For 43 cfDNA assays that did not detect RAS/RAF SNVs, 18 assays detected 34 other oncogenic variants, of which 80.6% were not also detected on tissue. CONCLUSIONS: Non-RAS/RAF dominant oncogenic mutation MAF ≥1% on cfDNA NGS predicts high sensitivity to detect RAS/RAF oncogenic SNVs in CRC and PDAC. MAF £0.34% indicates an assay may not reliably detect RAS/RAF SNVs, despite detection on tissue testing. Most variants from assays that did not detect RAS/RAF had MAF <1% and were not detected on tissue, suggesting potential confounding. These data suggest a practical approach to determining cfDNA assay adequacy, with implications for guiding clinical decisions in CRC and PDAC. - UGT1A1遺伝子型がQUATTRO-II試験の有効性と安全性に及ぼす影響
濱口 哲弥; 小谷 大輔; 塩澤 学; 坂東 英明; 佐竹 悠良; 沖 英次; 小松 嘉人; 谷口 浩也; 室 圭; 小高 雅人; 山崎 健太郎; 三角 俊裕; 吉野 孝之; 加藤 健志; 辻 晃仁
日本癌治療学会学術集会抄録集, 61回, FR1, 6, (一社)日本癌治療学会, 2023年10月
英語 - 進行大腸癌に対するCAPOXIRI+Bev療法とFOLFOXIRI+Bev療法のランダム化第II相臨床研究
安井 久晃; 板東 英明; 佐竹 悠良; 小谷 大輔; 濱口 哲弥; 小高 雅人; 谷口 浩也; 室 圭; 小松 嘉人; 沖 英次; 山崎 健太郎; 三角 俊裕; 吉野 孝之; 加藤 健志; 辻 晃仁
日本癌治療学会学術集会抄録集, 61回, EN1, 3, (一社)日本癌治療学会, 2023年10月
英語 - 転移性大腸癌におけるレゴラフェニブの開始用量が治療成績に対する影響
胡 慶江; 原田 一顕; 川上 武志; 緒方 貴次; 伏木 邦博; 谷口 浩也; 室 圭; 安藤 幸滋; 南原 翔; 川本 泰之; 小松 嘉人; 沖 英次; 舛石 俊樹; 山崎 健太郎; 結城 敏志
日本癌治療学会学術集会抄録集, 61回, O15, 5, (一社)日本癌治療学会, 2023年10月
英語 - 当科におけるがん悪液質患者へのアナモレリン塩酸塩の使用経験
石田 浩一; 川本 泰之; 金子 志帆; 中村 赳晶; 原田 一顕; 結城 敏志; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 133回・127回, 59, 59, 日本消化器病学会-北海道支部, 2023年09月
日本語 - Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment.
Yoshitaka Saito; Kazuki Uchiyama; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 31, 8, 504, 504, 2023年08月02日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies are effective in treating RAS wild-type metastatic colorectal cancer (mCRC). However, their administration induces skin toxicity, markedly reducing patients' quality of life. This study is aimed at identifying the risk factors associated with anti-EGFR monoclonal antibody-induced skin toxicities. METHODS: Patients with mCRC (n = 116) who received anti-EGFR monoclonal antibody treatment were retrospectively evaluated. Primary endpoint was evaluation of the risk factors for grade ≥ 2 overall skin toxicities during all the treatment periods. Furthermore, factors associated with each grade ≥ 2 skin symptoms were assessed. RESULTS: Incidence of total grade ≥ 2 skin toxicity symptoms was 61.2%, and those of grade ≥ 2 rash, dry skin, fissures, and paronychia were 34.5%, 25.9%, 20.7%, and 25.0%, respectively. Multivariate logistic regression analyses revealed that liver metastasis was an independent risk factor for overall grade ≥ 2 skin toxicities (adjusted odds ratio [OR], 2.88; 95% confidence interval [CI], 1.22-6.78; P = 0.02) and prophylactic administration of antibiotics as a preventive factor (OR 0.10; 95%CI 0.01-0.91; P = 0.04). For grade ≥ 2 rash, prophylactic use of systemic antibiotics and topical steroid ointment was a preventive factor (OR 0.37; 95%CI 0.16-0.89; P = 0.03). Moreover, liver metastasis (OR 8.37; 95%CI 1.98-35.47; P = 0.004) and prophylactic administration of antibiotics (OR 0.15; 95%CI 0.03-0.76; P = 0.02) were significantly associated with grade ≥ 2 paronychia. CONCLUSION: Liver metastasis was suggested to be a risk factor for the incidence of overall grade ≥ 2 skin toxicities; moreover, preemptive systemic antibiotic administration drastically decreased this risk during all periods of anti-EGFR treatment for mCRC. - 実臨床における切除不能進行・再発胆道癌に対するGEM+CDDP+S-1療法(GCS)と三剤逐次投与のの治療成績に関する検討
川本 泰之; 原田 一顕; 坂本 直哉; 中村 赳晶; 金子 志帆; 石田 浩一; 結城 敏志; 桑谷 将城; 小松 嘉人
胆道, 37, 3, 597, 597, (一社)日本胆道学会, 2023年08月
日本語 - 腫瘍破裂GISTにおける臨床・病理組織学的特徴の検討
後藤田 直人; 西田 俊朗; 佐藤 真輔; 尾阪 将人; 中原 裕次郎; 小松 嘉人; 近藤 正人; 長 晴彦; 黒川 幸典; 北川 雄光
日本消化器外科学会総会, 78回, P015, 1, (一社)日本消化器外科学会, 2023年07月
日本語 - Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment.
Hiroshi Imaoka; Masafumi Ikeda; Kumiko Umemoto; Yu Sunakawa; Makoto Ueno; Hideki Ueno; Masato Ozaka; Takamichi Kuwahara; Naohiro Okano; Masashi Kanai; Terumasa Hisano; Yuko Suzuki; Akinori Asagi; Kazuhiko Shioji; Akiko Todaka; Kunihiro Tsuji; Kenji Ikezawa; Ikuya Miki; Yoshito Komatsu; Noriyuki Akutsu; Tatsuya Yamashita; Hiroyuki Okuyama; Junji Furuse; Hiroaki Nagano
Japanese journal of clinical oncology, 2023年06月15日, [国際誌]
英語, 研究論文(学術雑誌), Undifferentiated carcinoma (UC) of the pancreas is a rare subtype of pancreatic cancer displaying no definitive direction of differentiation. UC has been reported as a highly aggressive malignant neoplasm, with a median overall survival of <1 year, except for several surgical series. On the other hand, UC tissue sometimes contains non-neoplastic osteoclast-like giant cells (OGCs), and such cases have been reported to have relatively longer survival. Thus, the World Health Organization (WHO) classification histologically distinguishes UC with OGCs (UCOGCs) from UC, and UCs were subclassified into three subtypes: anaplastic UC, sarcomatoid UC and carcinosarcoma. However, still less is known about UC due to its rarity, and such situations lead to further difficulties in treatment for UC. To date, only surgical resection can offer curative treatment for patients with UC, and no clear evidence for chemotherapy exists for them. However, a retrospective cohort study and case reports showed that relatively promising results paclitaxel-containing regimens for treatment of patients with unresectable UC. Furthermore, high programmed cell death protein 1 expression has been reported in sarcomatoid UCs and UCOGCs, and promising responses to anti-programmed death-ligand 1 therapy have been described in case reports of UCOGCs. Recent advances in chemotherapeutic agents and molecular technologies are opening up the possibilities for expanded treatments. - Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
International journal of clinical oncology, 28, 9, 1183, 1190, 2023年06月15日, [国内誌]
英語, 研究論文(学術雑誌), PURPOSE: Regorafenib is the first multikinase inhibitor used for metastatic colorectal cancer (mCRC) treatment. Reports regarding other multikinase inhibitors have suggested that the development of hypertension is associated with improved clinical benefits. We aimed to reveal the relationship between the development of severe hypertension and regorafenib efficacy in an mCRC real-world setting. METHODS: Patients with mCRC (n = 100) who received regorafenib were assessed retrospectively. The primary endpoint was a comparison of progression-free survival (PFS) between patients with and without ≥ grade 3 hypertension. The secondary endpoints were overall survival (OS), disease control rate (DCR), and adverse effects. RESULTS: Patients developing ≥ grade 3 hypertension accounted for 30%, and obtained significantly longer PFS than control patients (median PFS of 53 and 56 days, 95% confidence interval [CI] of 46-144 and 49-63 days, respectively; P = 0.04). In contrast, OS and DCR were not statistically different between the groups (P = 0.13 and P = 0.46, respectively). The incidence and severity of adverse effects were not significantly different, except for hypertension. Treatment interruption was significantly more frequent in patients with hypertension (P = 0.04). Multivariate Cox hazard analysis suggested that the development of ≥ grade 3 severe hypertension was an independent factor for improved PFS (adjusted hazard ratio 0.57, 95% CI 0.35-0.93; P = 0.02). In contrast, baseline hypoalbuminemia was associated with a worse PFS (1.85, 1.14-3.01; P = 0.01). CONCLUSION: We have revealed that patients who develop severe hypertension after regorafenib treatment for mCRC have improved PFS. Management of hypertension is important for effective treatment with less burden; therefore, further evaluation is needed. - TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer.
Shonosuke Wakayama; Kota Ouchi; Shin Takahashi; Yasuhide Yamada; Yoshito Komatsu; Ken Shimada; Tatsuro Yamaguchi; Hidekazu Shirota; Masanobu Takahashi; Chikashi Ishioka
Clinical colorectal cancer, 2023年06月07日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Neither TP53 mutation nor DNA methylation status has been established as a biomarker alone of metastatic colorectal cancer. We analyzed the association between TP53 mutation functional subtypes and genome-wide DNA methylation status (GWMS) as combined prognostic markers. METHODS: Patient clinical data were obtained from the TRICOLORE study, a randomized phase III trial. The TP53 mutations were classified into wild-type, gain-of-function (GOF) mutations, and non-gain-of-function (non-GOF) mutations. GWMS of the tumor tissues classified them into high-methylated colorectal cancer (HMCC) and low-methylated colorectal cancer (LMCC). Overall survival (OS) was compared based on these subgroups. RESULTS: Of the 209 patients, 60 (28.7%) were HMCC and 149 (71.3%) were LMCC, 35 (16.7%) were TP53 wild-type and 174 (83.3%) were TP53 mutants including 79 (45.4%) GOF mutations and 95 (54.6%) non-GOF mutations. The OS of the HMCC group was shorter than that of the LMCC group (median 25.3 vs. 40.3 months, P < .001, hazard ratio 1.87) in the total cohort. The combined subgroup analyses of GWMS and TP53 mutation subtypes showed that the HMCC/GOF group had significantly shorter OS than the HMCC/non-GOF group, the LMCC/GOF group, and the LMCC/non-GOF group (median 17.7; 35.3, 40.3, and 41.2 months, P = .007, P < .001, and P < .001, respectively), regardless of the primary tumor location. By the multivariate analysis, only HMCC (P = .009) was a poor prognostic factor in the GOF mutation group. CONCLUSIONS: TP53 GOF with HMCC is a newly identified poorest prognostic molecular subset in metastatic colorectal cancer. - Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy.
Yu Aoki; Yoshiaki Nakamura; Tadamichi Denda; Takashi Ohta; Taito Esaki; Manabu Shiozawa; Kensei Yamaguchi; Kentaro Yamazaki; Yu Sunakawa; Takeshi Kato; Naohiro Okano; Hiroya Taniguchi; Taro Sato; Eiji Oki; Tomohiro Nishina; Yoshito Komatsu; Nobuhisa Matsuhashi; Masahiro Goto; Hisateru Yasui; Koushiro Ohtsubo; Toshikazu Moriwaki; Naoki Takahashi; Yosuke Horita; Shogen Boku; Masashi Wakabayashi; Takashi Ikeno; Ryuta Mitani; Mihoko Yuasa; Takayuki Yoshino
JCO precision oncology, 7, e2200688, 2023年06月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Circulating tumor DNA (ctDNA) genotyping on the basis of next-generation sequencing (NGS) may guide targeted therapy for metastatic colorectal cancer (mCRC). However, the validity of NGS-based ctDNA genotyping for RAS/BRAF V600E mutation assessment and the efficacy of anti-EGFR and BRAF-targeted therapies on the basis of ctDNA results remains unclear. PATIENTS AND METHODS: The performance of NGS-based ctDNA genotyping for RAS/BRAF V600E mutation assessment was compared with that of a validated polymerase chain reaction-based tissue testing in patients with mCRC enrolled in the GOZILA study, a nationwide plasma genotyping study. The primary end points were concordance rate, sensitivity, and specificity. The efficacy of anti-EGFR and BRAF-targeted therapies on the basis of ctDNA were also evaluated. RESULTS: In 212 eligible patients, the concordance rate, sensitivity, and specificity were 92.9% (95% CI, 88.6 to 96.0), 88.7% (95% CI, 81.1 to 94.0), and 97.2% (95% CI, 92.0 to 99.4) for RAS and 96.2% (95% CI, 92.7 to 98.4), 88.0% (95% CI, 68.8 to 97.5), and 97.3% (95% CI, 93.9 to 99.1) for BRAF V600E, respectively. In patients with a ctDNA fraction of ≥1.0%, sensitivity rose to 97.5% (95% CI, 91.2 to 99.7) and 100% (95% CI, 80.5 to 100.0) for RAS and BRAF V600E mutations, respectively. In addition to a low ctDNA fraction, previous chemotherapy, lung and peritoneal metastases, and interval between dates of tissue and blood collection were associated with discordance. The progression-free survival of anti-EGFR therapy and BRAF-targeted treatment was 12.9 months (95% CI, 8.1 to 18.5) and 3.7 (95% CI, 1.3 to not evaluated) months, respectively, for matched patients with RAS/BRAF V600E results by ctDNA. CONCLUSION: ctDNA genotyping effectively detected RAS/BRAF mutations, especially with sufficient ctDNA shedding. Clinical outcomes support ctDNA genotyping for determining the use of anti-EGFR and BRAF-targeted therapies in patients with mCRC. - Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
Kanako Hagio; Junko Kikuchi; Kohichi Takada; Hiroki Tanabe; Minako Sugiyama; Yoshihito Ohhara; Toraji Amano; Satoshi Yuki; Yoshito Komatsu; Takahiro Osawa; Kanako C Hatanaka; Yutaka Hatanaka; Takashi Mitamura; Ichiro Yabe; Yoshihiro Matsuno; Atsushi Manabe; Akihiro Sakurai; Atsushi Ishiguro; Masato Takahashi; Hiroshi Yokouchi; Hirohito Naruse; Yusuke Mizukami; Hirotoshi Dosaka-Akita; Ichiro Kinoshita
Cancer science, 2023年05月19日, [国際誌]
英語, 研究論文(学術雑誌), Comprehensive genomic profiling (CGP) tests have been covered by public insurance in Japan for patients with advanced solid tumors who have completed or are completing standard treatments or do not have them. Therefore, genotype-matched drug candidates are often unapproved or off-label, and improving clinical trial access is critical, involving the appropriate timing of CGP tests. To address this issue, we analyzed the previous treatment data for 441 patients from an observational study on CGP tests discussed by the expert panel at Hokkaido University Hospital between August 2019 and May 2021. The median number of previous treatment lines was two; three or more lines accounted for 49%. Information on genotype-matched therapies was provided to 277 (63%). Genotype-matched clinical trials were ineligible because of an excess number of previous treatment lines or use of specific agents were found in 66 (15%) patients, with the highest proportion in breast and prostate cancers. Many patients met the exclusion criteria of one to two or more treatment lines across cancer types. In addition, previous use of specific agents was a frequent exclusion criterion for breast, prostate, colorectal, and ovarian cancers. The patients with tumor types with a low median number (two or fewer) of previous treatment lines, including most rare cancers, primary unknown cancers, and pancreatic cancers, had significantly fewer ineligible clinical trials. The earlier timing of CGP tests may improve access to genotype-matched clinical trials, with their proportion varying by cancer type. Each relevant society needs to advocate the desirable timing of CGP testing nationwide. - Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Jun Watanabe; Kei Muro; Kohei Shitara; Kentaro Yamazaki; Manabu Shiozawa; Hisatsugu Ohori; Atsuo Takashima; Mitsuru Yokota; Akitaka Makiyama; Naoya Akazawa; Hitoshi Ojima; Yasuhiro Yuasa; Keisuke Miwa; Hirofumi Yasui; Eiji Oki; Takeo Sato; Takeshi Naitoh; Yoshito Komatsu; Takeshi Kato; Masamitsu Hihara; Junpei Soeda; Toshihiro Misumi; Kouji Yamamoto; Kiwamu Akagi; Atsushi Ochiai; Hiroyuki Uetake; Katsuya Tsuchihara; Takayuki Yoshino
JAMA, 329, 15, 1271, 1282, 2023年04月18日, [国際誌]
英語, 研究論文(学術雑誌), IMPORTANCE: For patients with RAS wild-type metastatic colorectal cancer, adding anti-epidermal growth factor receptor (anti-EGFR) or anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibodies to first-line doublet chemotherapy is routine, but the optimal targeted therapy has not been defined. OBJECTIVE: To evaluate the effect of adding panitumumab (an anti-EGFR monoclonal antibody) vs bevacizumab (an anti-VEGF monoclonal antibody) to standard first-line chemotherapy for treatment of RAS wild-type, left-sided, metastatic colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, phase 3 clinical trial at 197 sites in Japan in May 2015-January 2022 among 823 patients with chemotherapy-naive RAS wild-type, unresectable metastatic colorectal cancer (final follow-up, January 14, 2022). INTERVENTIONS: Panitumumab (n = 411) or bevacizumab (n = 412) plus modified fluorouracil, l-leucovorin, and oxaliplatin (mFOLFOX6) every 14 days. MAIN OUTCOMES AND MEASURES: The primary end point, overall survival, was tested first in participants with left-sided tumors, then in the overall population. Secondary end points were progression-free survival, response rate, duration of response, and curative (defined as R0 status) resection rate. RESULTS: In the as-treated population (n = 802; median age, 66 years; 282 [35.2%] women), 604 (75.3%) had left-sided tumors. Median follow-up was 61 months. Median overall survival was 37.9 months with panitumumab vs 34.3 months with bevacizumab in participants with left-sided tumors (hazard ratio [HR] for death, 0.82; 95.798% CI, 0.68-0.99; P = .03) and 36.2 vs 31.3 months, respectively, in the overall population (HR, 0.84; 95% CI, 0.72-0.98; P = .03). Median progression-free survival for panitumumab vs bevacizumab was 13.1 vs 11.9 months, respectively, for those with left-sided tumors (HR, 1.00; 95% CI, 0.83-1.20) and 12.2 vs 11.4 months overall (HR, 1.05; 95% CI, 0.90-1.24). Response rates with panitumumab vs bevacizumab were 80.2% vs 68.6%, respectively, for left-sided tumors (difference, 11.2%; 95% CI, 4.4%-17.9%) and 74.9% vs 67.3% overall (difference, 7.7%; 95% CI, 1.5%-13.8%). Median duration of response with panitumumab vs bevacizumab was 13.1 vs 11.2 months for left-sided tumors (HR, 0.86; 95% CI, 0.70-1.10) and 11.9 vs 10.7 months overall (HR, 0.89; 95% CI, 0.74-1.06). Curative resection rates with panitumumab vs bevacizumab were 18.3% vs 11.6% for left-sided tumors; (difference, 6.6%; 95% CI, 1.0%-12.3%) and 16.5% vs 10.9% overall (difference, 5.6%; 95% CI, 1.0%-10.3%). Common treatment-emergent adverse events were acneiform rash (panitumumab: 74.8%; bevacizumab: 3.2%), peripheral sensory neuropathy (panitumumab: 70.8%; bevacizumab: 73.7%), and stomatitis (panitumumab: 61.6%; bevacizumab: 40.5%). CONCLUSIONS AND RELEVANCE: Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, compared with bevacizumab, to standard first-line chemotherapy significantly improved overall survival in those with left-sided tumors and in the overall population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02394795. - Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer.
Kei Muro; Kohei Shitara; Kensei Yamaguchi; Takaki Yoshikawa; Hironaga Satake; Hiroki Hara; Naotoshi Sugimoto; Nozomu Machida; Masahiro Goto; Hisato Kawakami; Kenji Amagai; Yasushi Omuro; Taito Esaki; Shuichi Hironaka; Tomohiro Nishina; Yoshito Komatsu; Hisahiro Matsubara; Shinichi Shiratori; Shirong Han; Taroh Satoh; Atsushi Ohtsu
Journal of gastrointestinal cancer, 2023年04月10日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Pembrolizumab demonstrated antitumor activity in programmed death ligand 1 positive (combined positive score (CPS) ≥ 1) gastric/gastroesophageal junction cancer in KEYNOTE-059 (third line or beyond), KEYNOTE-061 (second line), and KEYNOTE-062 (first line). We characterized efficacy and safety of pembrolizumab monotherapy in Japanese patients across several lines of therapy in these studies. METHODS: This analysis was conducted in 34 patients from KEYNOTE-059 cohort 1 (all pembrolizumab), including 13 patients with CPS ≥ 1, 65 patients with CPS ≥ 1 from KEYNOTE-061 (pembrolizumab, n = 27; chemotherapy, n = 38), and 70 patients with CPS ≥ 1 from KEYNOTE-062 (pembrolizumab, n = 38; chemotherapy, n = 32). Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety were evaluated. RESULTS: In KEYNOTE-059, ORR with pembrolizumab was 9%, median PFS was 2 months, and median OS was 10 months. In KEYNOTE-061, median OS was 12 months with pembrolizumab versus 10 months with chemotherapy (hazard ratio (HR), 0.67; 95% confidence interval (CI), 0.39-1.15). Median PFS (pembrolizumab vs. chemotherapy) was 2 months versus 4 months (HR, 1.21; 95% CI, 0.69-2.13); ORR was 7% versus 18%. In KEYNOTE-062, median OS was 20 months with pembrolizumab versus 18 months with chemotherapy (HR, 0.76; 95% CI, 0.43-1.33). Median PFS (pembrolizumab vs. chemotherapy) was 6 months versus 7 months (HR, 1.03; 95% CI, 0.61-1.74); ORR was 29% versus 34%. CONCLUSIONS: The current analysis provides valuable information that anti-PD-1 therapies are worthy of further assessment for gastric cancer. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02335411 (KEYNOTE-059), NCT02370498 (KEYNOTE-061), and NCT02494583 (KEYNOTE-062). - HGCSG1901 転移性大腸癌に対するIRIS/Bevの後方視的検討 UGT1A1 single heterozygousが与える影響
結城 敏志; 伊藤 憲; 原田 一顕; 川本 泰之; 八木澤 允貴; 澤田 憲太郎; 石黒 敦; 武藤 理; 畑中 一映; 奥田 博介; 佐藤 温; 笹木 有佑; 中村 路夫; 目黒 高志; 太宰 昌佳; 中積 宏之; 植田 亮; 坂本 直哉; 坂田 優; 小松 嘉人
日本消化器病学会雑誌, 120, 臨増総会, A295, A295, (一財)日本消化器病学会, 2023年03月
日本語 - S-1による術後補助化学療法中に早期再発しペムブロリズマブが著効したMSI-high胃癌の1例
渡辺 亮介; 原田 一顕; 中村 赳晶; 山村 貴洋; 川本 泰之; 結城 敏志; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 132回・126回, 60, 60, 日本消化器病学会-北海道支部, 2023年03月
日本語 - Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program.
Yoshiaki Nakamura; Riu Yamashita; Wataru Okamoto; Yoshito Komatsu; Satoshi Yuki; Makoto Ueno; Ken Kato; Hiroya Taniguchi; Yoshinori Kagawa; Tadamichi Denda; Hiroki Hara; Taito Esaki; Toshikazu Moriwaki; Yu Sunakawa; Eiji Oki; Fumio Nagashima; Tomohiro Nishina; Taroh Satoh; Hisato Kawakami; Kensei Yamaguchi; Koushiro Ohtsubo; Takeshi Kato; Yosuke Horita; Akihito Tsuji; Hisateru Yasui; Masahiro Goto; Yasuo Hamamoto; Masashi Wakabayashi; Takashi Ikeno; Kohei Shitara; Hideaki Bando; Katsuya Tsuchihara; Izumi Miki; Hiroko Ichiki; Atsushi Ohtsu; Takayuki Yoshino
JCO precision oncology, 7, e2200653, 2023年03月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Genomic profiling programs have been implemented to apply next-generation sequencing (NGS) for facilitating trial enrollment. SCRUM-Japan GI-SCREEN is a large-scale genomic profiling program in advanced gastrointestinal cancers using a validated genomic assay with the goal of facilitating enrollment in targeted clinical trials, generating real-world data, and performing clinicogenomic analysis for biomarker discovery. PATIENTS AND METHODS: Genotyping of tumor tissue samples from 5,743 patients with advanced gastrointestinal cancers enrolled in GI-SCREEN was centrally performed with NGS. Patients were enrolled in matched trials of targeted agents affiliated with GI-SCREEN on the basis of genotyping results. RESULTS: A total of 11 gastrointestinal cancers were included, with colorectal cancer being the most common. The median age ranged from 59 to 70.5 years across cancer types. Patients enrolled after initiation of first-line treatment had significantly longer overall survival (OS) than that before treatment initiation with a median survival time difference of 8.9 months and a hazard ratio (HR) ranging from 0.25 to 0.73 across cancer types, demonstrating an immortal time bias. One hundred and forty-nine patients received matched therapies in clinical trials on the basis of their identified alterations. Among patients with colorectal cancer harboring actionable alterations, the median OS was significantly longer in patients who received matched therapies in trials than in those who did not (HR, 0.52; 95% CI, 0.26 to 1.01; P = .049). Cancer-specific pathway alterations were significantly associated with shorter survival and related to primary resistance to matched trial therapies. CONCLUSION: Our genomic profiling program led to patient enrollment in targeted clinical trials and improved survival of patients with colorectal cancer who received matched therapies in clinical trials. To avoid immortal time bias, precautions are needed when using data from patients who have undergone NGS testing after initiation of the evaluated treatment line. - Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101).
Kazuaki Harada; Takahiro Yamamura; Osamu Muto; Michio Nakamura; Susumu Sogabe; Kentaro Sawada; Shintaro Nakano; Masataka Yagisawa; Tetsuhito Muranaka; Masayoshi Dazai; Miki Tateyama; Yoshimitsu Kobayashi; Sosuke Kato; Kazuteru Hatanaka; Yasuyuki Kawamoto; Satoshi Yuki; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
Journal of clinical medicine, 12, 4, 2023年02月17日, [国際誌]
英語, 研究論文(学術雑誌), The effects of UGT1A1 gene polymorphisms or prior irinotecan treatment on treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with unresectable pancreatic ductal adenocarcinoma (PDAC) are not established. This multicenter, retrospective cohort study compared treatment outcomes in patients with UGT1A1*1/*1 and those with UGT1A1*1/*6 or *1/*28 genotypes. We also analyzed the impact of prior irinotecan treatment on survival outcomes in 54 patients treated with nal-IRI+5-FU/LV. Comparable effectiveness was found regardless of the UGT1A1 genotypes. While no significant differences were found, grade ≥3 neutropenia and febrile neutropenia were more frequent in patients with UGT1A1*1/*6 or *1/*28 than in those with UGT1A1*1/*1 genotypes (grade ≥3 neutropenia, 50.0% vs. 30.8%, p = 0.24; febrile neutropenia, 9.1% vs. 0.0%, p = 0.20, respectively). No significant difference in progression-free survival (PFS) and overall survival (OS) was observed between irinotecan-naïve-patients and other patients. However, irinotecan-resistant patients showed significantly shorter PFS (hazard ratio (HR) 2.83, p = 0.017) and OS (HR 2.58, p = 0.033) than other patients. Our study indicated that patients with UGT1A1*1/*6 or *1/*28 may be prone to neutropenia, though further study is needed. The survival benefit of nal-IRI+5-FU/LV could be maintained in patients without disease progression after irinotecan therapy. - Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
Kohei Shitara; Motohiro Hirao; Satoru Iwasa; Takashi Oshima; Yoshito Komatsu; Akihito Kawazoe; Yasuyoshi Sato; Takuya Hamakawa; Kan Yonemori; Nozomu Machida; Satoshi Yuki; Takuya Suzuki; Shiori Okumura; Takao Takase; Taro Semba; Bob Zimmermann; Angela Teng; Kensei Yamaguchi
Clinical Cancer Research, 29, 8, 1460, 1467, American Association for Cancer Research (AACR), 2023年02月02日
研究論文(学術雑誌), Abstract
Purpose:
In the dose-expansion part of this open-label, phase I study, we explored the efficacy and safety of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced gastric cancer.
Patients and Methods:
Patients with advanced gastric cancer who had been previously treated with ≥2 lines of chemotherapy received E7389-LF 2.0 mg/m2 every 3 weeks (the previously determined maximum tolerated dose, the primary objective of Study 114). Secondary objectives included objective response rate (ORR), progression-free survival (PFS), and safety; exploratory objectives included disease control rate (DCR) and clinical benefit rate (CBR), as well as pharmacodynamic measurements of serum biomarkers.
Results:
As of June 24, 2021, 34 patients were enrolled and treated (10 from the original dose-expansion cohort, expanded to include 24 additional patients). Six patients had partial responses, for an ORR of 17.6% [95% confidence interval (CI), 6.8–34.5], and the median PFS was 3.7 months (95% CI, 2.7–4.8). The DCR was 79.4% (95% CI, 62.1–91.3), and the CBR was 32.4% (95% CI, 17.4–50.5). Overall, 32 patients (94.1%) experienced treatment-related adverse events, and 26 patients (76.5%) experienced grade ≥3 events, most commonly neutropenia (41.2%) and leukopenia (29.4%). Of the 8 endothelial cell/vasculature markers tested in this study, 7 were significantly increased among patients treated with E7389-LF; these changes were generally consistent regardless of best overall response.
Conclusions:
E7389-LF 2.0 mg/m2 every 3 weeks was tolerable and showed preliminary activity for the treatment of patients with gastric cancer. - 腸内細菌叢に影響を与える薬剤の投与歴と胃癌化学療法の治療効果に関する検討
中村 赳晶; 渡辺 亮介; 山村 貴洋; 原田 一顕; 川本 泰之; 結城 敏志; 小松 嘉人; 坂本 直哉
日本胃癌学会総会記事, 95回, 415, 415, (一社)日本胃癌学会, 2023年02月
日本語 - Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases.
Kazuaki Harada; Satoshi Yuki; Yasuyuki Kawamoto; Takeaki Nakamura; Shiho Kaneko; Koichi Ishida; Naoya Sakamoto; Yoshito Komatsu
Therapeutic advances in medical oncology, 15, 17588359231216090, 17588359231216090, 2023年, [国際誌]
英語, The NeoRAS phenomenon is defined as the conversion of tumor RAS status from mutant-type (MT) to wild-type (WT) after systemic chemotherapy in metastatic colorectal cancer (mCRC). Cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, is effective in patients with RAS WT mCRC but ineffective in those with RAS MT mCRC; however, its outcome in patients with NeoRAS WT mCRC is unclear. Herein, we report two cases of NeoRAS WT mCRC that responded clinically to anti-EGFR treatment. The first was a 40-year-old man with synchronous peritoneal metastatic rectosigmoid cancer. The first RAS testing on tumor tissue revealed a KRAS G12C mutation, which was converted to RAS WT after two lines of chemotherapy, as assessed by liquid biopsy. After initiating irinotecan plus cetuximab treatment, a computed tomography (CT) scan revealed that malignant ascites had resolved. The treatment was discontinued after 4 months because of disease progression. The second was a 68-year-old male patient with synchronous liver metastasis from sigmoid colon cancer. The KRAS G12D mutation, initially detected in tumor tissue, was not detected by liquid biopsy after six lines of chemotherapy. Cetuximab monotherapy was initiated, and the liver metastases shrank significantly. The patient continued cetuximab monotherapy for 8 months without disease progression. Our cases demonstrate the efficacy of anti-EGFR therapy for NeoRAS WT mCRC and highlight the importance of capturing the gene mutation profile throughout the clinical course for optimal treatment selection. - Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis.
Kensuke Sakurai; Takehiko Katsurada; Mutsumi Nishida; Satomi Omotehara; Shinya Fukushima; Shinsuke Otagiri; Kazunori Nagashima; Reizo Onishi; Ryo Takagi; Yoshito Komatsu; Naoya Sakamoto
Intestinal research, 21, 1, 126, 136, 2023年01月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND/AIMS: The usefulness of ultrasonography (US) in diseases of the gastrointestinal tract has been reported recently. This prospective study aimed to determine the features of US findings in immune-mediated colitis (IMC), an adverse event induced by immune checkpoint inhibitor, and examine the correlation between US findings, colonoscopy (CS) findings, and severity of colitis. METHODS: We studied patients examined using CS and US upon suspicion of IMC in Hokkaido University Hospital between April 2018 and February 2021. Endoscopic findings of IMC were assessed using the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). The severity of US findings in IMC was evaluated using US grade, which is the ultrasonographic grading scale in ulcerative colitis. Bowel wall thickness and the intensity of the color Doppler signal were also analyzed. Severity of colitis was evaluated using Common Terminology Criteria for Adverse Events (CTCAE) grade version 5. RESULTS: Fourteen patients with IMC were enrolled. The US findings were bowel wall thickening, loss of stratification, ulceration and increased blood flow signal. The US grade was moderately correlated with the UCEIS (r=0.687, p=0.009) and CTCAE grade (r=0.628, p=0.035). Bowel wall thickness and UCEIS (r=0.628, p=0.020), as well as color Doppler signal grade and CTCAE grade (r=0.724, p=0.008), were significantly correlated. CONCLUSIONS: US findings in IMC were mainly similar to those of ulcerative colitis, but there were some findings that were characteristic only of IMC. Significant correlation was found between US findings, CS findings, and severity of colitis. Hence, US could be useful for the evaluation of IMC. - A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
Masato Ozaka; Kohei Nakachi; Satoshi Kobayashi; Akihiro Ohba; Hiroshi Imaoka; Takeshi Terashima; Hiroshi Ishii; Junki Mizusawa; Hiroshi Katayama; Tomoko Kataoka; Takuji Okusaka; Masafumi Ikeda; Naoki Sasahira; Haruo Miwa; Eishiro Mizukoshi; Naohiro Okano; Nobumasa Mizuno; Tomohisa Yamamoto; Yoshito Komatsu; Akiko Todaka; Ken Kamata; Masayuki Furukawa; Nao Fujimori; Akio Katanuma; Yukiko Takayama; Hidetaka Tsumura; Haruhiko Fukuda; Makoto Ueno; Junji Furuse
European journal of cancer (Oxford, England : 1990), 181, 135, 144, 2022年12月27日, [国際誌]
英語, 研究論文(学術雑誌), AIM: We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) with that of gemcitabine plus nab-paclitaxel (GnP) for locally advanced pancreatic cancer (LAPC). METHODS: Patients with untreated LAPC were randomly assigned (1:1) to receive mFOLFIRINOX or GnP. One-year overall survival (OS) was the primary endpoint. The major secondary end-points included progression-free survival (PFS), response rate (RR), carbohydrate antigen 19-9 (CA19-9) response, and adverse events. The sample size was 124 patients to select a more effective regimen with a minimum probability of 0.85 and to examine the null hypothesis of the 1-year OS <53%. RESULTS: Of the 126 patients enrolled from 29 institutions, 125 were deemed eligible. The 1-year OS was 77.4% (95% CI, 64.9-86.0) and 82.5% (95% CI, 70.7-89.9) in the mFOLFIRINOX and GnP arms, respectively. The median PFS was 11.2 (95% CI, 9.9-15.9) and 9.4 months (95% CI, 7.4-12.8) in the mFOLFIRINOX and GnP arms, respectively. The RR and CA19-9 response rate were 30.9% (95% CI, 19.1-44.8) and 57.1% (95% CI, 41.0-72.3) and 42.1% (95% CI 29.1-55.9) and 85.0% (95% CI, 70.2-94.3) in the mFOLFIRINOX and GnP arms, respectively. Grade 3-4 diarrhoea and anorexia were predominant in the mFOLFIRINOX arm. CONCLUSION: GnP was considered the candidate for a subsequent phase III trial because of its better RR, CA19-9 response, and mild gastrointestinal toxicities. Both regimens displayed higher efficacy in the 1-year survival than in the historical data of gemcitabine monotherapy. - Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study.
Michio Nakamura; Atsushi Ishiguro; Masayoshi Dazai; Yasuyuki Kawamoto; Satoshi Yuki; Susumu Sogabe; Ayumu Hosokawa; Kentaro Sawada; Osamu Muto; Naoki Izawa; Koji Nakashima; Yoshiki Horie; Masataka Yagisawa; Shinya Kajiura; Takayuki Ando; Yosuke Mitsuhashi; Yu Sunakawa; Yasuka Kikuchi; Yoshito Komatsu
BMC cancer, 22, 1, 1322, 1322, 2022年12月16日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Although initial therapy with a parenteral anticoagulant is required before edoxaban, this strategy is frequently avoided in actual clinical practice because of its complexity. This study assessed the feasibility of edoxaban without initial heparin usage for asymptomatic cancer-associated thrombosis (CAT) in Japanese patients with gastrointestinal cancer (GIC) at high risk of bleeding. METHODS: In this multicenter prospective feasibility study conducted at 10 Japanese institutions, patients with active GIC who developed accidental asymptomatic CAT during chemotherapy were recruited. Edoxaban was orally administered once daily without initial parenteral anticoagulant therapy within 3 days after detecting asymptomatic CAT. The primary outcome was the incidence of major bleeding (MB) or clinically relevant non-major bleeding (CRNMB) during the first 3 months of edoxaban administration. RESULTS: Of the 54 patients enrolled from October 2017 to September 2020, one was excluded because of a misdiagnosis of CAT. In the remaining 53 patients, the primary outcome occurred in six patients (11.3%). MB occurred in four patients (7.5%), including gastrointestinal bleeding in three patients and intracranial hemorrhage in one patient. CRNMB occurred in two patients (3.8%), including bleeding from the stoma site and genital bleeding in one patient each. There were no deaths attributable to bleeding, and all patients who experienced MB or CRNMB recovered. CONCLUSIONS: The risk of bleeding after edoxaban without heparin pretreatment was acceptable, demonstrating new treatment options for asymptomatic CAT in patients with GIC. - Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 30, 12, 10203, 10211, 2022年10月11日, [国際誌]
英語, 研究論文(学術雑誌), Regorafenib, a multikinase inhibitor, is effective in treating metastatic colorectal cancer (mCRC). Hypertension is a frequently occurring adverse effect caused by regorafenib regardless of previous treatment with vascular endothelial growth factor (VEGF) inhibitors in almost all patients. We identified the risk factors associated with regorafenib-induced severe hypertension. Patients with mCRC (n = 100) who received regorafenib were evaluated retrospectively. The primary endpoint was the evaluation of the risk factors for grade ≥ 3 hypertension. The association between pre-existing hypertension at baseline and grade ≥ 3 hypertension symptoms was also assessed. Patients with pre-existing hypertension at baseline accounted for 55% of the total patients. The starting doses of regorafenib were 160 mg (49.0% of patients), 120 mg (29.0%), and 80 mg (22.0%). The incidence of grade ≥ 3 hypertension was 30.0%. The median time to grade ≥ 3 symptom development was 7 days (range: 1-56 days). Additional antihypertensive treatment was administered to 83.6% of patients who developed hypertension. Logistic regression analyses revealed that baseline pre-existing hypertension complications and previous anti-VEGF treatment for ≥ 700 days were independent risk factors for grade ≥ 3 hypertension development. Further analyses revealed that pre-existing hypertension before anti-VEGF treatment (primary hypertension) was significantly related to the symptom development (adjusted odds ratio, 8.74; 95% confidence interval, 2.86-26.72; P = 0.0001). Our study suggests that pre-existing primary hypertension and previous anti-VEGF treatment for ≥ 700 days are independent risk factors for regorafenib-induced severe hypertension. Deeper understanding of the symptom nature and management can significantly contribute to safer interventions, necessitating further studies. - 再発高リスクGISTに対する術後長期補助療法の有用性(STAR ReGISTry)
佐藤 真輔; 西田 俊朗; 尾阪 将人; 中原 裕次郎; 小松 嘉人; 近藤 正人; 長 晴彦; 廣田 誠一; 鍵村 達夫; 黒川 幸典; 北川 雄光
日本消化器病学会雑誌, 119, 臨増大会, A759, A759, (一財)日本消化器病学会, 2022年10月
日本語 - 進行胃癌・大腸癌における治療前の血中循環腫瘍DNA検出の臨床的妥当性
青木 優; 中村 能章; 谷口 浩也; 小松 嘉人; 砂川 優; 塩澤 学; 太田 高志; 江崎 泰斗; 山崎 健太郎; 佐竹 悠良; 松橋 延壽; 後藤 昌弘; 賀川 義規; 仁科 智裕; 吉野 孝之
日本癌治療学会学術集会抄録集, 60回, PS, 1, (一社)日本癌治療学会, 2022年10月
英語 - Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities
Shunsuke A. Sakai; Masato Aoshima; Kentaro Sawada; Satoshi Horasawa; Ayumu Yoshikawa; Takao Fujisawa; Shigenori Kadowaki; Tadamichi Denda; Nobuhisa Matsuhashi; Hisateru Yasui; Masahiro Goto; Kentaro Yamazaki; Yoshito Komatsu; Ryota Nakanishi; Yoshiaki Nakamura; Hideaki Bando; Yamato Hamaya; Shun-Ichiro Kageyama; Takayuki Yoshino; Katsuya Tsuchihara; Riu Yamashita
Frontiers in Cellular and Infection Microbiology, 12, Frontiers Media SA, 2022年09月14日
研究論文(学術雑誌), Colorectal cancer (CRC) is one of the most common malignant diseases. Generally, stoma construction is performed following surgery for the resection of the primary tumor in patients with CRC. The association of CRC with the gut microbiota has been widely reported, and the gut microbiota is known to play an important role in the carcinogenesis, progression, and treatment of CRC. In this study, we compared the microbiota of patients with CRC between with and without a stoma using fecal metagenomic sequencing data from SCRUM-Japan MONSTAR-SCREEN, a joint industry-academia cancer research project in Japan. We found that the composition of anaerobes was reduced in patients with a stoma. In particular, the abundance of Alistipes, Akkermansia, Intestinimonas, and methane-producing archaea decreased. We also compared gene function (e.g., KEGG Orthology and KEGG pathway) and found that gene function for methane and short-chain fatty acids (SCFAs) production was underrepresented in patients with a stoma. Furthermore, a stoma decreased Shannon diversity based on taxonomic composition but increased that of the KEGG pathway. These results suggest that the feces of patients with a stoma have a reduced abundance of favorable microbes for cancer immunotherapy. In conclusion, we showed that a stoma alters the taxonomic and functional profiles in feces and may be a confounding factor in fecal microbiota analysis. - Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world.
Toshirou Nishida; Shinsuke Sato; Masato Ozaka; Yujiro Nakahara; Yoshito Komatsu; Masato Kondo; Haruhiko Cho; Seiichi Hirota; Tatsuo Kagimura; Yukinori Kurokawa; Yuko Kitagawa
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 25, 5, 956, 965, 2022年09月, [国内誌]
英語, 研究論文(学術雑誌), PURPOSE: Three years of adjuvant imatinib is the standard therapy for gastrointestinal stromal tumors (GISTs) with high-risk features. The prognostic effects of long-term adjuvant therapy are unknown. PATIENTS AND METHODS: The prospective registry study recruited 515 patients with high-risk GISTs between Dec. 2012 and Dec. 2015 were analyzed. The primary endpoint was recurrence-free survival (RFS), and secondary endpoints include overall survival (OS) and safety. The study was designed to compare RFS after 3.5 years of 3-year adjuvant therapy (3.0 ± 0.5 years: 3-year group) with that of more than 3.5 years (median 5.2 years: longer group). RESULTS: Five-year RFS and 5-year OS were 68.2% (95% confidence interval [CI] 63.8-72.1) and 92.3% (95% CI 89.5-94.4), respectively. The recurrence rate during adjuvant was estimated to be 2.9/100 person-years (95% CI 2.0-4.1) and those after the end of adjuvant, which appeared similar irrespective of the adjuvant duration or reason to stop adjuvant, were estimated 12.0/100 person-years (95% CI 10.2-14.0). The 5-year RFS rates of 3-year and longer groups were 78.7% (95% CI 70.8-84.7) and 92.7% (95% CI 85.2-96.4), respectively. RFS after 3.5 years of the longer group was significantly better than that of the 3-year group (adjusted hazard ratio [HR] 0.56; 95% CI 0.39-0.78; P < 0.001). CONCLUSION: The recurrence risk of high-risk GISTs after adjuvant therapy is similar irrespective of the adjuvant duration and imatinib adjuvant may not cure but may delay recurrence. RFS after long-term adjuvant therapy appeared better than that after 3-year adjuvant. - 内科・外科による消化器病共同診療の現況と展望 局所進行直腸癌における術前FOLFOX療法の有効性の検討(RNAC01試験)の解釈とその発展
藤好 直; 本間 重紀; 市川 伸樹; 結城 敏志; 川本 泰之; 原田 一顕; 吉田 雅; 柴田 賢吾; 松井 博紀; 小松 嘉人; 坂本 直哉; 武冨 紹信
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 131回・125回, 26, 26, 日本消化器病学会-北海道支部, 2022年09月
日本語 - 内科・外科による消化器病共同診療の現況と展望 当科における切除可能境界膵癌に対する術前治療の現状
原田 一顕; 中村 赳晶; 渡辺 亮介; 山村 貴洋; 川本 泰之; 結城 敏志; 桑谷 将城; 田口 大志; 加藤 徳雄; 浅野 賢道; 中村 透; 平野 聡; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 131回・125回, 28, 28, 日本消化器病学会-北海道支部, 2022年09月
日本語 - Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome.
Rika Saito; Yasuyuki Kawamoto; Mutsumi Nishida; Takahito Iwai; Yasuka Kikuchi; Isao Yokota; Ryo Takagi; Takahiro Yamamura; Ken Ito; Kazuaki Harada; Satoshi Yuki; Yoshito Komatsu; Naoya Sakamoto
International journal of clinical oncology, 27, 11, 1780, 1790, 2022年08月30日, [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: Sinusoidal obstruction syndrome (SOS) refers to liver injury caused by hematopoietic stem cell transplantation (HSCT) and anticancer drugs including oxaliplatin. Increased splenic volume (SV) on computed tomography (CT) indicates oxaliplatin-induced SOS. Similarly, ultrasonography and liver stiffness measurement (LSM) by shear-wave elastography (SWE) can help diagnose SOS after HSCT; however, their usefulness for diagnosing oxaliplatin-induced SOS remains unclear. We investigated the usefulness of the Hokkaido ultrasonography-based scoring system with 10 ultrasonographic parameters (HokUS-10) and SWE in diagnosing oxaliplatin-induced SOS early. METHODS: In this prospective observational study, ultrasonography and SWE were performed before and at 2, 4, and 6 months after oxaliplatin-based chemotherapy. HokUS-10 was used for assessment. CT volumetry of the SV was performed in clinical practice, and an SV increase ≥ 30% was considered the diagnostic indicator of oxaliplatin-induced SOS. We assessed whether HokUS-10 and SWE can lead to an early detection of oxaliplatin-induced SOS before an increased SV on CT. RESULTS: Of the 30 enrolled patients with gastrointestinal cancers, 12 (40.0%) with an SV increase ≥ 30% on CT were diagnosed with SOS. The HokUS-10 score was not correlated with an SV increase ≥ 30% (r = 0.18). The change in rate of three HokUS-10 parameters were correlated with an SV increase ≥ 30% (r = 0.32-0.41). The change in rate of LSM by SWE was correlated with an SV increase ≥ 30% (r = 0.40). CONCLUSIONS: The usefulness of HokUS-10 score was not demonstrated; however, some HokUS-10 parameters and SWE could be useful for the early diagnosis of oxaliplatin-induced SOS. - An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors.
Yoshito Komatsu; Tsuneo Shimokawa; Kohei Akiyoshi; Masato Karayama; Akihiko Shimomura; Yasuyuki Kawamoto; Satoshi Yuki; Yuichi Tambo; Kazuo Kasahara
Investigational new drugs, 40, 5, 1011, 1020, 2022年08月06日, [国際誌]
英語, 研究論文(学術雑誌), This study compared the bioavailability of two pimitespib formulations (Formulations A and B), evaluated the food effect on Formulation A, and evaluated the safety and efficacy of multiple pimitespib doses in patients with solid tumors. This clinical, pharmacological multicenter study had two cohorts and periods. A single dose of Formulation A or B was administered in a crossover design to compare the pharmacokinetics in Cohort 1. In Cohort 2, the effects of fed vs fasting conditions were evaluated among those receiving Formulation A. Subsequently, multiple Formulation A doses were administered to all patients for safety and efficacy assessments. In Cohorts 1 and 2, 12 and 16 patients, respectively, were analyzed for pharmacokinetics. Thirty patients were analyzed for safety and efficacy. Maximum concentration (Cmax), area under the curve (AUC)last, and AUCinf geometric mean ratios for Formulations A and B (90% confidence interval [CI]) were 0.8078 (0.6569-0.9933), 0.7973 (0.6672-0.9529), and 0.8094 (0.6697-0.9782), respectively; 90% CIs were not within the bioequivalence range (0.80-1.25). In Cohort 2, mean Cmax, AUClast, and AUCinf were higher in fed vs fasting conditions. No safety concerns emerged with single or multiple administration. Overall response rate, disease control rate, and median progression-free survival were 0%, 33%, and 1.5 months, respectively. Four patients had stable disease ≥ 5 months. Bioequivalence of the two formulations was unconfirmed. Systemic exposure of Formulation A was approximately 20% less than Formulation B. A high-fat/calorie meal increased the relative pharmacokinetics and bioavailability of a single 160-mg dose. Trial Registration: JapicCTI-184191 (Japan Pharmaceutical Information Center) registered on November 5, 2018. - Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Yasuyuki Kawamoto; Satoshi Yuki; Kentaro Sawada; Michio Nakamura; Osamu Muto; Susumu Sogabe; Yoshiaki Shindo; Atsushi Ishiguro; Atsushi Sato; Yasushi Tsuji; Masayoshi Dazai; Hiroyuki Okuda; Takashi Meguro; Kazuaki Harada; Mari Sekiguchi; Kazufumi Okada; Yoichi M Ito; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
The oncologist, 27, 8, e642-e649, 2022年08月05日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Ramucirumab is a human IgG1 monoclonal vascular endothelial growth factor receptor-2 antibody that inhibits tumor cell growth and affects the tumor cell microenvironment. We assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with previously treated advanced gastric cancer. MATERIALS AND METHODS: Patients with advanced gastric cancer refractory or intolerant to primary chemotherapy were included. Ramucirumab 8 mg/kg plus irinotecan 150 mg/m2 combination therapy was administered every 2 weeks. The primary endpoint was progression-free survival rate at 6 months and secondary endpoints were overall survival, progression-free survival, response rate, safety, and dose intensity for each drug. RESULTS: Thirty-five patients were enrolled between January 2018 and September 2019. The progression-free survival rate at 6 months was 26.5% [95%CI, 13.2%-41.8%, P = .1353)]. Median progression-free and overall survivals were 4.2 months (95%CI, 2.5-5.4 months) and 9.6 months (95%CI, 6.4-16.6 months), respectively. The overall response rate was 25.9% (95%CI, 11.1-36.3%) and disease control rate was 85.2% (95%CI, 66.3-95.8%). Grade ≥3 adverse events that occurred in >10% of patients included neutropenia, leucopenia, anemia, anorexia, and febrile neutropenia. No death or new safety signals with a causal relation to the study treatment were observed. CONCLUSION: Although the primary endpoint was not achieved statistically, combination therapy of ramucirumab plus irinotecan showed anticancer activity and a manageable safety profile for second-line treatment of patients with advanced gastric cancer. - Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal Cancer.
Satoshi Fujii; Daisuke Kotani; Masahiro Hattori; Masato Nishihara; Toshihide Shikanai; Junji Hashimoto; Yuki Hama; Takuya Nishino; Mizuto Suzuki; Ayatoshi Yoshidumi; Makoto Ueno; Yoshito Komatsu; Toshiki Masuishi; Hiroki Hara; Taito Esaki; Yoshiaki Nakamura; Hideaki Bando; Tomoyuki Yamada; Takayuki Yoshino
Clinical cancer research : an official journal of the American Association for Cancer Research, 28, 12, 2623, 2632, 2022年06月13日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Rapid decision-making is essential in precision medicine for initiating molecular targeted therapy for patients with cancer. This study aimed to extract pathomorphologic features that enable the accurate prediction of genetic abnormalities in cancer from hematoxylin and eosin images using deep learning (DL). EXPERIMENTAL DESIGN: A total of 1,657 images (one representative image per patient) of thin formalin-fixed, paraffin-embedded tissue sections from either primary or metastatic tumors with next-generation sequencing-confirmed genetic abnormalities-including BRAFV600E and KRAS mutations, and microsatellite instability high (MSI-H)-that are directly relevant to therapeutic strategies for advanced colorectal cancer were obtained from the nationwide SCRUM-Japan GI-SCREEN project. The images were divided into three groups of 986, 248, and 423 images to create one training and two validation cohorts, respectively. Pathomorphologic feature-prediction DL models were first developed on the basis of pathomorphologic features. Subsequently, gene-prediction DL models were constructed for all possible combinations of pathomorphologic features that enabled the prediction of gene abnormalities based on images filtered by the combination of pathomorphologic feature-prediction models. RESULTS: High accuracies were achieved, with AUCs > 0.90 and 0.80 for 12 and 27, respectively, of 33 analyzed pathomorphologic features, with high AUCs being yielded for both BRAFV600E (0.851 and 0.859) and MSI-H (0.923 and 0.862). CONCLUSIONS: These findings show that novel next-generation pathology methods can predict genetic abnormalities without the need for standard-of-care gene tests, and this novel next-generation pathology method can be applied for colorectal cancer treatment planning in the near future. - Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound–Guided Fine-Needle Aspiration–Derived Samples
Shintaro Nakano; Yasuyuki Kawamoto; Yoshito Komatsu; Rika Saito; Ken Ito; Takahiro Yamamura; Kazuaki Harada; Satoshi Yuki; Kazumichi Kawakubo; Ryo Sugiura; Shin Kato; Koji Hirata; Hajime Hirata; Masahito Nakajima; Ryutaro Furukawa; Yunosuke Takishin; Kousuke Nagai; Isao Yokota; Keisuke H. Ota; Shinji Nakaoka; Masaki Kuwatani; Naoya Sakamoto
Pancreas, Publish Ahead of Print, 4, 351, 357, Ovid Technologies (Wolters Kluwer Health), 2022年06月13日
研究論文(学術雑誌) - Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
Akihiro Ohba; Chigusa Morizane; Yasuyuki Kawamoto; Yoshito Komatsu; Makoto Ueno; Satoshi Kobayashi; Masafumi Ikeda; Mitsuhito Sasaki; Junji Furuse; Naohiro Okano; Nobuyoshi Hiraoka; Hiroshi Yoshida; Aya Kuchiba; Ryo Sadachi; Kenichi Nakamura; Naoko Matsui; Yoshiaki Nakamura; Wataru Okamoto; Takayuki Yoshino; Takuji Okusaka
Journal of Clinical Oncology, 40, 16_suppl, 4006, 4006, American Society of Clinical Oncology (ASCO), 2022年06月01日
研究論文(学術雑誌), 4006
Background: BTCs have an aggressive tumor biology with limited treatment options. With a HER2-positivity rate of 5–20% in BTCs, case series and small clinical trials have shown signs of activity for HER2 blockade in these pts. T-DXd is an antibody-drug conjugate composed of a humanized monoclonal anti-HER2 antibody, a cleavable linker, and a topoisomerase I inhibitor. The HERB trial is an investigator-initiated, multicenter, single-arm phase 2 trial of T-DXd in pts with HER2-expressing BTCs. Methods: Centrally confirmed HER2-expressing (HER2-positive: IHC3+ or IHC2+/ISH+, and HER2-low-expressing [HER2-low]: IHC/ISH status of 0/+, 1+/-, 1+/+, or 2+/-) pts with BTCs who were refractory or intolerant to gemcitabine containing regimen received 5.4 mg/kg of T-DXd every 3 weeks. The primary endpoint was the confirmed objective response rate (ORR) in HER2-positive pts by independent central review. The sample size of 22 had 80% power with one-sided alpha error of 5%; threshold ORR, 15%; and expected ORR, 40%. The ORR, disease control rate (DCR), progression-free survival (PFS), overall survival (OS) in HER2-positive/-low pts, and incidence of treatment-emergent adverse events (TEAEs) were assessed as secondary endpoints. Results: A total of 32 pts, 24 with HER2-positive and 8 with HER2-low BTCs, received T-DXd. Twenty-two pts with HER2-positive, excluding 2 ineligible pts, were identified for primary efficacy analysis. Among the 22 pts, IHC3+ and IHC2+/ISH+ were 45.5% and 54.5%, primary sites: gallbladder/extrahepatic/intrahepatic/Vater were 11/6/3/2, median number of prior regimens was 2 (range, 1–4). The confirmed ORR in HER2-positive pts was 36.4% (8/22; 2 CR and 6 PR; 90% CI, 19.6–56.1), indicating statistically significant improvement in ORR (P = 0.01). The DCR, median (m) PFS, mOS were 81.8% (95% CI, 59.7–94.8), 4.4 months (mo) (95% CI, 2.8–8.3), 7.1 mo (95% CI, 4.7–14.6), respectively. In addition, encouraging efficacy were seen even in HER2-low pts; ORR, DCR, mPFS, and mOS were 12.5% (1/8; 1 PR; 95% CI, 0.3–52.7), 75.0% (95% CI, 34.9–96.8), 4.2 mo (95% CI, 1.3–6.2), and 8.9 mo (95% CI, 3.0–12.8), respectively. In the safety analysis set (n = 32), TEAEs of > = grade (G) 3 occurred in 81.3% (26/32); the common TEAEs were anemia (53.1%), neutropenia (31.3%), and leukopenia (31.3%). TEAEs leading to drug discontinuation occurred in 8 pts (25.0%). Eight pts (25.0%) had interstitial lung disease (ILD; G1/G2/G3/G5 were 3/1/2/2) not adjudicated by an independent committee. Conclusions: T-DXd showed promising activity in pts with HER2-expressing BTCs. Although the safety profile was generally consistent with other T-DXd studies, ILD, an important identified risk of T-DXd, requires more careful monitoring and intervention. These results support further exploration of T-DXd in this patient population. Clinical trial information: JMA-IIA00423. - Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.
Ken Ito; Satoshi Yuki; Hiroshi Nakatsumi; Yasuyuki Kawamoto; Kazuaki Harada; Shintaro Nakano; Rika Saito; Takayuki Ando; Kentaro Sawada; Masataka Yagisawa; Atsushi Ishiguro; Masayoshi Dazai; Ichiro Iwanaga; Kazuteru Hatanaka; Atsushi Sato; Ryusuke Matsumoto; Yoshiaki Shindo; Miki Tateyama; Tetsuhito Muranaka; Masaki Katagiri; Isao Yokota; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 30, 6, 5351, 5359, 2022年06月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in patients with gastrointestinal cancer. METHODS: This multicenter, prospective, observational study enrolled patients with dysgeusia during chemotherapy treatment. Patients received no intervention (control), polaprezinc p.o., or zinc acetate hydrate p.o., and serum zinc levels were measured at 0 (baseline), 6, and 12 weeks. Dysgeusia was assessed using CTCAE v5.0 and subjective total taste acuity (STTA) criteria using questionnaires at baseline and 12 weeks. RESULTS: From February 2020 to June 2021, 180 patients were enrolled from 17 institutes. There were no differences in mean baseline serum zinc levels among the groups (67.3, 66.6, and 67.5 μg/dL in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. P = 0.846). The changes in mean serum zinc levels after 12 weeks were - 3.8, + 14.3, and + 46.6 μg/dL, and the efficacy rates of dysgeusia were 33.3%, 36.8%, and 34.6% using CTCAE and 33.3%, 52.6%, 32.7% using STTA in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. The STTA scores improved in all groups, with significant improvement observed in the polaprezinc group compared with the no intervention group (P = 0.045). CONCLUSION: There was no significant correlation between the degree of serum zinc elevation and improvement in dysgeusia, suggesting that polaprezinc, but not zinc acetate hydrate, was effective in improving chemotherapy-induced dysgeusia. TRIAL REGISTRATION: UMIN000039653. Date of registration: March 2, 2020. - Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
Shintaro Nakano; Yasuyuki Kawamoto; Satoshi Yuki; Kazuaki Harada; Takuto Miyagishima; Susumu Sogabe; Masayoshi Dazai; Atsushi Sato; Atsushi Ishiguro; Michio Nakamura; Shinya Kajiura; Yasuo Takahashi; Miki Tateyama; Kazuteru Hatanaka; Yasushi Tsuji; Takahide Sasaki; Yoshiaki Shindo; Tomoe Kobayashi; Isao Yokota; Naoya Sakamoto; Yuh Sakata; Yoshito Komatsu
BMJ open, 12, 5, e048833, 2022年05月09日, [国際誌]
英語, 研究論文(学術雑誌), INTRODUCTION: Combination chemotherapy with oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) has become one of the standard treatments for metastatic pancreatic cancer. However, the use of FOLFIRINOX requires prolonged infusion. Therefore, we planned to develop a new combination chemotherapy regimen with oxaliplatin, irinotecan and S-1 (OX-IRIS) for advanced pancreatic cancer. In the phase Ⅰ study that was conducted previously, the safety and recommended dose of OX-IRIS were assessed. In this study, we will evaluate the efficacy and safety of OX-IRIS. METHODS AND ANALYSIS: The HGCSG1803 study started as a multicentre, non-randomised, single-arm, prospective, phase II study in December 2019. Eligible subjects were patients with untreated metastatic or relapsed pancreatic cancer. OX-IRIS is administered as follows: 30 min infusion of antiemetic; 2-hour infusion of oxaliplatin (65 mg/m2); 1.5-hour infusion of irinotecan (100 mg/m2) on day 1 and 15 of each 4-week cycle; and oral S-1 (40 mg/m2) twice daily from after dinner on day one to after breakfast on day 15, followed by a 14-day rest, to be repeated every 2 weeks until disease progression, unacceptable toxicity or patient refusal. The primary endpoint is response rate. The secondary endpoints are overall and progression-free survival, safety and dose for each drug. Using a binomial test, a sample size of 40 patients was set with a threshold value of 10% and expected value of 30%. Registration of 40 cases is planned from 18 institutions in Japan. ETHICS AND DISSEMINATION: All the procedures will be conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki of 1964 and its later versions. All the patients will receive written information about the trial and will provide informed consent before enrolment. This trial was approved by the Hokkaido University Certified Review Board (approval No: 018-037). TRIAL REGISTRATION NUMBER: jRCTs011190008. - Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
Yasuyuki Kawamoto; Satoshi Yuki; Takashi Meguro; Kazuteru Hatanaka; Minoru Uebayashi; Michio Nakamura; Hiroyuki Okuda; Ichiro Iwanaga; Takashi Kato; Shintaro Nakano; Atsushi Sato; Kazuaki Harada; Koji Oba; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
The oncologist, 27, 5, 340-e374, 2022年05月06日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: The efficacy of irinotecan plus continuous trastuzumab beyond progression in patients with gastric cancer previously treated with trastuzumab plus standard first-line chemotherapy has not been reported. METHODS: Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer who were previously treated with trastuzumab received trastuzumab every 3 weeks and irinotecan every 2 weeks. The primary endpoint was the overall response rate (ORR), and the secondary endpoints included progression-free survival (PFS), 6-month survival rates, safety, and subgroup analysis by HER2 status. RESULTS: Sixteen patients were enrolled in a 3-year pre-planned registration period. This study was prematurely closed due to poor patient accrual. The ORR and disease control rate were 6.7% (95% CI, 0.2-32.0) and 53.3% (95% CI, 26.6-78.7). The median PFS and overall survival (OS) were 2.4 months (95% CI, 0.0-5.2) and 9.7 months (95% CI, 8.2-11.2), respectively. The most frequently reported grades 3-4 adverse events were neutropenia (40%), anemia (27%), anorexia (33%), and fatigue (33%). CONCLUSION: With only 16 patients enrolled, the present study has very low power to detect any clinical benefit of trastuzumab plus irinotecan beyond disease progression in patients with HER2-positive advanced gastric cancer who previously received trastuzumab.Trial Identifier: UMIN000007636. - Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
Akihiro Ohba; Chigusa Morizane; Makoto Ueno; Satoshi Kobayashi; Yasuyuki Kawamoto; Yoshito Komatsu; Masafumi Ikeda; Mitsuhito Sasaki; Naohiro Okano; Junji Furuse; Nobuyoshi Hiraoka; Hiroshi Yoshida; Aya Kuchiba; Ryo Sadachi; Kenichi Nakamura; Naoko Matsui; Yoshiaki Nakamura; Wataru Okamoto; Takayuki Yoshino; Takuji Okusaka
Future oncology (London, England), 18, 19, 2351, 2360, 2022年05月05日, [国際誌]
英語, 研究論文(学術雑誌), Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of a humanized monoclonal anti-HER2 antibody, a cleavable tetrapeptide-based linker and a potent topoisomerase I inhibitor. The drug's efficacy has been proven in HER2-positive breast and gastric cancers. The rate of HER2 positivity in biliary tract cancer (BTC) has been reported to be 5-20%, and case reports and clinical trials have suggested that HER2 inhibitors might be active in HER2-positive BTC. Here we describe the rationale and design of the phase II HERB trial that will evaluate the efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing unresectable or recurrent BTC. The primary end point will be the centrally assessed objective response rate in HER2-positive patients. - 個別化医療を見据えた消化器診療の現状 超音波内視鏡下穿刺吸引法で得られた検体を用いた膵腫瘍内細菌叢の検討
中野 真太郎; 川本 泰之; 小松 嘉人; 伊藤 憲; 原田 一顕; 結城 敏志; 川久保 和道; 杉浦 諒; 加藤 新; 平田 幸司; 平田 甫; 中島 正人; 古川 龍太郎; 滝新 悠之介; 永井 孝輔; 横田 勲; 太田 圭祐; 中岡 慎治; 桑谷 将城; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130回・124回, 36, 36, 日本消化器病学会-北海道支部, 2022年03月
日本語 - The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study
Takeshi Kawakami; Toshiki Masuishi; Yasuyuki Kawamoto; Hirofumi Go; Kyoko Kato; Ryosuke Kumanishi; Kentaro Sawada; Satoshi Yuki; Kouji Yamamoto; Yoshito Komatsu; Kei Muro; Kunihiro Fushiki; Hiromichi Shirasu; Kentaro Yamazaki
Cancer Medicine, Wiley, 2022年02月19日
研究論文(学術雑誌) - 進行固形がん患者に対する保険診療による包括的がんゲノムプロファイリング検査の実施時期についての検討
菊地 順子; 大原 克仁; 天野 虎次; 矢部 一郎; 小松 嘉人; 松野 吉宏; 石黒 敦; 水上 裕輔; 櫻井 晃洋; 木下 一郎
日本内科学会雑誌, 111, Suppl., 190, 190, (一社)日本内科学会, 2022年02月
日本語 - Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy.
Yoshiaki Nakamura; Wataru Okamoto; Tadamichi Denda; Tomohiro Nishina; Yoshito Komatsu; Satoshi Yuki; Hisateru Yasui; Taito Esaki; Yu Sunakawa; Makoto Ueno; Eiji Shinozaki; Nobuhisa Matsuhashi; Takashi Ohta; Ken Kato; Koushiro Ohtsubo; Hideaki Bando; Hiroki Hara; Taroh Satoh; Kentaro Yamazaki; Yoshiyuki Yamamoto; Naohiro Okano; Tetsuji Terazawa; Takeshi Kato; Eiji Oki; Akihito Tsuji; Yosuke Horita; Yasuo Hamamoto; Akihito Kawazoe; Hiromichi Nakajima; Shogo Nomura; Ryuta Mitani; Mihoko Yuasa; Kiwamu Akagi; Takayuki Yoshino
JCO precision oncology, 6, e2100383, 2022年02月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Circulating tumor DNA (ctDNA) genotyping may guide targeted therapy for patients with advanced GI cancers. However, no studies have validated ctDNA genotyping for microsatellite instability (MSI) assessment in comparison with a tissue-based standard. PATIENTS AND METHODS: The performance of plasma-based MSI assessment using Guardant360, a next-generation sequencing-based ctDNA assay, was compared with that of tissue-based MSI assessment using a validated polymerase chain reaction-based method in patients with advanced GI cancers enrolled in GOZILA study, a nationwide ctDNA profiling study. The primary end points were overall percent agreement, positive percent agreement (PPA), and negative percent agreement. The efficacy of immune checkpoint inhibitor therapy was also evaluated. RESULTS: In 658 patients with advanced GI cancers who underwent both plasma and tissue testing for MSI, the overall percent agreement, PPA, and negative percent agreement were 98.2% (95% CI, 96.8 to 99.1), 71.4% (95% CI, 47.8 to 88.7), and 99.1% (95% CI, 98.0 to 99.7), respectively. In patients whose plasma samples had a ctDNA fraction ≥ 1.0%, the PPA was 100.0% (15/15; 95% CI, 78.2 to 100.0). Three patients with MSI-high (MSI-H) tumors detected only by ctDNA genotyping achieved clinical benefits after receiving anti-programmed cell death 1 therapy with the progression-free survival ranging from 4.3 to 16.7 months. One patient with an aggressive cancer of an unknown primary site benefited from pembrolizumab after rapid detection of MSI-H by ctDNA genotyping. CONCLUSION: ctDNA genotyping was able to detect MSI with high concordance to validated tissue-based MSI testing, especially in patients with tumors that have sufficient ctDNA shedding. Furthermore, ctDNA genotyping enabled identification of patients with MSI-H tumors who benefited from immune checkpoint inhibitor treatment. - Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
Hideaki Bando; Yuichiro Tsukada; Koji Inamori; Yosuke Togashi; Shohei Koyama; Daisuke Kotani; Shota Fukuoka; Satoshi Yuki; Yoshito Komatsu; Shigenori Homma; Akinobu Taketomi; Mamoru Uemura; Takeshi Kato; Makoto Fukui; Masashi Wakabayashi; Naoki Nakamura; Motohiro Kojima; Hiroshi Kawachi; Richard Kirsch; Tsutomu Yoshida; Yutaka Suzuki; Akihiro Sato; Hiroyoshi Nishikawa; Masaaki Ito; Takayuki Yoshino
Clinical cancer research : an official journal of the American Association for Cancer Research, 28, 6, 1136, 1146, 2022年01月21日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Preoperative chemoradiotherapy (CRT) and surgical resection are the standard treatment for locally advanced rectal cancer (LARC). Combining immune checkpoint inhibitors with radiation suggests a promising approach for enhancing efficacy. We investigated the efficacy of CRT followed by nivolumab and surgery in patients with LARC. PATIENTS AND METHODS: In phase I, we investigated the feasibility of sequentially combined CRT, 5 cycles of nivolumab, and radical surgery. In phase II, patients with microsatellite stable (MSS) and microsatellite instability-high (MSI-H) LARC were evaluated. RESULTS: Three patients in phase I received full courses of CRT and nivolumab without dose modification; the schedule was recommended for phase II. A pathologic complete response (pCR) was centrally confirmed in 30% [11/37; 90% confidence interval (CI), 18%-44%] and 60% (3/5) of the MSS and exploratory MSI-H cohorts, respectively. While immune-related severe adverse events were observed in 3 patients, no treatment-related deaths were observed. In 38 patients with MSS who underwent surgery, pCR rates of 75% (6/8) and 17% (5/30; P = 0.004, Fisher exact test) were observed in those with programmed cell death ligand 1 (PD-L1) tumor proportion score ≥1% and <1%, respectively; IHC staining was performed using pre-CRT samples. In 24 patients with MSS, pre-CRT samples were analyzed by flow cytometry; pCR rates of 78% (7/9) and 13% (2/15; P = 0.003, Fisher exact test) were observed for CD8+ T cell/effector regulatory T cell (CD8/eTreg) ratios of ≥2.5 and <2.5, respectively, in tumor-infiltrating lymphocytes. CONCLUSIONS: CRT followed by consolidation nivolumab could increase pCR. PD-L1 expression and an elevated CD8/eTreg ratio were positive predictors in patients with MSS LARC. - がん治療医・緩和ケアスタッフを対象としたターミナルケア態度尺度を用いた意識調査
熊井 正貴; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 伊藤 陽一; 山田 武宏; 武隈 洋; 菅原 満; 川本 泰之; 小松 嘉人
Palliative Care Research, 17, 2, 51, 58, (NPO)日本緩和医療学会, 2022年
日本語 - Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
Hiroshi Nakatsumi; Yoshito Komatsu; Tetsuhito Muranaka; Satoshi Yuki; Yasuyuki Kawamoto; Kazuaki Harada; Masayoshi Dazai; Miki Tateyama; Yusuke Sasaki; Takuto Miyagishima; Yasushi Tsuji; Masaki Katagiri; Michio Nakamura; Susumu Sogabe; Kazuteru Hatanaka; Takashi Meguro; Tomoe Kobayashi; Atsushi Ishiguro; Osamu Muto; Yoshiaki Shindo; Masahito Kotaka; Takayuki Ando; Ryo Takagi; Naoya Sakamoto; Yu Sakata
Frontiers in oncology, 12, 939425, 939425, 2022年, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: The first-line chemotherapy for patients with RAS and BRAF wild-type metastatic colorectal cancer (mCRC) commonly involves cytotoxic regimens, such as FOLFOX and FOLFIRI, combined with epidermal growth factor receptor (EGFR) antibodies. When progression occurs following anti-EGFR antibody-combined chemotherapy, anti-angiogenic inhibitors can be used as second-line treatment. Although randomized controlled trials have shown that anti-angiogenic inhibitors [bevacizumab, ramucirumab, and aflibercept (AFL)] carry survival benefit when combined with FOLFIRI as second-line chemotherapy, such trials did not provide data on patients with mCRC refractory to anti-EGFR antibody-combined chemotherapy. Therefore, our group planned a multicenter, nonrandomized, single-arm, prospective, phase II study to investigate the safety and efficacy of FOLFIRI plus AFL as a second-line chemotherapy for patients with mCRC refractory to oxaliplatin-based chemotherapy combined with anti-EGFR antibodies. METHODS: FOLFIRI (irinotecan 180 mg/m2, l-leucovorin 200 mg/m2, bolus 5-FU 400 mg/m2, and infusional 5-FU 2400 mg/m2/46 h) and AFL (4 mg/kg) will be administered every 2 weeks until progression or unacceptable toxicities occur. The primary endpoint will be the 6-month progression-free survival (PFS) rate, whereas the secondary endpoints will include overall survival, PFS, response rate, disease control rate, adverse events, and relative dose intensity for each drug. A sample size of 41 participants will be required. This study will be sponsored by the Non-Profit Organization Hokkaido Gastrointestinal Cancer Study Group and will be supported by a grant from Sanofi. DISCUSSION: There is only an observational study reporting data on FOLFIRI plus AFL for patients with mCRC who previously received anti-EGFR antibodies; therefore, a prospective clinical trial is needed. This study will prospectively evaluate the efficacy and safety of FOLFIRI plus AFL in patients with mCRC who are resistant to anti-EGFR antibodies and have limited data. Moreover, this study will reveal predictive biomarkers for AFL-based chemotherapy. CLINICAL TRIAL REGISTRATION: Japan Registry of Clinical Trials, jRCTs011190006. Registered 19 November, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs011190006. - がん治療医・緩和ケアスタッフを対象としたターミナルケア態度尺度を用いた意識調査
熊井 正貴; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 伊藤 陽一; 山田 武宏; 武隈 洋; 菅原 満; 川本 泰之; 小松 嘉人
Palliative Care Research, 17, 2, 51, 58, (NPO)日本緩和医療学会, 2022年
日本語 - A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain.
Kazuki Uchiyama; Yoshitaka Saito; Tatsuhiko Sakamoto; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Anticancer research, 42, 1, 343, 348, 2022年01月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND/AIM: Gemcitabine (GEM)-induced vascular pain often occurs in patients. A 5% glucose solution for the lyophilized formulation of GEM solvent is known to decrease the frequency of GEM-induced vascular pain compared with saline. In this study, we aimed to examine the availability of glucose for a liquid formulation GEM solvent for the prevention of GEM-induced vascular pain. PATIENTS AND METHODS: In total, 214 patients with bile tract or pancreatic cancer, who received GEM-containing regimens, were enrolled in this retrospective study. The patients were divided into a glucose group, which was administered the liquid formation GEM diluted with glucose, and a saline group. The frequency of GEM-induced vascular pain was compared between them. RESULTS: Glucose significantly decreased the frequency of GEM-induced vascular pain during the first GEM administration (36% vs. 55%, p=0.005). CONCLUSION: Switching the solution for liquid formulation GEM from saline to glucose significantly decreased the frequency of vascular pain. - A prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502‐A1
Kotoe Oshima; Ken Kato; Yoshinori Ito; Hiroyuki Daiko; Isao Nozaki; Satoru Nakagawa; Yuichi Shibuya; Takashi Kojima; Yasushi Toh; Morihito Okada; Shuichi Hironaka; Yuji Akiyama; Yoshito Komatsu; Kazuhiro Maejima; Hidewaki Nakagawa; Ritsuko Onuki; Momoko Nagai; Mamoru Kato; Keisuke Kanato; Aya Kuchiba; Kenichi Nakamura; Yuko Kitagawa
Cancer Science, 113, 3, 1018, 1027, Wiley, 2021年12月28日
研究論文(学術雑誌) - Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.
Yoshiaki Nakamura; Wataru Okamoto; Takeshi Kato; Taito Esaki; Ken Kato; Yoshito Komatsu; Satoshi Yuki; Toshiki Masuishi; Tomohiro Nishina; Hiromichi Ebi; Kentaro Sawada; Hiroya Taniguchi; Nozomu Fuse; Shogo Nomura; Makoto Fukui; Seiko Matsuda; Yasutoshi Sakamoto; Hiroshi Uchigata; Kana Kitajima; Naomi Kuramoto; Takashi Asakawa; Steve Olsen; Justin I Odegaard; Akihiro Sato; Satoshi Fujii; Atsushi Ohtsu; Takayuki Yoshino
Nature medicine, 27, 11, 1899, 1903, 2021年11月, [国際誌]
英語, 研究論文(学術雑誌), The applicability of circulating tumor DNA (ctDNA) genotyping to inform enrollment of patients with cancer in clinical trials has not been established. We conducted a phase 2 trial to evaluate the efficacy of pertuzumab plus trastuzumab for metastatic colorectal cancer (mCRC), with human epidermal growth factor receptor 2 (HER2) amplification prospectively confirmed by tumor tissue or ctDNA analysis ( UMIN000027887 ). HER2 amplification was confirmed in tissue and/or ctDNA in 30 patients with mCRC. The study met the primary endpoint with a confirmed objective response rate of 30% in 27 tissue-positive patients and 28% in 25 ctDNA-positive patients, as compared to an objective response rate of 0% in a matched real-world reference population treated with standard-of-care salvage therapy. Post hoc exploratory analyses revealed that baseline ctDNA genotyping of HER2 copy number and concurrent oncogenic alterations adjusted for tumor fraction stratified patients according to efficacy with similar accuracy to tissue genotyping. Decreased ctDNA fraction 3 weeks after treatment initiation associated with therapeutic response. Pertuzumab plus trastuzumab showed similar efficacy in patients with mCRC with HER2 amplification in tissue or ctDNA, showing that ctDNA genotyping can identify patients who benefit from dual-HER2 blockade as well as monitor treatment response. These findings warrant further use of ctDNA genotyping in clinical trials for HER2-amplified mCRC, which might especially benefit patients in first-line treatment. - 進行性固形癌患者における腸内細菌叢と免疫チェックポイント阻害剤の有効性
洞澤 智至; 澤田 憲太郎; 山下 理宇; 藤澤 孝夫; 吉河 歩; 中村 能章; 谷口 浩也; 門脇 重憲; 加藤 健; 佐藤 太郎; 小松 嘉人; 沖 英二; 安井 久晃; 山崎 健太郎; 吉野 孝之
日本癌治療学会学術集会抄録集, 59回, PS, 8, (一社)日本癌治療学会, 2021年10月
英語 - 胃癌の血中循環腫瘍DNAにおけるFGFR2増幅及びFGFR阻害薬に対する治療効果の検討
城後 友望子; 中村 能章; 設樂 紘平; 坂東 英明; 安井 久晃; 江崎 泰斗; 寺澤 哲志; 佐藤 太郎; 篠崎 英司; 仁科 智裕; 小倉 孝; 小松 嘉人; 谷口 浩也; 藤井 誠志; 吉野 孝之
日本癌治療学会学術集会抄録集, 59回, O47, 7, (一社)日本癌治療学会, 2021年10月
英語 - HGCSG2101 実臨床における進行膵癌に対するnal/IRI+5-FU/LVの治療成績
山村 貴洋; 原田 一顕; 曽我部 進; 澤田 憲太郎; 八木澤 允貴; 中野 真太郎; 太宰 昌佳; 舘山 美樹; 伊藤 憲; 斎藤 里佳; 川本 泰之; 結城 敏志; 坂本 直哉; 坂田 優; 小松 嘉人
日本癌治療学会学術集会抄録集, 59回, O43, 2, (一社)日本癌治療学会, 2021年10月
英語 - HGCSG1901 切除不能結腸直腸癌におけるIRIS/Bevの後方視的研究 抗EGFR抗体後の検討
斎藤 絢介; 伊藤 憲; 結城 敏志; 川本 泰之; 八木澤 允貴; 澤田 憲太郎; 佐藤 温; 辻 靖; 安藤 孝将; 中野 真太郎; 若林 俊樹; 小高 雅人; 高橋 康雄; 坂田 優; 小松 嘉人
日本癌治療学会学術集会抄録集, 59回, O56, 4, (一社)日本癌治療学会, 2021年10月
英語 - がん治療医・緩和ケアスタッフを対象としたターミナルケア態度尺度を用いた意識調査
熊井 正貴; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 伊藤 陽一; 山田 武宏; 川本 泰之; 武隈 洋; 菅原 満; 小松 嘉人
Palliative Care Research, 16, Suppl._Hokkaido, S492, S492, (NPO)日本緩和医療学会, 2021年10月
日本語 - がん治療医・緩和ケアスタッフを対象としたターミナルケア態度尺度を用いた意識調査
熊井 正貴; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 伊藤 陽一; 山田 武宏; 川本 泰之; 武隈 洋; 菅原 満; 小松 嘉人
Palliative Care Research, 16, Suppl._Hokkaido, S492, S492, (NPO)日本緩和医療学会, 2021年10月
日本語 - 大腸癌周術期治療の臨床開発と将来展望 進行直腸癌に対する化学放射線療法と免疫チェックポイント阻害剤を用いた術前治療
塚田 祐一郎; 坂東 英明; 稲守 宏冶; 冨樫 庸介; 結城 敏志; 小松 嘉人; 本間 重紀; 武冨 紹信; 植村 守; 加藤 健志; 若林 将史; 佐藤 暁洋; 西川 博嘉; 伊藤 雅昭; 吉野 孝之
日本癌治療学会学術集会抄録集, 59回, SY2, 4, (一社)日本癌治療学会, 2021年10月
英語 - A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403).
Yasuyuki Kawamoto; Hiroshi Nakatsumi; Kazuaki Harada; Tetsuhito Muranaka; Atsushi Ishiguro; Yoshimitsu Kobayashi; Hideyuki Hayashi; Satoshi Yuki; Kentaro Sawada; Masataka Yagisawa; Shintaro Nakano; Naoya Sakamoto; Yoshito Komatsu
The oncologist, 26, 10, e1675-e1682, 2021年10月, [国際誌]
英語, 研究論文(学術雑誌), LESSONS LEARNED: Because S-1 is orally administered, OX-IRIS does not necessitate the continuous infusion of 5-FU and is more convenient. The recommended dose of OX-IRIS was determined to be level -1 (oxaliplatin, 65 mg/m2 ; irinotecan, 100 mg/m2 ; S-1, 80 mg/m2 ), which has manageable safety and promising anticancer activities. BACKGROUND: OX-IRIS is a new combination therapy of oxaliplatin, irinotecan, and S-1 for unresectable pancreatic ductal adenocarcinoma (PDAC), which may be beneficial because S-1 is administered orally and continuous infusion of 5-fluorouracil (5-FU) is not needed. METHODS: Patients who had not received prior therapy for unresectable PDAC were enrolled. Adenocarcinoma or adenosquamous histology was required. Oxaliplatin and irinotecan were administered on days 1 and 15; S-1 was administered orally twice a day on days 1-14, followed by 14 days of rest (one cycle). Primary endpoints were dose-limiting toxicity (DLT) and maximum tolerated dose (MTD). Secondary endpoints were safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). RESULTS: In level 0 (oxaliplatin, 85 mg/m2 ; irinotecan, 100 mg/m2 ; S-1, 80 mg/m2 ), two of five patients experienced DLT. In level -1 (oxaliplatin, 65 mg/m2 ; irinotecan, 100 mg/m2 ; S-1, 80 mg/m2 ), DLT could not be evaluated in two of eight patients because one cycle was not completed; one of the remaining six patients experienced DLT. Anemia, thrombocytopenia, fatigue, nausea, anorexia, diarrhea, and peripheral sensory neuropathy were seen frequently in levels 0 and -1. ORR was 30% in levels 0 and -1. Median progression-free survival and median overall survival were 4.1 months (95% confidence interval [CI], 0.0-8.9 months) and 13.7 months (95% CI, 4.8-22.6 months), respectively. CONCLUSION: MTD of OX-IRIS therapy was estimated to be level 0, and the recommended dose (RD) for future trial was level -1. - The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
Keigo Chida; Daisuke Kotani; Toshiki Masuishi; Takeshi Kawakami; Yasuyuki Kawamoto; Kyoko Kato; Kunihiro Fushiki; Kentaro Sawada; Ryosuke Kumanishi; Hiromichi Shirasu; Yuki Matsubara; Satoshi Yuki; Yoshito Komatsu; Kentaro Yamazaki; Takayuki Yoshino
The oncologist, 26, 10, 845, 853, 2021年10月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: KRAS is one of the most frequently mutated oncogenes in colorectal cancer (CRC). Recently, a novel therapy targeting KRAS G12C mutation has demonstrated promising activities for corresponding advanced solid tumors, including metastatic CRC (mCRC). However, the prognostic impact of the KRAS G12C mutation remains unclear in patients with mCRC. MATERIALS AND METHODS: We retrospectively reviewed medical records of patients with mCRC who received first-line chemotherapy between January 2005 and December 2017 at four large oncology facilities in Japan. Survival outcomes were compared between patients with KRAS G12C and those with non-G12C mutations. RESULTS: Among 2,457 patients with mCRC, 1,632 met selection criteria, and of these, 696 had KRAS exon 2 mutations, including 45 with KRAS G12C mutation tumors. Patient characteristics were not significantly different between the KRAS G12C and non-G12C groups. At a median follow-up of 64.8 months, patients with the KRAS G12C mutation showed significantly shorter first-line progression-free survival (PFS; median, 9.4 vs. 10.8 months; p = .015) and overall survival (OS; median, 21.1 vs. 27.3 months; p = .015) than those with non-G12C mutations. Multivariate analysis also showed that KRAS G12C mutation was significantly associated with shorter PFS (hazard ratio [HR], 1.43; 95% confidence interval [CI], 1.04-1.96, p = .030) and OS (HR, 1.42; 95% CI, 1.01-2.00; p = .044). CONCLUSION: We demonstrate that, compared with non-G12C mutations, KRAS G12C mutation is significantly correlated with shorter first-line PFS and OS. These findings indicate the relevance of a stratified treatment targeting KRAS G12C mutation in mCRC. IMPLICATIONS FOR PRACTICE: Among patients with KRAS exon 2 mutated metastatic colorectal cancer (mCRC), median progression-free survival (PFS) and overall survival (OS) were 9.4 and 21.1 months, respectively, for G12C mutation and 10.8 and 27.3 months, respectively, for patients with non-G12C mutations, indicating significantly shorter PFS (hazard ratio [HR], 1.47; 95% confidence interval [CI], 1.08-2.01; p = .015) and OS (HR, 1.50; 95% CI, 1.08-2.08; p = .015) in patients with G12C mutation than in those with non-G12C mutations. Furthermore, multivariate analysis showed that KRAS G12C mutation was independently associated with shorter first-line PFS and OS. Thus, these findings underscore the relevance of a stratified treatment targeting KRAS G12C mutation in mCRC. - Severe hypertriglyceridemia induced by S-1: Subsequent case series of four patients and further review of the literature.
Yoshitaka Saito; Yoh Takekuma; Satoshi Takeuchi; Yoshito Komatsu; Mitsuru Sugawara
International journal of clinical pharmacology and therapeutics, 59, 12, 787, 793, 2021年09月10日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: We previously reported a case where S-1, containing tegafur, gimeracil, and oteracil potassium, induced severe hypertriglyceridemia. After the case, we regularly monitored serum lipid levels and surprisingly observed an additional 4 cases within 1.5 years. We here report the treatment process. CASE REPORT: At least 3 patients exhibited hyperlipidemia at baseline; in 2 of them, this was caused by previous fluoropyrimidine treatment. One patient experienced grade 4 hypertriglyceridemia, and the other 3 grade 3 hypertriglyceridemia. One patient developed temporary serum triglyceride elevation during the S-1 administration period, and the 3 experienced persistent elevation. The severity of serum triglyceride level worsened with increasing administration and peaked in cycles 2 - 6. Fenofibrate 80 - 160 mg/day and S-1 dose reduction were effective, with some significantly and others gradually decreasing to grade 0 - 1. DISCUSSION: The summarized clinical features are as follows: (1) Severe hypertriglyceridemia tends to appear after several treatment cycles and worsens with increasing administration. (2) It tends to occur in patients with hyperlipidemia at baseline. (3) Patients previously affected with fluoropyrimidines-induced hypertriglyceridemia can experience S-1 symptoms. (4) In some cases, it might decrease after the S-1 suspension period. (5) Fibrates and S-1 dose reductions were effective. As the final fluoropyrimidine product is fluorouracil, its presence or that of its metabolizing enzymes and the genetic background of the patients might have affected the results. We should be aware of the risk of temporal and asymptomatic occurrence of S-1-induced hypertriglyceridemia for early detection with appropriate treatment. - Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer.
Hiroyuki Okuyama; Yoshinori Kagawa; Toshiki Masuishi; Saori Mishima; Hiromichi Shirasu; Koji Ando; Satoshi Yuki; Kei Muro; Takayuki Yoshino; Kentaro Yamazaki; Eiji Oki; Yoshito Komatsu; Akihito Tsuji
International journal of clinical oncology, 26, 11, 2025, 2028, 2021年09月02日, [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: An infusion-related reaction (IRR) is a well-known adverse event related to monoclonal antibodies, and antihistamine premedication is recommended to prevent IRRs. Ramucirumab plus FOLFIRI therapy is the standard second-line treatment for metastatic colorectal cancer (CRC). Ramucirumab is a fully human antibody, suggesting that the incidence of IRRs is lower, however, the current recommendation for the proper use of ramucirumab is antihistamine premedication, but the incidence and severity of ramucirumab-induced IRR without antihistamine premedication have not been elucidated. METHODS: A retrospective study to evaluate the incidence of ramucirumab-induced IRRs in unresectable CRC patients treated by ramucirumab plus FOLFIRI therapy. If the incidence of IRR without antihistamine premedication was not higher than that of cetuximab in a previous report (5.7%), planning a prospective study was considered. RESULTS: A total of 147 patients with unresectable CRC who had been treated by ramucirumab plus FOLFIRI therapy were identified. Of them, 106 (72%) patients received intravenous antihistamine premedication. An IRR occurred in 2 patients (1.4%), 1 grade 2 and 1 grade 3. They received antihistamine and steroid premedication. On the other hand, IRRs were not observed in 41 patients without antihistamine premedication, and the incidence of IRRs was significantly lower compared with the previous report of cetuximab (p < 0.001). CONCLUSION: The incidence of ramucirumab-induced IRRs without antihistamine premedication is low. Not using antihistamine premedication can decrease medical costs. These findings warrant further investigation in large-scale cohorts to clarify the incidence and severity of ramucirumab-induced IRRs and further clarify the proper use of ramucirumab. - Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.
Tadamichi Denda; Atsuo Takashima; Makio Gamoh; Ichiro Iwanaga; Yoshito Komatsu; Masanobu Takahashi; Masato Nakamura; Hisatsugu Ohori; Akiko Sakashita; Masahiro Tsuda; Yoshimitsu Kobayashi; Hideo Baba; Masanori Kotake; Chikashi Ishioka; Yasuhide Yamada; Atsushi Sato; Satoshi Yuki; Satoshi Morita; Shin Takahashi; Tatsuro Yamaguchi; Ken Shimada
European journal of cancer (Oxford, England : 1990), 154, 296, 306, 2021年09月, [国際誌]
英語, 研究論文(学術雑誌), AIM: The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC). Overall survival (OS) data were immature at the time of the primary analysis. METHODS: In total, 487 patients from 53 institutions with previously untreated mCRC were randomly assigned (1:1) to receive either mFOLFOX6/CapeOX plus bevacizumab (control group) or S-1 and irinotecan plus bevacizumab (experimental group; 3- or 4-week regimen). The final OS data were analysed from follow-up data collected until 30th September 2017. RESULTS: With a median follow-up period of 48.7 months, median survival times were 32.6 and 34.3 months (hazard ratio [HR]: 0.89, 95% confidence interval [CI]: 0.72-1.10, P = 0.293) and median PFS durations were 10.8 and 14.0 months in the control and experimental groups, respectively (HR: 0.86, 95% CI: 0.71-1.04, P < 0.0001 for non-inferiority). In patients with left-sided RAS wild-type tumours, median PFS durations were 11.4 and 16.9 months in the control and experimental groups, respectively (HR: 0.68, 95% CI: 0.48-0.96, P = 0.028). CONCLUSION: S-1 and irinotecan plus bevacizumab resulted in comparable OS and non-inferior PFS with that of mFOLFOX6/CapeOX plus bevacizumab treatment as first-line chemotherapy for patients with mCRC. We recommend the use of S-1 and irinotecan plus bevacizumab as a standard first-line regimen independent of tumour sidedness or RAS status in mCRC. TRIAL REGISTRATION: UMIN-CTR: 000007834. - Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.
Tomoko Jogo; Yoshiaki Nakamura; Kohei Shitara; Hideaki Bando; Hisateru Yasui; Taito Esaki; Tetsuji Terazawa; Taroh Satoh; Eiji Shinozaki; Tomohiro Nishina; Yu Sunakawa; Yoshito Komatsu; Hiroki Hara; Eiji Oki; Nobuhisa Matsuhashi; Takashi Ohta; Takeshi Kato; Koushiro Ohtsubo; Takeshi Kawakami; Naohiro Okano; Yoshiyuki Yamamoto; Takanobu Yamada; Akihito Tsuji; Justin I Odegaard; Hiroya Taniguchi; Toshihiko Doi; Satoshi Fujii; Takayuki Yoshino
Clinical cancer research : an official journal of the American Association for Cancer Research, 27, 20, 5619, 5627, 2021年08月10日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: FGFR2 amplification is associated with poor prognosis in advanced gastric cancer and its subclonal heterogeneity has been revealed. Here, we examined whether circulating tumor DNA (ctDNA) was useful for detecting FGFR2 amplification and co-occurring resistance mechanisms in advanced gastric cancer. EXPERIMENTAL DESIGN: We assessed genomic characteristics of FGFR2-amplified advanced gastric cancer in a nationwide ctDNA screening study. We also analyzed FGFR2 amplification status in paired tissue and plasma samples with advanced gastric cancer. In addition, we examined patients with FGFR2-amplified advanced gastric cancer identified by ctDNA sequencing who received FGFR inhibitors. RESULTS: FGFR2 amplification was more frequently detected by ctDNA sequencing in 28 (7.7%) of 365 patients with advanced gastric cancer than by tissue analysis alone (2.6%-4.4%). FGFR2 amplification profiling of paired tissue and plasma revealed that FGFR2 amplification was detectable only by ctDNA sequencing in 6 of 44 patients, which was associated with a worse prognosis. Two patients in whom FGFR2 amplification was detected by ctDNA sequencing after tumor progression following previous standard chemotherapies but not by pretreatment tissue analysis had tumor responses to FGFR inhibitors. A third patient with FGFR2 and MET co-amplification in ctDNA showed a limitation of benefit from FGFR inhibition, accompanied by a marked increase in the MET copy number. CONCLUSIONS: ctDNA sequencing identifies FGFR2 amplification missed by tissue testing in patients with advanced gastric cancer, and these patients may respond to FGFR inhibition. The utility of ctDNA sequencing warrants further evaluation to develop effective therapeutic strategies for patients with FGFR2-amplified advanced gastric cancer. - 切除不能進行再発大腸癌に対する一次治療としてのCAPOXIRI+BEV療法の薬剤用量確認Stepの結果 QUATTRO-II
小高 雅人; 沖 英次; 佐竹 悠良; 坂東 英明; 山崎 健太郎; 山中 竹春; 小松 嘉人; 吉野 孝之; 辻 晃仁; 加藤 健志
日本消化器外科学会総会, 76回, P010, 1, (一社)日本消化器外科学会, 2021年07月
日本語 - P4-10 The impact of neutrophil/lymphocyte ratio (NLR) on overall survival for patients with metastatic colorectal cancer
Kazuaki Harada; Takeshi Kawakami; Toshiki Masuishi; Yasuyuki Kawamoto; Hirohumi Go; Kyoko Kato; Ryosuke Kumanishi; Satoshi Yuki; Kouji Yamamoto; Hirofumi Yasui; Yoshito Komatsu; Kei Muro; Takeharu Yamanaka; Kentaro Yamazaki
Annals of Oncology, 32, S332, S332, Elsevier BV, 2021年07月
研究論文(学術雑誌) - A case of immune checkpoint inhibitor-associated gastroenteritis detected by ultrasonography.
Satomi Omotehara; Mutsumi Nishida; Kana Yamanashi; Kensuke Sakurai; Takehiko Katsurada; Yoshito Komatsu; Ai Shimizu; Hitoshi Shibuya; Naofumi Shinagawa; Junichi Sugita; Takanori Teshima
Journal of clinical ultrasound : JCU, 49, 6, 605, 609, 2021年07月, [国際誌]
英語, While immune checkpoint inhibitors (ICIs) have antitumor effects, they also have characteristic side effects, including colitis. However, gastritis has rarely been reported. We report a case of a patient with lung adenocarcinoma who presented with epigastric pain and diarrhea following pembrolizumab administration. Sonography of the abdomen demonstrated diffuse, although mild, gastric wall thickening (mainly in the submucosa), as well as a slight decrease in echogenicity throughout the gastric wall. While the mucosal surface was relatively smooth, color Doppler examination showed increased vascularity. Esophagogastroduodenoscopy and pathological examination confirmed the diagnosis of ICI-related gastroenteritis. - Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study.
Takeshi Kato; Yoshinori Kagawa; Yasutoshi Kuboki; Makio Gamoh; Yoshito Komatsu; Hirofumi Yasui; Hironaga Satake; Eiji Oki; Hiroaki Tanioka; Masahito Kotaka; Akitaka Makiyama; Tadamichi Denda; Masahiro Goto; Takayuki Yoshino; Kentaro Yamazaki; Junpei Soeda; Kazunori Shibuya; Masaru Iwata; Koji Oba; Kensei Yamaguchi
International journal of clinical oncology, 26, 7, 1238, 1247, 2021年07月, [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: We aimed to assess the safety and efficacy of combination treatment with panitumumab plus trifluridine/tipiracil (FTD/TPI) in patients with wild-type RAS metastatic colorectal cancer (mCRC) who were refractory/intolerant to standard therapies other than anti-epidermal growth factor receptor therapy. METHODS: APOLLON was an open-label, multicentre, phase 1/2 trial. In the phase 1 part, 3 + 3 de-escalation design was used to investigate the recommended phase 2 dose (RP2D); all patients in the phase 2 part received the RP2D. The primary endpoint was investigator-assessed progression-free survival (PFS) rate at 6 months. Secondary endpoints included PFS, overall survival (OS), overall response rate (ORR), disease control rate (DCR), time to treatment failure (TTF), and safety. RESULTS: Fifty-six patients were enrolled (phase 1, n = 7; phase 2, n = 49) at 25 Japanese centres. No dose-limiting toxicities were observed in patients receiving panitumumab (6 mg/kg every 2 weeks) plus FTD/TPI (35 mg/m2 twice daily; days 1-5 and 8-12 in a 28-day cycle), which became RP2D. PFS rate at 6 months was 33.3% (90% confidence interval [CI] 22.8-45.3). Median PFS, OS, ORR, DCR, and TTF were 5.8 months (95% CI 4.5-6.5), 14.1 months (95% CI 12.2-19.3), 37.0% (95% CI 24.3-51.3), 81.5% (95% CI 68.6-90.8), and 5.8 months (95% CI 4.29-6.21), respectively. Neutrophil count decreased (47.3%) was the most common Grade 3/4 treatment-emergent adverse event. No treatment-related deaths occurred. CONCLUSION: Panitumumab plus FTD/TPI exhibited favourable anti-tumour activity with a manageable safety profile and may be a therapeutic option for pre-treated mCRC patients. - Hypertriglyceridemia induced by S-1: A novel case report and review of the literature.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 27, 4, 1020, 1025, 2021年06月, [国際誌]
英語, 研究論文(学術雑誌), INTRODUCTION: S-1, a compounding agent of tegafur, gimeracil, and oteracil potassium, is one of the most effective chemotherapeutic agents for colorectal cancer. In this case, following S-1 administration, we observed predominant elevation of serum triglyceride. CASE REPORT: A 49-year-old man with stage IV transverse colon adenocarcinoma received S-1 + irinotecan + bevacizumab. At the end of the S-1 administration period in every course, his serum triglyceride level was found to be elevated. Finally, it reached grade 4, without any symptoms of acute pancreatitis in the fifth course, and fenofibrate 80 mg once a day was administered.Management & outcome: Interestingly, the elevation spontaneously normalized without any pharmacotherapy 14 days after S-1 withdrawal, and this elevation did not occur when S-1 was not administered. Further, fenofibrate administration attenuated the hypertriglyceridemia to grades 1-3, with no complications. DISCUSSION: S-1 administration induced hypertriglyceridemia owing to the elevated serum triglyceride; however, a contrasting result was observed in the S-1 withdrawal period and during the S-1-cessation cycle. Since dietary intake was poorer during the S-1 administration period, it is considered that S-1 might have disturbed lipid metabolism. Further, we know that capecitabine, which is a prodrug of fluorouracil, also induces hypertriglyceridemia. As the end product of these medicines is fluorouracil, the presence of fluorouracil or its metabolizing enzymes, the genetic background of the patient might have affected the results. We have to be aware of the risk of asymptomatic and temporal occurrence of hypertriglyceridemia by S-1 administration for the early detection with appropriate pre-emptive treatment. - Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment.
Yoshitaka Saito; Yoh Takekuma; Masaki Kobayashi; Yoshito Komatsu; Mitsuru Sugawara
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29, 6, 3277, 3285, 2021年06月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: The combination of gemcitabine (GEM) and nanoparticle albumin-bound paclitaxel (nab-PTX) is an effective chemotherapeutic regimen for locally advanced and metastatic pancreatic cancer. The dose-limiting toxicities (DLTs) of this treatment are sepsis and neutropenia, while the relative dose intensity (RDI) of GEM is approximately 75% and of nab-PTX is 70-80%. In this study, we evaluated the risk factor(s) regarding treatment suspension, which leads to reduction in the RDI of these agents, enabling appropriate schedule management. METHODS: Two hundred patients with pancreatic cancer who received GEM + nab-PTX were retrospectively investigated. Frequency and risk factor(s) of suspension of the treatment and grade 3/4 neutropenia in the first course were evaluated. RESULTS: The frequency of treatment suspension in the first course was 61%. The frequency of grade 3/4 neutropenia was 51%, while that of thrombocytopenia was 7.5%. The RDI was 78.0% for GEM and 77.7% for nab-PTX. Univariate and multivariate analyses to identify risk or preventive factors related to treatment suspension suggested that low platelet count at baseline was a risk factor, whereas dose reduction from the treatment initiation was a preventive factor. The most common cause of abeyance was grade 3/4 neutropenia (83.6%), the risk factors of which were low platelet count and age ≥ 65 years at baseline, while dose reduction was a preventive factor. CONCLUSION: We found that a low platelet level at baseline was a risk factor, whereas dose reduction from initiation was a preventive factor in regard to treatment suspension and severe neutropenia occurrence in GEM + nab-PTX treatment. - Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer.
Masataka Yagisawa; Kentaro Sawada; Yoshiaki Nakamura; Satoshi Fujii; Satoshi Yuki; Yoshito Komatsu; Takayuki Yoshino; Naoya Sakamoto; Hiroya Taniguchi
Clinical colorectal cancer, 20, 2, 113, 120, 2021年06月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: The prognostic value and molecular landscape of human epidermal growth factor receptor 2 (HER2) low-expressing (HER2-L) metastatic colorectal cancer (mCRC) remain unclear. PATIENTS AND METHODS: This study enrolled patients with mCRC who had undergone surgical resection of primary tumor. Using the specimen, we evaluated HER2 expression by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). HER2 positivity was defined as follows: HER2 positivity (HER2-Pos) as IHC 3 + or IHC 2+/FISH positive, HER2-L as IHC 2+/FISH negative or IHC 1+, and HER2 negativity (HER2-Neg) as IHC 0+. Gene alterations were determined by next-generation sequencing. RESULTS: Between 2005 and 2015, a total of 370 patients were analyzed, comprising 15 patients (4%) with HER2-Pos, 21 (6%) with HER2-L, and 334 (90%) with HER2-Neg disease. The clinicopathologic characteristics among groups had no differences. HER2-L had a significantly higher proportion of coaltered RAS mutation than HER2-Pos (P = .037). With a median follow-up of 101.8 months, HER2-L had a significantly better median overall survival than HER2-Pos (P = .029) (18.2 months in HER2-Pos vs. 33.3 in HER2-L vs. 27.9 in HER2-Neg). In 58 patients harboring wild-type RAS and receiving anti-EGFR antibody therapy, HER2-L had a better median progression-free survival tendency than HER2-Pos, with 2.2 months in HER2-Pos, 7.8 in HER2-L, and 5.1 in HER2-Neg (P = .036). CONCLUSION: HER2-L mCRC showed a better prognosis than HER2-Pos mCRC, and it is similar to HER2-Neg mCRC. Hence, HER2-L mCRC might have different biologic behavior in terms of prognostic value and molecular landscape of mCRC, suggesting the possibility of implementation of HER2-guided clinical development against HER2-expressing mCRC. - Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Salvatore Siena; Maria Di Bartolomeo; Kanwal Raghav; Toshiki Masuishi; Fotios Loupakis; Hisato Kawakami; Kensei Yamaguchi; Tomohiro Nishina; Marwan Fakih; Elena Elez; Javier Rodriguez; Fortunato Ciardiello; Yoshito Komatsu; Taito Esaki; Ki Chung; Zev Wainberg; Andrea Sartore-Bianchi; Kapil Saxena; Eriko Yamamoto; Emarjola Bako; Yasuyuki Okuda; Javad Shahidi; Axel Grothey; Takayuki Yoshino
The Lancet. Oncology, 22, 6, 779, 789, 2021年06月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: HER2 amplification has been identified in 2-3% of patients with colorectal cancer, although there are currently no approved HER2-targeted therapies for colorectal cancer. We aimed to study the antitumour activity and safety of trastuzumab deruxtecan (an antibody-drug conjugate of humanised anti-HER2 antibody with topoisomerase I inhibitor payloads) in patients with HER2-expressing metastatic colorectal cancer. METHODS: DESTINY-CRC01 is an open-label, phase 2 study that recruited patients from 25 clinics and hospitals in Italy, Japan, Spain, the UK, and the USA. Eligible patients had centrally confirmed HER2-expressing metastatic colorectal cancer that had progressed on two or more previous regimens (HER2-targeted therapies other than trastuzumab deruxtecan permitted), were aged 18 years or older (≥20 years in Japan), had an Eastern Cooperative Oncology Group score of 0 or 1, and had RAS and BRAFV600E wild-type tumours. Patients were enrolled into one of three cohorts by HER2 expression level: cohort A (HER2-positive, immunohistochemistry [IHC] 3+ or IHC2+ and in-situ hybridisation [ISH]-positive), cohort B (IHC2+ and ISH-negative), or cohort C (IHC1+). Patients received 6·4 mg/kg trastuzumab deruxtecan intravenously every 3 weeks until disease progression, unacceptable adverse events, withdrawal of consent, or death. The primary endpoint was confirmed objective response rate in cohort A by independent central review which was assessed in the full analysis set and safety was assessed in the safety analysis set. Both the full analysis set and the safety analysis set included all patients who received one or more doses of trastuzumab deruxtecan. This ongoing trial is registered with ClinicalTrials.gov, number NCT03384940. FINDINGS: Between Feb 23, 2018, and July 3, 2019, 78 patients were enrolled in the study (53 in cohort A, seven in cohort B, and 18 in cohort C), all of whom received at least one dose of study drug. For the 53 (68%) patients with HER2-positive tumours (cohort A), a confirmed objective response was reported in 24 (45·3%, 95% CI 31·6-59·6) patients after a median follow-up of 27·1 weeks (IQR 19·3-40·1). Grade 3 or worse treatment-emergent adverse events that occurred in at least 10% of all participants were decreased neutrophil count (17 [22%] of 78) and anaemia (11 [14%]). Five patients (6%) had adjudicated interstitial lung disease or pneumonitis (two grade 2; one grade 3; two grade 5, the only treatment-related deaths). INTERPRETATION: Trastuzumab deruxtecan showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with that reported in previous trastuzumab deruxtecan trials. Interstitial lung disease and pneumonitis are important risks requiring careful monitoring and prompt intervention. FUNDING: Daiichi Sankyo. - Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
Kensei Yamaguchi; Nozomu Fuse; Yoshito Komatsu; Hirofumi Fujii; Shuichi Hironaka; Yasushi Omuro; Kei Muro; Hirofumi Yasui; Shinya Ueda; Tomohiro Nishina; Morihiro Watanabe; Atsushi Ohtsu
Japanese journal of clinical oncology, 51, 6, 879, 885, 2021年05月28日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: We evaluated the efficacy and safety of first-line S-1 plus cisplatin in combination with cetuximab for Japanese patients with advanced gastric cancer, including gastroesophageal junction adenocarcinoma. METHODS: This open-label, single arm, multicenter, phase 2 trial was conducted to assess first-line cetuximab plus S-1 plus cisplatin for advanced gastric cancer. A total of 40 patients from 10 centers were enrolled. Cetuximab was administered weekly, with the initial infusion at 400 mg/m2 and then 250 mg/m2 each subsequent week. S-1 plus cisplatin chemotherapy was concomitantly conducted in a 5-week cycle: S-1 (40-60 mg, adjusted for body surface area) was given twice daily for 3 consecutive weeks, followed by a 2-week rest period, and cisplatin (60 mg/m2) was given on day 8 of each cycle for a maximum of 8 cycles. Treatment continued until the occurrence of radiographically confirmed progressive disease, unacceptable toxicity or withdrawal of consent. The primary endpoint was the best overall response. Secondary endpoints included progression-free survival and safety. RESULTS: A total of 40 patients were evaluable. One patient (2.5%) had a complete response; 15 patients (37.5%) had a partial response. The observed overall response rate according to the independent review committee was 40.0% (95% confidence interval, 24.9-56.7; P = 0.7043 [one-sided null hypothesis: overall response rate ≤ 43%]); median PFS was 5.6 months (95% confidence intervals, 4.2-8.3). No adverse events leading to death were reported during the study, and no specific safety concerns were observed. CONCLUSIONS: Overall, the addition of cetuximab to S-1 plus cisplatin was well tolerated in patients with advanced gastric cancer but provided no additional clinical benefit in this study. ClinicalTrials.gov identifier: NCT01388790. - Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
Daisuke Kotani; Takayuki Yoshino; Masahito Kotaka; Akihito Kawazoe; Toshiki Masuishi; Hiroya Taniguchi; Kentaro Yamazaki; Takeharu Yamanaka; Eiji Oki; Kei Muro; Yoshito Komatsu; Hideaki Bando; Hironaga Satake; Takeshi Kato; Akihito Tsuji
Investigational new drugs, 39, 6, 1649, 1655, 2021年05月21日, [国際誌]
英語, 研究論文(学術雑誌), Background FOLFOXIRI plus bevacizumab is the first-line treatment for metastatic colorectal cancer (mCRC) but demonstrates high neutropenia incidence among Asian patients. Hence, we conducted the randomized phase II QUATTRO-II study (ClinicalTrials.gov identifier: NCT04097444; Japan Registry of Clinical Trials identifier: jRTCs041190072) to evaluate the safety and efficacy of capecitabine, oxaliplatin, and irinotecan (CAPOXIRI) combination plus bevacizumab versus FOLFOXIRI plus bevacizumab, expecting a lower incidence of neutropenia without compromising the efficacy. Methods We investigated the recommended doses (RD) of oxaliplatin and irinotecan as a safety lead-in portion of Step 1 before initiating the randomized portion as Step 2. Four dose levels of CAPOXIRI (fixed dose of capecitabine, 1600 mg/m2; escalated/de-escalated doses of oxaliplatin and irinotecan) plus bevacizumab (7.5 mg/kg) were investigated in a 3 + 3 manner. A dose level of ≤ 2/6 of dose-limiting toxicity (DLT) cases was expected as the RD. Results In Step 1, we included nine patients (three and six in levels 0 and + 1, respectively). Level 0 (irinotecan, 200 mg/m2; oxaliplatin, 100 mg/m2) did not demonstrate DLTs. In level + 1 (irinotecan, 200 mg/m2; oxaliplatin, 130 mg/m2), although one patient experienced grade 4 febrile neutropenia, no further safety concerns were observed. As a preliminary efficacy result, the objective response rate in all nine patients was 89 % (100 and 83 % in levels 0 and + 1, respectively). Conclusions The RD of CAPOXIRI plus bevacizumab was 200, 130, and 1600 mg/m2 for irinotecan, oxaliplatin, and capecitabine, respectively, and 7.5 mg/kg for bevacizumab. The randomized portion is still ongoing. - Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study.
Yoshinori Kagawa; Elena Elez; Jesús García-Foncillas; Hideaki Bando; Hiroya Taniguchi; Ana Vivancos; Kiwamu Akagi; Ariadna García; Tadamichi Denda; Javier Ros; Tomohiro Nishina; Iosune Baraibar; Yoshito Komatsu; Davide Ciardiello; Eiji Oki; Toshihiro Kudo; Takeshi Kato; Takeharu Yamanaka; Josep Tabernero; Takayuki Yoshino
Clinical cancer research : an official journal of the American Association for Cancer Research, 27, 9, 2515, 2522, 2021年05月01日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: OncoBEAM™ is a circulating tumor DNA (ctDNA) test that uses the BEAMing digital PCR technology. We clarified the association between the baseline tumor burden and discordance in the RAS status by metastatic sites in patients with a single metastatic site. EXPERIMENTAL DESIGN: Data from previous Spanish and Japanese studies investigating the concordance of the RAS status between OncoBEAM™ and tissue biopsy in 221 patients with metastatic colorectal cancer (mCRC) were used. We collected data from patients with liver, peritoneal, or lung metastases and evaluated the concordance rates according to the metastatic site and the association between the concordance rate and tumor burden. RESULTS: Patients had metastases in the liver (n = 151), peritoneum (n = 25), or lung (n = 45) with concordance rates of 91% (95% confidence interval, 85%-95%), 88% (68%-97%), and 64% (49%-78%), respectively. Factors associated with concordance included the baseline longest diameter and lesion number (P = 0.004), and sample collection interval (P = 0.036). Concordance rates ≥90% were observed in the following groups: liver metastases alone, regardless of the baseline longest diameter and lesion number; peritoneal metastases alone in patients with a baseline longest diameter ≥20 mm; and lung metastases alone in patients with a baseline longest diameter ≥20 mm and/or number of lesions ≥10. CONCLUSIONS: Plasma ctDNA-based liquid biopsy in patients with mCRC may be useful depending on the metastatic site. The maximum diameter and lesion number should be carefully considered when determining patients' RAS status with only peritoneal or lung metastases. - Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
Junko Kikuchi; Yoshihito Ohhara; Kohichi Takada; Hiroki Tanabe; Kazuteru Hatanaka; Toraji Amano; Kanako C Hatanaka; Yutaka Hatanaka; Takashi Mitamura; Momoko Kato; Yuka Shibata; Ichiro Yabe; Akira Endoh; Yoshito Komatsu; Yoshihiro Matsuno; Minako Sugiyama; Atsushi Manabe; Akihiro Sakurai; Masato Takahashi; Hirohito Naruse; Yoshihiro Torimoto; Hirotoshi Dosaka-Akita; Ichiro Kinoshita
Japanese journal of clinical oncology, 51, 5, 753, 761, 2021年04月30日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Comprehensive cancer genomic profiling has been used recently for patients with advanced solid cancers. Two cancer genomic profiling tests for patients with no standard treatment are covered by Japanese public health insurance since June 2019. METHODS: We prospectively analyzed data of 189 patients with solid cancers who underwent either of the two-cancer genomic profiling tests at Hokkaido University Hospital and its liaison hospitals and whose results were discussed in molecular tumor board at Hokkaido University Hospital between August 2019 and July 2020. RESULTS: All 189 patients had appropriate results. Actionable gene alterations were identified in 93 patients (49%). Frequent mutations included PIK3CA (12%) mutation, BRCA1/2 alteration (7%), ERBB2 amplification (6%) and tumor mutation burden-High (4%). The median turnaround time from sample shipping to acquisition by the expert panel was 26 days. Although 115 patients (61%) were provided with information for genotype-matched therapies, only 21 (11%) received them. Notably, four of eight patients below the age of 20 years were provided information for genotype-matched therapies, and three received them. Their response rates and disease control rates were 29% and 67%, respectively. Most patients who did not undergo the genotype-matched therapies were provided information for only investigational drugs in phases I and II at distant clinical trial sites in central Japan. Twenty-six patients were informed of suspected germline findings, while 11 patients (42%) received genetic counseling. CONCLUSIONS: The publicly reimbursed cancer genomic profilings may lead to the modest but favorable therapeutic efficacy of genotype-matched therapy for solid cancer patients with no standard therapy. However, poor access to genotype-matched therapy needs to be resolved. - IBD診療における超音波の有用性 免疫チェックポイント阻害薬誘発性大腸炎における体外式超音波検査の有用性
桜井 健介; 西田 睦; 表原 里実; 小田切 信介; 長島 一哲; 桂田 武彦; 小松 嘉人; 坂本 直哉
超音波医学, 48, Suppl., S306, S306, (公社)日本超音波医学会, 2021年04月
日本語 - Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
Shin Takahashi; Yasuhiro Sakamoto; Tadamichi Denda; Atsuo Takashima; Yoshito Komatsu; Masato Nakamura; Hisatsugu Ohori; Tatsuro Yamaguchi; Yoshimitsu Kobayashi; Hideo Baba; Masanori Kotake; Kenji Amagai; Hitoshi Kondo; Ken Shimada; Atsushi Sato; Satoshi Yuki; Akira Okita; Kota Ouchi; Keigo Komine; Mika Watanabe; Satoshi Morita; Chikashi Ishioka
Cancer science, 112, 4, 1567, 1578, 2021年04月, [国際誌]
英語, 研究論文(学術雑誌), Oxaliplatin (OX) and irinotecan (IRI) are used as key drugs for the first-line treatment of metastatic colorectal cancer (mCRC). However, no biomarkers have been identified to decide which of the drugs is initially used. In this translational research (TR) of the TRICOLORE trial, the advanced colorectal cancer subtype (aCRCS) was analyzed as a potential biomarker for the selection of OX or IRI. We collected 335 (68.8%) formalin-fixed, paraffin-embedded (FFPE) primary tumor specimens from 487 patients registered in the TRICOLORE trial and performed direct sequencing and immunohistochemical staining of CRC-related genes, comprehensive gene-expression analysis, and genome-wide methylation analysis. The progression-free survival (PFS) of the IRI group was significantly better compared with the OX group in BRAF wild-type (WT), PTEN-positive, and aCRCS A1 patients. Among the molecular factors, aCRCS were only associated with the PFS of OX and IRI groups. The PFS of the IRI group was significantly better compared with the OX group in aCRCS A1 + B1 (hazard ratio [HR] = 0.58; 95% confidence interval [CI] = 0.41-0.82; P = .0023). In contrast, the OX group had better PFS compared with the IRI group in aCRCS B2, although this was not statistically significant (HR = 1.66; 95% CI = 0.94-2.96; P = .083). Nearly half of patients with mCRC (46.8%, aCRCS A1 + B1) respond well to IRI, while only about 18.5% (aCRCS B2) of patients with mCRC responded well to OX. In conclusion, the aCRCS might be a predictive factor for the clinical outcomes of OX-based and IRI-based therapies. - 進展胃癌に対する薬物治療はこれからどう変わるか? MSI-H進行胃癌に対する1次治療としてのニボルマブと低用量イピリムマブ併用の第II相試験(NO LIMIT試験)(Phase II study of Nivolumab plus Low dose Ipilimumab In gastric MSI-H Tumor(NO LIMIT))
川上 尚人; 小松 嘉人; 藪崎 裕; 原 浩樹; 平田 賢郎; 平野 秀和; 町田 望; 牧山 明資; 門脇 重憲; 杉本 直俊; 津田 政広; 茶山 一彰; 江崎 泰斗; 廣中 秀一; 室 圭
日本胃癌学会総会記事, 93回, 210, 210, (一社)日本胃癌学会, 2021年03月
英語 - Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial.
Kazumasa Fujitani; Kohei Shitara; Atsuo Takashima; Keisuke Koeda; Hiroki Hara; Norisuke Nakayama; Shuichi Hironaka; Kazuhiro Nishikawa; Yutaka Kimura; Kenji Amagai; Hisashi Hosaka; Yoshito Komatsu; Ken Shimada; Ryohei Kawabata; Hideki Ohdan; Yasuhiro Kodera; Masato Nakamura; Takako Eguchi Nakajima; Yoshinori Miyata; Toshikazu Moriwaki; Tetsuya Kusumoto; Kazuo Nishikawa; Kazuhiro Ogata; Masashi Shimura; Satoshi Morita; Wasaburo Koizumi
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 24, 2, 467, 476, 2021年03月, [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: This study evaluated the association between early tumor response at 8 weeks, previously reported as a positive outcome prognosticator, and health-related quality of life (HRQOL) in advanced gastric cancer (AGC) patients enrolled in the ABSOLUTE trial. METHODS: HRQOL was assessed using the EuroQol-5 Dimension (EQ-5D) utility index score in patients with complete response (CR) + partial response (PR) and progressive disease (PD) at 8 weeks, and time-to-deterioration (TtD) of the EQ-5D score, with the preset minimally important difference (MID) of 0.05, was compared between these populations. Among the enrolled patients, 143 and 160 patients were assessable in weekly solvent-based paclitaxel (Sb-PTX) arm and weekly nanoparticle albumin-bound paclitaxel (nab-PTX) arm, respectively. RESULTS: Changes of the EQ-5D score from baseline to 8 weeks in the nab-PTX arm were 0.0009 and - 0.1229 in CR + PR and PD patients, respectively; the corresponding values for the Sb-PTX arm were - 0.0019 and - 0.1549. For both treatments, changes of the EQ-5D score from baseline at 8 weeks were significantly larger in patients with PD than in those with CR + PR. The median TtD was 3.9 and 2.2 months in patients with CR + PR and PD, respectively, for nab-PTX [hazard ratio (HR) = 0.595, 95% confidence interval (CI) 0.358-0.989]. For Sb-PTX, the corresponding values were 4.7 and 2.0 months (HR = 0.494, 95% CI 0.291-0.841). CONCLUSIONS: Early tumor shrinkage was associated with maintained HRQOL in AGC patients on the second-line chemotherapy with taxanes. - Correction to: Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial.
Kazumasa Fujitani; Kohei Shitara; Atsuo Takashima; Keisuke Koeda; Hiroki Hara; Norisuke Nakayama; Shuichi Hironaka; Kazuhiro Nishikawa; Yutaka Kimura; Kenji Amagai; Hisashi Hosaka; Yoshito Komatsu; Ken Shimada; Ryohei Kawabata; Hideki Ohdan; Yasuhiro Kodera; Masato Nakamura; Takako Eguchi Nakajima; Yoshinori Miyata; Toshikazu Moriwaki; Tetsuya Kusumoto; Kazuo Nishikawa; Kazuhiro Ogata; Masashi Shimura; Satoshi Morita; Wasaburo Koizumi
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 24, 2, 477, 478, 2021年03月, [国内誌]
英語 - A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Makoto Ueno; Chigusa Morizane; Masayuki Furukawa; Daisuke Sakai; Yoshito Komatsu; Yousuke Nakai; Masahiro Tsuda; Masato Ozaka; Nobumasa Mizuno; Manabu Muto; Akira Fukutomi; Masafumi Ikeda; Akihito Tsuji; Akio Katanuma; Toshikazu Moriwaki; Takeshi Kajiwara; Hiroshi Ishii; Yuji Negoro; Satoshi Shimizu; Noriko Nemoto; Shingo Kobayashi; Keigo Makino; Junji Furuse
Cancer medicine, 10, 6, 2088, 2099, 2021年03月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Effective second-line chemotherapy options are limited in treating advanced biliary tract cancers (BTCs). Resminostat is an oral histone deacetylase inhibitor. Such inhibitors increase sensitivity to fluorouracil, the active form of S-1. In the phase I study, addition of resminostat to S-1 was suggested to have promising efficacy for pre-treated BTCs. This study investigated the efficacy and safety of resminostat plus S-1 in second-line therapy for BTCs. METHODS: Patients were randomly assigned to receive resminostat or placebo (200 mg orally per day; days 1-5 and 8-12) and S-1 group (80-120 mg orally per day by body surface area; days 1-14) over a 21-day cycle. The primary endpoint was progression-free survival (PFS). Secondary endpoints comprised overall survival (OS), response rate (RR), disease control rate (DCR), and safety. RESULTS: Among 101 patients enrolled, 50 received resminostat+S-1 and 51 received placebo+S-1. Median PFS was 2.9 months for resminostat+S-1 vs. 3.0 months for placebo+S-1 (HR: 1.154, 95% CI: 0.759-1.757, p = 0.502); median OS was 7.8 months vs. 7.5 months, respectively (HR: 1.049, 95% CI: 0.653-1.684, p = 0.834); the RR and DCR were 6.0% vs. 9.8% and 70.0% vs. 78.4%, respectively. Treatment-related adverse events (TrAEs) of grade ≥ 3 occurring more frequently (≥10% difference) in the resminostat+S-1 than in the placebo+S-1 comprised platelet count decreased (18.0% vs. 2.0%) and decreased appetite (16.0% vs. 2.0%). CONCLUSIONS: Resminostat plus S-1 therapy improved neither PFS nor OS for patients with pre-treated BTCs. Addition of resminostat to S-1 was associated with higher incidence of TrAEs, but these were manageable (JapicCTI-183883). - An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7).
Hisato Kawakami; Shuichi Hironaka; Taito Esaki; Kazuaki Chayama; Masahiro Tsuda; Naotoshi Sugimoto; Shigenori Kadowaki; Akitaka Makiyama; Nozomu Machida; Hidekazu Hirano; Kenro Hirata; Hiroki Hara; Hiroshi Yabusaki; Yoshito Komatsu; Kei Muro
Cancers, 13, 4, 2021年02月15日, [国際誌]
英語, 研究論文(学術雑誌), Nivolumab (NIVO) plus low-dose ipilimumab (IPI) has shown a promising survival benefit in first-line treatment of microsatellite instability-high (MSI-H) colorectal cancer. We hypothesized that this regimen might also be beneficial for MSI-H gastric cancer (GC), which accounts for ~5% of all GC cases. NO LIMIT (WJOG13320G/CA209-7W7) is an investigator-initiated, single-arm, open-label, 14-center phase 2 trial of NIVO plus low-dose IPI for MSI-H GC in the first-line setting. Eligibility criteria include unresectable advanced, recurrent, or metastatic gastric or esophagogastric junction cancer with a histologically confirmed diagnosis of adenocarcinoma; confirmed MSI-H status with the MSI-IVD Kit (FALCO); no prior systemic anticancer therapy; an Eastern Cooperative Oncology Group performance status of 0 or 1; and a measurable lesion per RECIST 1.1. The primary objective of the study is to determine the overall response rate (ORR) for the NIVO+IPI regimen as assessed by blinded independent central review. Secondary end points include progression-free survival, overall survival, duration of response, safety, tolerability, and biomarkers. The number of patients was set at 28 on the basis of the threshold and expected ORR values of 35 and 65%, respectively, with a one-sided alpha error of 0.025 and power of 0.80. Subjects will receive treatment with nivolumab (240 mg) biweekly in combination with ipilimumab (1 mg/kg) every 6 weeks. The results of this study should clarify the therapeutic potential of NIVO+IPI for MSI-H GC in the first-line setting. Trial registration: JapicCTI-205400. - Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study
Yoshito Komatsu; Shuichi Hironaka; Yoshinori Tanizawa; Zhihong Cai; Yongzhe Piao; Narikazu Boku
Advances in Therapy, Adis, 2021年
英語, 研究論文(学術雑誌) - Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Biological & pharmaceutical bulletin, 44, 12, 1819, 1823, 2021年, [国内誌]
英語, 研究論文(学術雑誌), We have reported that a strict denosumab administration management system with oral calcium/vitamin D supplementation attenuates denosumab-induced hypocalcemia in 158 cancer patients with bone metastasis. In this report, 27.8% of the patients experienced hypocalcemia, including 0.6% with grade 2. So far, the risk factors for ≥grade 2 hypocalcemia incidence have been identified in denosumab-treated cancer patients, including patients without calcium/vitamin D supplementation. Therefore, the present study aimed to reveal the factors that affect all-grade hypocalcemia incidence with calcium/vitamin D supplementation and team medical care according to the management system. A receiver operating characteristic curve analysis suggested that the cutoff of baseline serum calcium level for all-grade hypocalcemia incidence was 9.3 mg/dL. Multivariate analysis revealed that age ≥65 years (odds ratio, 95% confidence interval: 2.57, 1.11-5.95, p = 0.03), grade 1 or higher serum alkaline phosphatase elevation (3.70, 1.71-8.00, p < 0.01), an adjusted serum calcium level of less than 9.3 mg/dL (3.21. 1.25-8.24, p = 0.02) at baseline, and co-administration of cytotoxic agents (2.33, 1.06-7.11, p = 0.03) are risk factors for the incidence of all-grade hypocalcemia. However, renal dysfunction, which has been suggested to be a risk factor in previous reports, was not a factor. In conclusion, we revealed the risk factors for all-grade hypocalcemia in calcium/vitamin D supplementation and awareness, as demonstrated by the management system. Moreover, renal dysfunction was not a risk factor in our strict denosumab administration management system. Our results support the value of early detection of hypocalcemia incidence to guide the selection of an appropriate management strategy. - Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report
Yoshitaka Saito; Yoh Takekuma; Satoshi Yuki; Yoshito Komatsu; Mitsuru Sugawara
Case Reports in Oncology, 14, 1, 207, 211, 2021年01月
研究論文(学術雑誌) - Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial.
Kensei Yamaguchi; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Yoshito Komatsu; Tomohiro Nishina; Yasushi Omuro; Takao Tamura; Yongzhe Piao; Gosuke Homma; Min-Hua Jen; Astra M Liepa; Kei Muro
Clinical drug investigation, 41, 1, 53, 64, 2021年01月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND AND OBJECTIVE: Gastric cancer has been associated with notable geographic heterogeneity in previous multi-regional studies. In particular, patients from Japan have better outcomes compared with patients from other regions. Here, we assess patient-focused outcomes for the subgroup of Japanese patients in the global RAINBOW study. METHODS: Quality of life (QoL) was assessed using the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (QLQ-C30) at baseline and 6-week intervals. Investigators assessed performance status before each 4-week cycle. Time-to-deterioration in each QLQ-C30 scale was defined as randomization to first worsening of ≥ 10 points (on a 100-point scale). Time-to-deterioration in performance status was defined as first worsening to ≥ 2. Hazard ratios were estimated using Cox proportional hazards models. RESULTS: The Japan subgroup contained 140 patients (ramucirumab plus paclitaxel, n = 68; placebo plus paclitaxel, n = 72); baseline QoL data were available for all patients. At baseline, QLQ-C30 scores were similar between study arms. Of the 15 QLQ-C30 scales, nine had a hazard ratio < 1, indicating similar or numerically longer time-to-deterioration in QoL for ramucirumab plus paclitaxel; all 95% confidence intervals included 1. Best mean change from baseline numerically favored ramucirumab plus paclitaxel in most QoL scales. The hazard ratios for time-to-deterioration of performance status to ≥ 2 were 0.64 in the Japan subgroup and 0.88 in the non-Asian subgroup. The Japan subgroup had better QoL at baseline compared with the non-Asian subgroup. CONCLUSIONS: Treatment with ramucirumab plus paclitaxel maintained QoL and performance status over time compared with placebo plus paclitaxel in the Japan subgroup of the RAINBOW trial. These data suggest that the heterogeneity in gastric cancer between geographic regions includes multiple measures of QoL. TRIAL REGISTRATION NUMBER: NCT01170663 (first submitted 21 July, 2010). - Evaluation of Chemotherapy Regimen Management Practice by Oncology-Specialized and Non-specialized Pharmacists Collaboration.
Yoshitaka Saito; Kazuki Uchiyama; Tatsuhiko Sakamoto; Kosei Kubota; Hiromitsu Oki; Miwako Iwai; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Biological & pharmaceutical bulletin, 44, 3, 293, 297, 2021年, [国内誌]
英語, 研究論文(学術雑誌), Chemotherapy regimen management is one of the most important oncology pharmacy practices, because chemotherapy is conducted according to the registered regimens. In this study, we evaluated the pharmaceutical practice that assumes the initial confirmation of chemotherapy regimens and the quality of practice sharing between oncology-specialized and non-specialized pharmacists in regimen management committee. Pharmacists initially confirmed the applied regimen prescribed by physicians regarding chemotherapeutic agents and prophylactic supportive care medicines. Following confirmation, the regimens were reviewed by the Hokkaido University Hospital Regimen Management Committee. A total of 233 regimens were reviewed by the committee over three years. In total, 110 pharmaceutical inquiries were conducted, 45% of inquiries were concerning chemotherapeutic agents, of which approximately half were regarding supportive care medicines. Most inquiries were regarding premedication, followed by those on administration time, solvent of infusion medicines, and dosage. Correction was performed for 84.5% of inquiries. There was no significant difference in inquiry rates between practice and trial regimens. We have entrusted the first basic regimen review according to the checklist, creation of the chemotherapy plan document, and registry of the adopted regimens in the ordering system from oncology-certified pharmacists to non-certified pharmacists. Basic regimen review was well conducted by a non-certified pharmacist, and a more advanced review was additionally performed by certified pharmacists. In conclusion, we demonstrated the utility of pharmaceutical confirmation in a chemotherapeutic regimen review, suitable review coverage, and quality practice sharing between oncology-certified and non-certified pharmacists, which is one of the recommended methods in chemotherapy regimen review. - Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study.
Yoshitaka Saito; Shinya Tamaki; Haruka Hasegawa; Kenta Takahashi; Akira Tokutome; Yoh Takekuma; Hiroko Yamashita; Yoshito Komatsu; Mitsuru Sugawara
Biological & pharmaceutical bulletin, 44, 4, 474, 477, 2021年, [国内誌]
英語, 研究論文(学術雑誌), CT-P6 is a biosimilar of trastuzumab and is recommended to be administered for 30-90 min in subsequent maintenance infusions to prevent infusion-related reactions (IRRs). We administered CT-P6 for 30 min as the first injection and as an alternative to reference trastuzumab in the maintenance infusion and evaluated the safety of the administration. A total of 140 patients with breast or gastric cancer, who received a switch from tri-weekly reference trastuzumab to CT-P6 for 30 min in maintenance infusions, were retrospectively evaluated. Premedication was administered prior to an infusion of CT-P6 and a cytotoxic agent. However, premedication was not provided when CT-P6 was co-administered with pertuzumab or administered alone. The primary endpoint was the incidence of IRRs. The secondary endpoint was the incidence of diarrhea and skin toxicity. Ninety-five percent of the patients had breast cancer, and 44.3% had advance-stage cancer. The treatment included CT-P6 alone (17.9%) or with cytotoxic agents (23.6%), antihormonal drugs (25.7%), and pertuzumab (62.9%). Median administration time of trastuzumab at the switch was 13 administrations (range 2-140). Premedication was administered to 20.7% patients. One patient (0.7%) experienced grade 3 IRR. The frequency of diarrhea in the reference trastuzumab group and the CT-P6 group was 7.1 and 6.4%, respectively, and that of skin toxicity was 6.4 and 5.0%, respectively, without differences. In conclusion, we first demonstrated that an initial CT-P6 administration for 30 min during the switch from reference trastuzumab in maintenance infusion is an acceptable administration method. - [Pharmaceutical Intervention According to Strict Management System Can Normalize Decreased Serum Calcium Level by Denosumab and Prevent Its Aggravation].
Yoshitaka Saito; Kazuki Uchiyama; Tatsuhiko Sakamoto; Kojiro Yamazaki; Kosei Kubota; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 141, 8, 1023, 1030, 2021年, [国内誌]
日本語, 研究論文(学術雑誌), Denosumab is a fully monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL), and prevents skeletal-related events by bone metastasis. Hypocalcemia is the most typical adverse effect of denosumab use. We have developed a management system for the more efficient and safer management of denosumab administration, and evaluated pharmaceutical interventions for the better control of hypocalcemia. All pharmaceutical interventions in the system from April 2016 to March 2020 were retrospectively evaluated. We have also assessed the incidence of hypocalcemia in 158 patients who were administered denosumab for six months or more in the period. A total of 282 pharmaceutical interventions (7.0% of the total administration) were conducted. The most conducted intervention was regarding hypocalcemia, which involved the suspension of the injection and/or the increase of calcium and vitamin D supplement with 65% adoption and 17% temporary treatment suspensions. Other interventions were about hypercalcemia, request of laboratory examination and ordering supplements, dental consultation, and poor renal function. A total of 199 interventions (70.6%) were adopted, with 33 administrations suspended. The frequency of hypocalcemia was 27.8% with just one patient having grade 2 hypocalcemia, suggesting that there were no severe cases. Moreover, hypocalcemia was significantly normalized following pharmaceutical intervention and/or handling by physicians (p=0.02) according to the system. Conversely, the normalization rate in hypercalcemia did not differ according to the countermeasures. In conclusion, pharmaceutical interventions according to our management system benefit safe denosumab treatment, especially in severe hypocalcemia prevention. - Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.
Yoshiaki Nakamura; Hiroya Taniguchi; Masafumi Ikeda; Hideaki Bando; Ken Kato; Chigusa Morizane; Taito Esaki; Yoshito Komatsu; Yasuyuki Kawamoto; Naoki Takahashi; Makoto Ueno; Yoshinori Kagawa; Tomohiro Nishina; Takeshi Kato; Yoshiyuki Yamamoto; Junji Furuse; Tadamichi Denda; Hisato Kawakami; Eiji Oki; Takako Nakajima; Naohiro Nishida; Kensei Yamaguchi; Hisateru Yasui; Masahiro Goto; Nobuhisa Matsuhashi; Koushiro Ohtsubo; Kentaro Yamazaki; Akihito Tsuji; Wataru Okamoto; Katsuya Tsuchihara; Takeharu Yamanaka; Izumi Miki; Yasutoshi Sakamoto; Hiroko Ichiki; Masayuki Hata; Riu Yamashita; Atsushi Ohtsu; Justin I Odegaard; Takayuki Yoshino
Nature medicine, 26, 12, 1859, 1864, 2020年12月, [国際誌]
英語, 研究論文(学術雑誌), Comprehensive genomic profiling enables genomic biomarker detection in advanced solid tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we compare trial enrollment using ctDNA sequencing in 1,687 patients with advanced gastrointestinal (GI) cancer in SCRUM-Japan GOZILA (no. UMIN000016343), an observational ctDNA-based screening study, to enrollment using tumor tissue sequencing in the same centers and network (GI-SCREEN, 5,621 patients). ctDNA genotyping significantly shortened the screening duration (11 versus 33 days, P < 0.0001) and improved the trial enrollment rate (9.5 versus 4.1%, P < 0.0001) without compromising treatment efficacy compared to tissue genotyping. We also describe the clonal architecture of ctDNA profiles in ~2,000 patients with advanced GI cancer, which reinforces the relevance of many targetable oncogenic drivers and highlights multiple new drivers as candidates for clinical development. ctDNA genotyping has the potential to accelerate innovation in precision medicine and its delivery to individual patients. - nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Makoto Ueno; Shoji Nakamori; Kazuya Sugimori; Masashi Kanai; Masafumi Ikeda; Masato Ozaka; Masayuki Furukawa; Takuji Okusaka; Ken Kawabe; Junji Furuse; Yoshito Komatsu; Hiroshi Ishii; Atsushi Sato; Satoshi Shimizu; Priti Chugh; Rui Tang; Tatsuya Ioka
Cancer medicine, 9, 24, 9396, 9408, 2020年12月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: In the NAPOLI-1 phase 3 trial, liposomal irinotecan (nal-IRI) +5-fluorouracil/leucovorin (5-FU/LV) significantly increased mPFS versus 5-FU/LV (3.1 vs. 1.5 months [unstratified HR = 0.56, p = 0.0001]) in patients with mPAC that progressed on prior gemcitabine-based therapy. This randomized phase 2 trial evaluated nal-IRI+5-FU/LV tolerability (Part 1), safety, and efficacy (Part 2; outcomes reported here) in Japanese patients with mPAC that progressed on gemcitabine-based therapy. METHODS: Patients were randomized 1:1 and stratified by KPS (70 and 80 vs. ≥90) and baseline albumin (≥4.0 g/dl vs. <4.0 g/dl). Primary endpoint was PFS; secondary endpoints were ORR, DCR, OS, TTF, CA19-9 response, and QoL. The ITT population comprised all randomized patients. RESULTS: Patient characteristics differed between nal-IRI+5-FU/LV (n = 40) and 5-FU/LV (n = 39) arms, including baseline hepatic lesions (63% vs. 51%), stage IV disease at diagnosis (78% vs. 51%), and post-study anticancer therapy (55% vs. 72%). Investigator-assessed mPFS increase with nal-IRI+5-FU/LV was clinically meaningful and statistically significant versus 5-FU/LV (2.7 vs. 1.5 months, HR = 0.60). Independently assessed mPFS showed similar trends (1.7 vs. 1.6 months, HR = 0.79). mOS was 6.3 months with nal-IRI+5-FU/LV and not reached with 5-FU/LV. ORR increased significantly with nal-IRI+5-FU/LV versus 5-FU/LV (18% vs. 0, rate difference 17.5). Commonly reported grade ≥3 treatment-emergent AEs were decreased neutrophil count (37% vs. 3%), decreased white blood cell count (20% vs. 0), and diarrhea (17% vs. 3%). CONCLUSIONS: In conclusion, clinically meaningful and statistically significant gains in investigator-assessed PFS and ORR were observed with nal-IRI+5-FU/LV versus 5-FU/LV in Japanese patients, with no new or unexpected safety signals. (Clinicaltrials.gov ID: NCT02697058). - BRAF V600E変異転移性大腸がんにおけるEncorafenib±Binimetinib+Cetuximab併用療法
吉野 孝之; 加藤 健志; 江崎 泰斗; 高島 淳生; 塩澤 学; 中島 貴子; 竹内 伸司; 佐藤 太郎; 小松 嘉人; 室 圭
日本癌治療学会学術集会抄録集, 58回, O26, 4, (一社)日本癌治療学会, 2020年10月
英語 - FOLFIRI+ラムシルマブ療法におけるインフュージョンリアクションの頻度に関する検討
賀川 義規; 舛石 俊樹; 三島 沙織; 白数 洋充; 安藤 幸滋; 結城 敏志; 奥山 浩之; 室 圭; 吉野 孝之; 山崎 健太郎; 沖 英次; 小松 嘉人; 辻 晃仁
日本癌治療学会学術集会抄録集, 58回, O31, 1, (一社)日本癌治療学会, 2020年10月
日本語 - Oxaliplatinによる類洞閉塞症候群の診断における腹部超音波検査の有用性の検討
斎藤 里佳; 西田 睦; 岩井 孝仁; 菊池 穏香; 吉野 裕紀; 横田 勲; 高木 諒; 川本 泰之; 山村 貴洋; 伊藤 憲; 中野 真太郎; 原田 一顕; 結城 敏志; 小松 嘉人; 坂本 直哉
日本癌治療学会学術集会抄録集, 58回, P, 178, (一社)日本癌治療学会, 2020年10月
英語 - 消化管間質腫瘍(GIST)におけるレゴラフェニブ治療と骨格筋量の変化に関する検討
伊藤 憲; 原田 一顕; 川本 泰之; 中積 宏之; 中野 真太郎; 斎藤 里佳; 山村 貴洋; 結城 敏志; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 127回・121回, 62, 62, 日本消化器病学会-北海道支部, 2020年10月
日本語 - IRIS/Bev療法時の下痢に対する半夏瀉心湯予防投与の第二相試験 生存期間の解析
原田 一顕; 中積 宏之; 川本 泰之; 結城 敏志; 石黒 敦; 舘山 美樹; 宮城島 拓人; 中村 路夫; 太宰 昌佳; 奥田 博介; 畑中 一映; 天野 虎次; 小松 嘉人
日本癌治療学会学術集会抄録集, 58回, P, 122, (一社)日本癌治療学会, 2020年10月
英語 - 消化器癌の化学療法で味覚異常を発症した症例の多施設共同医師主導前向き観察研究
伊藤 憲; 結城 敏志; 中積 宏之; 安藤 孝将; 太宰 昌佳; 畑中 一映; 宮城島 拓人; 久居 弘幸; 石黒 敦; 植田 亮; 佐々木 尚英; 進藤 吉明; 坂本 直哉; 坂田 優; 小松 嘉人
日本癌治療学会学術集会抄録集, 58回, P, 180, (一社)日本癌治療学会, 2020年10月
英語 - 切除不能大腸癌における一次化学療法開始からの生存期間に対する後方治療の影響
加藤 恭子; 川上 武志; 舛石 俊樹; 川本 泰之; 郷 洋文; 熊西 亮介; 澤田 憲太郎; 結城 敏志; 山本 紘司; 安井 博史; 小松 嘉人; 室 圭; 山中 竹春; 山崎 健太郎
日本癌治療学会学術集会抄録集, 58回, O25, 3, (一社)日本癌治療学会, 2020年10月
英語 - 大腸癌化学療法の治療選択に有用なバイオマーカー 切除不能大腸がんに対するがん薬物療法効果予測バイオマーカーとしてのCMSの意義
大堀 久詔; 坂本 康寛; 傳田 忠道; 高島 淳生; 高畑 武功; 小松 嘉人; 山口 達郎; 嶋田 顕; 高橋 信; 森田 智視; 石岡 千加史
日本癌治療学会学術集会抄録集, 58回, WS7, 2, (一社)日本癌治療学会, 2020年10月
英語 - Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Takashi Kitagataya; Goki Suda; Kazunori Nagashima; Takehiko Katsurada; Koji Yamamoto; Megumi Kimura; Osamu Maehara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Yoshito Komatsu; Hiroo Hata; Satoshi Takeuchi; Takashige Abe; Jun Sakakibara-Konishi; Takanori Teshima; Akihiro Homma; Naoya Sakamoto
Journal of gastroenterology and hepatology, 35, 10, 1782, 1788, 2020年10月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND AND AIM: Immune checkpoint inhibitors (ICI) have revolutionized anti-malignancy therapy and thus have been increasingly used. Although ICI may cause immune-related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clarified. METHODS: In this retrospective study, consecutive patients who had malignancies and were treated with ICI without other chemotherapeutic agents at Hokkaido University Hospital between 2014 and 2019 were screened. Patients were excluded if they were < 20 years old and had insufficient clinical data. RESULTS: Of the 233 patients screened, 202 patients met the inclusion criteria and were included in the analysis. The patients were aged 25-92 years, and 60.9% were male. The patients received nivolumab (n = 137), pembrolizumab (n = 45), ipilimumab (n = 17), atezolizumab (n = 2), and avelumab (n = 1). The prevalence of any grade and grade ≥ 3 irAE hepatitis was 8.4% (17/202) and 4.0% (8/202), respectively. irAE hepatitis occurred at a median duration of 42 days in any grade and 36 days in grade ≥ 3 after ICI initiation. The clinical course of grade ≥ 3 irAE hepatitis was generally favorable; however, 50% required corticosteroid treatment and two patients required additional mycophenolate mofetil. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis. CONCLUSIONS: Grade ≥ 3 irAE hepatitis was observed in 4.0% of the patients who were treated with ICI. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis. - Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
Shintaro Nakano; Satoshi Yuki; Yasuyuki Kawamoto; Hiroshi Nakatsumi; Takayuki Ando; Shinya Kajiura; Ayumu Yoshikawa; Kazuaki Harada; Kazuteru Hatanaka; Aya Tanimoto; Atsushi Ishiguro; Takuya Honda; Masayoshi Dazai; Takahide Sasaki; Naoya Sakamoto; Yoshito Komatsu
International journal of clinical oncology, 25, 10, 1800, 1806, 2020年10月, [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: It is unclear whether the UGT1A1 status, single heterozygous (SH) or wild type (WT), is associated with the efficacy and toxicity of irinotecan monotherapy in advanced gastric cancer (AGC). We investigated the association between clinical outcomes (efficacy and safety) and UGT1A1 status in patients who received irinotecan monotherapy. METHODS: We evaluated AGC patients who received irinotecan monotherapy between January 2011 and December 2017. Efficacy was assessed according to overall survival (OS) and progression-free survival (PFS). Toxicity was graded using the Common Toxicity Criteria for Adverse Events (version 4.0). RESULTS: A total of 100 patients were evaluated (62 and 38 patients with UGT1A1 WT and SH, respectively). In the WT and SH groups, the irinotecan dose was reduced in 19 (30.6%) and 18 (47.2%) patients (p = 0.135), respectively; treatment was delayed due to adverse events (AEs) in 19 (30.6%) and 13 (34.2%) patients (p = 0.826), respectively; the median PFS was 3.15 and 3.25 months (HR, 0.734; 95% CI 0.465-1.158; p = 0.184), respectively; and the median OS was 10.4 and 7.26 months (HR, 1.137; 95% CI 0.752-1.721; p = 0.543), respectively. Severe hematological AEs (Grade ≥ 3) were significantly more frequent in the SH group than in the WT group (63% vs. 36%; p = 0.008), while severe non-hematological AEs was not significantly different (16.0% vs. 6.5%; p = 0.173). CONCLUSION: There was no significant difference in the efficacy of irinotecan monotherapy between UGT1A1 WT and UGT1A1 SH, but UGT1A1 SH was associated with a high frequency of severe hematological toxicity. - Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer.
Shintaro Nakano; Yoshito Komatsu; Yasuyuki Kawamoto; Rika Saito; Ken Ito; Hiroshi Nakatsumi; Satoshi Yuki; Naoya Sakamoto
Medicine, 99, 39, e22250, 2020年09月25日, [国際誌]
英語, 研究論文(学術雑誌), It is unclear whether the use of antibiotics is related to the efficacy of gemcitabine plus nab-paclitaxel (GnP). Therefore, we investigated the association between the use of antibiotics and efficacy of GnP.We conducted a retrospective single center study from January 2014 to December 2018 in Hokkaido University Hospital.Ninety-nine patients were eligible for the study. Thirty-seven used antibiotics (U) and 62 did not use antibiotics (NU) during GnP therapy. In the U group, 15 patients used β-lactam antibiotics, 21 used new quinolones, and 1 used carbapenem. The median progression-free survival was 5.8 and 2.7 months (hazards ratio [HR] .602, 95% confidence interval [CI] .391-.928, P = .022) and the median overall survival was 11.0 and 8.4 months (HR .768, 95% CI .491-1.202, P = .248) in the U and not use antibiotics groups, respectively. Antibiotic use (HR .489, 95% CI .287-.832, P = .008) and locally advanced pancreatic cancer (HR 1.808, 95% CI 1.051-3.112, P = .032) were independent prognostic factors for progression-free survival.Antibiotic use was associated with a higher efficacy of GnP, and therefore, it may be employed as a novel treatment strategy. - 大腸がん薬物療法における免疫チェックポイント阻害薬の役割 マイクロサテライト不安定性のない(MMS)切除可能直腸癌症例に対する術前化学放射線療法(CRT)後の逐次治療としてのニボルマブ(nivo)療法の検討VOLTAGE試験
加藤 健志; 坂東 英明; 植村 守; 小松 嘉人; 本間 重紀; 塚田 祐一郎; 伊藤 雅昭; 吉野 孝之
日本大腸肛門病学会雑誌, 73, 9, A50, A50, (一社)日本大腸肛門病学会, 2020年09月
日本語 - Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Hideyuki Hayashi; Shigeki Tanishima; Kyoko Fujii; Ryo Mori; Chihiro Okada; Emmy Yanagita; Yuka Shibata; Ryosuke Matsuoka; Toraji Amano; Takahiro Yamada; Ichiro Yabe; Ichiro Kinoshita; Yoshito Komatsu; Hirotoshi Dosaka-Akita; Hiroshi Nishihara
Cancer science, 111, 10, 3926, 3937, 2020年08月08日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Precision medicine is a promising strategy for cancer treatment. In this study, we developed an in-house clinical sequencing system to perform a comprehensive cancer genomic profiling test as a clinical examination and analyzed the utility of this system. Genomic DNA was extracted from tumor tissues and peripheral blood cells collected from 161 patients with different stages and types of cancer. A comprehensive targeted amplicon exome sequencing for 160 cancer-related genes was performed using next-generation sequencing (NGS). The sequencing data were analyzed using an original bioinformatics pipeline, and multiple cancer-specific gene alterations were identified. The success rate of our test was 99% (160/161), while re-biopsy was required for 24% (39/161) of the cases. Potentially actionable and actionable gene alterations were detected in 91% (145/160) and 46% (73/160) of the patients, respectively. The actionable gene alterations were frequently detected in PIK3CA (9%), ERBB2 (8%), and EGFR (4%). High tumor mutation burden (TMB) (≥10 mut/Mb) was observed in 12% (19/160) of the patients. The secondary findings in germline variants considered to be associated with hereditary tumors were detected in 9% (15/160) of the patients. Seventeen patients (11%, 17/160) were treated with genotype-matched therapeutic agents, and the response rate was 47% (8/17). The median turnaround time for physicians was 20 days, and the median survival time after the initial visit was 8.7 months. The results of the present study prove the feasibility of implementing in-house clinical sequencing as a promising laboratory examination technique for precision cancer medicine. - Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
Masaaki Miyo; Takeshi Kato; Takayuki Yoshino; Takeharu Yamanaka; Hideaki Bando; Hironaga Satake; Kentaro Yamazaki; Hiroya Taniguchi; Eiji Oki; Masahito Kotaka; Koji Oba; Yoshinori Miyata; Kei Muro; Yoshito Komatsu; Hideo Baba; Akihito Tsuji
BMC cancer, 20, 1, 687, 687, 2020年07月23日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, showed that modified CAPIRI+BEV [capecitabine (CAP: 1600 mg/m2), irinotecan (IRI: 200 mg/m2), and BEV (7.5 mg/m2)] was non-inferior to FOLFIRI+BEV as a second-line therapy for mCRC patients and was associated with a lower incidence of hematologic toxicities. Thus, a reduced dose of the CAP and IRI regimen in combination with oxaliplatin (OX) and BEV (CAPOXIRI+BEV) may be more feasible than FOLFOXIRI+BEV, without compromising efficacy. METHODS: QUATTRO-II is an open-label, multicenter, randomized phase II study. In Step 1, the recommended doses of OX and IRI will be investigated as a safety lead-in. In Step 2, patients will be randomized to the recommended dose of either CAPOXIRI+BEV or FOLFOXIRI+BEV. Induction triplet chemotherapy plus BEV treatments will be administered for up to 4 months followed by fluoropyrimidine plus BEV maintenance. The primary endpoint is progression-free survival (PFS). The similarity in PFS between the two arms will be evaluated by observing whether the point estimate of hazard ratio (HR) for PFS falls between 0.80 and 1.25. Ensuring a 70% probability that the observed HR will be "0.8 < HR < 1.25" under the assumption of the true HR of 1.0, and 100 patients will be evaluated during the 3-year study period. Secondary endpoints include overall survival, overall response rate, safety, and patient reported outcome (PRO) (FACT/GOG-Ntx4). DISCUSSION: Considering the lower incidence of hematologic toxicities with modified CAPIRI+BEV than with FOLFIRI+BEV, CAPOXIRI+BEV may be a promising treatment option if sufficient efficacy and lower hematologic toxicities are indicated in this study. Additionally, a lower incidence of peripheral sensory neuropathy (PSN) reported following CAPEOX treatment compared to that after FOLFOX in ACHIEVE, an adjuvant phase III trial, suggest that CAPOXIRI+BEV can mitigate OX-induced PSN. TRIAL REGISTRATION: Clinicaltrials.gov NCT04097444 . Registered September 20, 2019, https://clinicaltrials.gov/ct2/show/study/NCT04097444 / Japan Registry of Clinical Trials jRCTs041190072. Registered October 9, 2019. - Multicenter phase 1/2 Trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial).
Akihito Kawazoe; Yasutoshi Kuboki; Eiji Shinozaki; Hiroki Hara; Tomohiro Nishina; Yoshito Komatsu; Satoshi Yuki; Masashi Wakabayashi; Shogo Nomura; Akihiro Sato; Takeshi Kuwata; Masahito Kawazu; Hiroyuki Mano; Yosuke Togashi; Hiroyoshi Nishikawa; Takayuki Yoshino
Clinical cancer research : an official journal of the American Association for Cancer Research, 26, 22, 5887, 5894, 2020年07月21日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: This is a phase 1/2 trial of napabucasin plus pembrolizumab for metastatic colorectal cancer (mCRC). EXPERIMENTAL DESIGN: Phase 1 was conducted to determine the recommended phase 2 dose (RP2D) in a dose escalation design of napabucasin (240mg to 480 mg twice daily) with 200mg pembrolizumab every 3 weeks. Phase 2 included cohort A (n = 10, microsatellite instability high) and cohort B (n = 40, microsatellite stable). The primary endpoint was immune-related objective response rate (irORR). PD-L1 combined positive score (CPS), genomic profiles and the consensus molecular subtypes (CMS) of colorectal cancer were assessed. RESULTS: A total of 55 patients were enrolled in this study. In phase 1, no patients experienced dose-limiting toxicities and napabucasin 480 mg was determined as RP2D. The irORR was 50.0% in cohort A and 10.0% in cohort B. In cohort B, the irORR was 0%, 5.3%, and 42.9% in CPS <1, 1≤ CPS <10 and CPS ≥10, respectively. Patients with objective response tended to have higher tumor mutation burden than those without. Of evaluable 18 patients for CMS classification in cohort B, the irORR was 33.3%, 0%, 33.3% and 33.3% in CMS1, CMS2, CMS3 and CMS4, respectively. The common grade 3 or higher treatment-related adverse events included fever (10.0%) in cohort A and decreased appetite (7.5%) and diarrhea (5.0%) in cohort B. CONCLUSIONS: Napabucasin with pembrolizumab showed anti-tumor activity with acceptable toxicities for MSS mCRC patients as well as MSI-H mCRC, although it did not meet the primary end point. - Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS study).
Hironaga Satake; Takeshi Kato; Koji Oba; Masahito Kotaka; Yoshinori Kagawa; Hisateru Yasui; Masato Nakamura; Takanori Watanabe; Toshihiko Matsumoto; Akayuki Kii; Tetsuji Terazawa; Akitaka Makiyama; Nao Takano; Mitsuru Yokota; Yoshihiro Okita; Koreatsu Matoba; Hiroko Hasegawa; Akihito Tsuji; Yoshito Komatsu; Takayuki Yoshino; Kentaro Yamazaki; Hideyuki Mishima; Eiji Oki; Naoki Nagata; Junichi Sakamoto
The oncologist, 25, 12, e1855-e1863, 2020年07月14日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), LESSONS LEARNED: A biweekly TAS-102 plus BEV schedule in patients with heavily pretreated mCRC showed equivalent efficacy with less toxicity compared with the current schedule of TAS-102 plus BEV combination. Biweekly TAS-102 plus BEV combination could reduce unnecessary dose reduction of TAS-102, maintain higher doses, and possibly be effective even in cases without CIN. The pre-specified subgroup analysis of this study showed an obvious association between CIN within the first two cycles and prognosis of biweekly TAS-102 plus BEV. BACKGROUND: TAS-102 (trifluridine/tipiracil) plus bevacizumab (BEV) combination therapy has shown promising activity in patients with metastatic colorectal cancer (mCRC). However, the previously reported dose and schedule for the TAS-102 (70mg/m2 /day on day 1-5 and 8-12, every 4 weeks) plus BEV (5mg/kg, day1, every 2 weeks) regimen is complicated by severe hematological toxicities and difficult administration schedules. Here, we evaluated the efficacy and safety of a more convenient biweekly TAS-102 plus BEV combination. METHODS: Patients with mCRC who were refractory or intolerant to standard chemotherapies were enrolled. Patients received biweekly TAS-102 (twice daily, on days 1-5, every 2 weeks) with BEV (5mg/kg, day1, every 2 weeks). The primary endpoint was progression-free survival rate at 16 weeks (16-w PFS rate). RESULTS: From October 2017 to January 2018, 46 patients were enrolled. The recommended phase II dose was determined to be TAS-102 (70mg/m2 /day). Of the 44 eligible patients, 16-w PFS rate was 40.9% (95% confidence interval: 26.3% to 56.8%) and the null hypothesis was rejected (p < 0.0001). Median PFS and overall survival was 4.29 months and 10.86 months, respectively. Disease control rate was 59.1%. Common grade 3 or higher adverse events were hypertension (40.9%), neutropenia (15.9%) and leucopenia (15.9%). CONCLUSION: Biweekly TAS-102 plus BEV showed promising anti-tumor activity with safety. - Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603).
Eiji Oki; Masahiro Kawahira; Tetsuya Kusumoto; Satoshi Yuki; Kazuteru Hatanaka; Yoshimitsu Kobayashi; Akihiro Nishie; Satoshi Kawanami; Akitaka Makiyama; Hiroshi Saeki; Sanae Sakamoto; Yoshito Komatsu; Mototsugu Shimokawa; Masaki Mori; Taito Esaki
Oncology, 98, 10, 1, 8, 2020年07月08日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Molecular targeted drugs having angiogenesis-inhibiting properties allow the induction of necrosis inside tumors. We retrospectively investigated the relationship between changes on imaging associated with regorafenib (REGO) and treatment outcomes using real-world data. PATIENTS AND METHODS: The eligibility criteria included an ECOG PS of 0-1, a starting dose of 120 or 160 mg/day of REGO, and a duration of treatment of at least 35 days. Regarding changes on imaging, cavitation in lung lesions (CLL), morphologic response of liver lesions (MRL), and change of liver metastasis density (CLD) were evaluated. RESULTS: We finally screened 671 cases, and 226 cases were eligible. In total, 172 and 145 patients had lung and liver metastases, respectively. Among the patients with lung metastasis, CLL was found in 69 patients (40.0%). The median progression-free survival (PFS) of the patients with and those without CLL was 3.2 and 2.4 months, respectively (hazard ratio [HR] = 0.758; 95% confidence interval [CI]: 0.529-1.087), and the median overall survival (OS) of these groups was 10.5 and 8.9 months, respectively (HR = 0.862; 95% CI: 0.579-1.285). MRL and CLD of liver metastasis were analyzed in 145 and 90 patients, respectively. The median OS with and without MRL was 8.9 and 8.2 months, respectively, whereas the median OS with and without CLD was 11.6 and 7.7 months, respectively (HR = 0.523; 95% CI: 0.275-0.992). CONCLUSION: CLL may predict PFS but not OS among patients with lung metastasis. CLD was predictive of favorable outcomes for REGO in patients with liver metastasis. - Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.
Hideaki Bando; Yoshinori Kagawa; Takeshi Kato; Kiwamu Akagi; Tadamichi Denda; Tomohiro Nishina; Yoshito Komatsu; Eiji Oki; Toshihiro Kudo; Hiroshi Kumamoto; Takeharu Yamanaka; Takayuki Yoshino
British journal of cancer, 122, 8, 1271, 1271, 2020年04月, [国際誌]
英語, An amendment to this paper has been published and can be accessed via a link at the top of the paper. - Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Toshikazu Moriwaki; Shota Fukuoka; Toshiki Masuishi; Atsuo Takashima; Yosuke Kumekawa; Takeshi Kajiwara; Kentaro Yamazaki; Taito Esaki; Akitaka Makiyama; Tadamichi Denda; Yukimasa Hatachi; Takeshi Suto; Naotoshi Sugimoto; Masanobu Enomoto; Toshiaki Ishikawa; Tomomi Kashiwada; Eiji Oki; Yoshito Komatsu; Akihito Tsuji; Kenji Tsuchihashi; Daisuke Sakai; Hideki Ueno; Takao Tamura; Kimihiro Yamashita; Yasuhiro Shimada
International journal of clinical oncology, 25, 4, 614, 621, 2020年04月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: Although regorafenib or trifluridine/tipiracil (FTD/TPI) has been recognized as a later-line standard treatment in patients with metastatic colorectal cancer (mCRC), not all patients have beneficial outcomes. This study aimed to develop a prognostic scoring system for evaluating the overall survival (OS) benefit. METHODS: Patients included in the REGOTAS study, which comprised 489 patients (regorafenib group: 199; FTD/TPI group: 290 patients), were evaluated. OS was analyzed using multivariate Cox proportional model. The prognostic score was calculated using the worst four individual factors weighted by hazard ratio, and the total scores were categorized as low-, moderate-, and high-OS benefit. RESULTS: The worst four factors in the regorafenib group were AST > 40 IU/dL (point, + 3), CRP ≥ 1.0 mg/dL (+ 2), number of metastatic organ site ≥ 3 (+ 2), and duration from initiation of 1st-line chemotherapy < 18 months (+ 2), while they were AST (+ 2), CRP (+ 2), CA19-9 > 37.0 U/mL (+ 2), and ECOG PS ≥ 1 (+ 2) in the FTD/TPI group. These corresponded to a total prognostic score of > 5, 2-4, and 0 points in the regorafenib group and 8, 2-6, and 0 points in the FTD/TPI group. The median OS in the low, moderate, and high OS benefit group was 3.3 (95% CI 3.0-3.7), 8.1 (95% CI 6.4-9.7), and 12.6 months (95% CI 10.6-14.6) in the regorafenib group and 2.8 (95% CI 2.0-3.5), 7.5 (95% CI 6.6-8.3), and 15.4 months (95% CI 9.7-21.2) in the FTD/TPI group. CONCLUSION: These prognostic scores are useful for identifying patients with mCRC who will obtain survival benefits from these drugs. - Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Akihito Kawazoe; Kensei Yamaguchi; Hisateru Yasui; Yuji Negoro; Mizutomo Azuma; Kenji Amagai; Hiroki Hara; Hideo Baba; Masahiro Tsuda; Hisashi Hosaka; Hisato Kawakami; Takashi Oshima; Yasushi Omuro; Nozomu Machida; Taito Esaki; Kazuhiro Yoshida; Tomohiro Nishina; Yoshito Komatsu; Shi R Han; Shinichi Shiratori; Kohei Shitara
European journal of cancer (Oxford, England : 1990), 129, 97, 106, 2020年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), AIM: The KEYNOTE-659 study evaluated the efficacy and safety of pembrolizumab in combination with chemotherapy as the first-line treatment in Japanese patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer. In this paper, we report results from cohort 1 (S-1 plus oxaliplatin [SOX] with pembrolizumab). METHODS: This was a non-randomised, multicentre, open-label phase IIb study in patients with advanced programmed death-ligand 1 (PD-L1)-positive, human epidermal growth factor receptor 2-negative G/GEJ tumours. The primary endpoint was the objective response rate (ORR) assessed by blinded independent central review (BICR). Secondary endpoints were duration of response (DOR), disease control rate (DCR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and safety. Exploratory analyses were performed based on the PD-L1 combined positive score (CPS) status. RESULTS: Fifty-four patients were evaluated. The median follow-up was 10.1 months. ORR and DCR by BICR were 72.2% (95% confidence interval [CI] 58.4-83.5) and 96.3% (95% CI 87.3-99.5), respectively. Median DOR, TTR, PFS and OS were as follows: not reached, 1.5 months, 9.4 months and not reached. The ORR was 73.9% in patients with CPS ≥1 to <10 and 71.0% in those with CPS ≥10. Grade ≥3 treatment-related adverse events (TRAEs) were reported by 57.4% of patients. The most common grade ≥3 TRAEs were decreased platelet count (14.8%), decreased neutrophil count (13.0%), colitis (5.6%) and adrenal insufficiency (5.6%). CONCLUSIONS: SOX with pembrolizumab showed encouraging efficacy and a manageable safety profile for the first-line treatment of advanced G/GEJ cancer. TRIAL REGISTRATION: NCT03382600/JapicCTI-183829. - ペムブロリズマブが奏効した高頻度マイクロサテライト不安定性の肝内胆管癌の1例
斎藤 里佳; 伊藤 憲; 中野 真太郎; 川本 泰之; 中積 宏之; 結城 敏志; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会プログラム・抄録集, 126回, 41, 41, 日本消化器病学会-北海道支部, 2020年03月
日本語 - 進行膵癌における化学療法施行例の予後因子解析
中野 真太郎; 小松 嘉人; 斉藤 里佳; 伊藤 憲; 川本 泰之; 中積 宏之; 結城 敏志; 坂本 直哉
日本消化器病学会北海道支部例会プログラム・抄録集, 126回, 58, 58, 日本消化器病学会-北海道支部, 2020年03月
日本語 - 【肝・胆・膵がんの薬物療法】胆道がん 進行胆道がんに対する分子標的治療薬と免疫チェックポイント阻害薬
川本 泰之; 小松 嘉人
腫瘍内科, 25, 2, 159, 166, (有)科学評論社, 2020年02月
日本語 - S-1またはカペシタビンを含む標準治療に不応・不耐の胃癌に対するbolus 5-FU/I-LV療法の多施設共同第II相試験 前治療別の解析
村中 徹人; 小松 嘉人; 結城 敏志; 中野 真太郎; 澤田 憲太郎; 川本 泰之; 中積 宏之; 原田 一顕; 宮城島 拓人; 畑中 一映; 太宰 昌佳; 植田 亮; 笹木 祐介; 辻 靖; 西本 尚樹; 坂田 優; 坂本 直哉
日本消化管学会雑誌, 4, Suppl., 262, 262, (一社)日本消化管学会, 2020年01月
日本語 - Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world
Toshirou Nishida; Yoshiharu Sakai; Masakazu Takagi; Masato Ozaka; Yuko Kitagawa; Yukinori Kurokawa; Toru Masuzawa; Yoichi Naito; Tatsuo Kagimura; Seiichi Hirota; Takuro Saito; Yoshito Komatsu; Masato Kondo; Tsutomu Hayashi; Naoto Gotoda; Nobuhiro Takiguchi; Atsuhiko Maki; Hideo Baba; Hajime Orita; Hiroshi Yabusaki; Gaku Chiguchi; Dai Manaka; Kazuhito Nabeshima; Hiromitsu Akabane; Koichi Ono; Norihito Wada; Masahide Kaji; Kazuhiro Yoshida; Ikuo Takahashi; Kazumasa Fujitani; Sohei Matsumoto; Yutaka Tamamori; Hiroaki Saito; Shugo Ueda; Masahiro Yamamura; Hirofumi Fujii; Shigefumi Yoshino; Akihiro Suzuki; Eigo Otsuji; Shigeyuki Kawachi; Tsuyoshi Takahashi; Kazuya Muguruma; Suguru Ishikawa; Masaaki Mitsutsuji; Hiroshi Takamori; Takashi Kaiho; Akihiro Sako; Seiji Ito; Masahiro Mori; Makoto Tokuhara; Yoshihiko Kawaguchi; Naoki Hirabayashi; Motohira Yoshida; Masazumi Takahashi; Shiro Takase; Keishi Yamashita; Yoshiaki Iwasaki; Yutaka Ozeki; Yasunori Nishida; Keisuke Koeda; Toshimasa Tsujinaka; Hiroshi Kanie; Shinji Hato; Junya Morimoto; Hiroshi Honda; Hirotaka Tashiro; Yoshihiro Kakeji; Hiroaki Hata; Toshiro Sugiyama; Takayuki Nobuoka; Ryoji Fukushima; Katsuro Sugiyama; Junichi Hasegawa; Tsunehiro Yoshimura; Atsuo Takashima; Chikara Kunisaki; Hiroharu Shinozaki; Naoto Senmaru; Hiroshi Imamura; Satoshi Otsu; Daisuke Kobayashi; Akinori Noguchi; Akinori Takagane; Atsushi Mitsunaga; Shigeyuki Tamura; Jin Matsuyama; Yoshio Oka; Kiyoshi Kajiyama; Takuji Yamada; Sumito Hoshino; Hideki Ohdan; Tomokazu Kakishita; Katsuhiko Yanaga; Yasushi Rino; Takayuki Takahashi; Hisahiro Matsubara; Masahiro Ishizaki; Songtae Kim; Noriyuki Inaki; Noriyuki Hirahara
Gastric Cancer, 23, 1, 118, 125, 2020年01月01日
研究論文(学術雑誌) - Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors.
Yoshitaka Saito; Kazuki Uchiyama; Tatsuhiko Sakamoto; Kojiro Yamazaki; Kosei Kubota; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Biological & pharmaceutical bulletin, 43, 12, 1969, 1974, 2020年, [国内誌]
英語, 研究論文(学術雑誌), We previously reported that successive pharmaceutical care by oncology pharmacy specialists contributes to quality outpatient chemotherapy. However, there are a few reports regarding such care during immune checkpoint inhibitors (ICIs) treatment, despite increasing patients being treated with ICIs and the profile of immune-related adverse events being quite different from that of the adverse effects of cytotoxic agents. We retrospectively evaluated the effectiveness of continuous pharmaceutical care in outpatient ICI treatment, focusing especially on the period of providing pharmaceutical recommendations. The adoption rate, efficacy, and period of pharmaceutical interventions, such as prescription questions and pharmaceutical recommendations, were evaluated. A total of 3597 ICI administrations (366 patients) were evaluated. We performed 2625 face-to-face medication counseling. A total of 282 prescription questions and 147 pharmaceutical recommendations were conducted. Approximately 70% of the questions were regarding ordering of laboratory examination, and 86.5% of these questions were adopted. Pharmaceutical recommendations were categorized into medication recommendations (81.1%), examination recommendations (10.8%), and recommendation of expert consultation (8.1%). The adoption rate of pharmaceutical recommendations was 96.0, and 70% of the medication recommendations attenuated the symptoms. Finally, the provision rate of pharmaceutical recommendations was significantly higher in the first 3 months after ICI treatment initiation. We found that pharmaceutical care contributes to an improved quality of outpatient ICI treatment, and face-to-face pharmaceutical counseling up to 3 months after ICI treatment initiation is the most important. - BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer.
Daisuke Kotani; Hideaki Bando; Hiroya Taniguchi; Toshiki Masuishi; Yoshito Komatsu; Kensei Yamaguchi; Takako Nakajima; Taroh Satoh; Tomohiro Nishina; Taito Esaki; Shogo Nomura; Koji Takahashi; Shinobu Iida; Seiko Matsuda; Shinya Motonaga; Nozomu Fuse; Akihiro Sato; Satoshi Fujii; Atsushi Ohtsu; Hiromichi Ebi; Takayuki Yoshino
ESMO open, 5, 1, e000624, 2020年, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: While the BRAF V600E mutation occurs in 5%-15% of metastatic colorectal cancer (mCRC), BRAF non-V600E mutations were recently reported to range from 1.6% to 5.1%. We have previously reported that BRAF non-V600E mutations could have a negative impact on efficacy outcomes as well as BRAF V600E mutation for antiepidermal growth factor receptor (EGFR) antibody treatment for pretreated patients with mCRC. Recently, simultaneous inhibitions of mitogen-activated protein kinase kinase (MEK), BRAF and EGFR exhibited relevant antitumour activities in patients with BRAF V600E mutant and also in BRAF non-V600E mutant but only in the preclinical model. TRIAL DESIGN: The BIG BANG (study is a multicentre, phase II study to assess the efficacy, safety and proof of concept of the combinations of binimetinib+encorafenib+cetuximab in patients with BRAF non-V600E mutated mCRC, identified by either tumour tissue (tumour tissue group) or blood samples (liquid biopsy group). Key eligibility criteria include Eastern Cooperative Oncology Group Performance Status of ≤1, mCRC with BRAF non-V600E mutant and RAS wild type, refractory or intolerant to at least one fluoropyrimidine-based regimen and no prior history of regorafenib, and no prior history of anti-EGFR antibody treatment (primary analysis cohort and liquid biopsy cohort) or refractory to prior anti-EGFR antibody treatment in patients with class 3 BRAF mutations (anti-EGFR antibody refractory class three cohort). Enrolled patients receive binimetinib (45 mg, two times per day), encorafenib (300 mg, once a day) and cetuximab (initially 400 mg/m2 and subsequently 250 mg/m2, once per week). The primary endpoint is the confirmed objective response rate in the primary analysis cohort. TRIAL REGISTRATION NUMBERS: UMIN000031857 and 000031860. - Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial
Yasuhide Yamada; Kei Muro; Keiichi Takahashi; Hideo Baba; Yoshito Komatsu; Taroh Satoh; Masahiro Goto; Hideyuki Mishima; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Naruhito Takenaka; Tadashi Hirooka; Kenichi Sugihara
Global Health & Medicine, 2, 4, 240, 246, National Center for Global Health and Medicine (JST), 2020年, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), Mechanisms accounting for sex differences in the incidence of adverse events caused by fluoropyrimidine treatments, and histologic differences in efficacy are insufficiently understood. We determined differences between the sexes in terms of the safety of S-1 plus oxaliplatin (SOX)/bevacizumab-versus-l-leucovorin, 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX)/bevacizumab, and the impact of histology on their therapeutic effects, in 512 unresectable metastatic colorectal cancer patients from the SOFT phase III study. Nausea (OR: 2.88, P < 0.001) and vomiting (OR: 3.04, P = 0.005) occurred more frequently in females than males treated with SOX/bevacizumab, while nausea (OR: 2.12, P = 0.006), vomiting (OR: 3.26, P = 0.004), leukopenia (OR: 2.61, P < 0.001), neutropenia (OR: 2.92, P < 0.001), and alopecia (OR: 4.13, P < 0.001) were higher in females on FOLFOX/bevacizumab. Mean relative dose intensities (RDIs) of S-1 during all cycles of SOX/bevacizumab were significantly lower in females (73.9%) than males (81.5%) (P < 0.001), while RDIs of continuous infusion of 5-FU in the FOLFOX/bevacizumab regimen were 75.0% in females and 80.5% in males (P = 0.005). No significant differences in efficacy with regard to overall survival (OS) and progression-free survival (PFS) were identified between the sexes for either SOX/bevacizumab or FOLFOX/bevacizumab treatment. Patients with poorly-differentiated adenocarcinoma had significantly worse OS (HR: 2.72, 95% CI: 1.67-4.44, P < 0.0001) and PFS (HR: 1.89, 95% CI: 1.18-3.02, P = 0.0079) than patients with well- or moderately-differentiated adenocarcinoma. Female patients experienced more frequent and severe adverse reactions to SOX/bevacizumab and FOLFOX/bevacizumab and a worse prognosis for poorly-differentiated adenocarcinoma were confirmed in this phase III study. This warrants further translational research to identify the responsible mechanisms. - Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
T Yoshino; J M Cleary; E Van Cutsem; R J Mayer; A Ohtsu; E Shinozaki; A Falcone; K Yamazaki; T Nishina; R Garcia-Carbonero; Y Komatsu; H Baba; G Argilés; A Tsuji; A Sobrero; K Yamaguchi; M Peeters; K Muro; A Zaniboni; N Sugimoto; Y Shimada; Y Tsuji; H S Hochster; T Moriwaki; B Tran; T Esaki; C Hamada; T Tanase; F Benedetti; L Makris; F Yamashita; H-J Lenz
Annals of oncology : official journal of the European Society for Medical Oncology, 31, 1, 88, 95, 2020年01月, [査読有り], [国際誌]
英語, BACKGROUND: The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer. This post hoc analysis investigated pharmacokinetic data of FTD/TPI exposure and pharmacodynamic markers, such as chemotherapy-induced neutropenia (CIN) and clinical outcomes. PATIENTS AND METHODS: A total of 210 patients from RECOURSE were enrolled in this substudy. A limited sampling approach was used, with three pharmacokinetic samples drawn on day 12 of cycle 1. Patients were categorized as being above or below the median area under the plasma concentration-time curve (AUC) for FTD and TPI. We conducted a post hoc analysis using the entire RECOURSE population to determine the correlations between CIN and clinical outcome. We then carried out a similar analysis on the J003 trial to validate the results. RESULTS: In the RECOURSE subset, patients in the high FTD AUC group had a significantly increased CIN risk. Analyses of the entire population demonstrated that FTD/TPI-treated patients with CIN of any grade in cycles 1 and 2 had significantly longer median overall survival (OS) and progression-free survival (PFS) than patients who did not develop CIN and patients in the placebo group. Patients who required an FTD/TPI treatment delay had increased OS and PFS versus those in the placebo group and those who did not develop CIN. Similar results were obtained in the J003 cohort. CONCLUSIONS: In RECOURSE, patients with higher FTD drug exposure had an increased CIN risk. FTD/TPI-treated patients who developed CIN had improved OS and PFS versus those in the placebo group and those who did not develop CIN. Similar findings were reported in the J003 cohort, thus validating the RECOURSE results. The occurrence of CIN may be a useful predictor of treatment outcomes for FTD/TPI-treated patients. CLINICALTRIALS. GOV IDENTIFIER: NCT01607957 (RECOURSE). JAPAN PHARMACEUTICAL INFORMATION CENTER NUMBER: JapicCTI-090880 (J003). - Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.
Satoshi Yuki; Katsunori Shinozaki; Tomomi Kashiwada; Tetsuya Kusumoto; Masaaki Iwatsuki; Hironaga Satake; Kazuma Kobayashi; Taito Esaki; Yuichiro Nakashima; Hirofumi Kawanaka; Yasunori Emi; Yoshito Komatsu; Mototsugu Shimokawa; Akitaka Makiyama; Hiroshi Saeki; Eiji Oki; Hideo Baba; Masaki Mori
Cancer chemotherapy and pharmacology, 85, 1, 217, 223, 2020年01月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Trastuzumab (T-mab) combined with cisplatin and fluoropyrimidines is a standard first-line treatment for HER2+ advanced gastric cancer (AGC). We conducted the first phase II trial among four Japanese study groups to assess the efficacy and safety of T-mab + S-1 and oxaliplatin (T-SOX130) for HER2+ AGC or recurrent gastric cancer. METHODS: Patients with IHC 3+ or IHC 2+/FISH+ tumors received 80 mg/m2 (80-120 mg/day) oral S-1 on days 1-14, 130 mg/m2 intravenous oxaliplatin on day 1, and intravenous T-mab (8 mg/kg loading dose, 6 mg/kg thereafter) on day 1 of a 21-day cycle. The primary endpoint was centrally assessed response rate (RR). Adverse events were based on the Common Terminology Criteria for Adverse Events (CTCAE) Ver.4.0. RESULTS: We enrolled 42 patients from June 2015 to May 2016. Efficacy and safety analyses were conducted for 39 patients. The data cutoff was May 31, 2018. The confirmed RR was 82.1% (32/39; 90% CI 70.0-90.0); the disease control rate was 87.2% (34/39; 95% CI 73.3-94.4). Nine patients underwent curative surgery after T-SOX130. Median Time to treatment failure (TTF), Progression-free survival (PFS) and Overall survival (OS) was 5.7 (95% CI 4.6-7.0), 7.0 (95% CI 5.5-14.1), and 27.6 (95% CI 15.6-Not reached) months, respectively. Incidences of grade 3-4 adverse events > 10% were thrombocytopenia (17.9%), anorexia (17.9%), anemia (12.8%), neutropenia (10.3%), and hyponatremia (10.3%). CONCLUSIONS: T-SOX130 showed promising response and survival with a favorable safety profile and should be considered for patients with HER2+ AGC. - 【遺伝子・免疫異常に伴う消化管病変-最新のトピックスを中心に】免疫チェックポイント阻害薬関連消化管病変
長島 一哲; 桂田 武彦; 大塚 拓也; 西田 睦; 表原 里実; 桜井 健介; 小田切 信介; 山梨 香菜; 小松 嘉人; 三橋 智子; 坂本 直哉
胃と腸, 54, 13, 1723, 1732, (株)医学書院, 2019年12月
日本語 - One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis.
Okada Y; Oba K; Furukawa N; Kosaka Y; Okita K; Yuki S; Komatsu Y; Celio L; Aapro M
The oncologist, 24, 12, 1593, 1600, 2019年12月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: A dexamethasone-sparing regimen consisting of palonosetron plus 1-day dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) has been studied previously. Here, we evaluate the noninferiority of the dexamethasone-sparing regimen in overall antiemetic control using a meta-analysis based on individual patient data (IPD). MATERIALS AND METHODS: We conducted a systematic review for randomized trials reporting CINV outcomes for the comparison of palonosetron plus 1-day dexamethasone (d1 arm) versus the same regimen followed by dexamethasone on days 2-3 after chemotherapy (d3 arm) in chemotherapy-naïve adult patients undergoing either moderately emetogenic chemotherapy (MEC) or anthracycline plus cyclophosphamide (AC)-containing chemotherapy. PubMed and MEDLINE were searched electronically. A manual search was also conducted. The primary endpoint was complete response (CR; no emesis and no rescue medication) in the overall 5-day study period. The noninferiority margin was set at -8.0% (d1 arm-d3 arm). RESULTS: Five studies (n = 1,194) were eligible for analysis and all IPD was collected. In the overall study period, the d1 arm showed noninferiority to the d3 arm for CR as well as complete control (pooled risk difference in CR rate - 1.5%, 95% confidence interval [CI] -7.1 to 4.0%, I2 = 0%; in complete control rate - 2.4%, 95% CI -7.7 to 2.9%, I2 = 0%). There was no significant interaction between dexamethasone regimen and risk factors (type of chemotherapy, sex, age, and alcohol consumption). CONCLUSION: This IPD meta-analysis indicates that the dexamethasone-sparing regimen is not associated with a significant loss in overall antiemetic control in patients undergoing MEC or AC-containing chemotherapy, irrespective of known risk factors for CINV. IMPLICATIONS FOR PRACTICE: Although dexamethasone in combination with other antiemetic agents has been used to prevent chemotherapy-induced nausea and vomiting (CINV), it is of clinical importance to minimize total dose of dexamethasone in patients undergoing multiple cycles of emetogenic chemotherapy. This individual-patient-data meta-analysis from five randomized controlled trials (1,194 patients) demonstrated a noninferiority of the dexamethasone-sparing regimen for complete response and complete control of CINV. The outcomes were comparable across patients with different characteristics. These findings thus help physicians minimize use of the steroid and further reduce the burden of dexamethasone-related side effects in patients undergoing multiple consecutive courses of emetogenic chemotherapy. - 胸部食道扁平上皮癌に対する術前補助化学療法・根治切除術および根治的化学放射線療法についての後方視的検討
中積 宏之; 村中 徹人; 川本 泰之; 小松 嘉人; 結城 敏志; 中野 真太郎; 澤田 憲太郎; 坂本 直哉; 打浪 雄介; 田口 大志; 白土 博樹; 海老原 裕磨; 七戸 俊明; 平野 聡
北海道医学雑誌, 94, 2, 120, 121, 北海道医学会, 2019年11月
日本語 - Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Tetsuya Hamaguchi; Tadamichi Denda; Toshihiro Kudo; Naotoshi Sugimoto; Takashi Ura; Kentaro Yamazaki; Hirofumi Fujii; Takeshi Kajiwara; Takako Eguchi Nakajima; Shin Takahashi; Satoshi Otsu; Yoshito Komatsu; Fumio Nagashima; Toshikazu Moriwaki; Taito Esaki; Takeo Sato; Michio Itabashi; Eiji Oki; Toru Sasaki; Marielle Chiron; Takayuki Yoshino
Cancer science, 110, 11, 3565, 3572, 2019年11月, [国際誌]
英語, 研究論文(学術雑誌), Aflibercept plus 5-fluorouracil/levofolinate/irinotecan (FOLFIRI) is a second-line treatment for metastatic colorectal cancer. This ancillary exploratory analysis of data in Japanese people was aimed at exploring the relationship between a set of potential prognostic biomarkers and efficacy endpoints following aflibercept plus FOLFIRI therapy. Sixty-two patients with metastatic colorectal cancer received aflibercept (4 mg/kg) plus FOLFIRI every 2 weeks. Seventy-eight potential protein biomarkers were chosen for analysis based on their roles in angiogenesis, tumor progression, and tumor-stroma interaction. Plasma levels of biomarkers at baseline and at pre-dose 3 (day 1 of treatment cycle 3) were measured in all patients by ELISA. Relationships between these levels and efficacy endpoints were assessed. Ten potential biomarkers had a ±30% change from baseline to pre-dose 3 (adjusted P < .001), with the greatest changes occurring in placental growth factor (median: +4716%) and vascular endothelial growth factor receptor 1 (+2171%). Baseline levels of eight potential biomarkers correlated with overall survival in a univariate Cox regression analysis: extracellular newly identified receptor for advanced glycation end-products binding protein, insulin-like growth factor-binding protein 1, interleukin-8, kallikrein 5, pulmonary surfactant-associated protein D, tissue inhibitor of metalloproteinases 1, tenascin-C, and tumor necrosis factor receptor 2. None correlated with progression-free survival or maximum tumor shrinkage. Pre-dose 3 levels did not correlate with any efficacy endpoints. Preliminary data show that these eight biomarkers could be associated with overall survival. ClinicalTrials.gov identifier: NCT01882868. - Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
Toshiki Masuishi; Hiroya Taniguchi; Takeshi Kawakami; Yasuyuki Kawamoto; Shigenori Kadowaki; Yusuke Onozawa; Tetsuhito Muranaka; Masahiro Tajika; Hirofumi Yasui; Hiroshi Nakatsumi; Satoshi Yuki; Kei Muro; Katsuhiro Omae; Yoshito Komatsu; Kentaro Yamazaki
ESMO open, 4, 6, 2019年11月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been recognised as standard treatments in metastatic colorectal cancer (mCRC), the best option remains unclear. Pretreatment tumour growth rate (TGR) is associated with radiotherapeutic efficacy in laryngeal cancer. However, no reports are available on the association between TGR during preceding treatment and the efficacy of REG or FTD/TPI. PATIENTS AND METHODS: We retrospectively analysed the data of consecutive mCRC patients treated with REG or FTD/TPI and classified them into slow-growing or rapid-growing (SG or RG) groups according to TGR and emergence of new lesion (NL+) or their absence (NL-) during preceding treatment period [SG: NL- with low TGR (<0.33%/day); RG: NL+ or high TGR (≥0.33%/day)]. RESULTS: A total of 244 patients (RG/SG, 133/111; REG/FTD/TPI, 132/112) were eligible. The RG proportion with a long duration from first-line chemotherapy and the SG proportion with elevated alkaline phosphatase were higher in REG, whereas the SG proportion with performance status 2 was higher in FTD/TPI. The disease control rates (DCRs) were similar between REG and FTD/TPI (24%/30%; OR: 0.74; p=0.44; adjusted OR: 0.73; p=0.47) in the RG, whereas the DCR was significantly higher for FTD/TPI than for REG (47%/26%; OR: 2.56; p=0.029; adjusted OR: 3.38; p=0.01) in the SG. CONCLUSIONS: TGR and NL during preceding treatment may be helpful for drug selection in refractory mCRC patients to be treated with REG or FTD/TPI. However, further studies are needed to confirm the value of TGR for drug selection. - Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
Toshihiko Doi; Yukinori Kurokawa; Akira Sawaki; Yoshito Komatsu; Masato Ozaka; Tsuyoshi Takahashi; Yoichi Naito; Shuichi Ohkubo; Toshirou Nishida
European journal of cancer (Oxford, England : 1990), 121, 29, 39, 2019年11月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), AIM: We evaluated the efficacy and safety of TAS-116, a novel class of an orally active selective inhibitor of heat shock protein 90, in patients with advanced gastrointestinal stromal tumour (GIST) after failure of three or more lines of standard treatment with imatinib, sunitinib and regorafenib. METHODS: In this single-arm phase II study, patients received 160 mg/day oral TAS-116 for five consecutive days, followed by a 2-day rest. The primary end-point was centrally assessed progression-free survival (PFS). The secondary end-points were objective response rate, disease control rate, overall survival (OS), metabolic response rate, safety, pharmacokinetics and pharmacogenomics. RESULTS: Forty-one patients were enrolled in Japan, and 40 patients underwent efficacy and safety evaluation. At the cut-off date, the median PFS was 4.4 months (95% confidence interval [CI], 2.8-6.0) and 12-week progression-free rate was 73.4% (95% CI, 58.1-88.7). Thirty-four patients (85.0%) had stable disease for ≥ 6 weeks. The median OS was 11.5 months (95% CI, 7.0-not reached). All patients experienced at least one treatment-related adverse event (AE), including diarrhoea (80.0%), decreased appetite (45.0%) and increase in blood creatinine level (42.5%). Grade ≥3 AEs and treatment-related grade ≥3 AEs occurred in 23 (57.5%) and 21 (52.5%) patients, respectively. All AEs resolved after dose modification, and no TAS-116-related AEs led to treatment discontinuation. CONCLUSION: TAS-116 showed significant activity in advanced GIST refractory to standard treatment. Further development of TAS-116 is warranted. TRIAL REGISTRATION: JapicCTI-163182. - TRICOLORE試験(大腸癌第3相試験:mFOLFOX6/CapeOX+Bev vs S-1/CPT-11+Bev)のQOL解析
佐藤 温; 高島 淳生; 傳田 忠道; 蒲生 真紀夫; 高畑 武功; 天貝 賢二; 倉持 英和; 近藤 仁; 的場 周一郎; 有岡 仁; 小松 嘉人; 山口 達郎; 嶋田 顕; 森田 智視; 石岡 千加史
日本癌治療学会学術集会抄録集, 57回, O38, 1, (一社)日本癌治療学会, 2019年10月
英語 - The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC)
T. Kawakami; T. Masuishi; Y. Kawamoto; H. Go; H. Shirasu; K. Kato; R. Kumanishi; K. Sawada; K. Yamamoto; S. Yuki; Y. Komatsu; H. Yasui; K. Muro; T. Yamanaka; K. Yamazaki
Annals of Oncology, 30, v222, v222, Elsevier BV, 2019年10月
研究論文(学術雑誌) - 経口フッ化ピリミジン不応の胃がんに対するRPMI療法(HGCSG1502試験)OS・QOL解析結果
太宰 昌佳; 村中 徹人; 川本 泰之; 中積 宏之; 原田 一顕; 宮城島 拓人; 畑中 一映; 植田 亮; 加藤 総介; 笹木 有佑; 結城 敏志; 坂本 直哉; 西本 尚樹; 坂田 優; 小松 嘉人
日本癌治療学会学術集会抄録集, 57回, P69, 1, (一社)日本癌治療学会, 2019年10月
英語 - 転移を有する膵癌に対する化学療法薬剤使用歴と治療成績の関係の検討
川本 泰之; 斎藤 里佳; 伊藤 憲; 中野 真太郎; 中積 宏之; 結城 敏志; 小松 嘉人; 坂本 直哉
日本癌治療学会学術集会抄録集, 57回, P86, 7, (一社)日本癌治療学会, 2019年10月
英語 - TRICOLORE試験に基づいた転移を有する大腸癌に対する一次治療の費用効果分析
後藤 励; 高島 淳生; 傳田 忠道; 蒲生 真紀夫; 倉持 英和; 天貝 賢二; 近藤 仁; 杉山 克郎; 中村 路夫; 畑中 一映; 石岡 千加史; 小松 嘉人; 山口 達郎; 嶋田 顕; 森田 智視
日本癌治療学会学術集会抄録集, 57回, O38, 2, (一社)日本癌治療学会, 2019年10月
英語 - 局所進行膵癌における化学療法および化学放射線療法の検討
中野 真太郎; 小松 嘉人; 川本 泰之; 斎藤 里佳; 伊藤 憲; 中積 宏之; 結城 敏志; 坂本 直哉
日本消化器病学会北海道支部例会プログラム・抄録集, 125回, 55, 55, 日本消化器病学会-北海道支部, 2019年09月
日本語 - mFOLFIRINOX療法にて完全奏効が得られた進行膵癌の2例
伊藤 憲; 小松 嘉人; 結城 敏志; 中積 宏之; 川本 泰之; 中野 真太郎; 齋藤 里佳
日本消化器病学会北海道支部例会プログラム・抄録集, 125回, 55, 55, 日本消化器病学会-北海道支部, 2019年09月
日本語 - Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.
Kohei Shitara; Taroh Satoh; Satoru Iwasa; Kensei Yamaguchi; Kei Muro; Yoshito Komatsu; Tomohiro Nishina; Taito Esaki; Jun Hasegawa; Yasuyuki Kakurai; Emi Kamiyama; Tomoko Nakata; Kota Nakamura; Hayato Sakaki; Ichinosuke Hyodo
Journal for immunotherapy of cancer, 7, 1, 219, 219, 2019年08月14日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosylated to enhance antibody-dependent cellular cytotoxicity activity. We conducted a two-step, phase I, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of DS-8895a in patients with advanced solid tumors. METHODS: Step 1 was a dose escalation cohort in advanced solid tumor patients (six dose levels, 0.1-20 mg/kg) to determine Step 2 dosing. Step 2 was a dose expansion cohort in EPHA2-positive esophageal and gastric cancer patients. DS-8895a was intravenously administered every 2 weeks for the duration of the study, with a 28-day period to assess dose-limiting toxicity (DLT). Safety, pharmacokinetics, tumor response, and potential biomarkers were evaluated. RESULTS: Thirty-seven patients (Step 1: 22, Step 2: 15 [9: gastric cancer, 6: esophageal cancer]) were enrolled. Although one DLT (Grade 4 platelet count decreased) was observed in Step 1 (dose level 6, 20 mg/kg), the maximum tolerated dose was not reached; the highest dose (20 mg/kg) was used in Step 2. Of the 37 patients, 24 (64.9%) experienced drug-related adverse events (AEs) including three (8.1%) with Grade ≥ 3 AEs. Infusion-related reactions occurred in 19 patients (51.4%) but were manageable. All patients discontinued the study (evident disease progression, 33; AEs, 4). Maximum and trough serum DS-8895a concentrations increased dose-dependently. One gastric cancer patient achieved partial response and 13 patients achieved stable disease. Serum inflammatory cytokines transiently increased at completion of and 4 h after the start of DS-8895a administration. The proportion of CD16-positive natural killer (NK) cells (CD3-CD56+CD16+) decreased 4 h after the start of DS-8895a administration, and the ratio of CD3-CD56+CD137+ to CD3-CD56+CD16+ cells increased on day 3. CONCLUSIONS: Twenty mg/kg DS-8895a infused intravenously every 2 weeks was generally safe and well tolerated in patients (n = 21) with advanced solid tumors. The exposure of DS-8895a seemed to increase dose-dependently and induce activated NK cells. TRIAL REGISTRATION: Phase 1 Study of DS-8895a in patients with advanced solid tumors ( NCT02004717 ; 7 November 2013 to 2 February 2017); retrospectively registered on 9 December 2013. - A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.
Hideaki Bando; Yoshinori Kagawa; Takeshi Kato; Kiwamu Akagi; Tadamichi Denda; Tomohiro Nishina; Yoshito Komatsu; Eiji Oki; Toshihiro Kudo; Hiroshi Kumamoto; Takeharu Yamanaka; Takayuki Yoshino
British journal of cancer, 120, 10, 982, 986, 2019年05月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: OncoBEAMTM RAS CRC kit using BEAMing technology is a circulating tumour DNA (ctDNA) test for detecting plasma RAS mutational status in metastatic colorectal cancer (mCRC). We conducted a multicentre, prospective study to investigate the concordance of the RAS mutational status between plasma ctDNA and tumour tissue DNA. METHODS: mCRC patients without prior anti-EGFR antibodies or regorafenib treatment were enroled. Plasma- and tissue-based RAS mutational status were determined by BEAMing, respectively. RESULTS: A total of 280 patients from eight institutions were eligible. The overall agreement between plasma- and tissue-based analyses was 86.4%, with a positive percent agreement of 82.1% and negative percent agreement of 90.4%. From logistic regression analysis, lung metastasis alone indicated the most significant factor associated with discordance. The agreement between plasma- and tissue-based analyses was 64.5% in patients with lung metastasis alone (n = 31) indicating lower amount of ctDNA. Among the cases with lung metastasis alone, all plasma- and tissue-based analyses were perfectly concordant in cases with ≥20 mm of maximum lesion diameter or ≥10 lesions. CONCLUSION: The clinical validity of OncoBEAMTM RAS CRC kit was confirmed. Careful attention should be paid for mCRC patients with lung metastases alone having fewer metastases or smaller diameter lesions. - Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
Masuishi, Toshiki; Moriwaki, Toshikazu; Fukuoka, Shota; Takashima, Atsuo; Kumekawa, Yosuke; Kajiwara, Takeshi; Yamazaki, Kentaro; Esaki, Taito; Makiyama, Akitaka; Denda, Tadamichi; Satake, Hironaga; Suto, Takeshi; Sugimoto, Naotoshi; Katsumata, Kenji; Ishikawa, Toshiaki; Kashiwada, Tomomi; Oki, Eiji; Komatsu, Yoshito; Yoshimura, Kenichi; Shimada, Yasuhiro
JOURNAL OF CLINICAL ONCOLOGY, 37, 15::S, AMER SOC CLINICAL ONCOLOGY, 2019年05月
英語, 研究論文(国際会議プロシーディングス) - Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer.
Okamoto, Wataru; Nakamura, Yoshiaki; Shiozawa, Manabu; Komatsu, Yoshito; Denda, Tadamichi; Hara, Hiroki; Kagawa, Yoshinori; Narita, Yukiya; Kawakami, Hisato; Esaki, Taito; Nishina, Tomohiro; Izawa, Naoki; Ando, Koji; Moriwaki, Toshikazu; Kato, Takeshi; Nagashima, Fumio; Satoh, Taroh; Nomura, Shogo; Yoshino, Takayuki; Akagi, Kiwamu
JOURNAL OF CLINICAL ONCOLOGY, 37, 15::S, AMER SOC CLINICAL ONCOLOGY, 2019年05月
英語, 研究論文(国際会議プロシーディングス) - 免疫チェックポイント阻害薬関連大腸炎3例の超音波所見
表原 里実; 西田 睦; 長島 一哲; 桂田 武彦; 村中 徹人; 小松 嘉人; 澁谷 斉; 秋沢 宏次; 杉田 純一; 豊嶋 崇徳
超音波医学, 46, Suppl., S650, S650, (公社)日本超音波医学会, 2019年04月
日本語 - 下部直腸癌に対する術前治療 切除可能局所進行性直腸癌患者における術前化学放射線療法後のnivolumab単剤療法とその後の広汎切除術に関する多施設共同第Ib/II相研究 VOLTAGE試験(Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following pre-operative chemoradiotherapy in patients with resectable locally advanced rectal cancer:VOLTAGE trial)
塚田 祐一郎; 坂東 英明; 稲守 宏治; 佐々木 剛志; 西澤 祐吏; 若林 将史; 小嶋 基寛; 結城 敏志; 小松 嘉人; 吉田 雅; 市川 伸樹; 本間 重紀; 畑中 豊; 松野 吉宏; 植村 守; 三宅 正和; 加藤 健志; 関本 貢嗣; 佐藤 暁洋; 伊藤 雅昭; 吉野 孝之
日本外科学会定期学術集会抄録集, 119回, PD, 7, (一社)日本外科学会, 2019年04月
英語 - Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
Harada K; Okamoto W; Mimaki S; Kawamoto Y; Bando H; Yamashita R; Yuki S; Yoshino T; Komatsu Y; Ohtsu A; Sakamoto N; Tsuchihara K
BMC cancer, 19, 1, 255, 255, 2019年03月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: In the era of genome-guided personalized cancer treatment, we must understand chemotherapy-induced genomic changes in tumors. This study evaluated whether adjuvant FOLFOX chemotherapy modifies the mutational profile of recurrent colorectal cancer (CRC). METHODS: Whole exome sequencing was performed on samples from primary CRC tumors, untreated metastatic tumors, and recurrent tumors following adjuvant FOLFOX chemotherapy. The samples were resected from four patients. RESULTS: The number of mutations or the mutation spectrum in individual patients was nearly identical. Copy number variants persisted regardless of FOLFOX therapy administration. The genomic signature of oxaliplatin exposure (G > T/C > A, T > A/A > T) was not enriched after FOLFOX chemotherapy. Overlapping single nucleotide variants (SNVs) and indels remained in 26-65% of the patient-matched tumor samples. One patient harbored an AKT1 E17K mutation in the recurrent tumor, whereas PIK3CA E542K and E88Q mutations were detected in the primary and untreated metastatic tumor samples. Genes related to intracellular Ca2+ homeostasis were enriched among the genes uniquely mutated after FOLFOX chemotherapy. CONCLUSIONS: We found that the mutation rates, mutation spectrum, and copy number variants were nearly identical regardless of the administration of FOLFOX therapy in the four CRC cases. The mutational discordance between the patient-matched tumor samples is likely caused by tumor heterogeneity and chemotherapy-induced clonal selection. These findings might be useful as pilot data for larger studies to clarify the changes in the mutational landscape induced by adjuvant FOLFOX chemotherapy. - Treatment guidelines
Muranaka Tetsuhito; Yoshito Komatsu
Gastrointestinal Stromal Tumor: Research and Practice, 79, 87, Springer Singapore, 2019年02月20日
英語, 論文集(書籍)内論文 - Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.
Masuishi T; Taniguchi H; Kotani D; Bando H; Komatsu Y; Shinozaki E; Nakajima TE; Satoh T; Nishina T; Esaki T; Wakabayashi M; Nomura S; Takahashi K; Ono H; Hirano N; Fujishiro N; Fuse N; Sato A; Ohtsu A; Yoshino T
ESMO open, 4, 6, e000590, 2019年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Background: BRAF V600E mutations are associated with aggressive biology and limited response to standard chemotherapy, especially during second-line and beyond therapies. BRAF V600E mutant and wild-type colorectal cancers (CRCs) differ in their expression profiles, and preclinical evidence suggests that microtubule inhibitors have an antitumour effect on xenograft models of BRAF V600E mutant CRCs. Eribulin has the best growth inhibitory activity in vitro of the microtubule inhibitors. Also, we have evidenced a hint of activity for patients with BRAF V600E mutant metastatic CRC (mCRC) with tumour shrinkage following eribulin treatment. Trial design: The BRAVERY study is a multicentre phase II study to evaluate the efficacy and safety of eribulin in patients with BRAF V600E mutant mCRC detected in either tumour tissues (primary analysis part) or circulating tumour DNA assays (liquid biopsy part). Key eligibility criteria are refractoriness and intolerance to at least one regimen (including irinotecan or oxaliplatin) containing fluoropyrimidine and Eastern Cooperative Oncology Group performance status of 0-1. Eribulin is to be administered intravenously at a dose of 1.4 mg/m2 on days 1 and 8 and repeated every 21 days. The primary endpoint is the confirmed objective response rate (ORR) by investigator's assessment. We calculated the sample size of the primary analysis part at 27 patients using a two-stage design with 25% ORR deemed promising and 5% unacceptable (one-sided α, 0.05; β, 0.1). Secondary endpoints include disease control rate, progression-free survival, overall survival and adverse events. Moreover, we will collect pretreated tissue and serial blood samples for biomarker analyses, focusing on gene expression associated with BRAF mutant-like CRC to find predictive markers and acquired gene alterations to detect resistance mechanisms to eribulin. We initiated patient enrolment in March 2018, completed the primary analysis on May 2019, and are currently continuing with the liquid biopsy part. Trial registration number: UMIN000031221 and 000031552. - Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
The oncologist, 24, 7, e450-e457, 2019年01月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Regorafenib improved the overall survival (OS) of patients with metastatic colorectal cancer (mCRC) who progress after standard therapies in two phase III trials. The present large-scale prospective observational study evaluated the safety and effectiveness of regorafenib administered to Japanese patients with mCRC in real-life setting. MATERIALS AND METHODS: Patients with mCRC were prospectively registered and initially received ≤160 mg oral regorafenib daily, at the investigator's discretion, for weeks 1-3 of each 4-week cycle. The study's primary aim was to assess safety, particularly unexpected clinically significant adverse drug reactions (ADRs). A Cox's proportional hazards model was used to evaluate the association between OS, hand-foot skin reaction (HFSR), and baseline characteristics. RESULTS: We evaluated 1,227 of 1,301 patients (enrolled from March 2013 to May 2015). ADRs occurred in 89.3% of patients (mostly within the first 4 weeks) and were a major reason for discontinuing treatment. The most frequent ADRs were HFSR, liver injury, and hypertension. The cumulative incidence of HFSR and liver injury was higher in patients who initially received 160 mg than in those who received ≤120 mg. The incidence of hypertension and fatigue was similar between groups. Median OS was 6.9 months (95% confidential interval, 6.4-7.4). OS was associated with early onset of HFSR and good performance status (PS) but not with the initial dose. CONCLUSION: The outcomes of this study were consistent with those of clinical trials. There were no new safety concerns. Regorafenib treatment would not be recommended for patients with higher PS. IMPLICATIONS FOR PRACTICE: Previous clinical trials demonstrated regorafenib improved overall survival in patients with metastatic colorectal cancer who progress after standard chemotherapies. Because the eligibility criteria of the trials were restricted compared with a real-world setting, the data from the trials may not fully represent the profiles of regorafenib in clinical practice. This large-scale observational study showed that the safety and effectiveness of regorafenib in clinical practice were generally consistent with previous trials. The majority of patients reported adverse drug reactions within the first 4 weeks, most commonly hand-foot skin reaction. Regorafenib treatment would not be recommended for patients with higher performance status. - Phase II trial of aflibercept with FOLFIRI as a 2nd-line treatment for Japanese patients with metastatic colorectal cancer.
Denda T; Sakai D; Hamaguchi T; Sugimoto N; Ura T; Yamazaki K; Fujii H; Kajiwara T; Nakajima TE; Takahashi S; Otsu S; Komatsu Y; Nagashima F; Moriwaki T; Esaki T; Sato T; Itabashi M; Oki E; Sasaki T; Sunaga Y; Ziti-Ljajic S; Brillac C; Yoshino T
Cancer science, 110, 3, 1032, 1043, 2019年01月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Aflibercept targets vascular endothelial growth factor. The present study involved assessing the efficacy, safety and pharmacokinetics of aflibercept plus 5-fluorouracil/levofolinate/irinotecan (FOLFIRI) as a second-line treatment for metastatic colorectal cancer (mCRC) in Japanese patients. Aflibercept (4 mg/kg) plus FOLFIRI was administered every 2 weeks in 62 patients with mCRC until disease progression, unacceptable toxicity or patient withdrawal. Tumors were imaged every 6 weeks. The primary endpoint was objective response rate (ORR); secondary endpoints were progression-free survival, overall survival, safety, and pharmacokinetics of aflibercept, irinotecan and 5-fluorouracil. A total of 60 patients were evaluated for ORR; 50 had received prior bevacizumab. The ORR was 8.3% (95% confidence interval [CI]: 1.3%-15.3%), and the disease control rate (DCR) was 80.0% (69.9%-90.1%). The median progression-free survival was 5.42 months (4.14-6.70 months) and the median overall survival was 15.59 months (11.20-19.81 months). No treatment-related deaths were observed, and no significant drug-drug interactions were found. The most common treatment-emergent adverse events were neutropenia and decreased appetite. Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62). Aflibercept did not significantly affect the pharmacokinetics of irinotecan or 5-fluorouracil: The clearance was 11.1 L/h/m2 (28%) for irinotecan and, at steady state, 72.6 L/h/m2 (56%) for 5-fluorouracil (N = 10). Adding aflibercept to FOLFIRI was shown to be beneficial and well-tolerated in Japanese patients with mCRC. ClinicalTrials.gov Identifier: NCT01882868. - Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Kenji Tsuchihashi; Mamoru Ito; Toshikazu Moriwaki; Shota Fukuoka; Hiroya Taniguchi; Atsuo Takashima; Yosuke Kumekawa; Takeshi Kajiwara; Kentaro Yamazaki; Taito Esaki; Akitaka Makiyama; Tadamichi Denda; Hironaga Satake; Takeshi Suto; Naotoshi Sugimoto; Kenji Katsumata; Toshiaki Ishikawa; Tomomi Kashiwada; Eiji Oki; Yoshito Komatsu; Hiroyuki Okuyama; Daisuke Sakai; Hideki Ueno; Takao Tamura; Kimihiro Yamashita; Junji Kishimoto; Yasuhiro Shimada; Eishi Baba
Clinical colorectal cancer, 17, 4, e687-e697, 2018年12月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Assessment of patient factors is essential for selecting later-line chemotherapy in patients with metastatic colorectal cancer (mCRC). The efficacy, prognosis, and safety of each treatment regimen according to nutritional and inflammatory status still remain to be elucidated. PATIENTS AND METHODS: A total of 550 patients with mCRC who were registered in the REGOTAS study (Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study, UMIN 000020416) and treated with trifluridine/tipiracil (TFTD) or regorafenib as a later-line therapy were retrospectively stratified according to the modified Glasgow Prognostic Score (mGPS), which divided patients into mGPS 0 to 2 by serum albumin and C-reactive protein, and compared. RESULTS: The median overall survival (OS) of patients with mGPS 0, 1, and 2 was 10.0 months (95% confidence interval [CI], 9.2-11.6 months), 6.5 months (95% CI, 5.3-7.1 months), and 3.9 months (95% CI, 3.3-4.9 months), respectively. The median progression-free survival (PFS) with mGPS 0, 1, and 2 was 2.5 months (95% CI, 2.1-3.0 months), 2.0 months (95% CI, 1.9-2.3 months), and 1.7 months (95% CI, 1.4-1.9 months), respectively. There were significant differences by mGPS in both OS and PFS (all P < .001). No significant differences in OS and PFS were observed between the patient groups treated with TFTD and regorafenib in each mGPS group. In patients aged ≥ 65 years with mGPS 2, the OS and PFS were worse with regorafenib than with TFTD (OS: hazard ratio, 1.45; 95% CI, 0.93-2.25; P = .097; PFS: hazard ratio, 1.57, 95% CI, 1.01-2.44; P = .047), but there were no consistent trends observed as mGPS increased. The frequency of grade 3 and more adverse events was generally similar in each mGPS group. The multivariate analyses showed that mGPS was the strongest predictive factor for OS. CONCLUSIONS: The mGPS before later-line chemotherapy is strongly correlated with survival in patients with mCRC. - Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 22, 4, 817, 827, 2018年12月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in several advanced cancers. We report results from JAVELIN Solid Tumor JPN, a phase 1 trial of avelumab in Japanese patients with advanced solid tumors with expansion in patients with advanced gastric cancer/gastroesophageal junction cancer. METHODS: In the dose-escalation part, eligible patients had various previously treated metastatic or advanced solid tumors. In the dose-expansion part, patients had stage IV gastric cancer/gastroesophageal junction adenocarcinoma and disease progression after prior therapy that included a platinum and fluoropyrimidine agent. Patients received avelumab every 2 weeks intravenously at 3, 10, or 20 mg/kg during dose escalation and 10 mg/kg during dose expansion. RESULTS: Among 17 patients who received avelumab in the dose-escalation part, no dose-limiting toxicities occurred, and the maximum tolerated dose was not reached. 40 patients were enrolled in the dose-expansion part, of whom 21 (52.5%) had received ≥ 3 prior lines of therapy for advanced disease. In these patients, the objective response rate was 10.0% (95% CI, 2.8-23.7%) and median overall survival was 9.1 months (95% CI, 7.2-11.2 months). Three of 40 patients (7.5%) had a grade 3 treatment-related adverse event (alanine aminotransferase increase, anemia, and hyponatremia), and no grade ≥ 4 treatment-related adverse events occurred. Five patients (12.5%) had an immune-related adverse event (all grade 1/2). CONCLUSIONS: Avelumab showed acceptable safety in Japanese patients with advanced solid tumors and clinical activity in patients with advanced gastric cancer/gastroesophageal junction cancer and disease progression after chemotherapy. - A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy re
Kato K; Satoh T; Muro K; Yoshikawa T; Tamura T; Hamamoto Y; Chin K; Minashi K; Tsuda M; Yamaguchi K; Machida N; Esaki T; Goto M; Komatsu Y; Nakajima TE; Sugimoto N; Yoshida K; Oki E; Nishina T; Tsuji A; Fujii H; Kunieda K; Saitoh S; Omuro Y; Azuma M; Iwamoto Y; Taku K; Fushida S; Chen LT; Kang YK; Boku N
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 22, 2, 344, 354, 2018年12月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: Nivolumab, an anti-programmed death-1 agent, showed survival benefits in Asian patients, including Japanese, with gastric/gastro-esophageal junction (G/GEJ) cancer. We report the analysis of the Japanese subpopulation from ATTRACTION-2 that evaluated nivolumab versus placebo in unresectable advanced or recurrent G/GEJ cancer after ≥ 2 chemotherapy regimens. METHODS: Data from the Japanese subpopulation in the randomized, double-blind, placebo-controlled, phase 3 trial were analyzed (data cutoff, February 25, 2017). Primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS) and objective response rate (ORR). RESULTS: Among the overall study population of 493 patients, 226 (nivolumab 152; placebo 74) were enrolled from 28 sites in Japan. In the Japanese subset, median OS was longer with nivolumab versus placebo (5.4 months, 95% CI 4.6-7.4 versus 3.6 months, 95% CI 2.8-5.0). The risk of death was lower in the nivolumab versus placebo group (hazard ratio 0.58, 95% CI 0.42-0.78; p = 0.0002). Incidences of serious adverse events were 23% (35/152) and 25% (18/72) in the nivolumab and placebo groups, respectively. In the Japanese ITT population, 22% of nivolumab-treated and 28% of placebo-treated patients received prior ramucirumab treatment. Overall, clinical activity of nivolumab was observed regardless of prior ramucirumab use. In the nivolumab group, ORR and PFS were numerically higher in patients with prior ramucirumab use than in those without. CONCLUSIONS: In the Japanese subpopulation, patients receiving nivolumab had longer OS, similar to the overall population, with a manageable safety profile. The interaction between nivolumab and ramucirumab will be clarified in ongoing clinical trials. - 外来化学療法におけるがん専門薬剤師による長期継続的な薬学的患者管理の有用性の検討
齋藤 佳敬; 原田 幸子; 小林 正紀; 植田 孝介; 山崎 浩二郎; 熊井 正貴; 宮本 剛典; 笠師 久美子; 山田 武宏; 小松 嘉人; 井関 健
薬学雑誌, 138, 11, 1409, 1416, (公社)日本薬学会, 2018年11月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌), がん専門薬剤師による外来がん化学療法施行患者に対する長期継続的な薬学的管理の有用性について評価した。当院にてがん専門薬剤師が専従配置された2016年5月から2017年5月を各種調査期間に設定し、疑義照会数及び処方提案数、それらの内訳や実施時期について検討した。治療当日に実施された疑義照会件数は約25〜50件/月で変動し、処方提案件数は概ね経時的に増加した。がん専門薬剤師専従配置後の疑義照会は、必要薬剤の処方漏れ、治療当日の患者の検査値用量、治療レジメン内容に関するものの順で多く、疑義照会による処方変更率は約73%であった。一方、処方提案については、悪心・嘔吐、皮膚障害、口内炎、排便コントロールに関するものの順で多く、その採択率は約98%であった。全処方に占める全薬学的介入件数は、専従配置以前(2015年4月〜2016年4月)に対し、専従配置後で有意に増加した。また、提案薬剤による該当症状の改善効果は、約70%の症例で認められた。がん専門薬剤師専従配置後における薬学的介入の実施時期について検討すると、全薬学的介入のうち初回・2回目治療時に実施されたものが約40%を占め、約60%の薬学的介入が治療3回目以降に、約20%が治療10回以降に実施された。処方提案に関しては、3回目以降の治療時に実施されたものが約半数を占め、6回目以降の治療時に実施されたものが約20%認められた。 - 外来化学療法におけるがん専門薬剤師による長期継続的な薬学的患者管理の有用性の検討
齋藤 佳敬; 原田 幸子; 小林 正紀; 植田 孝介; 山崎 浩二郎; 熊井 正貴; 宮本 剛典; 笠師 久美子; 山田 武宏; 小松 嘉人; 井関 健
薬学雑誌, 138, 11, 1409, 1416, (公社)日本薬学会, 2018年11月
日本語, It is important that pharmacists ensure safe chemotherapy implementation. In addition to inspecting chemotherapeutic prescriptions according to patient condition and drug-drug interactions, the management of chemotherapy-induced adverse effects and associated pharmaceutical intervention is one of the most important responsibilities of pharmacists in medical care teams. In May 2016, an oncology pharmacist was set responsible for the specialized, long-term, and successive pharmaceutical care, including instructions about appropriate use of medication at an outpatient chemotherapy center. We evaluated the effectiveness of the continuous pharmaceutical care. The number of medication counseling and associated pharmaceutical interventions increased with time. Specifically, the number of pharmaceutical interventions (prescription questions and pharmaceutical proposals) was 745 (459 and 286, respectively) in the surveillance period, which significantly increased compared to that observed within the same duration before posting an oncology pharmacist. The adoption rate was approximately 70% for prescription questions and 98% for pharmaceutical proposals. We also found that approximately 70% of the proposals attenuated the painful symptoms. Furthermore, approximately 60% of all pharmaceutical interventions were established after the third visit; in particular, approximately 20% of the pharmaceutical proposals were suggested after the sixth visit, indicating that continuous medication counseling results in an increase in pharmaceutical proposals. In conclusion, long-term and successive pharmaceutical care by oncology pharmacy specialists in outpatient chemotherapy contributes to a safe and less onerous chemotherapy implementation, as it has been highly adopted, is effective in many cases, and has been proven to be important for risk management in chemotherapy. - TRICOLORE追跡結果 大腸癌一次治療のS-1/CPT-11+Bevの有用性を検証する第3相試験
高橋 信; 沖田 南津子; 傳田 忠道; 蒲生 真紀夫; 中村 路夫; 杉山 克郎; 岩指 元; 武藤 理; 佐藤 敏彦; 濱田 和幸; 小松 嘉人; 山口 達郎; 嶋田 顕; 森田 智視; 石岡 千加史
日本癌治療学会学術集会抄録集, 56回, O47, 1, (一社)日本癌治療学会, 2018年10月
英語 - The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring.
Yanagiya S; Cho KY; Nakamura A; Nomoto H; Kawamoto Y; Kawakubo K; Komatsu Y; Mitsuhashi T; Miyoshi H; Atsumi T
Internal medicine (Tokyo, Japan), 57, 17, 2527, 2531, 2018年09月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), An 84-year-old Japanese woman with metastatic insulinoma suffered from frequent hypoglycemic events. Continuous glucose monitoring (CGM) confirmed severe and frequent symptomatic/asymptomatic hypoglycemia. After the initiation of everolimus treatment, the hypoglycemic events were rapidly eliminated. CGM revealed that her blood glucose levels were maintained without hypoglycemia throughout the day. Furthermore, everolimus reduced the duration of time above the upper limit (>180 mg/dL) along with the standard deviation and mean amplitude of glycemic excursions. This case shows the potential effects of everolimus on hypoglycemia and glycemic control in a patient with inoperable metastatic insulinoma evaluated by CGM. - Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer.
Sawada K; Nakamura Y; Yamanaka T; Kuboki Y; Yamaguchi D; Yuki S; Yoshino T; Komatsu Y; Sakamoto N; Okamoto W; Fujii S
Clinical colorectal cancer, 17, 3, 198, 205, 2018年09月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: To evaluate a prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Patients with mCRC who underwent surgical resection of the primary tumor and who received best supportive care with or without palliative chemotherapy between 2005 and 2015 were included. HER2 immunohistochemistry was performed using formalin-fixed, paraffin-embedded primary tumor specimens. HER2 amplification was confirmed by fluorescence in-situ hybridization. The RAS and BRAFV600E mutations were centrally assessed using a PCR-based method. Patients were divided into 4 subgroups: R (RAS mutant), B (BRAFV600E mutant), H (wild-type RAS/BRAF with HER2 amplification), and W (wild-type RAS/BRAF without HER2 amplification). Overall survival (OS) and progression-free survival of anti-epidermal growth factor receptor (EGFR) therapy were assessed. RESULTS: Among 370 eligible patients, data of 359 were successfully analyzed. Fifteen tumors harbored HER2 amplifications, including 4 tumors with concomitant RAS mutation (group R). The number of patients in groups R, B, H, and W was 204, 13, 11, and 131, respectively. The median OS was 27.4 months, and the median follow-up time was 63.2 months. The median OS for groups R, B, H, and W was 24.0, 14.2, 19.9, and 39.1 months, respectively. The number of patients who received anti-EGFR therapy in groups R, B, H, and W was 17, 4, 5, and 49, respectively. Progression-free survival of anti-EGFR therapy was significantly shorter in groups R, B, and H than in group W. CONCLUSION: HER2 amplification was predictive of anti-EGFR therapy response and appeared to be prognostic in mCRC patients. - Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara; Mustafa Özgüroğlu; Yung-Jue Bang; Maria Di Bartolomeo; Mario Mandalà; Min-Hee Ryu; Lorenzo Fornaro; Tomasz Olesiński; Christian Caglevic; Hyun C Chung; Kei Muro; Eray Goekkurt; Wasat Mansoor; Raymond S McDermott; Einat Shacham-Shmueli; Xinqun Chen; Carlos Mayo; S Peter Kang; Atsushi Ohtsu; Charles S Fuchs; Guillermo Lerzo; Juan Manuel O'Connor; Guillermo Ariel Mendez; James Lynam; Niall Tebbutt; Mark Wong; Andrew Strickland; Chris Karapetis; David Goldstein; Paul Vasey; Jean-Luc Van Laethem; Eric Van Cutsem; Scott Berry; Mark Vincent; Bettina Muller; Felipe Rey; Angela Zambrano; Joaquin Guerra; Merete Krogh; Lene Baeksgaard; Mette Yilmaz; Anneli Elme; Andrus Magi; Paivi Auvinen; Tuomo Alanko; Markus Moehler; Volker Kunzmann; Thomas Seufferlein; Peter Thuss-Patience; Thomas Hoehler; Georg Haag; Salah-Eddin Al-Batran; Hugo Castro; Karla Lopez; Mynor Aguilar Vasquez; Mario Sandoval; Ka On Lam; Sinead Cuffe; Cathy Kelly; Ravit Geva; Ayala Hubert; Alex Beny; Baruch Brenner; Aprile Giuseppe; Alfredo Falcone; Evaristo Maiello; Rodolfo Passalacqua; Vincenzo Montesarchio; Hiroki Hara; Keisho Chin; Tomohiro Nishina; Yoshito Komatsu; Nozumo Machida; Shuichi Hironaka; Taroh Satoh; Takao Tamura; Naotaoshi Sugimoto; Haruhiko Cho; Yashushi Omuro; Ken Kato; Masahiro Goto; Ichinosuke Hyodo; Kazuhiro Yoshida; Hideo Baba; Taito Esaki; Junji Furuse; Wan Zamaniah Wan Mohammed; Carlos Hernandez Hernandez; Juan Casas Garcia; Adriana Dominguez Andrade; Katriona Clarke; Geir Hjortland; Nils Glenjen; Tomasz Kubiatowski; Jassem Jacek; Marek Wojtukiewicz; Sergey Lazarev; Yuri Lancukhay; Sergey Afanasayev; Vladimir Moiseyenko; Vladimir Kostorov; Svetlana Protsenko; Vadim Shirinkin; Dina Sakaeva; Natalia Fadeeva; Wei Peng Yong; Chau Hsien Matthew Ng; Barbara Robertson; Bernardo Rapaport; Graham Cohen; Lydia Dreosti; Paul Ruff; Conrad Jacobs; Gregory Landers; Waldemar Szpak; Sang-Young Roh; Jeeyun Lee; Yeul Hong Kim; Yung-Jue Bang; Min-Hee Ryu; Maria Alsina Maqueda; Federico Longo Munoz; Andres Cervantes Aguilar; Enrique Aranda Aguilar; Pilar Garcia Alfonso; Fernando Rivera; Jaime Feliu Batle; Roberto Pazo Cid; Kun-Huei Yeh; Jen-Shi Chen; Yee Chao; Chia-Jui Yen; Mustafa Özgüroğlu; Oguz Kara; Suayib Yalcin; Daniel Hochhauser; Ian Chau; Al Benson; Veena Shankaran; Walid Shaib; Philip Philip; Vivek Sharma; Robert Siegel; Weijing Sun; Zev Wainberg; Ben George; Andrea Bullock; Samuel Myrick; Josephine Faruol; Richard Siegel; Timothy Larson; Carlos Becerra; Suresh Ratnam; Donald A. Richards; Stephen L. Riche; KEYNOTE-061 investigators
The Lancet, 392, 10142, 123, 133, Elsevier B.V., 2018年07月14日
英語, 研究論文(学術雑誌) - Genomic testing for pancreatic cancer in clinical practice as real-world evidence.
Hayashi H; Tanishima S; Fujii K; Mori R; Okamura Y; Yanagita E; Matsuoka R; Amano T; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 18, 6, 647, 654, 2018年07月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Precision medicine guided by comprehensive genome sequencing represents a potential treatment strategy for pancreatic cancer. However, clinical sequencing for pancreatic cancer entails several practical difficulties. We have launched an in-house clinical sequencing system and started genomic testing for patients with cancer in clinical practice. We have analyzed the clinical utility of this system in pancreatic cancer. METHODS: We retrospectively reviewed 20 patients with pancreatic cancer who visited our division. Genomic DNA was extracted from both tumor tissue and peripheral blood mononuclear cells obtained from the patients. We performed a comprehensive genomic testing using targeted amplicon sequencing for 160 cancer-related genes. The primary endpoints were the detection rates of potential actionable and druggable gene alterations. The secondary endpoints were the detection rate of secondary germline findings, the rate of re-biopsy required for genome sequencing, survival time after the initial visit (post-sequencing survival time), and turnaround time. RESULTS: Although re-biopsy was required for 25% (5/20) of all patients, genomic testing was performed in all patients. Actionable and druggable gene alterations were detected in 100% (20/20) and 35% (7/20) of patients, respectively, whereas secondary germline findings were detected in 5% (1/20) of patients. The median turnaround times for physicians and patients were 20 and 26 days, respectively. The median post-sequencing survival time was 10.3 months. Only 10% (2/20) of all patients were treated with therapeutic agents based on the outcomes of genomic testing. CONCLUSIONS: The clinical application of comprehensive genomic testing for pancreatic cancer was feasible and promising in clinical practice. - Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.
Yoshino T; Yamazaki K; Shinozaki E; Komatsu Y; Nishina T; Baba H; Tsuji A; Tsuji Y; Yamaguchi K; Sugimoto N; Denda T; Muro K; Takayama T; Esaki T; Hamamoto Y; Moriwaki T; Shimada Y; Goto M; Nakayama N; Fujii H; Tanase T; Ohtsu A
Clinical colorectal cancer, 17, 4, e719-e732, 2018年07月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: High thymidine kinase 1 (TK1) activity increases the incorporation of trifluridine (FTD) into DNA; thus, FTD antitumor activity is likely to increase in patients with high tumoral TK1 activity. To date, no established predictive biomarker to indicate the clinical benefit of FTD/tipiracil (TPI) has been identified. We aimed to determine the relationship between TK1 expression and FTD/TPI efficacy in refractory metastatic colorectal cancer. PATIENTS AND METHODS: Individual patient data from 2 randomized placebo-controlled trials were analyzed. We measured TK1 protein expression in tumor tissue samples and its relationship with FTD/TPI clinical efficacy using overall survival (OS), progression-free survival, and disease control rate. RESULTS: This study comprised 329 patients (FTD/TPI, 224; placebo, 105). FTD/TPI significantly improved OS versus placebo in the high-expression (cutoff ≥ 15%) TK1 group (median OS, 7.8 vs. 6.8 months; hazard ratio = 0.65; 95% confidence interval, 0.46-0.93; P = .018). The low-expression (cutoff < 15%) TK1 group experienced a smaller OS benefit (9.3 vs. 7.4 months; hazard ratio = 0.88; 95% confidence interval, 0.63-1.23; P = .45). For patients who received placebo, the high-expression TK1 group had a slightly worse prognosis than the low-expression TK1 group. The tendency of FTD/TPI efficacy concerning progression-free survival and disease control rate was not similar to that concerning OS between groups. CONCLUSION: Patients with high TK1 expression showed an improvement in OS when treated with FTD/TPI. Further investigations are warranted to confirm this relationship. - Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.
Akira Sawaki; Yasuhide Yamada; Kensei Yamaguchi; Tomohiro Nishina; Toshihiko Doi; Taroh Satoh; Keisho Chin; Narikazu Boku; Yasushi Omuro; Yoshito Komatsu; Yasuo Hamamoto; Wasaburo Koizumi; Shigehira Saji; Manish A Shah; Eric Van Cutsem; Yoon-Koo Kang; Junko Iwasaki; Hiroshi Kuriki; Wataru Ohtsuka; Atsushi Ohtsu
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 21, 3, 429, 438, 2018年05月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: AVAGAST was an international, randomized, placebo-controlled phase III study of chemotherapy with or without bevacizumab as first-line therapy for patients with advanced gastric cancer. We performed exploratory analyses to evaluate regional differences observed in the trial. METHODS: Analyses were performed in the placebo plus chemotherapy arm (intention-to-treat population). Chemotherapy was cisplatin 80 mg/m2 for six cycles plus capecitabine (1000 mg/m2 orally bid days 1-14) or 5-fluorouracil (800 mg/m2/day continuous IV infusion days 1-5) every 3 weeks until disease progression or unacceptable toxicity. RESULTS: Overall, 387 patients were assigned to placebo plus chemotherapy (eastern Europe/South America, n = 118; USA/western Europe, n = 81; Korea/other Asia, n = 94; Japan, n = 94). At baseline, poor performance status, liver metastases, and larger tumors were most frequent in eastern Europe/South America and least frequent in Japan. Patients received subsequent chemotherapy after disease progression as follows: eastern Europe/South America (14%); USA/western Europe (37%); Korea/other Asia (61%); and Japan (77%). Hazard ratios for overall survival versus USA/western Europe were 1.47 (95% CI, 1.09-1.99) for eastern Europe/South America, 0.91 (95% CI, 0.67-1.25) for Korea/other Asia, and 0.87 (95% CI, 0.64-1.19) for Japan. CONCLUSIONS: Regional differences in the healthcare environment may have contributed to the differences in overall survival observed in the AVAGAST study. - S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Yamada Y; Denda T; Gamoh M; Iwanaga I; Yuki S; Shimodaira H; Nakamura M; Yamaguchi T; Ohori H; Kobayashi K; Tsuda M; Kobayashi Y; Miyamoto Y; Kotake M; Shimada K; Sato A; Morita S; Takahashi S; Komatsu Y; Ishioka C
Annals of oncology : official journal of the European Society for Medical Oncology, 29, 3, 624, 631, 2018年03月, [査読有り] - A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer
Hideaki Bando; Hideki Shimodaira; Kazumasa Fujitani; Atsuo Takashima; Kensei Yamaguchi; Norisuke Nakayama; Takehiro Takahashi; Eiji Oki; Mizutomo Azuma; Tomohiro Nishina; Shuichi Hironaka; Yoshito Komatsu; Kohei Shitara
European Journal of Cancer, 91, 86, 91, Elsevier Ltd, 2018年03月01日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703)
Kotani, D.; Bando, H.; Masuishi, T.; Komatsu, Y.; Yamaguchi, K.; Nakajima, T.E.; Satoh, T.; Nishina, T.; Esaki, T.; Nomura, S.; Sakamoto, S.; Iida, S.; Matsuda, S.; Yonemura, M.; Fuse, N.; Sato, A.; Fujii, S.; Ebi, H.; Ohtsu, A.; Yoshino, T.
Annals of oncology : official journal of the European Society for Medical Oncology, 29, 2018年
研究論文(学術雑誌) - BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701)
Masuishi, T.; Taniguchi, H.; Kotani, D.; Bando, H.; Komatsu, Y.; Yamaguchi, K.; Nakajima, T.E.; Satoh, T.; Nishina, T.; Esaki, T.; Wakabayashi, M.; Nomura, S.; Sakamoto, S.; Ono, H.; Hirano, N.; Fujishiro, N.; Fuse, N.; Sato, A.; Ohtsu, A.; Yoshino, T.
Annals of oncology : official journal of the European Society for Medical Oncology, 29, 2018年
研究論文(学術雑誌) - Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402)
Tanioka H; Miyamoto Y; Tsuji A; Asayama M; Shiraishi T; Yuki S; Kotaka M; Makiyama A; Shimokawa M; Shimose T; Masuda S; Yamaguchi T; Komatsu Y; Saeki H; Emi Y; Baba H; Oki E; Maehara Y; Kyushu Study; Group of Clinical Cancer; KSC
Oncology, 94, 5, 289, 296, 2018年, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Regorafenib is an oral multikinase inhibitor with a proven survival benefit for metastatic colorectal cancer patients. The KSCC1402/HGCSG1402 study investigated the prophylactic effect of oral dexamethasone (DEX) on regorafenib-related fatigue and/or malaise. PATIENTS AND METHODS: Patients who progressed after standard chemotherapy were randomized 1: 1 to a DEX group (2 mg/day; days 1-28) with regorafenib or a placebo group with regorafenib. The primary endpoint was the incidence of fatigue and/or malaise, based on version 4.0 of the National Cancer Institute's CTCAE (Common Terminology Criteria for Adverse Events). One of the secondary endpoints was the in-cidence of fatigue and/or malaise based on the CTCAE assessed by patient-reported outcome (PRO). RESULTS: The incidence of any grade of fatigue and/or malaise assessed by the investigators was 58.8% in the DEX group and 61.1% in the placebo group (p = 0.8101), and that assessed by PRO was 47.2 and 58.3%, respectively (p = 0.3450). The incidence of grade ≥2 fatigue and/or malaise, as assessed by the investigators, was 19.4% for the DEX group and 38.9% for the placebo group (p = 0.0695), and that assessed by PRO was 27.8 and 52.8%, respectively (p = 0.0306). CONCLUSION: Our results suggest that prophylactic oral DEX is clinically effective in improving regorafenib-related fatigue and/or malaise. - [Survey of the Efficacy of Long-term and Successive Pharmaceutical Care in Outpatient Chemotherapy by Oncology Pharmacy Specialists].
Saito Y; Harada S; Kobayashi M; Ueda K; Yamazaki K; Kumai M; Miyamoto T; Kasashi K; Yamada T; Komatsu Y; Iseki K
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 138, 11, 1409, 1416, 公益社団法人 日本薬学会, 2018年, [査読有り]
日本語, It is important that pharmacists ensure safe chemotherapy implementation. In addition to inspecting chemotherapeutic prescriptions according to patient condition and drug-drug interactions, the management of chemotherapy-induced adverse effects and associated pharmaceutical intervention is one of the most important responsibilities of pharmacists in medical care teams. In May 2016, an oncology pharmacist was set responsible for the specialized, long-term, and successive pharmaceutical care, including instructions about appropriate use of medication at an outpatient chemotherapy center. We evaluated the effectiveness of the continuous pharmaceutical care. The number of medication counseling and associated pharmaceutical interventions increased with time. Specifically, the number of pharmaceutical interventions (prescription questions and pharmaceutical proposals) was 745 (459 and 286, respectively) in the surveillance period, which significantly increased compared to that observed within the same duration before posting an oncology pharmacist. The adoption rate was approximately 70% for prescription questions and 98% for pharmaceutical proposals. We also found that approximately 70% of the proposals attenuated the painful symptoms. Furthermore, approximately 60% of all pharmaceutical interventions were established after the third visit; in particular, approximately 20% of the pharmaceutical proposals were suggested after the sixth visit, indicating that continuous medication counseling results in an increase in pharmaceutical proposals. In conclusion, long-term and successive pharmaceutical care by oncology pharmacy specialists in outpatient chemotherapy contributes to a safe and less onerous chemotherapy implementation, as it has been highly adopted, is effective in many cases, and has been proven to be important for risk management in chemotherapy. - Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
Toshikazu Moriwaki; Shota Fukuoka; Hiroya Taniguchi; Atsuo Takashima; Yusuke Kumekawa; Takeshi Kajiwara; Kentaro Yamazaki; Taito Esaki; Chinatsu Makiyama; Tadamichi Denda; Hironaga Satake; Takeshi Suto; Naotoshi Sugimoto; Masanobu Enomoto; Toshiaki Ishikawa; Tomomi Kashiwada; Masahiko Sugiyama; Yoshito Komatsu; Hiroyuki Okuyama; Eishi Baba; Daisuke Sakai; Tomoki Watanabe; Takao Tamura; Kimihiro Yamashita; Masahiko Gosho; Yasuhiro Shimada
Oncologist, 23, 1, 7, 15, Wiley-Blackwell, 2018年01月01日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
Daisuke Sakai; Hyun Cheol Chung; Do-Youn Oh; Se Hoon Park; Shigenori Kadowaki; Yeul Hong Kim; Akihito Tsuji; Yoshito Komatsu; Yoon-Koo Kang; Kazunori Uenaka; Sameera R. Wijayawardana; Volker Wacheck; Xuejing Wang; Ayuko Yamamura; Toshihiko Doi
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 80, 6, 1197, 1207, 2017年12月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
Yasuyuki Kawamoto; Yoshito Komatsu; Satoshi Yuki; Kentaro Sawada; Tetsuhito Muranaka; Kazuaki Harada; Hiroshi Nakatsumi; Hiraku Fukushima; Atsushi Ishiguro; Masayoshi Dazai; Kazuteru Hatanaka; Michio Nakamura; Ichiro Iwanaga; Minoru Uebayashi; Susumu Sogabe; Yoshimitsu Kobayashi; Takuto Miyagishima; Kota Ono; Naoya Sakamoto; Yuh Sakata
BMC CANCER, 17, 1, 837, 837, 2017年12月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma
Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Shunsuke Ohnishi; Yoshito Komatsu; Fumiyuki Sato; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Tomoe Shimazaki; Megumi Kimura; Ayaka Asano; Yoshiyuki Fujimoto; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Seiji Naganuma; Kelly A. Whelan; Hiroshi Nakagawa; Koji Nakagawa; Hiroshi Takeda; Naoya Sakamoto
CARCINOGENESIS, 38, 11, 1073, 1083, 2017年11月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer
Toshihiko Doi; Kensei Yamaguchi; Yoshito Komatsu; Kei Muro; Tomohiro Nishina; Takako Eguchi Nakajima; Rui Tang; Hui Yang; Yilong Zhang; A. Scott Jung; Agnes Ang; Hirofumi Yasui
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 47, 11, 1002, 1009, 2017年11月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - 前治療における腫瘍増殖速度がレゴラフェニブとTAS-102の抗腫瘍効果に与える影響
舛石 俊樹; 谷口 浩也; 川上 武志; 川本 泰之; 門脇 重憲; 小野澤 祐輔; 村中 徹人; 田近 正洋; 安井 博史; 中積 宏之; 結城 敏志; 室 圭; 大前 勝弘; 小松 嘉人; 山崎 健太郎
日本癌治療学会学術集会抄録集, 55回, O31, 6, (一社)日本癌治療学会, 2017年10月
日本語 - Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib
Y. Kurokawa; T. Doi; A. Sawaki; Y. Komatsu; M. Ozaka; T. Takahashi; Y. Naito; S. Okubo; T. Nishida
ANNALS OF ONCOLOGY, 28, 2017年09月, [査読有り]
英語 - HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
Sasaki Takahide; Kawamoto Yasuyuki; Yuki Satoshi; Meguro Takashi; Hatanaka Kazuteru; Uebayashi Minoru; Iwanaga Ichiro; Nakamura Michio; Eto Kazunori; Okuda Hiroyuki; Abe Masakazu; Oba Ayane; Abe Nobuhiko; Sato Atsushi; Nakatsumi Hiroshi; Harada Kazuaki; Muranaka Tetsuhito; Yagisawa Masataka; Oba Koji; Sakata Yuh; Komatsu Yoshito
ANNALS OF ONCOLOGY, 28, 2017年06月, [査読有り]
英語 - Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naive Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer
Takayuki Yoshino; Hiroyuki Uetake; Katsuya Tsuchihara; Kohei Shitara; Kentaro Yamazaki; Eiji Oki; Takeo Sato; Takeshi Naitoh; Yoshito Komatsu; Takeshi Kato; Kazunori Yamanaka; Kouji Iwasaki; Jumpei Soeda; Masamitsu Hihara; Takeharu Yamanaka; Atsushi Ochiai; Kei Muro
CLINICAL COLORECTAL CANCER, 16, 2, 158, 163, 2017年06月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
Tetsuhito Muranaka; Masaki Kuwatani; Yoshito Komatsu; Kentaro Sawada; Hiroshi Nakatsumi; Yasuyuki Kawamoto; Satoshi Yuki; Yoshimasa Kubota; Kimitoshi Kubo; Shuhei Kawahata; Kazumichi Kawakubo; Hiroshi Kawakami; Naoya Sakamoto
Journal of Gastrointestinal Oncology, 8, 3, 566, 571, AME Publishing Company, 2017年06月01日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Systematic review and individual patient data based meta-analysis of palonosetron trials for chemotherapy induced nausea and vomiting.
Yuki Okada; Koji Oba; Naoto Furukawa; Yoshito Komatsu; Yoshimasa Kosaka; Kenji Okita; Satoshi Yuki; Luigi Celio; Matti S. Aapro
JOURNAL OF CLINICAL ONCOLOGY, 35, 2017年05月, [査読有り]
英語 - Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Hideyuki Hayashi; Takashi Kohno; Hideki Ueno; Nobuyoshi Hiraoka; Shunsuke Kondo; Motonobu Saito; Yoko Shimada; Hitoshi Ichikawa; Mamoru Kato; Tatsuhiro Shibata; Chigusa Morizane; Yasunari Sakamoto; Kazuaki Shimada; Yoshito Komatsu; Naoya Sakamoto; Takuji Okusaka
Pancreas, 46, 3, 335, 340, 2017年03月, [査読有り], [国際誌]
英語 - Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer
Hideyuki Hayashi; Takashi Kohno; Hideki Ueno; Nobuyoshi Hiraoka; Shunsuke Kondo; Motonobu Saito; Yoko Shimada; Hitoshi Ichikawa; Mamoru Kato; Tatsuhiro Shibata; Chigusa Morizane; Yasunari Sakamoto; Kazuaki Shimada; Yoshito Komatsu; Naoya Sakamoto; Takuji Okusaka
PANCREAS, 46, 3, 335, 340, 2017年03月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Decreased RNA-binding motif 5 expression is associated with tumor progression in gastric cancer
Takahiko Kobayashi; Junich Ishida; Yuichi Shimizu; Hiroshi Kawakami; Goki Suda; Tetsuhito Muranaka; Yoshito Komatsu; Masahiro Asaka; Naoya Sakamoto
TUMOR BIOLOGY, 39, 3, 1010428317694547, 1010428317694547, 2017年03月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
T. Ioka; Y. Komatsu; N. Mizuno; A. Tsuji; S. Ohkawa; M. Tanaka; H. Iguchi; A. Ishiguro; M. Kitano; T. Satoh; T. Yamaguchi; K. Takeda; M. Kida; K. Eguchi; T. Ito; M. Munakata; T. Itoi; J. Furuse; C. Hamada; Y. Sakata
British Journal of Cancer, 116, 4, 464, 471, Nature Publishing Group, 2017年02月14日, [査読有り]
英語, 研究論文(学術雑誌) - A phase II study of panitumumab with FOLFOX or FOLFIRI as first-line chemotherapy for KRAS-wild type metastatic colorectal cancer: The PaFF-J study.
Eiji Shinozaki; Megumi Ishiguro; Eiji Nakatani; Tatsuro Yamaguchi; Masato Nakamura; Yuji Miyamoto; Hitoshi Ojima; Yoshitaka Honma; Masahiro Gotoh; Toshiaki Ishikawa; Keiichi Takahashi; Yasuhiro Shimada; Kazuhiro Yoshida; Nobuyuki Mizunuma; Kei Muro; Yoshito Komatsu; Kensei Yamaguchi; Hiroshi Nakano; Junki Koike; Kenichi Sugihara
JOURNAL OF CLINICAL ONCOLOGY, 35, 4, 2017年02月
英語 - Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo.
Yoshino Takayuki; Shinozaki Eiji; Yamazaki Kentaro; Komatsu Yoshito; Nishina Tomohiro; Baba Hideo; Tsuji Akihito; Tsuji Yasushi; Yamaguchi Kensei; Sugimoto Naotoshi; Denda Tadamichi; Muro Kei; Takayama Tetsuji; Esaki Taito; Hamamoto Yasuo; Moriwaki Toshikazu; Shimada Yasuhiro; Goto Masahiro; Tanase Takanori; Ohtsu Atsushi
JOURNAL OF CLINICAL ONCOLOGY, 35, 4, 2017年02月01日, [査読有り]
英語 - A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01)
Michio Nakamura; Atsushi Ishiguro; Tetsuhito Muranaka; Hiraku Fukushima; Satoshi Yuki; Kota Ono; Taichi Murai; Chika Matsuda; Ayane Oba; Kazufumi Itaya; Takayuki Sone; Masataka Yagisawa; Yuta Koike; Ayana Endo; Yoko Tsukuda; Yuji Ono; Takahiko Kudo; Atsushi Nagasaka; Shuji Nishikawa; Yoshito Komatsu
ONCOLOGIST, 22, 5, 592, 600, 2017年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study.
Hideo Baba; Yasuhide Yamada; Daisuke Takahari; Hiroshi Matsumoto; Kazuhiro Yoshida; Masato Nakamura; Motoki Yoshida; Shigeyoshi Iwamoto; Ken Shimada; Yoshito Komatsu; Yasutsuna Sasaki; Taroh Satoh; Keiichi Takahashi; Hideyuki Mishima; Kei Muro; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Kenichi Sugihara
ESMO open, 2, 1, e000135, 2017年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: The SOFT study previously demonstrated that S-1 and oxaliplatin (SOX) plus bevacizumab was non-inferior to l-leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) plus bevacizumab in terms of the primary end point of progression-free survival (PFS) as first-line chemotherapy for metastatic colorectal cancer (mCRC). The overall survival (OS) data were immature at the time of the primary analysis. METHODS: A total of 512 patients were enrolled and randomly assigned to receive either mFOLFOX6 plus bevacizumab (5 mg/kg of bevacizumab, followed by 200 mg/m2 of l-leucovorin given simultaneously with 85 mg/m2 of oxaliplatin, followed by a 400 mg/m2 bolus of 5-FU on day 1 and then 2400 mg/m2 of 5-FU as an intravenous infusion over the course of 46 hours, every 2 weeks) or SOX plus bevacizumab (7.5 mg/kg of bevacizumab, 130 mg/m2 of oxaliplatin on day 1 and 40-60 mg of S-1 two times per day for 2 weeks, followed by a 1-week rest). The primary end point was PFS. After the primary analysis, the follow-up survey was cut-off on 30 September 2013, and the final OS data were analysed. RESULTS: With a median follow-up of 37.7 months, the median survival time (MST) was 29.7 months with mFOLFOX6 plus bevacizumab and 29.6 months with SOX plus bevacizumab (HR, 1.018; 95% CI 0.823 to 1.258). Median PFS was 11.7 months in the mFOLFOX6 plus bevacizumab group and 12.2 months in the SOX plus bevacizumab group (HR, 1.051; 95% CI 0.876 to 1.262; pnon-inferiority=0.0115). CONCLUSION: Our results reconfirmed that SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab in terms of PFS. MST did not differ between the groups. SOX plus bevacizumab is considered an effective regimen for first-line chemotherapy in patients with mCRC and can be used instead of mFOLFOX6 plus bevacizumab. TRIAL REGISTRATION NUMBER: JapicCTI-090699. - Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial.
Van Cutsem E; Falcone A; Garcia-Carbonero R; Komatsu Y; Pastorino A; Peeters M; Shimada Y; Yamazaki K; Yoshino T; Zaniboni A; Amellal N; Kanehisa A; Winkler R; Makris L; Mayer RJ; Ohtsu A; Tabernero J
ESMO open, 2, 5, e000261, 2017年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Background: In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). There was no formal analysis of quality of life (QoL) in RECOURSE. The aim of the present analysis was to assess proxies of QoL during the RECOURSE treatment period, in terms of adverse events (AEs) likely to affect QoL and Eastern Cooperative Oncology Group performance status (ECOG PS). Patients and methods: Enrolled patients had documented, previously treated (≥2 prior chemotherapy lines) mCRC and an ECOG PS of 0 or 1. Patients received best supportive care plus trifluridine/tipiracil 35 mg/m2 twice daily (n=534) or placebo (n=266) in a 28-day cycle. AEs analysed included nausea, vomiting, diarrhoea, dysgeusia and fatigue/asthenia. ECOG PS was determined at baseline, on day 1 of each treatment cycle, at treatment end and 30 days post-treatment discontinuation. Results: AEs that affect QoL were more frequent in patients treated with trifluridine/tipiracil than placebo. Median treatment duration for patients experiencing at least one of these AEs was longer than that observed for the overall RECOURSE population (trifluridine/tipiracil: 12 vs 7 weeks; placebo: 10 vs 6 weeks). Versus placebo, the duration of most AEs was longer in trifluridine/tipiracil recipients; however, all AEs except nausea and vomiting occupied a lower proportion of the total treatment period. Of the patients who had their PS recorded at discontinuation, PS was maintained in 67% and 63% of trifluridine/tipiracil and placebo recipients, and 84% and 81% of the trifluridine/tipiracil and placebo patients remained at a PS of 0 or 1 at discontinuation. Conclusions: Analysis of ECOG PS and AEs thought to affect QoL in the RECOURSE patient population suggests that trifluridine/tipiracil treatment does not result in a deterioration of patient QoL versus placebo. - Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors
Ralf-Dieter Hofheinz; Gael Deplanque; Yoshito Komatsu; Yoshimitsu Kobayashi; Janja Ocvirk; Patrizia Racca; Silke Guenther; Jun Zhang; Mario E. Lacouture; Aminah Jatoi
ONCOLOGIST, 21, 12, 1483, 1491, 2016年12月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur
Hideyuki Hayashi; Yoshito Komatsu; Takumi Uchida; Nobuhiko Abe; Ken Ito; Kouji Hirata; Kana Matsuda; Akira Fujinaga
JOURNAL OF INFECTION AND CHEMOTHERAPY, 22, 12, 826, 829, 2016年12月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - [III. The Association between Location and Colorectal Cancer Characteristics].
Komatsu Y
Gan to kagaku ryoho. Cancer & chemotherapy, 43, 11, 1357, 1360, 2016年11月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌) - Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience
Tetsuhito Muranaka; Satoshi Yuki; Yoshito Komatsu; Kentaro Sawada; Kazuaki Harada; Yasuyuki Kawamoto; Hiroshi Nakatsumi; Naoya Sakamoto
JOURNAL OF GASTRIC CANCER, 16, 3, 177, 181, 2016年09月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
Kohei Shitara; Kei Muro; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Yoshito Komatsu; Tomohiro Nishina; Kensei Yamaguchi; Yoshihiko Segawa; Yasushi Omuro; Takao Tamura; Toshihiko Doi; Seigo Yukisawa; Hirofumi Yasui; Fumio Nagashima; Masahiro Gotoh; Taito Esaki; Michael Emig; Kumari Chandrawansa; Astra M. Liepa; Hansjochen Wilke; Yukako Ichimiya; Atsushi Ohtsu
GASTRIC CANCER, 19, 3, 927, 938, 2016年07月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌) - The adjuvant therapy for high risk GIST patients after complete resection in the clinical practice.
Nishida Toshirou; Takagi Masakazu; Ozaka Masato; Kitagawa Yuko; Kurokawa Yukinori; Komatsu Yoshito; Ishioka Chikashi; Doi Toshihiko; Cho Haruhiko; Kanda Tetsuo; Sugiyama Toshiro; Sawaki Akira; Kakeji Yoshihiro; Hirai Toshihiro; Hato Shinji; Baba Hideo; Shirao Kuniaki; Hirota Seiichi; Kagimura Tatsuo; Masuzawa Toru
JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月20日, [査読有り] - A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402).
Yuji Miyamoto; Satoshi Yuki; Mototsugu Shimokawa; Hiroaki Tanioka; Akihito Tsuji; Masako Asayama; Takeshi Shiraishi; Masahito Kotaka; Akitaka Makiyama; Yoshito Komatsu; Satohiro Masuda; Takuhiro Yamaguchi; Hiroshi Saeki; Eiji Oki; Yasunori Emi; Hideo Baba; Yoshihiko Maehara
JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月, [査読有り]
英語 - Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030).
Tomohiro Nishina; Takayuki Yoshino; Eiji Shinozaki; Kentaro Yamazaki; Yoshito Komatsu; Hideo Baba; Akihito Tsuji; Kensei Yamaguchi; Kei Muro; Naotoshi Sugimoto; Yasushi Tsuji; Toshikazu Moriwaki; Taito Esaki; Chikuma Hamada; Takanori Tanase; Atsushi Ohtsu
JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月, [査読有り]
英語 - A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
M. Ueno; T. Okusaka; Y. Omuro; H. Isayama; A. Fukutomi; M. Ikeda; N. Mizuno; K. Fukuzawa; M. Furukawa; H. Iguchi; K. Sugimori; J. Furuse; K. Shimada; T. Ioka; S. Nakamori; H. Baba; Y. Komatsu; M. Takeuchi; I. Hyodo; N. Boku
ANNALS OF ONCOLOGY, 27, 3, 502, 508, 2016年03月
英語, 研究論文(学術雑誌) - Clinicopathological features of ruptured GIST in the ReGISTry study of high risk GIST patients after complete resection in Japan
Toshirou Nishida; Masato Kondo; Masato Ozaka; Haruhiko Cho; Yoshito Komatsu; Toshihiko Doi; Hideo Baba; Yuko Kitagawa; Yukinori Kurokawa; Tetsuo Kanda; Toshiro Sugiyama; Akira Sawaki; Yoshihiro Kakeji; Toshihiro Hirai; Shinji Hato; Kuniaki Shirao; Chikashi Ishioka; Seiichi Hirota; Tatsuo Kagimura; Masakazu Takagi
JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月, [査読有り]
英語 - Observational cohort study of first-line bevacizumab with oxaliplatin or irinotecan and fluoropyrimidines in metastatic colorectal cancer: HGCSG0802-Analysis of early tumor shrinkage (ETS).
Yuki Satoshi; Nakatsumi Hiroshi; Sawada Kentaro; Kato Takashi; Meguro Takashi; Nakamura Michio; Iwanaga Ichiro; Ehira Nobuyuki; Sonoda Norikazu; Kudo Mineo; Kato Kanji; Sogabe Susumu; Amano Toraji; Ono Kota; Sakamoto Keita; Miyamoto Noriyuki; Kudo Kohsuke; Sakamoto Naoya; Sakata Yuh; Komatsu Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月01日, [査読有り] - S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
Shuichi Hironaka; Naotoshi Sugimoto; Kensei Yamaguchi; Toshikazu Moriwaki; Yoshito Komatsu; Tomohiro Nishina; Akihito Tsuji; Takako Eguchi Nakajima; Masahiro Gotoh; Nozomu Machida; Hideaki Bando; Taito Esaki; Yasunori Emi; Takashi Sekikawa; Shigemi Matsumoto; Masahiro Takeuchi; Narikazu Boku; Hideo Baba; Ichinosuke Hyodo
LANCET ONCOLOGY, 17, 1, 99, 108, 2016年01月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor
Yoshito Komatsu; Emiko Ohki; Naomi Ueno; Ai Yoshida; Yasuharu Toyoshima; Eiji Ueda; Hiroyuki Houzawa; Kanae Togo; Toshirou Nishida
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 45, 11, 1016, 1022, 2015年11月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - A pivotal role of Kruppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma
Osamu Maehara; Fumiyuki Sato; Mitsuteru Natsuizaka; Ayaka Asano; Yoshimasa Kubota; Jun Itoh; Seiji Tsunematsu; Katsumi Terashita; Yoko Tsukuda; Masato Nakai; Takuya Sho; Goki Suda; Kenichi Morikawa; Koji Ogawa; Makoto Chuma; Koji Nakagawa; Shunsuke Ohnishi; Yoshito Komatsu; Kelly A. Whelan; Hiroshi Nakagawa; Hiroshi Takeda; Naoya Sakamoto
CANCER BIOLOGY & THERAPY, 16, 10, 1453, 1461, 2015年10月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Taroh Satoh; Kyung Hee Lee; Sun Young Rha; Yasutsuna Sasaki; Se Hoon Park; Yoshito Komatsu; Hirofumi Yasui; Tae-You Kim; Kensei Yamaguchi; Nozomu Fuse; Yasuhide Yamada; Takashi Ura; Si-Young Kim; Masaki Munakata; Soh Saitoh; Kazuto Nishio; Satoshi Morita; Eriko Yamamoto; Qingwei Zhang; Jung-mi Kim; Yeul Hong Kim; Yuh Sakata
GASTRIC CANCER, 18, 4, 824, 832, 2015年10月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌) - Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial
Yoshito Komatsu; Toshihiko Doi; Akira Sawaki; Tatsuo Kanda; Yasuhide Yamada; Iris Kuss; George D. Demetri; Toshirou Nishida
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 20, 5, 905, 912, 2015年10月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌) - Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
Yoshito Komatsu; Chikashi Ishioka; Ken Shimada; Yasuhide Yamada; Makio Gamoh; Atsushi Sato; Tatsuro Yamaguchi; Satoshi Yuki; Satoshi Morita; Shin Takahashi; Rei Goto; Minoru Kurihara
BMC CANCER, 15, 626, 626, 2015年09月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Yoshito Komatsu; Kenji Okita; Satoshi Yuki; Tomohisa Furuhata; Hiraku Fukushima; Hiroyuki Masuko; Yasuyuki Kawamoto; Hiroshi Isobe; Takuto Miyagishima; Kazuaki Sasaki; Michio Nakamura; Yoshinobu Ohsaki; Junta Nakajima; Miki Tateyama; Kazunori Eto; Shinya Minami; Ryoji Yokoyama; Ichiro Iwanaga; Hitoshi Shibuya; Mineo Kudo; Koji Oba; Yasuo Takahashi
Cancer science, 106, 7, 891, 5, 2015年07月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), The purpose of this study is to compare the efficacy of a single administration of dexamethasone (DEX) on day 1 against DEX administration on days 1-3 in combination with palonosetron (PALO), a second-generation 5-HT3 receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in non-anthracycline and cyclophosphamide (AC) moderately-emetogenic chemotherapy (MEC). This phase III trial was conducted with a multi-center, randomized, open-label, non-inferiority design. Patients who received non-AC MEC as an initial chemotherapy were randomly assigned to either a group administered PALO (0.75 mg, i.v.) and DEX (9.9 mg, i.v.) prior to chemotherapy (study treatment group), or a group administered additional DEX (8 mg, i.v. or p.o.) on days 2-3 (control group). The primary endpoint was complete response (CR) rate. The CR rate difference was estimated by logistic regression with allocation factors as covariates. The non-inferiority margin was set at -15% (study treatment group - control group). From April 2011 to March 2013, 305 patients who received non-AC MEC were randomly allocated to one of two study groups. Overall, the CR rate was 66.2% in the study treatment group (N = 151) and 63.6% in the control group (N = 154). PALO plus DEX day 1 was non-inferior to PALO plus DEX days 1-3 (difference, 2.5%; 95% confidence interval [CI]: -7.8%-12.8%; P-value for non-inferiority test = 0.0004). There were no differences between the two groups in terms of complete control rate (64.9 vs 61.7%) and total control rate (49.7% vs 47.4%). Anti-emetic DEX administration on days 2-3 may be eliminated when used in combination with PALO in patients receiving non-AC MEC. - EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition
Fumiyuki Sato; Yoshimasa Kubota; Mitsuteru Natsuizaka; Osamu Maehara; Yutaka Hatanaka; Katsuji Marukawa; Katsumi Terashita; Goki Suda; Shunsuke Ohnishi; Yuichi Shimizu; Yoshito Komatsu; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Kelly A. Whelan; Hiroshi Nakagawa; Naoya Sakamoto
CANCER BIOLOGY & THERAPY, 16, 6, 933, 940, 2015年06月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations
Takayuki Yoshino; Yoshito Komatsu; Yasuhide Yamada; Kentaro Yamazaki; Akihito Tsuji; Takashi Ura; Axel Grothey; Eric Van Cutsem; Andrea Wagner; Frank Cihon; Yoko Hamada; Atsushi Ohtsu
INVESTIGATIONAL NEW DRUGS, 33, 3, 740, 750, 2015年06月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - ReGISTry Study of High Risk GIST Patients After Complete Resection: The adjuvant therapy and pathological diagnosis in Japan.
Nishida Toshirou; Kitagawa Yuko; Kurokawa Yukinori; Komatsu Yoshito; Ishioka Chikashi; Doi Toshihiko; Yamada Yasuhide; Ozaka Masato; Cho Haruhiko; Kanda Tetsuo; Sugiyama Toshiro; Sawaki Akira; Kakeji Yoshihiro; Hirai Toshihiro; Hato Shinji; Baba Hideo; Shirao Kuniaki; Hirota Seiichi; Kagimura Tatsuo
JOURNAL OF CLINICAL ONCOLOGY, 33, 15, 2015年05月20日, [査読有り] - Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer; Eric Van Cutsem; Alfredo Falcone; Takayuki Yoshino; Rocio Garcia-Carbonero; Nobuyuki Mizunuma; Kentaro Yamazaki; Yasuhiro Shimada; Josep Tabernero; Yoshito Komatsu; Alberto Sobrero; Eveline Boucher; Marc Peeters; Ben Tran; Heinz-Josef Lenz; Alberto Zaniboni; Howard Hochster; James M. Cleary; Hans Prenen; Fabio Benedetti; Hirokazu Mizuguchi; Lukas Makris; Masanobu Ito; Atsushi Ohtsu
NEW ENGLAND JOURNAL OF MEDICINE, 372, 20, 1909, 1919, 2015年05月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - [Somatostatin analog].
Muranaka T; Yuki S; Komatsu Y
Nihon rinsho. Japanese journal of clinical medicine, 73 Suppl 2, 286, 290, 2015年02月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌) - [Gastrointestinal ulcer, gastrointestinal perforation].
Nakatsumi H; Komatsu Y
Nihon rinsho. Japanese journal of clinical medicine, 73 Suppl 2, 380, 383, 2015年02月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌) - Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.
Yuki Satoshi; Nakatsumi Hiroshi; Hayashi Hideyuki; Fukushima Hiraku; Kato Takashi; Meguro Takashi; Nakamura Michio; Iwanaga Ichiro; Eto Kazunori; Sato Atsushi; Okuda Hiroyuki; Oba Ayane; Miyagishima Takuto; Muto Osamu; Yabusaki Satoshi; Miyamoto Noriyuki; Kudo Kohsuke; Sakamoto Naoya; Sakata Yuh; Komatsu Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 33, 3, 2015年01月20日, [査読有り] - Association of early tumor shrinkage with progression-free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.
Nakatsumi Hiroshi; Yuki Satoshi; Muranaka Tetsuhito; Fukushima Hiraku; Kato Takashi; Meguro Takashi; Nakamura Michio; Iwanaga Ichiro; Ehira Nobuyuki; Sonoda Norikazu; Kudo Mineo; Kato Kanji; Miyashita Kencho; Abe Masakazu; Miyamoto Noriyuki; Sakamoto Keita; Kudo Kohsuke; Sakamoto Naoya; Sakata Yuh; Komatsu Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 33, 3, 2015年01月20日, [査読有り] - P0988-23-AM オキサリプラチンによる血管痛発現における患者背景の調査(がん薬物療法(他の副作用対策)2,ポスター,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)
坂本 和央; 柴山 良彦; 小林 正紀; 井関 健; 久保田 康生; 速水 章一; 大江 利治; 齋藤 佳敬; 熊井 正貴; 笠師 久美子; 山田 武宏; 小松 嘉人
日本医療薬学会年会講演要旨集, 25, 0, 430, 430, 一般社団法人 日本医療薬学会, 2015年, [査読有り]
日本語 - The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer
Masato Nakamura; Yasuhide Yamada; Kei Muro; Keiichi Takahashi; Hideo Baba; Yasutsuna Sasaki; Yoshito Komatsu; Taroh Satoh; Hideyuki Mishima; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Kenichi Sugihara
FUTURE ONCOLOGY, 11, 10, 1471, 1478, 2015年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study
Hirofumi Yasui; Kei Muro; Yasuhiro Shimada; Akihito Tsuji; Shinichi Sameshima; Hideo Baba; Taroh Satoh; Tadamichi Denda; Kenji Ina; Tomohiro Nishina; Kensei Yamaguchi; Taito Esaki; Shinya Tokunaga; Hiroyuki Kuwano; Narikazu Boku; Yoshito Komatsu; Masahiko Watanabe; Ichinosuke Hyodo; Satoshi Morita; Kenichi Sugihara
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 141, 1, 153, 160, 2015年01月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients
Takahide Sasaki; Nozomu Fuse; Takeshi Kuwata; Shogo Nomura; Kazuhiro Kaneko; Toshihiko Doi; Takayuki Yoshino; Hiromichi Asano; Atsushi Ochiai; Yoshito Komatsu; Naoya Sakamoto; Atsushi Ohtsu
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 45, 1, 43, 48, 2015年01月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.
Yoshimitsu Kobayashi; Yoshito Komatsu; Satoshi Yuki; Hiraku Fukushima; Takahide Sasaki; Ichiro Iwanaga; Minoru Uebayashi; Hiroyuki Okuda; Takaya Kusumi; Takuto Miyagishima; Susumu Sogabe; Miki Tateyama; Kazuteru Hatanaka; Yasushi Tsuji; Michio Nakamura; Jun Konno; Fumiyasu Yamamoto; Manabu Onodera; Kazuhiro Iwai; Yuh Sakata; Riichiro Abe; Koji Oba; Naoya Sakamoto
Future oncology (London, England), 11, 4, 617, 27, 4, 2015年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), AIM: We planned a randomized, open-label trial to evaluate differences between pre-emptive and reactive skin treatment for panitumumab (Pmab)-associated skin toxicities in Japanese patients with metastatic colorectal cancer. PATIENTS & METHODS: Patients receiving third-line Pmab-containing regimens were randomized to pre-emptive or reactive treatment. The primary end point was the cumulative incidence of ≥grade 2 skin toxicities during 6 weeks. Retrospectively, a dermatologist reviewed skin toxicities, in a blinded manner. RESULTS: A total of 95 patients were enrolled (pre-emptive: 47, reactive: 48). The primary end point was achieved (21.3 and 62.5% [risk ratio: 0.34; p < 0.001], for pre-emptive and reactive treatment, respectively). A similar trend was observed in central review. CONCLUSION: Pre-emptive skin treatment could reduce the severity of Pmab-associated skin toxicities in Japanese metastatic colorectal cancer patients. - Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; Gyoergy Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D. Schwartz; Atsushi Ohtsu
LANCET ONCOLOGY, 15, 11, 1224, 1235, 2014年10月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer
Yoshito Komatsu; Takayuki Yoshino; Kentaro Yamazaki; Satoshi Yuki; Nozomu Machida; Takahide Sasaki; Ichinosuke Hyodo; Yutaka Yachi; Hiroshi Onuma; Atsushi Ohtsu
INVESTIGATIONAL NEW DRUGS, 32, 3, 473, 480, 2014年06月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGSGl001 (Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP)-Additional analysis of antitumor effica
Kobayashi Yoshimitsu; Komatsu Yoshito; Yuki Satoshi; Nakatsumi Hiroshi; Fukushima Hiraku; Miyagishima Takuto; Ehira Nobuyuki; Iwanaga Ichiro; Okuda Hiroyuki; Kusumi Takaya; Tateyama Miki; Tsuji Yasushi; Hatanaka Kazuteru; Nakamura Michio; Kudo Mineo; Takagi Tomofumi; Hisai Hiroyuki; Abe Riichiro; Oba Koji; Sakata Yuh
JOURNAL OF CLINICAL ONCOLOGY, 32, 15, 2014年05月20日, [査読有り] - Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
Y. Kurokawa; N. Sugimoto; H. Miwa; M. Tsuda; S. Nishina; H. Okuda; H. Imamura; M. Gamoh; D. Sakai; T. Shimokawa; Y. Komatsu; Y. Doki; T. Tsujinaka; H. Furukawa
BRITISH JOURNAL OF CANCER, 110, 5, 1163, 1168, 2014年03月, [査読有り]
英語, 研究論文(学術雑誌) - Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol with Panitumumab; J-STEPP).
Iwanaga Ichiro; Komatsu Yoshito; Yuki Satoshi; Kobayashi Yoshimitsu; Sakamoto Naoya; Uebayashi Minoru; Okuda Hiroyuki; Kusumi Takaya; Sogabe Susumu; Miyagishima Takuto; Tateyama Miki; Tsuji Yasushi; Hatanaka Kazuteru; Nakamura Michio; Konno Jun; Yamamoto Fumiyasu; Iwai Kazuhiro; Onodera Manabu; Oba Koji; Sakata Yuh
JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月20日, [査読有り] - Updated analysis of HERBIS-1: A phase ll study of trastuzumab (T-mab) in combination with tri-weekly S-1 plus CDDP in HER2-positive advanced gastric cancer.
Gamoh Makio; Sugimoto Naotoshi; Miwa Hiroto; Tsuda Masahiro; Nishina Shinichi; Okuda Hiroyuki; Imamura Hiroshi; Matsuyama Jin; Shimokawa Toshio; Sakai Daisuke; Kurokawa Yukinori; Komatsu Yoshito; Tsujinaka Toshimasa; Ishioka Chikashi; Furukawa Hiroshi
JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月20日, [査読有り]
英語 - Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
Akira Sawaki; Tatsuo Kanda; Yoshito Komatsu; Toshirou Nishida
GASTROENTEROLOGY RESEARCH AND PRACTICE, 2014, 342986, 342986, 2014年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - [New molecular targeting drugs for metastatic colorectal cancer].
Komatsu Y; Harada K; Fukushima H; Yuki S
Nihon rinsho. Japanese journal of clinical medicine, 72, 1, 120, 126, 1, 2014年01月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌), I explain an outline of the molecular target of new drugs for colorectal cancer. First, regorafenib is an orally active, multikinase inhibitor. Second, as angiogenesis inhibitors, aflibercept and ramucirumab. Aflibercept is the second anti-angiogenic agent after bevacizumab with a FDA approval for metastatic colorectal cancer. Ramucirumab is a fully human mAb that binds human VEGFR-2, thus blocking VEGF binding and inhibiting angiogenesis. Finally, I introduce a new combination chemotherapy regimen with molecular targetting drugs. - Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
Yasuhide Yamada; Daisuke Takahari; Hiroshi Matsumoto; Hideo Baba; Masato Nakamura; Kazuhiro Yoshida; Motoki Yoshida; Shigeyoshi Iwamoto; Ken Shimada; Yoshito Komatsu; Yasutsuna Sasaki; Taroh Satoh; Keiichi Takahashi; Hideyuki Mishima; Kei Muro; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Kenichi Sugihara
LANCET ONCOLOGY, 14, 13, 1278, 1286, 2013年12月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - 【大腸癌肝転移;Consensus & Controversy】
有井 滋樹; 小松 嘉人; 島田 安博; 椎名 秀一朗
肝胆膵, 67, 4, 605, 619, (株)アークメディア, 2013年10月
日本語 - Pharmacokinetic assessment of irinotecan, SN-38, and SN-38-glucuronide: A substudy of the FIRIS study
Taroh Satoh; Hirofumi Yasui; Kei Muro; Yoshito Komatsu; Shinichi Sameshima; Kensei Yamaguchi; Kenichi Sugihara
Anticancer Research, 33, 9, 3845, 3854, 9, 2013年09月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - 【分子標的治療薬の選び方、使い方】 分子標的治療薬の選び方、使い方 レゴラフェニブ
小松 嘉人; 結城 敏志; 福島 拓
臨床腫瘍プラクティス, 9, 3, 280, 281, (株)ヴァンメディカル, 2013年08月
日本語 - Randomized phase III clinical study comparing postoperative UFT/LV, UFT plus LV/UFT and UFT plus LV plus PSK/UFT plus PSK as adjuvant therapy for curatively resected stage III colorectal cancer HGCSG-CAD study
Shichinohe Toshiaki; Komatsu Yoshito; Akazawa Kohei; Yuki Satoshi; Fukushima Hiraku; Ohno Kouichi; Nakamura Fumitaka; Kusumi Takaya; Morita Takayuki; Senmaru Naoto; Kumagai Naoko; Hirano Satoshi
JOURNAL OF CLINICAL ONCOLOGY, 31, 15, 2013年05月20日, [査読有り] - Erratum: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: Subset analyses of the AVAGAST study and the ToGA study (Gastric Cancer DOI: 10.1007/s10120-012-0167-0)
Kensei Yamaguchi; Akira Sawaki; Toshihiko Doi; Taroh Satoh; Yasuhide Yamada; Yasushi Omuro; Tomohiro Nishina; Narikazu Boku; Keisho Chin; Yasuo Hamamoto; Hiroya Takiuchi; Yoshito Komatsu; Shigehira Saji; Wasaburo Koizumi; Yoshinori Miyata; Atsushi Sato; Eishi Baba; Takao Tamura; Takashi Abe; Atsushi Ohtsu
Gastric Cancer, 16, 2, 183, 184, 2013年04月, [査読有り]
英語, 研究論文(学術雑誌) - Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
Kensei Yamaguchi; Akira Sawaki; Toshihiko Doi; Taroh Satoh; Yasuhide Yamada; Yasushi Omuro; Tomohiro Nishina; Narikazu Boku; Keisho Chin; Yasuo Hamamoto; Hiroya Takiuchi; Yoshito Komatsu; Shigehira Saji; Wasaburo Koizumi; Yoshinori Miyata; Atsushi Sato; Eishi Baba; Takao Tamura; Takashi Abe; Atsushi Ohtsu
GASTRIC CANCER, 16, 2, 175, 182, 2013年04月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌) - Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy
Kohei Shitara; Satoshi Yuki; Kentaro Yamazaki; Yoichi Naito; Hiraku Fukushima; Yoshito Komatsu; Hirofumi Yasui; Toshimi Takano; Kei Muro
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 139, 4, 595, 603, 2013年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer
Nobumasa Mizuno; Kenji Yamao; Yoshito Komatsu; Masaki Munakata; Atsushi Ishiguro; Taketo Yamaguchi; Shinichi Ohkawa; Mitsuhiro Kida; Tatsuya Ioka; Koji Takeda; Toshihiro Kudo; Masayuki Kitano; Haruo Iguchi; Akihito Tsuji; Tetsuhide Ito; Masao Tanaka; Junji Furuse; Chikuma Hamada; Yuh Sakata
JOURNAL OF CLINICAL ONCOLOGY, 31, 4, 2013年02月, [査読有り]
英語 - A phase II study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HERBIS-1)
Sugimoto Naotoshi; Tanaka Junji; Tsuda Masahiro; Okamoto Wataru; Okuda Hiroyuki; Lmamura Hiroshi; Shimokawa Toshio; Sakai Daisuke; Kurokawa Yukinori; Komatsu Yoshito; Ishioka Chikashi; Tsujinaka Toshimasa; Takiuchi Hiroya; Furukawa Hiroshi
JOURNAL OF CLINICAL ONCOLOGY, 31, 4, 2013年02月01日, [査読有り]
英語 - Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients
Tatsuo Kanda; Toshirou Nishida; Norihito Wada; Osamu Kobayashi; Masakazu Yamamoto; Akira Sawaki; Narikazu Boku; Masato Koseki; Toshihiko Doi; Yasushi Toh; Yoshihiro Kakeji; Toshiro Sugiyama; Yoshito Komatsu; Shojiro Kikuchi; Kyoji Ogoshi; Hitoshi Katai; Kazuhito Miyachi; Seiichi Hirota; Atsushi Ohtsu
International Journal of Clinical Oncology, 18, 1, 38, 45, 1, 2013年02月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌) - Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors
Sachi Morita; Satoshi Oizumi; Hironobu Minami; Koichi Kitagawa; Yoshito Komatsu; Yutaka Fujiwara; Megumi Inada; Satoshi Yuki; Naomi Kiyota; Ayako Mitsuma; Masataka Sawaki; Hiromi Tanii; Junko Kimura; Yuichi Ando
INVESTIGATIONAL NEW DRUGS, 30, 5, 1950, 1957, 2012年10月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Takayuki Yoshino; Nobuyuki Mizunuma; Kentaro Yamazaki; Tomohiro Nishina; Yoshito Komatsu; Hideo Baba; Akihito Tsuji; Kensei Yamaguchi; Kei Muro; Naotoshi Sugimoto; Yasushi Tsuji; Toshikazu Moriwaki; Taito Esaki; Chikuma Hamada; Takanori Tanase; Atsushi Ohtsu
LANCET ONCOLOGY, 13, 10, 993, 1001, 2012年10月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer
Yoshito Komatsu; Satoshi Yuki; Susumu Sogabe; Hiraku Fukushima; Hiroshi Nakatsumi; Yoshimitsu Kobayashi; Ichiro Iwanaga; Michio Nakamura; Kazuteru Hatanaka; Takuto Miyagishima; Mineo Kudo; Masaki Munakata; Takashi Meguro; Miki Tateyama; Yuh Sakata
ACTA ONCOLOGICA, 51, 7, 867, 872, 2012年09月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - 研修医からの質問Q&A 転移臓器の臨床症状に乏しい進行大腸癌症例にも、初回よりセツキシマブを用いるべきか?
結城 敏志; 小松 嘉人
臨床腫瘍プラクティス, 8, 3, 305, 305, (株)ヴァンメディカル, 2012年08月
日本語 - First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study
Yasushi Tsuji; Taroh Satoh; Akihito Tsuji; Kei Muro; Motoki Yoshida; Tomohiro Nishina; Michitaka Nagase; Yoshito Komatsu; Takeshi Kato; Yoshinori Miyata; Naoko Mizutani; Satoshi Hashigaki; Maria Jose Lechuga; Tadamichi Denda
CANCER SCIENCE, 103, 8, 1502, 1507, 2012年08月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
Y. Kawamoto; K. Tsuchihara; T. Yoshino; N. Ogasawara; M. Kojima; M. Takahashi; A. Ochiai; H. Bando; N. Fuse; M. Tahara; T. Doi; H. Esumi; Y. Komatsu; A. Ohtsu
British Journal of Cancer, 107, 2, 340, 344, 2012年07月10日, [査読有り]
英語, 研究論文(学術雑誌) - Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Kohei Shitara; Satoshi Yuki; Motoki Yoshida; Daisuke Takahari; Setsuo Utsunomiya; Tomoya Yokota; Yozo Sato; Yoshitaka Inaba; Masahiro Tajika; Hiroki Kawai; Hidekazu Yamaura; Mina Kato; Kentaro Yamazaki; Yoshito Komatsu; Kei Muro
INVESTIGATIONAL NEW DRUGS, 30, 2, 787, 793, 2012年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Therapeutic effect of TAS-102 (A) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy by the Kohne model (Km).
Tomohiro Nishina; Takayuki Yoshino; Nobuyuki Mizunuma; Kentaro Yamazaki; Yoshito Komatsu; Hideo Baba; Akihito Tsuji; Kensei Yamaguchi
JOURNAL OF CLINICAL ONCOLOGY, 30, 4, 2012年02月, [査読有り]
英語 - Retrospective cohort study on the risk factors of admission due to serious adverse events during S-1 (tegaful, gimeracil, oteracil potassium) containing chemotherapy for gastric cancer.
Kawamoto Yasuyuki; Yuki Satoshi; Kobayashi Yoshimitsu; Oba Koji; Hayashi Hideyuki; Nakatsumi Hiroshi; Komatsu Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 30, 4, 2012年02月01日, [査読有り] - Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study.
Hiroshi Nakatsumi; Yoshito Komatsu; Satoshi Yuki; Susumu Sogabe; Miki Tateyama; Shuichi Muto; Mineo Kudo; Kanji Kato; Takuto Miyagishima; Minoru Uebayashi; Takashi Meguro; Koji Oba; Masahiro Asaka
Chemotherapy, 58, 6, 439, 44, 6, 2012年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Indisetron is a serotonin (5-hydroxytryptamine type 3) receptor antagonist that also antagonizes 5-hydroxytryptamine type 4 receptors. We designed a pilot study in order to explore the optimal dosing period for indisetron during modified FOLFOX6 (mFOLFOX6). PATIENTS AND METHODS: Forty-two chemotherapy-naive patients with advanced colorectal cancer scheduled to receive mFOLFOX6 were randomly assigned to either a 1- or 3-day indisetron regimen arm. The primary endpoint was complete protection from vomiting. RESULTS: Proportions of patients with complete protection from vomiting were 85.7% [95% confidence interval (CI) 63.7-97.0] with the 3-day regimen and 81.0% (95% CI 58.1-94.6) with the 1-day regimen. Proportions of patients with complete protection from nausea were 47.6% in each arm (95% CI 25.7-70.2). No rescue therapy rates were 66.7% (95% CI 43.0-85.4) versus 57.1% (95% CI 34.0-78.2). No severe adverse events were observed in either arm. CONCLUSION: Both 1- and 3-day indisetron regimens were feasible for preventing nausea and vomiting induced by mFOLFOX6. - Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer
Kohei Shitara; Takashi Ura; Keitaro Matsuo; Daisuke Takahari; Tomoya Yokota; Satoshi Yuki; Motoki Yoshida; Setsuo Utsunomiya; Yozo Sato; Hidekazu Yamaura; Mina Kato; Yoshitaka Inaba; Masahiro Tajika; Hiroki Kawai; Kentaro Yamazaki; Yoshito Komatsu; Kei Muro
EUROPEAN JOURNAL OF CANCER, 47, 18, 2673, 2680, 2011年12月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - PHASE II STUDY OF CHEMORADIOTHERAPY WITH 5-FLUOROURACIL AND CISPLATIN FOR STAGE II-III ESOPHAGEAL SQUAMOUS CELL CARCINOMA: JCOG TRIAL (JCOG 9906)
Ken Kato; Kei Muro; Keiko Minashi; Atsushi Ohtsu; Satoshi Ishikura; Narikazu Boku; Hiroya Takiuchi; Yoshito Komatsu; Yoshinori Miyata; Haruhiko Fukuda
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 3, 684, 690, 2011年11月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Phase 2 Study of Nilotinib as Third-Line Therapy for Patients With Gastrointestinal Stromal Tumor
Akira Sawaki; Toshirou Nishida; Toshihiko Doi; Yasuhide Yamada; Yoshito Komatsu; Tatsuo Kanda; Yoshihiro Kakeji; Yusuke Onozawa; Makoto Yamasaki; Atsushi Ohtsu
CANCER, 117, 20, 4633, 4641, 2011年10月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)
Yoshito Komatsu; Yutaka Takahashi; Yutaka Kimura; Hisashi Oda; Yusuke Tajima; Shigeyuki Tamura; Jo Sakurai; Takehiro Wakasugi; Shigeru Tatebe; Masahiro Takahashi; Yuh Sakata; Masaki Kitajima; Junichi Sakamoto; Shigetoyo Saji
ANTI-CANCER DRUGS, 22, 6, 576, 583, 2011年07月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab with Chemotherapy for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study
Susumu Sogabe; Yoshito Komatsu; Satoshi Yuki; Takaya Kusumi; Kazuteru Hatanaka; Michio Nakamura; Takashi Kato; Takuto Miyagishima; Ayumu Hosokawa; Ichiro Iwanaga; Yuh Sakata; Masahiro Asaka
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 41, 4, 490, 497, 2011年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - [Colorectal cancer chemotherapy and QOL (benefits and problems of outpatient-chemotherapy)].
Nakatsumi H; Yuki S; Kobayashi Y; Komatsu Y
Nihon rinsho. Japanese journal of clinical medicine, 69 Suppl 3, 585, 588, 2011年04月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌) - A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan
Susumu Sogabe; Satoshi Yuki; Hironobu Takano; Yoshimitsu Kobayashi; Hiroshi Nakatsumi; Takahide Sasaki; Yasuyuki Kawamoto; Hiraku Fukushima; Ichiro Iwanaga; Yasuko Uehata; Yoshito Komatsu; Masahiro Asaka
Japanese Journal of Cancer and Chemotherapy, 38, 8, 1375, 1377, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2011年, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌) - Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer (JO19380): Evaluation of long-term treatment cases
Atsushi Sato; Toshihiko Doi; Narikazu Boku; Ken Kato; Yoshito Komatsu; Kensei Yamaguchi; Kei Muro; Yasuo Hamamoto; Wasaburo Koizumi; Nobuyuki Mizunuma; Hiroya Takiuchi
Japanese Journal of Cancer and Chemotherapy, 38, 4, 561, 569, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2011年, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌) - Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)
Yoshito Komatsu; Satoshi Yuki; Susumu Sogabe; Hiraku Fukushima; Ichiro Iwanaga; Mineo Kudo; Miki Tateyama; Takashi Meguro; Minoru Uebayashi; Akiyoshi Saga; Yuh Sakata; Masahiro Asaka
ONCOLOGY, 80, 1-2, 70, 75, 2011年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
Kuniaki Shirao; Toshirou Nishida; Toshihiko Doi; Yoshito Komatsu; Kei Muro; Yinhua Li; Eiji Ueda; Atsushi Ohtsu
INVESTIGATIONAL NEW DRUGS, 28, 6, 866, 875, 2010年12月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - FIRIS STUDY: A RANDOMIZED PHASE III NON-INFERIORITY STUDY OF FOLFIRI VS. IRIS AS SECOND-LINE CHEMOTHERAPY OF MCRC
Taroh Satoh; Kei Muro; Hirofumi Yasui; Yasuhiro Shimada; Akihito Tsuji; Tadamichi Denda; Kenji Ina; Tomohiro Nishina; Kensei Yamaguchi; Hiroya Takiuchi; Taito Esaki; Shinya Tokunaga; Yoshito Komatsu; Hisateru Yasui; Kenichi Sugihara
ANNALS OF ONCOLOGY, 21, 13, 14, 2010年11月, [査読有り]
英語 - Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro; Narikazu Boku; Yasuhiro Shimada; Akihito Tsuji; Shinichi Sameshima; Hideo Baba; Taroh Satoh; Tadamichi Denda; Kenji Ina; Tomohiro Nishina; Kensei Yamaguchi; Hiroya Takiuchi; Taito Esaki; Shinya Tokunaga; Hiroyuki Kuwano; Yoshito Komatsu; Masahiko Watanabe; Ichinosuke Hyodo; Satoshi Morita; Kenichi Sugihara
LANCET ONCOLOGY, 11, 9, 853, 860, 2010年09月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Phase 1/2 Clinical Study of Irinotecan and Oral S-1 (IRIS) in Patients with Advanced Gastric Cancer
Yoshito Komatsu; Satoshi Yuki; Nozomu Fuse; Takashi Kato; Takuto Miyagishima; Mineo Kudo; Yasuyuki Kunieda; Miki Tateyama; Osamu Wakahama; Takashi Meguro; Yuh Sakata; Masahiro Asaka
ADVANCES IN THERAPY, 27, 7, 483, 492, 2010年07月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate
Akira Sawaki; Yasuhide Yamada; Yoshito Komatsu; Tatsuo Kanda; Toshihiko Doi; Masato Koseki; Hideo Baba; Yu-Nien Sun; Koji Murakami; Toshirou Nishida
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 65, 5, 961, 967, 2010年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
Toshihiko Doi; Kei Muro; Narikazu Boku; Yasuhide Yamada; Tomohiro Nishina; Hiroya Takiuchi; Yoshito Komatsu; Yasuo Hamamoto; Nobutsugu Ohno; Yoshie Fujita; Matthew Robson; Atsushi Ohtsu
JOURNAL OF CLINICAL ONCOLOGY, 28, 11, 1904, 1910, 2010年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer
Shouko Ono; Mototsugu Kato; Kikuko Takagi; Junichi Kodaira; Kanako Kubota; Yoshihiro Matsuno; Yoshito Komatsu; Masahiro Asaka
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 25, 4, 804, 809, 2010年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs
Susumu Sogabe; Satoshi Yuki; Tomofumi Takagi; Takuji Miyazaki; Hironobu Takano; Yasuyuki Kawamoto; Hiroshi Nakatsumi; Takahide Sasaki; Ichiro Iwanaga; Yasuko Uehata; Masahiro Asaka; Yoshito Komatsu
Japanese Journal of Cancer and Chemotherapy, 37, 3, 535, 538, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2010年03月06日, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌) - Sunitinib
Yoshito Komatsu; Ichiro Iwanaga; Satoshi Yuuki; Susumu Sogabe; Hiroshi Nakatsumi; Takahide Sasaki
Biotherapy, 24, 2, 172, 177, 2010年03月
日本語, 研究論文(国際会議プロシーディングス) - Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer Results of Phase I and II Studies
Satoshi Yuuki; Yoshito Komatsu; Nozomu Fuse; Takashi Kato; Takuto Miyagishima; Mineo Kudo; Masao Watanabe; Miki Tateyama; Yasuyuki Kunieda; Osamu Wakahama; Yu Sakata; Masahiro Asaka
CLINICAL DRUG INVESTIGATION, 30, 4, 243, 249, 2010年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Second-line chemotherapy for colorectal cancer
Yoshito Komatsu; Susumu Sogabe; Yasuyuki Kawamoto; Ichiro Iwanaga; Yasuko Uehata; Satoshi Yuki; Masahiro Asaka
Japanese Journal of Cancer and Chemotherapy, 36, 5, 721, 725, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2009年, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌) - Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer
Kohei Shitara; Yoshito Komatsu; Satoshi Yuki; Masaki Munakata; Osamu Muto; Sen Shimaya; Yuh Sakata
ONCOLOGY, 75, 1-2, 67, 70, 2008年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Eradication of Helicobacter pylori for primary gastric cancer and secondary gastric cancer after endoscopic mucosal resection
Motosugu Kato; Masahiro Asaka; Shouko Ono; Manabu Nakagawa; Souichi Nakagawa; Yuichi Shimizu; Makoto Chuma; Hiroshi Kawakami; Yoshito Komatsu; Shuhei Hige; Hiroshi Takeda
JOURNAL OF GASTROENTEROLOGY, 42, 16, 20, 2007年01月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌) - 【S-1の基礎と臨床】 大腸癌に対するCPT-11+S-1併用(IRIS)療法 S-12週投薬法
小松 嘉人; 結城 敏志; 舘山 美樹; 工藤 峰生; 浅香 正博
癌と化学療法, 33, Suppl.I, 131, 134, (株)癌と化学療法社, 2006年06月
日本語 - 【S-1の基礎と臨床】 胃癌に対するCPT-11+S-1併用(IRIS)療法 S-1 2週投薬法
小松 嘉人; 結城 敏志; 宮城島 拓人; 浅香 正博
癌と化学療法, 33, Suppl.I, 75, 78, (株)癌と化学療法社, 2006年06月
日本語 - [Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
Komatsu Y; Yuki S; Miyagishima T; Asaka M
Gan to kagaku ryoho. Cancer & chemotherapy, 33 Suppl 1, 75, 78, 2006年06月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌), We reported the results of phase I study with CPT-11 and S-1 (IRIS) in advanced gastric cancer (AGC) patients at ASCO 2002. Now I present an outline of this phase I/II trial. A combined treatment of IRIS (CPT-11 + S-1) was given to the AGC patients who had not received prior chemotherapy. S-1 was orally administered twice a day for 14 days, and CPT-11 was administered as a 90-minute intravenous infusion on days 1 and 15. This schedule was repeated every 4 weeks. Fifteen patients were registered in this phase I study and 9 patients were added in this phase II study. Non-hematological toxicities were almost classified as grade 2 or lower, except for grade 3 nausea and grade 3 dermatitis of level 2. These adverse events were manageable by administering anti-emetic drugs and a drug rest. As for hematological toxicities, grade 4 neutropenia occurred with one patient at level 1 and level 2 in phase I. And grade 4 neutropenia occurred with four patients at level 2 in phase II. However, they recovered after the drug rest, and we could continue the administration based on the standard dose modifications. These side effects were tolerable, and the overall response rate was 54.2%. MST of this regimen is 581 days. The IRIS treatment is effective and tolerable for outpatient treatments. - [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Komatsu Y; Yuki S; Tateyama M; Kudo M; Asaka M
Gan to kagaku ryoho. Cancer & chemotherapy, 33 Suppl 1, 131, 134, 2006年06月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌), We planned to conduct a phase II clinical study of combination therapy with CPT-11 and S-1. The antitumor effect was the primary endpoint, while the safety, progression-free survival time, and median survival time were the secondary endpoints. The subjects were untreated patients with inoperable advanced colorectal cancer aged 20-75 years. Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy. CPT-11 was administered at a dose of 100 mg/m2 (on days 1 and 15) as an intravenous infusion over 90 minutes, and oral S-1 (40 mg/m2) was administered after breakfast and dinner and then withdrawn for 2 weeks. No other serious adverse reactions occurred (either hematological or non-hematological), and all patients could receive therapy safely on an outpatient basis. Interim analysis suggested excellent results, with a response rate of 50%. Combination therapy with CPT-11 and S-1 achieved a high response rate and could be given safely. These findings suggest that the therapy has potential as first-line treatment for inoperable advanced recurrent colorectal cancer. - Phase I-II study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancer
Kensei Yamaguchi; Tomotaka Shimamura; Yoshito Komatsu; Akinori Takagane; Takashi Yoshioka; Soh Saitoh; Masaki Munakata; Yu Sakata; Tsukasa Sato; Tatsuhiro Arai; Hiroshi Saitoh
Gastric Cancer, 9, 1, 36, 43, 1, 2006年02月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌) - 症例提示 切除不能進行胃がんに対する塩酸イリノテカン+ティーエスワン併用療法によって著効であった2例 Hokkaido Gastrointestinal Cancer Study Group(HGCSG0303)
結城 敏志; 小松 嘉人; 宮城島 拓人; 若浜 理; 浅香 正博; 坂田 優
臨床腫瘍プラクティス, 1, 1, 101, 104, (株)ヴァンメディカル, 2005年08月
日本語, 切除不能進行胃癌に対する塩酸イリノテカン(以下,CPT-11)+ティーエスワン(以下,S-1)併用療法が著効した2例(61歳男性,69歳男性)を報告した.レジメンは,CPT-11を100mg/m2でday1・15に,S-1は体表面積に応じた用量をday1〜14に投与し,28日間を1コースとしたものであった - Treatment of a Gilbert's syndrome patient with irinotecan, leucovorin and 5-fluorouracil
Y Komatsu; M Takei; S Yuki; N Fuse; S Furukawa; T Kato; H Takeda; M Kato; M Asaka
JOURNAL OF CHEMOTHERAPY, 17, 1, 111, 114, 2005年02月, [査読有り]
英語, 研究論文(学術雑誌) - Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido gastrointestinal cancer study group HGCSG0302
Y Komatsu; S Yuuki; N Fuse; M Takei; T Kato; T Miyagishima; M Kudo; Y Kunieda; M Tateyama; O Wakahama; T Meguro; H Ohizumi; M Watanabe; H Akita; Y Sakata; M Asaka
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 35, 2, 88, 89, 2005年02月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - Endoscopic clip application for closure of esophageal perforations caused by EMR
Y Shimizu; M Kato; J Yamamoto; S Nakagawa; Y Komatsu; H Tsukagoshi; M Fujita; M Hosokawa; M Asaka
GASTROINTESTINAL ENDOSCOPY, 60, 4, 636, 639, 2004年10月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - A randomized phase II clinical trial of tailored CPT-11+S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy
Y Takahashi; J Sakamoto; T Takeuchi; M Mai; T Kubota; M Kitajima; Y Tanigawara; Y Komatsu; T Toge; S Saji
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 34, 6, 342, 345, 2004年06月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - 【胃・十二指腸潰瘍 基礎・臨床の最新動向】 診断学の進歩 H.pylori感染診断・評価 ガイドライン後の新しい検査法 免疫学的迅速ウレアーゼ試験法
加藤 元嗣; 中川 宗一; 清水 勇一; 結城 敏志; 布施 望; 武居 正明; 古川 滋; Perez-Aldana LA; 鄭 日男; 小松 嘉人; 斎藤 永仁; 武田 宏司; 杉山 敏郎; 浅香 正博
日本臨床, 62, 3, 470, 476, (株)日本臨床社, 2004年03月
日本語 - [Immunological rapid urease test].
Kato M; Nakagawa S; Shimizu Y; Yuki S; Fuse N; Takei M; Furukawa S; Perez-Aldana LA; Rinan Z; Komatsu Y; Saito N; Takeda H; Sugiyama T; Asaka M
Nihon rinsho. Japanese journal of clinical medicine, 62, 3, 470, 476, 3, 2004年03月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌), Immunological rapid urease test for detection of Helicobacter pylori infection, composed of a solid-phase tip coated with monoclonal antibody against H. pylori's urease and ion-sensitive field transistor (ISFT)-based pH sensor system, was developed. The monoclonal antibody against H. pylori's urease was useful to avoid the contamination of urease activity in other bacteria. Because ISFTT had high ability to detect pH change, the sensitivity and specificity of immunological rapid urease test was significantly improved comparing with that of conventional rapid urease test. The utility of immunological rapid urease test was evaluated in some clinical studies. - 【消化管悪性リンパ腫に対する治療法の選択】 H.pylori陰性胃MALTリンパ腫の治療方針
小平 純一; 結城 敏志; 布施 望; 武居 正明; 小野 尚子; 森 康明; 山本 純司; 中川 学; 古川 滋; 河原崎 暢; 小松 嘉人; 武田 宏司; 杉山 敏郎; 浅香 正博; 中川 宗一; 清水 勇一; 加藤 元嗣
消化器科, 38, 1, 6, 12, (有)科学評論社, 2004年01月
日本語 - Spontaneous resolution of cap polyposis: case report
T Ohkawara; M Kato; S Nakagawa; M Nakamura; M Takei; Y Komatsu; Y Shimizu; H Takeda; T Sugiyama; M Asaka
GASTROINTESTINAL ENDOSCOPY, 57, 4, 599, 602, 2003年04月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - [Rapid urease test].
Kato M; Shimizu Y; Kobayashi T; Komatsu Y; Takeda H; Sugiyama T; Asaka M
Nihon rinsho. Japanese journal of clinical medicine, 61, 1, 72, 78, 1, 2003年01月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌), Rapid urease test(RUT) is one of the invasive methods for detection of H. pylori infection. H. pylori in the biopsy specimen splits the urea to ammonia in the test container. Elevation of pH by ammonium hydroxide are detected as color change of pH indicator. The advantage of RUT are low-priced, easy-to-use, and rapid time to diagnosis. The disadvantage of RUT are necessity of endoscopy performance and occurrence of false negative. RUT is useful for diagnosis of H. pylori infection before and after eradication treatment. However, the sensitivity of RUT is comparatively low within 6 months after completion of eradication. - The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance
LP Aldana; M Kato; S Nakagawa; M Kawarasaki; T Nagasako; T Mizushima; H Oda; J Kodaira; Y Shimizu; Y Komatsu; R Zheng; H Takeda; T Sugiyama; M Asaka
HELICOBACTER, 7, 5, 306, 309, 2002年10月, [査読有り]
英語, 研究論文(学術雑誌) - Intense F-18FDG accumulation in the stomach in a patient with Menetrier's disease
T Kato; Y Komatsu; E Tsukamoto; M Takei; T Takei; F Yamamoto; Y Kuge; M Asaka; N Tamaki
CLINICAL NUCLEAR MEDICINE, 27, 5, 376, 377, 2002年05月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - [Clinical significance of serum antibodies against Helicobacter pylori VacA protein].
Komatsu Y
[Hokkaido igaku zasshi] The Hokkaido journal of medical science, 77, 2, 185, 192, 2, 2002年03月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌) - [Guidelines for the management of Helicobacter pylori infection in Japan].
Kato M; Shimizu Y; Komatsu Y; Takeda H; Sugiyama T; Asaka M
Nihon rinsho. Japanese journal of clinical medicine, 60 Suppl 2, 397, 402, 2002年02月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌) - Decreased adherence of cagG-deleted Helicobacter pylori to gastric epithelial cells in Japanese clinical isolates
T Mizushima; T Sugiyama; T Kobayashi; Y Komatsu; J Ishizuka; M Kato; M Asaka
HELICOBACTER, 7, 1, 22, 29, 2002年02月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌) - [Analysis of H. pylori eradicated patients during more-than-5-year follow-up].
Kato M; Shimizu Y; Nakagawa S; Kodaira J; Takei M; Furukawa S; Yamamoto F; Takano M; Nagasako T; Nakaya H; Kato T; Oda H; Okawara T; Mizushima T; Komatsu Y; Takeda H; Sugiyama T; Asaka M
Nihon rinsho. Japanese journal of clinical medicine, 60 Suppl 2, 491, 496, 2002年02月, [査読有り], [国内誌]
日本語, 研究論文(学術雑誌) - Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism
K Hokari; T Sugiyama; M Kato; M Saito; T Miyagishima; M Kudo; K Nishikawa; J Ishizuka; Y Komatsu; T Mizushima; H Kagaya; S Hige; H Takeda; M Asaka
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 15, 9, 1479, 1484, 2001年09月, [査読有り]
英語, 研究論文(学術雑誌) - Clinical relevance of the babA2 genotype of Helicobacter pylori in Japanese clinical isolates
T Mizushima; T Sugiyama; Y Komatsu; J Ishizuka; M Kato; M Asaka
JOURNAL OF CLINICAL MICROBIOLOGY, 39, 7, 2463, 2465, 2001年07月, [査読有り]
英語, 研究論文(学術雑誌) - Attributable risk of H. pylori in peptic ulcer disease - Does declining prevalence of infection in general population explain increasing frequency of non-H. pylori ulcers?
T Sugiyama; K Nishikawa; Y Komatsu; J Ishizuka; T Mizushima; A Kumagai; M Kato; N Saito; H Takeda; M Asaka; JW Freston
DIGESTIVE DISEASES AND SCIENCES, 46, 2, 307, 310, 2001年02月, [査読有り]
英語, 研究論文(学術雑誌) - High-dose ecabet sodium improves the eradication rate of Helicobacter pylori in dual therapy with lansoprazole and amoxicillin
H Kagaya; M Kato; Y Komatsu; T Mizushima; M Sukegawa; K Nishikawa; K Hokari; H Takeda; T Sugiyama; M Asaka
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 14, 11, 1523, 1527, 2000年11月, [査読有り]
英語, 研究論文(学術雑誌) - Characterization of C-terminal-truncated urinary metabolites of a recombinant hirudin in rats
Y. Komatsu; H. Hayashi
Peptides, 20, 12, 1401, 1409, 1999年12月
英語, 研究論文(学術雑誌) - Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy
K Nishikawa; T Sugiyama; J Ishizuka; T Kudo; Y Komatsu; M Katagiri; M Sukegawa; H Kagaya; M Kudo; M Kato; H Takeda; J Toyota; M Asaka
JOURNAL OF GASTROENTEROLOGY, 34, 72, 75, 1999年12月, [査読有り]
英語, 研究論文(学術雑誌) - Ten minute C-13-urea breath test for the diagnosis of Helicobacter pylori infection
M Kato; M Asaka; T Kudo; M Katagiri; Y Komatsu; F Sato; M Sukegawa; T Kobayashi; H Kagaya; K Nishikawa; M Kudo; K Hokari; S Hige; M Watanabe; H Takeda; T Sugiyama
JOURNAL OF GASTROENTEROLOGY, 33, 40, 43, 1998年11月, [査読有り]
英語, 研究論文(学術雑誌) - 早期胃癌切除後に腸間膜デスモイド腫瘍の合併が認められた1例.
馬場秀雄; 横田敏広; 横山正; 斉藤大三; 小松嘉人; 木場崇剛; 小野裕之; 山尾剛一; 白尾国昭; 近藤仁; 山口肇; 小黒八七郎; 石川勉; 杉原健一; 下田忠和
消化器内視鏡の進歩 Prog Dig Endosc, 47, 228, 229, 1995年07月, [査読有り] - 食道粘膜癌に対する内視鏡的粘膜切除の検討.
木場崇剛; 山口肇; 白尾国昭; 近藤仁; 小野裕之; 佃博; 小松嘉人; 清水靖仁; 平山敦; 小黒八七郎; 加藤抱一; 日月裕司; 渡辺寛; 中西幸浩; 落合淳志; 下田忠和
消化器内視鏡の進歩 Prog Dig Endosc, 47, 52, 55, 1995年07月, [査読有り]
- Impact of postoperative ctDNA dynamics on eligibility for the ALTAIR randomized trial in patients with colorectal cancer: Implications for clinical trial enrollment.
Yoshiaki Nakamura; Hideaki Bando; Vasily N. Aushev; Jun Watanabe; Yusuke Takahashi; Masahito Kotaka; Nobuhisa Matsuhashi; Eiji Oki; Yoshito Komatsu; Manabu Shiozawa; Keiji Hirata; Yuji Miyamoto; Kentaro Yamazaki; Kun-Huei Yeh; Adham A. Jurdi; Saori Mishima; Daisuke Kotani; Hiroya Taniguchi; Takayuki Yoshino; Takeshi Kato, JOURNAL OF CLINICAL ONCOLOGY, 44, 2_SUPPL, 12, 12, 2026年01月
英語, 研究発表ペーパー・要旨(国際会議) - Post-hoc central radiological review of the ALTAIR study in patients with molecular residual disease (MRD) following curative resection of colorectal cancer (CRC).
Jun Watanabe; Hideaki Bando; Masahito Kotaka; Nobuhisa Matsuhashi; Eiji Oki; Yoshito Komatsu; Manabu Shiozawa; Keiji Hirata; Yuji Miyamoto; Kun-Huei Yeh; Adham A. Jurdi; Alexey Aleshin; Daisuke Kotani; Akihiro Sato; Toshihiro Misumi; Yoshiaki Nakamura; Qian Shi; Hiroya Taniguchi; Takayuki Yoshino; Takeshi Kato, JOURNAL OF CLINICAL ONCOLOGY, 44, 2_SUPPL, 138, 138, 2026年01月
英語, 研究発表ペーパー・要旨(国際会議) - A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): The ALTAIR Study Free
Hideaki Bando; Jun Watanabe; Masahito Kotaka; Nobuhisa Matsuhashi; Eiji Oki; Yoshito Komatsu; Manabu Shiozawa; Keiji Hirata; Yuji Miyamoto; Kun-Huei Yeh; Shruti Sharma; Vasily Aushev; Adham Jurdi; Minetta C. Liu; Alexey Aleshin; Ichiro Takemasa; Daisuke Kotani; Akihito Sato; Toshihiro Misumi; Yoshiaki Nakamura; Qian Shi; Hiroya Taniguchi; Takeshi Kato; Takayuki Yoshino, CANCER RESEARCH, 85, 8, 2025年04月15日
英語, 研究発表ペーパー・要旨(国際会議) - A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): The ALTAIR study.
Hideaki Bando; Jun Watanabe; Masahito Kotaka; Nobuhisa Matsuhashi; Eiji Oki; Yoshito Komatsu; Manabu Shiozawa; Keiji Hirata; Yuji Miyamoto; Kun-Huei Yeh; Alexey Aleshin; Ichiro Takemasa; Daisuke Kotani; Akihiro Sato; Toshihiro Misumi; Yoshiaki Nakamura; Qian Shi; Hiroya Taniguchi; Takeshi Kato; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 43, 4_SUPPL, LBA22, LBA22, 2025年02月
英語, 研究発表ペーパー・要旨(国際会議) - HER2陽性大腸癌の臨床的特徴に関する多施設共同後ろ向き研究(HGCSG2304)
金子志帆; 澤田憲太郎; 畑中一映; 太宰昌佳; 中積宏之; 安藤孝将; 小高雅人; 辻靖; 中村路夫; 武藤理; 目黒高志; 横山達也; 石田浩一; 中村赳晶; 原田一顕; 川本泰之; 結城敏志; 坂本直哉; 坂田優; 小松嘉人, 日本臨床腫瘍学会学術集会(CD-ROM), 22nd, 2025年 - Correlation of enriched specific subset of immune cells nearby tumor associated macrophage (TAM) with pathologic complete response (pCR) of concurrent chemoradiotherapy followed by nivolumab in locally advanced rectal cancer (LARC).
Hideaki Bando; Yuichiro Tsukada; Koji Inamori; Takeshi Kato; Yoshito Komatsu; Mamoru Uemura; Satoshi Yuki; Akinobu Taketomi; Takao Fujisawa; Yoshiaki Nakamura; Motohiro Kojima; Shohei Koyama; Sanghoon Song; Chan-Young Ock; Hiroyoshi Nishikawa; Masaaki Ito; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 42, 23_SUPPL, 58, 58, 2024年08月10日
英語, 研究発表ペーパー・要旨(国際会議) - Neoadjuvant anti-programmed death 1 (PD-1) therapy in patients (pts) with resectable mismatch repair-deficient (dMMR) locally advanced rectal cancer (LARC): EPOC2201.
Hideaki Bando; Yuichiro Tsukada; Akinobu Taketomi; Satoshi Yuki; Yoshito Komatsu; Takashi Akiyoshi; Eiji Shinozaki; Yukihide Kanemitsu; Atsuo Takashima; Manabu Shiozawa; Akio Shiomi; Kentaro Yamazaki; Nobuhisa Matsuhashi; Hiroko Hasegawa; Takeshi Kato; Eiji Oki; Masashi Wakabayashi; Nozomu Fuse; Masaaki Ito; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 42, 3_SUPPL, TPS226, TPS226, 2024年01月20日
英語, 研究発表ペーパー・要旨(国際会議) - Predictive value of tumor-infiltrating lymphocyte (TIL) dynamics in the tumor microenvironment (TME) during preoperative chemoradiotherapy (CRT) on pathologic complete response (pCR) in microsatellite-stable (MSS) locally advanced rectal cancer (LARC).
Mitsuho Imai; Hideaki Bando; Yuichiro Tsukada; Takeshi Kato; Yoshito Komatsu; Mamoru Uemura; Satoshi Yuki; Akinobu Taketomi; Takao Fujisawa; Yoshiaki Nakamura; Motohiro Kojima; Shohei Koyama; Chiyoon Oum; Seunghwan Shin; Chan-Young Ock; Hiroyoshi Nishikawa; Masaaki Ito; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 41, 16_SUPPL, 2023年06月01日
英語, 研究発表ペーパー・要旨(国際会議) - Predictive value of tumor-infiltrating lymphocyte (TIL) dynamics in the tumor micro-environment (TME) during preoperative chemoradiotherapy (CRT) on pathologic complete response (pCR) in microsatellite-stable (MSS) locally advanced rectal cancer (LARC)
Mitsuho Imai; Hideaki Bando; Yuichiro Tsukada; Takeshi Kato; Yoshito Komatsu; Mamoru Uemura; Satoshi Yuki; Akinobu Taketomi; Takao Fujisawa; Yoshiaki Nakamura; Motohiro Kojima; Shohei Koyama; Chiyoon Oum; Seunghwan Shin; Chan-Young Ock; Hiroyoshi Nishikawa; Masaaki Ito; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 41, 16, 2023年06月01日
英語, 研究発表ペーパー・要旨(国際会議) - Survival outcomes and functional results of VOLTAGE-A: Preoperative chemoradiotherapy (CRT) and consolidation nivolumab (nivo) in patients (pts) with both microsatellite stable (MSS) and microsatellite instability-high (MSI-H) locally advanced rectal cancer (LARC).
Yuichiro Tsukada; Hideaki Bando; Koji Inamori; Masashi Wakabayashi; Yosuke Togashi; Shohei Koyama; Daisuke Kotani; Satoshi Yuki; Yoshito Komatsu; Shigenori Homma; Akinobu Taketomi; Mamoru Uemura; Takeshi Kato; Makoto Fukui; Motohiro Kojima; Akihiro Sato; Hiroyoshi Nishikawa; Masaaki Ito; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 41, 108, 108, 2023年02月01日
英語, 研究発表ペーパー・要旨(国際会議) - ctDNAにFGFR遺伝子異常を有する進行固形がんに対するフチバチニブの有効性の検討
篠崎英司; 城後友望子; 衣斐寛倫; 舛石俊樹; 加藤健志; 仁科智裕; 江崎泰斗; 小松嘉人; 加藤健; 佐藤暁洋; 坂東英明; JUSTIN Odegaard; 藤井誠志; 吉野孝之; 中村能章, 日本癌治療学会学術集会(Web), 61st, 2023年 - 高齢者・非高齢者の転移を有する膵癌患者の臨床的背景と薬物療法治療成績に関する単施設後方視的検討
川本泰之; 川本泰之; 原田一顕; 山村貴洋; 山村貴洋; 渡辺亮介; 中村赳晶; 中村赳晶; 結城敏志; 桑谷将城; 桑谷将城; 小松嘉人; 坂本直哉, 日本高齢消化器病学会誌, 25, 2, 2023年 - 実臨床における切除不能進行・再発胆道癌に対するGEM+CDDP+S-1療法(GCS)と三剤逐次投与の治療成績に関する検討
川本泰之; 川本泰之; 原田一顕; 坂本直哉; 中村赳晶; 金子志帆; 石田浩一; 結城敏志; 桑谷将城; 小松嘉人, 胆道(Web), 37, 3, 2023年 - Safety of encorafenib, binimetinib, plus cetuximab for Japanese patients with BRAF V600E metastatic colorectal cancer
Toshifumi Yamaguchi; Kotani Daisuke; Takashima Atsuo; Kato Takeshi; Masuishi Toshiki; Komatsu Yoshito; Shiozawa Manabu; Esaki Taito; Izawa Naoki; Takeuchi Shinji; Bando Hideaki; Iwasa Satoru; Hasegawa Hiroko; Satoh Taroh; Taniguchi Hiroya; Yoshino Takayuki, ANNALS OF ONCOLOGY, 33, S479, S479, 2022年07月
英語, 研究発表ペーパー・要旨(国際会議) - Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
Takayuki Yoshino; Jun Watanabe; Kohei Shitara; Hirofumi Yasui; Hisatsugu Ohori; Manabu Shiozawa; Kentaro Yamazaki; Eiji Oki; Takeo Sato; Takeshi Naitoh; Yoshito Komatsu; Takeshi Kato; Masamitsu Hihara; Junpei Soeda; Kouji Yamamoto; Kiwamu Akagi; Atsushi Ochiai; Hiroyuki Uetake; Katsuya Tsuchihara; Kei Muro, JOURNAL OF CLINICAL ONCOLOGY, 40, 17, 2022年06月
英語, 研究発表ペーパー・要旨(国際会議) - 切除不能大腸がんにおける腫瘍内HER2不均一性の検討
澤田憲太郎; NITTA Hiroaki; 中村能章; 岡本渉; 谷口浩也; 小松嘉人; 原浩樹; 加藤健志; 仁科智裕; 太田高志; 薦田正人; 吉野孝之; 藤井誠志, 日本癌治療学会学術集会(Web), 60th, 2022年 - 切除不能進行・再発胆道がんに対するがん遺伝子関連検査と個別化医療の現状
川本泰之; 川本泰之; 原田一顕; 山村貴洋; 山村貴洋; 斎藤里佳; 斎藤里佳; 伊藤憲; 伊藤憲; 結城敏志; 桑谷将城; 小松嘉人; 小松嘉人; 坂本直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130th-124th, 2022年 - 高齢者・非高齢者に転移を有する膵癌患者の臨床的背景と薬物療法治療成績に関する単施設後方視的検討
川本泰之; 川本泰之; 渡辺亮介; 中村赳晶; 中村赳晶; 山村貴洋; 山村貴洋; 原田一顕; 結城敏志; 桑谷将城; 小松嘉人; 坂本直哉, 日本高齢消化器病学会誌, 25, 1, 2022年 - 転移を有する高齢・非高齢膵がん患者の臨床的背景と薬物療法治療成績の後方視的検討
川本泰之; 川本泰之; 渡辺亮介; 中村赳晶; 中村赳晶; 山村貴洋; 山村貴洋; 原田一顕; 結城敏志; 桑谷将城; 桑谷将城; 小松嘉人; 坂本直哉, 日本癌治療学会学術集会(Web), 60th, 2022年 - 大腸癌周術期治療の臨床開発と将来展望 進行直腸癌に対する化学放射線療法と免疫チェックポイント阻害剤を用いた術前治療
塚田 祐一郎; 坂東 英明; 稲守 宏冶; 冨樫 庸介; 結城 敏志; 小松 嘉人; 本間 重紀; 武冨 紹信; 植村 守; 加藤 健志; 若林 将史; 佐藤 暁洋; 西川 博嘉; 伊藤 雅昭; 吉野 孝之, 日本癌治療学会学術集会抄録集, 59回, SY2, 4, 2021年10月
(一社)日本癌治療学会, 英語 - Efficacy predictors of preoperative CRT and consolidation nivolumab in patients with locally advanced rectal cancer
Koji Inamori; Yosuke Togashi; Hideaki Bando; Yuichiro Tsukada; Shota Fukuoka; Ayako Suzuki; Yutaka Suzuki; Daisuke Kotani; Motohiro Kojima; Makoto Fukui; Satoshi Yuki; Yoshito Komatsu; Shigenori Homma; Akinobu Taketomi; Mamoru Uemura; Takeshi Kato; Masaaki Ito; Hiroyoshi Nishikawa; Takayuki Yoshino, ANNALS OF ONCOLOGY, 32, S343, S343, 2021年07月
英語, 研究発表ペーパー・要旨(国際会議) - Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).
Yoshitaka Honma; Yukinori Kurokawa; Akira Sawaki; Yoichi Naito; Shiro Iwagami; Hideo Baba; Yoshito Komatsu; Toshirou Nishida; Toshihiko Doi, JOURNAL OF CLINICAL ONCOLOGY, 39, 15, 2021年05月
英語, 研究発表ペーパー・要旨(国際会議) - 進行固形がんにおける血漿マイクロサテライト不安定性検査の臨床的妥当性および有用性
中村能章; 岡本渉; 傳田忠道; 仁科智裕; 小松嘉人; 安井久晃; 江崎泰斗; 土井綾子; 上野誠; 篠崎英司; 松橋延壽; 坂東英明; 野村尚吾; 赤木究; 吉野孝之, 日本癌治療学会学術集会(Web), 59th, 2021年 - 切除不能進行・再発胆道癌に対するGEM・CDDP・S-1の逐次投与と同時併用投与の比較検討
川本泰之; 小松嘉人; 山村貴洋; 斎藤里佳; 伊藤憲; 原田一顕; 結城敏志; 桑谷将城; 坂本直哉, 日本癌治療学会学術集会(Web), 59th, 2021年 - Quadruplet regimen with capecitabine, irinotecan, oxaliplatin, and bevacizumab in chemo-naive patients with metastatic colorectal cancer: Results from the safety lead-in of QUATTRO-II study.
Hideaki Bando; Daisuke Kotani; Masahito Kotaka; Akihito Kawazoe; Toshiki Masuishi; Hironaga Satake; Hiroya Taniguchi; Kentaro Yamazaki; Takeharu Yamanaka; Eiji Oki; Takayuki Yoshino; Kei Muro; Yoshito Komatsu; Takeshi Kato; Akihito Tsuji, JOURNAL OF CLINICAL ONCOLOGY, 39, 3, 2021年01月
英語, 研究発表ペーパー・要旨(国際会議) - Translational research of VOLTAGE-A: Efficacy predictors of preoperative chemoradiotherapy and consolidation nivolumab in patients with both microsatellite stable and microsatellite instability-high locally advanced rectal cancer
Koji Inamori; Yosuke Togashi; Hideaki Bando; Yuichiro Tsukada; Shota Fukuoka; Ayako Suzuki; Yutaka Suzuki; Daisuke Kotani; Motohiro Kojima; Makoto Fukui; Satoshi Yuki; Yoshito Komatsu; Shigenori Homma; Akinobu Taketomi; Mamoru Uemura; Takeshi Kato; Masaaki Ito; Hiroyoshi Nishikawa; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 39, 3, 2021年01月
英語, 研究発表ペーパー・要旨(国際会議) - The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC): Updated analysis
T. Kawakami; K. Yamazaki; H. Go; T. Masuishi; Y. Kawamoto; K. Kato; R. Kumanishi; K. Sawada; H. Shirasu; S. Yuki; K. Yamamoto; T. Yamanaka; Y. Komatsu; K. Muro; H. Yasui, ANNALS OF ONCOLOGY, 31, S433, S434, 2020年09月
英語, 研究発表ペーパー・要旨(国際会議) - Translational research of voltage-A1: Efficacy predictors of preoperative chemoradiotherapy and subsequent nivolumab monotherapy in patients with microsatellite-stable locally advanced rectal cancer.
Koji Inamori; Yosuke Togashi; Hideaki Bando; Yuichiro Tsukada; Ayako Suzuki; Yutaka Suzuki; Daisuke Kotani; Shota Fukuoka; Motohiro Kojima; Makoto Fukui; Satoshi Yuki; Yoshito Komatsu; Shigenori Homma; Mamoru Uemura; Takeshi Kato; Masaaki Ito; Hiroyoshi Nishikawa; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 38, 15, 2020年05月
英語, 研究発表ペーパー・要旨(国際会議) - Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
Satoshi Yuki; Hideaki Bando; Yuichiro Tsukada; Koji Inamori; Yoshito Komatsu; Shigenori Homma; Mamoru Uemura; Takeshi Kato; Daisuke Kotani; Shota Fukuoka; Naoki Nakamura; Makoto Fukui; Masashi Wakabayashi; Motohiro Kojima; Yosuke Togashi; Akihiro Sato; Hiroyoshi Nishikawa; Masaaki Ito; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 38, 15, 2020年05月
英語, 研究発表ペーパー・要旨(国際会議) - A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial).
Masataka Yagisawa; Yoshiaki Nakamura; Takayuki Yoshino; Yoshito Komatsu; Shigenori Kadowaki; Kei Muro; Yu Sunakawa; Taroh Satoh; Tomohiro Nishina; Taito Esaki; Satoshi Fujii; Hiromi Ono; Daiki Tomita; Noriko Fujishiro; Nami Hirano; Nozomu Fuse; Akihiro Sato; Gakuto Ogawa; Shogo Nomura; Hiroya Taniguchi, JOURNAL OF CLINICAL ONCOLOGY, 38, 15, 2020年05月
英語, 研究発表ペーパー・要旨(国際会議) - Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment
Akihito Tsuji; Takayuki Yoshino; Takeharu Yamanaka; Hideaki Bando; Hironaga Satake; Kentaro Yamazaki; Hiroya Taniguchi; Eiji Oki; Masahito Kotaka; Koji Oba; Yoshinori Miyata; Kei Muro; Yoshito Komatsu; Hideo Baba; Takeshi Kato, JOURNAL OF CLINICAL ONCOLOGY, 38, 4, 2020年02月
英語, 研究発表ペーパー・要旨(国際会議) - VOLTAGE-B study: Nivolumab monotherapy and subsequent curative surgery following preoperative chemoradiotherapy in patients with locally recurrent rectal cancer (LRRC) without previous radiotherapy
Takeshi Kato; Hideaki Bando; Yuichiro Tsukada; Koji Inamori; Mamoru Uemura; Satoshi Yuki; Yoshito Komatsu; Shigenori Homma; Daisuke Kotani; Shota Fukuoka; Takeshi Sasaki; Yuji Nishizawa; Naoki Nakamura; Masashi Wakabayashi; Motohiro Kojima; Yosuke Togashi; Akihiro Sato; Hiroyoshi Nishikawa; Takayuki Yoshino; Masaaki Ito, JOURNAL OF CLINICAL ONCOLOGY, 38, 4, 2020年02月
英語, 研究発表ペーパー・要旨(国際会議) - 免疫チェックポイント阻害薬関連胃腸炎の1例
表原里実; 表原里実; 西田睦; 西田睦; 山梨香菜; 桜井健介; 桂田武彦; 小松嘉人; 清水亜衣; 澁谷斉; 品川尚文; 杉田純一; 豊嶋崇徳, 日本超音波検査学会学術集会講演抄録集(Web), 45th, 2020年 - 食道癌の治療中に横紋筋融解症を発症したことを契機に診断された甲状腺機能低下症の一例
大江悠希; 亀田啓; 関崎知紀; 宮愛香; 野本博司; 曹圭龍; 中村昭伸; 原田一顕; 結城敏志; 小松嘉人; 坂本直哉; 三好秀明; 三好秀明; 渥美達也, 日本内分泌学会雑誌, 96, 4 (Web), 2020年 - The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC)
T. Kawakami; T. Masuishi; Y. Kawamoto; H. Go; H. Shirasu; K. Kato; R. Kumanishi; K. Sawada; K. Yamamoto; S. Yuki; Y. Komatsu; H. Yasui; K. Muro; T. Yamanaka; K. Yamazaki, ANNALS OF ONCOLOGY, 30, 222, 222, 2019年10月
英語, 研究発表ペーパー・要旨(国際会議) - 胃癌に対するゲノム医療の展開
若井 俊文; 小松 嘉人; 辻 晃仁; 西原 広史, 胃がんperspective, 10, 4, 261, 270, 2019年10月
(株)メディカルレビュー社, 日本語 - Voltage: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer.
Takayuki Yoshino; Hideaki Bando; Yuichiro Tsukada; Koji Inamori; Satoshi Yuki; Yoshito Komatsu; Shigenori Homma; Mamoru Uemura; Takeshi Kato; Daisuke Kotani; Shota Fukuoka; Takeshi Sasaki; Yuji Nishizawa; Naoki Nakamura; Masashi Wakabayashi; Motohiro Kojima; Yosuke Togashi; Akihiro Sato; Hiroyoshi Nishikawa; Masaaki Ito, JOURNAL OF CLINICAL ONCOLOGY, 37, 15, 2019年05月
英語, 研究発表ペーパー・要旨(国際会議) - 第II相試験(PaFF-J試験)におけるPanitumumab併用一次治療の原発巣占居部位別の治療成績の検討
宮本 裕士; 石黒 めぐみ; 中谷 英仁; 篠崎 英司; 山口 達郎; 中村 将人; 尾嶋 仁; 本間 義崇; 後藤 昌弘; 石川 敏昭; 山口 研成; 高橋 慶一; 島田 安博; 吉田 和弘; 水沼 信之; 室 圭; 小松 嘉人; 杉原 健一; PaFF-J Study Group, 日本大腸肛門病学会雑誌, 72, 5, 289, 289, 2019年05月
(一社)日本大腸肛門病学会, 日本語 - 第II相試験(PaFF-J試験)におけるPanitumumab併用一次治療の原発巣占居部位別の治療成績の検討
宮本 裕士; 石黒 めぐみ; 中谷 英仁; 篠崎 英司; 山口 達郎; 中村 将人; 尾嶋 仁; 本間 義崇; 後藤 昌弘; 石川 敏昭; 山口 研成; 高橋 慶一; 島田 安博; 吉田 和弘; 水沼 信之; 室 圭; 小松 嘉人; 杉原 健一; PaFF-J Study Group, 日本大腸肛門病学会雑誌, 72, 5, 289, 289, 2019年05月
(一社)日本大腸肛門病学会, 日本語 - Gastrointestinal stromal tumor: Research and practice
Yukinori Kurokawa; Yoshito Komatsu, Gastrointestinal Stromal Tumor: Research and Practice, 1, 156, 2019年02月20日
Springer Singapore, 英語, その他 - A retrospective analysis of neoadjuvant chemotherapy followed by surgery or definitive chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma.
Hiroshi Nakatsumi; Yoshito Komatsu; Shintaro Nakano; Kentaro Sawada; Tetsuhito Muranaka; Yasuyuki Kawamoto; Satoshi Yuki; Yusuke Uchinami; Hiroshi Taguchi; Hiroki Shirato; Yuma Ebihara; Toshiaki Shichinohe; Satoshi Hirano; Naoya Sakamoto, JOURNAL OF CLINICAL ONCOLOGY, 37, 4, 2019年02月
英語, 研究発表ペーパー・要旨(国際会議) - bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB).
Yoshiaki Nakamura; Yoshito Komatsu; Ken Kato; Eiji Shinozaki; Hideaki Bando; Takeshi Kato; Tomohiro Nishina; Taito Esaki; Shogo Nomura; Gakuto Ogawa; Ayako Sugama; Miki Fukutani; Akihiro Sato; Justin Odegaard; Takeshi Kuwata; Kouji Matsushima; Tetsuya Nakatsura; Hiromichi Nakajima; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 37, 4, 2019年02月
英語, 研究発表ペーパー・要旨(国際会議) - DOAC服用者の内視鏡治療後出血と周術期血栓出血マーカー
小野尚子; 松田可奈; 大野正芳; 津田桃子; 村中徹人; 小松嘉人, 日本消化管学会雑誌, 3, Supplement, 2019年 - 第II相試験(PaFF-J試験)におけるPanitumumab併用一次治療の原発巣占居部位別の治療成績の検討
宮本裕士; 石黒めぐみ; 中谷英仁; 篠崎英司; 山口達郎; 中村将人; 尾嶋仁; 本間義崇; 後藤昌弘; 石川敏昭; 山口研成; 高橋慶一; 島田安博; 吉田和弘; 水沼信之; 室圭; 小松嘉人; 杉原健一, 日本大腸肛門病学会雑誌(Web), 72, 5, 2019年 - NORTH/HGCSG1003 Stage III結腸癌に対する術後補助化学療法FOLFOXの第II相研究 腫瘍内科医と外科医の比較
村中 徹人; 小松 嘉人; 結城 敏志; 川本 泰之; 高橋 典彦; 七戸 俊明; 久須美 貴哉; 中村 文隆; 大森 一吉; 伊藤 陽一; 武冨 紹信; 平野 聡; 坂本 直哉, 日本大腸肛門病学会雑誌, 72, 1, 48, 48, 2019年01月
(一社)日本大腸肛門病学会, 日本語 - APOLLON study:標準化学療法不応・不耐となったRAS野生型進行再発大腸癌に対するパニツムマブとトリフルリジン/チピラシル併用療法を検討する第I/II試験(最終結果)
賀川義規; 山口研成; 吉野孝之; 久保木恭利; 安井博史; 山崎健太郎; 小松嘉人; 沖英次; 小高雅人; 添田純平; 渋谷和憲; 岩田勝; 大庭幸治; 加藤健志, 日本外科学会定期学術集会(Web), 119th, ROMBUNNO.SY‐8‐3 (WEB ONLY), 3, 2019年
(一社)日本外科学会, 日本語 - A multicentre,prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancerの解説
賀川 義規; 加藤 健志; 坂東 英明; 赤木 究; 傳田 忠道; 仁科 智裕; 小松 嘉人; 沖 英次; 工藤 敏啓; 山中 竹春; 吉野 孝之, 腫瘍内科, 22, 5, 566, 570, 2018年11月
(有)科学評論社, 日本語 - REVERCE:大腸癌のRegorafenib-Cetuximab逐次投与ランダム化第II相試験(biomarker解析)
傳田 忠道; 設楽 紘平; 山中 竹春; 辻 靖; 篠崎 勝則; 小松 嘉人; 小林 良充; 古瀬 純司; 加藤 健志; 大橋 靖雄; 吉野 孝之, 日本癌治療学会学術集会抄録集, 56回, O48, 1, 2018年10月
(一社)日本癌治療学会, 英語 - XELOX+bevacizumab療法が奏効しR0切除が得られたAFP産生大腸癌同時性肝転移の1例
沢田 尭史; 本間 重紀; 吉田 雅; 柴崎 晋; 川村 秀樹; 若山 顕治; 柿坂 達彦; 横尾 英樹; 神山 俊哉; 小松 嘉人; 結城 敏志; 畑中 佳奈子; 武冨 紹信, 日本外科系連合学会誌, 43, 5, 845, 854, 2018年10月
日本外科系連合学会, 日本語 - XELOX+bevacizumab療法が奏効しR0切除が得られたAFP産生大腸癌同時性肝転移の1例
沢田 尭史; 本間 重紀; 吉田 雅; 柴崎 晋; 川村 秀樹; 若山 顕治; 柿坂 達彦; 横尾 英樹; 神山 俊哉; 小松 嘉人; 結城 敏志; 畑中 佳奈子; 武冨 紹信, 日本外科系連合学会誌, 43, 5, 845, 854, 2018年10月
日本外科系連合学会, 日本語 - REVERCE:化学療法不応・不耐の進行・再発結腸・直腸癌に対するRegorafenibとcetuximabの逐次投与ランダム化第II相試験(REVERCE: A Randomized Phase II trial of Regorafenib-Cetuximab for mCRC previously treated with chemotherapy)
賀川 義規; 設楽 紘平; 山中 竹春; 傳田 忠道; 辻 靖; 篠崎 勝則; 小松 嘉人; 小林 良充; 古瀬 純司; 加藤 健志; 大橋 靖雄; 吉野 孝之, 日本癌学会総会記事, 77回, 364, 364, 2018年09月
日本癌学会, 英語 - 北海道の外来がん化学療法の向上に向けて~北海道大学病院腫瘍センターにおける外来がん治療研修会の取り組み~
石岡 明子; 三宅 亜矢; 中野 政子; 齋藤 佳敬; 熊井 正貴; 中積 宏之; 小松 嘉人, 第16回日本臨床腫瘍学会学術集会講演要旨集, 2018年07月
研究発表ペーパー・要旨(全国大会,その他学術会議) - Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.
Mototsugu Shimokawa; Eiji Oki; Takuhiro Yamaguchi; Hiroaki Tanioka; Yuji Miyamoto; Akihito Tsuji; Masako Asayama; Takeshi Shiraishi; Satoshi Yuki; Masahito Kotaka; Akitaka Makiyama; Takayuki Shimose; Satohiro Masuda; Yoshito Komatsu; Hiroshi Saeki; Yasunori Emi; Hideo Baba; Yoshihiko Maehara, JOURNAL OF CLINICAL ONCOLOGY, 36, 15, 2018年05月
英語, 研究発表ペーパー・要旨(国際会議) - An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial).
Daisuke Sakai; Narikazu Boku; Yasuhiro Kodera; Yoshito Komatsu; Masashi Fujii; Satoru Iwasa; Eiji Oki; Wasaburo Koizumi; Makio Gamoh; Kei Muro; Toshio Shimokawa; Taroh Satoh, JOURNAL OF CLINICAL ONCOLOGY, 36, 15, 2018年05月
英語, 研究発表ペーパー・要旨(国際会議) - HER2陽性切除不能進行胃癌に対してSOX+トラスツズマブ療法を施行後に根治切除可能となった3例(Three cases that became resectable after SOX/Tmab for HER2-positive unresectable gastric cancer)
川本 泰之; 結城 敏志; 八木澤 允貴; 村中 徹人; 中積 宏之; 川村 秀樹; 神山 俊哉; 高桑 恵美; 三橋 智子; 武冨 紹信; 坂本 直哉; 小松 嘉人; 本間 重紀, 日本胃癌学会総会記事, 90回, 552, 552, 2018年03月
(一社)日本胃癌学会, 英語 - HER2陽性切除不能進行胃癌に対してSOX+トラスツズマブ療法を施行後に根治切除可能となった3例(Three cases that became resectable after SOX/Tmab for HER2-positive unresectable gastric cancer)
川本 泰之; 結城 敏志; 八木澤 允貴; 村中 徹人; 中積 宏之; 川村 秀樹; 神山 俊哉; 高桑 恵美; 三橋 智子; 武冨 紹信; 坂本 直哉; 小松 嘉人; 本間 重紀, 日本胃癌学会総会記事, 90回, 552, 552, 2018年03月
(一社)日本胃癌学会, 英語 - VOLTAGE: Multicenter phase 1b/II study of nivolumab monotherapy and subsequent radical surgery after preoperative chemoradiotherapy with capecitabine in patients with locally advanced rectal cancer.
Yuichiro Tsukada; Hideaki Bando; Koji Inamori; Shota Fukuoka; Takeshi Sasaki; Yuji Nishizawa; Daisuke Kotani; Motohiro Kojima; Yosuke Togashi; Naoki Nakamura; Tetsuo Akimoto; Yoshito Komatsu; Satoshi Yuki; Shigenori Homma; Yutaka Hatanaka; Yoshihiro Matsuno; Akihiro Sato; Hiroyoshi Nishikawa; Masaaki Ito, JOURNAL OF CLINICAL ONCOLOGY, 36, 4, 2018年02月
英語, 研究発表ペーパー・要旨(国際会議) - Predictive value of tumor growth rate during previous treatment for tumor response to regorafenib (REGO) and trifluridine/tipiracil (TFTD) in metastatic colorectal cancer (mCRC).
Takeshi Kawakami; Toshiki Masuishi; Yasuyuki Kawamoto; Katsuhiro Omae; Tetsuhito Muranaka; Hiroshi Nakatsumi; Satoshi Yuki; Yoshito Komatsu; Kentaro Yamazaki; Yusuke Onozawa; Hirofumi Yasui; Masahiro Tajika; Shigenori Kadowaki; Hiroya Taniguchi; Kei Muro, JOURNAL OF CLINICAL ONCOLOGY, 36, 4, 2018年02月
英語, 研究発表ペーパー・要旨(国際会議) - プロクロルペラジンによるアカシジア発現および制吐効果に関する検討
熊谷卓博; 齋藤佳敬; 山田武宏; 小林正紀; 熊井正貴; 笠師久美子; 小松嘉人; 井関 健, 日本医療薬学会第27回年会講演要旨集, 27, 2017年11月
研究発表ペーパー・要旨(全国大会,その他学術会議) - 同種末梢血幹細胞移植8年後に発症した若年発症の食道扁平上皮癌の1例
村中徹人; 小松嘉人; 原田一顕; 中積宏之; 川本泰之; 村中徹人; 原田一顕; 結城敏志; 山本桂子; 清水勇一; 坂本直哉; 海老原裕磨; 倉島庸; 七戸俊明; 三橋智子, 北海道医学雑誌, 92, 2, 111‐112, 2017年11月01日
日本語 - 化学療法時のB型肝炎再活性化防止への取り組み
沖洋充; 沖洋充; 山崎浩二郎; 熊井正貴; 岡林靖子; 根岸淳; 小川浩司; 遠藤晃; 小松嘉人; 井関健; 南須原康行, 医療の質・安全学会誌, 12, Supplement, 255, 2017年10月31日
日本語 - がん領域におけるPrecision Medicineはどこまで進んだか?―臨床腫瘍医に求められる新たなスキル―近隣病院との連携強化によるがん患者の開発治験のアクセス向上のための方策:Hub‐and‐Spokeの実際
結城敏志; 畑中豊; 小松嘉人, 月刊腫瘍内科, 20, 4, 293‐298, 2017年10月28日
日本語 - 切除不能大腸癌に対するPanitumumab併用一次治療におけるETS・DoR PaFF-J試験
石黒 めぐみ; 中谷 英仁; 山口 研成; 高橋 慶一; 島田 安博; 吉田 和弘; 水沼 信之; 室 圭; 小松 嘉人; 杉原 健一, 日本癌治療学会学術集会抄録集, 55回, IS7, 3, 2017年10月
(一社)日本癌治療学会, 英語 - Phase II trial of Panitumumab for patients with KRAS exon2 wild type mCRC after progression on Cetuximab: HGCSG1101
Ayumu Hosokawa; Satoshi Yuki; Kazuaki Harada; Yasushi Tsuji; Kazuteru Hatanaka; Atsushi Sato; Yoshimitsu Kobayashi; Hiroyuki Okuda; Yuh Sakata; Yoshito Komatsu, ANNALS OF ONCOLOGY, 28, 2017年10月
英語, 研究発表ペーパー・要旨(国際会議) - Phase II study of trastuzumab with irinotecan in HER2-positive gastric cancer previously treated with trastuzumab
Kazuteru Hatanaka; Yasuyuki Kawamoto; Satoshi Yuki; Takashi Meguro; Minoru Uebayashi; Masakazu Abe; Michio Nakamura; Hiroyuki Okuda; Yuh Sakata; Yoshito Komatsu, ANNALS OF ONCOLOGY, 28, 2017年10月
英語, 研究発表ペーパー・要旨(国際会議) - Clinical Sequencing for Patients with Pancreatic Cancer
Hideyuki Hayashi; Shigeki Tanishima; Ryo Mori; Yasunobu Okamura; Toraji Amano; Ichiro Kinoshita; Yoshito Komatsu; Hirotoshi Dosaka-akita; Hiroshi Nishihara, ANNALS OF ONCOLOGY, 28, 88, 88, 2017年10月
英語, 研究発表ペーパー・要旨(国際会議) - 免疫チェックポイント阻害薬投与中に発症した大腸炎の2例
長島 一哲; 桂田 武彦; 小田切 信介; 山梨 香菜; 木下 賢治; 村中 徹人; 秦 洋郎; 竹内 啓; 本間 理央; 合田 智宏; 三橋 智子; 小松 嘉人; 坂本 直哉, 日本癌治療学会学術集会抄録集, 55回, O23, 2, 2017年10月
(一社)日本癌治療学会, 日本語 - 大腸癌レゴラフェニブ療法に対する経口ステロイドの検討(KSCC1402/HGCSG1402)
白石 猛; 佐竹 悠良; 宮本 裕士; 谷岡 洋亮; 辻 晃仁; 朝山 雅子; 結城 敏志; 小高 雅人; 牧山 明資; 小松 嘉人; 佐伯 浩司; 沖 英次; 江見 泰徳; 馬場 秀夫; 前原 喜彦, 日本癌治療学会学術集会抄録集, 55回, O31, 3, 2017年10月
(一社)日本癌治療学会, 英語 - 前治療における腫瘍増殖速度がレゴラフェニブとTAS-102の抗腫瘍効果に与える影響
舛石 俊樹; 谷口 浩也; 川上 武志; 川本 泰之; 門脇 重憲; 小野澤 祐輔; 村中 徹人; 田近 正洋; 安井 博史; 中積 宏之; 結城 敏志; 室 圭; 大前 勝弘; 小松 嘉人; 山崎 健太郎, 日本癌治療学会学術集会抄録集, 55回, O31, 6, 2017年10月
(一社)日本癌治療学会, 日本語 - HER2陽性胃癌に対するトラスツズマブ/イリノテカン併用療法の第II相試験(HGCSG1201)
岩永 一郎; 川本 泰之; 結城 敏志; 目黒 高志; 畑中 一映; 上林 実; 中村 路夫; 江藤 和範; 奥田 博介; 阿部 雅一; 中積 宏之; 村中 徹人; 大庭 幸治; 坂田 優; 小松 嘉人, 日本癌治療学会学術集会抄録集, 55回, P84, 4, 2017年10月
(一社)日本癌治療学会, 日本語 - Imatinib不応・不耐GISTに対するsunitinibの有効性について 遺伝子変異別の検討
中積 宏之; 小松 嘉人; 八木澤 允貴; 村中 徹人; 川本 泰之; 結城 敏志; 坂本 直哉, 日本癌治療学会学術集会抄録集, 55回, P174, 3, 2017年10月
(一社)日本癌治療学会, 日本語 - HER2陽性胃癌に対するトラスツズマブ/イリノテカン併用療法の第II相試験(HGCSG1201)
岩永 一郎; 川本 泰之; 結城 敏志; 目黒 高志; 畑中 一映; 上林 実; 中村 路夫; 江藤 和範; 奥田 博介; 阿部 雅一; 中積 宏之; 村中 徹人; 大庭 幸治; 坂田 優; 小松 嘉人, 日本癌治療学会学術集会抄録集, 55回, P84, 4, 2017年10月
(一社)日本癌治療学会, 日本語 - 「それぞれの生」支持療法の工夫 嘔気対策・栄養管理 CINV予防におけるステロイド投与期間に関する個人データに基づくメタアナリシス
沖田 憲司; 岡田 優基; 大庭 幸治; 小坂 愉賢; 古川 直人; 結城 敏志; 小松 嘉人; Celio Luigi; Aapro Matti, 日本癌治療学会学術集会抄録集, 55回, WS5, 1, 2017年10月
(一社)日本癌治療学会, 日本語 - TRICOLORE 切除不能大腸癌に対するmFOLFOX6/CapeOX+BevとS-1/CPT-11+Bevとの第3相試験
岩永 一郎; 岩佐 悟; 高畑 武功; 天貝 賢二; 倉持 英和; 辻 靖; 的場 周一郎; 有岡 仁; 江藤 和範; 畑中 一映; 石岡 千加史; 嶋田 顕; 山口 達郎; 森田 智視; 小松 嘉人, 日本癌治療学会学術集会抄録集, 55回, O30, 2, 2017年10月
(一社)日本癌治療学会, 日本語 - 切除不能進行/再発結腸直腸癌症例に対するTAS‐102投与症例の後方視的検討:HGCSG1503―初回報告―
結城敏志; 小松嘉人; 坂本直哉, 肝臓, 58, Supplement 2, A560, 2017年09月10日
日本語 - Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer
Y. Komatsu; A. Takashima; T. Denda; M. Gamoh; I. Iwanaga; H. Shimodaira; M. Nakamura; T. Yamaguchi; H. Takahashi; K. Kobayashi; M. Tsuda; Y. Kobayashi; H. Baba; M. Kotake; C. Ishioka; A. Sato; S. Yuki; S. Morita; S. Takahashi; K. Shimada, ANNALS OF ONCOLOGY, 28, 2017年09月
英語, 研究発表ペーパー・要旨(国際会議) - North Japan multicenter phase II study of FOLFOX as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003): Analysis of tumor location
A. Ishiguro; S. Yuki; Y. Kawamoto; H. Nakatsumi; N. Takahashi; T. Shichinohe; T. Kusumi; I. Iwanaga; T. Miyagishima; K. Hatanaka; K. Oomori; M. Nakamura; N. Senmaru; K. Iwai; M. Koike; N. Sakamoto; A. Taketomi; S. Hirano; Y. M. Ito; Y. Komatsu, ANNALS OF ONCOLOGY, 28, 2017年09月
英語, 研究発表ペーパー・要旨(国際会議) - PSM解析による切除不能転移性大腸癌における原発巣切除の意義の検討
市川 伸樹; 本間 重紀; 吉田 雅; 大野 陽介; 川村 秀樹; 川本 泰之; 中積 宏之; 結城 敏志; 小松 嘉人; 石川 倫啓; 江本 慎; 小笠原 和宏; 曽我部 進; 中西 一彰; 数井 啓蔵; 古家 乾; 上泉 洋; 加藤 寛士; 坂本 直哉; 武冨 紹信, 日本大腸肛門病学会雑誌, 70, 抄録号, A137, A137, 2017年09月
(一社)日本大腸肛門病学会, 日本語 - ゲノム医療と消化器癌 院内完結型網羅的がん遺伝子検査(CLHURC検査)を用いた消化器がん個別化医療の実践
林 秀幸; 小松 嘉人; 西原 広史, 日本消化器病学会雑誌, 114, 臨増大会, A669, A669, 2017年09月
(一財)日本消化器病学会, 日本語 - PSM解析による切除不能転移性大腸癌における原発巣切除の意義の検討
市川伸樹; 本間重紀; 吉田雅; 大野陽介; 川村秀樹; 川本泰之; 中積宏之; 結城敏志; 小松嘉人; 石川倫啓; 江本慎; 小笠原和宏; 曽我部進; 中西一彰; 数井啓蔵; 古家乾; 上泉洋; 加藤寛士; 坂本直哉; 武冨紹信, 日本大腸肛門病学会雑誌(Web), 70, A137, 2017年09月
日本語 - 切除不能・進行再発大腸がん薬物治療―そのレジメン選択は正解か?3.症例ごとの「標準治療」をどう掴みとるか―治療の選択肢とその実践 4)経口5‐FU製剤のベースのレジメン
中積宏之; 小松嘉人, 臨床腫瘍プラクティス, 13, 3, 216‐219, 208, 2017年08月10日
ヴァン・メディカル, 日本語 - A retrospective cohort study of the relations between progress of chemotherapy and outcomes for metastatic pancreatic cancer
Kawamoto Yasuyuki; Yuki Satoshi; Yagisawa Masataka; Muranaka Tetsuhito; Harada Kazuaki; Nakatsumi Hiroshi; Kawakubo Kazumichi; Kuwatani Masaki; Sakamoto Naoya; Komatsu Yoshito, ANNALS OF ONCOLOGY, 28, 2017年06月
英語, 研究発表ペーパー・要旨(国際会議) - A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer [HGCSG1401]: Analysis of tumor location
Yuki Satoshi; Komatsu Yoshito; Muranaka Tetsuhito; Tsuji Yasushi; Harada Kazuaki; Ota Yumiko; Hatanaka Kazuteru; Okuda Hiroyuki; Sasaki Takahide; Dazai Masayoshi; Konno Jun; Nakamura Michio; Ohta Tomoyuki; Honda Takuya; Ishiguro Atsushi; Muto Osamu; Kato Sosuke; Sato Atsushi; Abe Masakazu; Eto Kazunori; Sakamoto Naoya; Sakata Yuh, ANNALS OF ONCOLOGY, 28, 2017年06月
英語, 研究発表ペーパー・要旨(国際会議) - First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503
Dazai Masayoshi; Yuki Satoshi; Nakatsumi Hiroshi; Tsuji Yasushi; Kobayashi Yoshimitsu; Hatanaka Kazuteru; Okuda Hiroyuki; Hosokawa Ayumu; Furukawa Koichi; Ogawa Kohei; Minami Shinya; Ishiguro Atsushi; Honda Takuya; Ohta Tomoyuki; Eto Kazunori; Kato Takashi; Nakajima Junta; Sasaki Takahide; Nakamura Michio; Shindo Yoshiaki; Sakata Yuh; Komatsu Yoshito, ANNALS OF ONCOLOGY, 28, 2017年06月
英語, 研究発表ペーパー・要旨(国際会議) - Clinical implementation of a comprehensive targeted amplicon sequencing system for cancer in Japan.
Hideyuki Hayashi; Shigeki Tanishima; Ryo Mori; Yasunobu Okamura; Toraji Amano; Ichiro Kinoshita; Yoshito Komatsu; Hirotoshi Akita; Hiroshi Nishihara, JOURNAL OF CLINICAL ONCOLOGY, 35, 2017年05月
英語, 研究発表ペーパー・要旨(国際会議) - Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
Yasutoshi Kuboki; Akihito Kawazoe; Yoshito Komatsu; Tomohiro Nishina; Eiji Shinozaki; Hiroki Hara; Satoshi Yuki; Miki Fukutani; Natsuko Tsukahara; Hiromi Hasegawa; Nami Hirano; Shogo Nomura; Yosuke Togashi; Hiroyoshi Nishikawa; Akihiro Sato; Atsushi Ohtsu; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 35, 2017年05月
英語, 研究発表ペーパー・要旨(国際会議) - 網羅的がん遺伝子解析による膵がん個別化治療への挑戦
林 秀幸; 上野 秀樹; 小松 嘉人; 坂本 康成; 近藤 俊輔; 森実 千種; 河野 隆志; 奥坂 拓志; 西原 広史, 膵臓, 32, 3, 464, 464, 2017年05月
日本膵臓学会, 日本語 - ゲノム解析に基づく固形がん個別化治療 日本の現状 がん遺伝子診断外来―院内完結型網羅的がん遺伝子検査(CLHURC検査)を用いたクリニカルシークエンスの臨床応用―
林秀幸; 小松嘉人; 秋田弘俊; 西原広史, 最新医学, 72, 3, 381‐387, 2017年03月10日
日本語 - イマチニブ耐性GISTに対するスニチニブの有効性・安全性(Retrospective analysis of the efficacy and safety of sunitinib in patients with advanced GIST)
中積 宏之; 小松 嘉人; 村中 徹人; 原田 一顕; 川本 泰之; 結城 敏志; 坂本 直哉, 日本胃癌学会総会記事, 89回, 259, 259, 2017年03月
(一社)日本胃癌学会, 英語 - 進行胃癌化学療法時の成分栄養剤併用の有効性に関する探索的臨床試験 HGCSG1202(Feasibility study to evaluate the efficacy of elemental diet with chemotherapy for AGC: HGCSG1202)
結城 敏志; 小松 嘉人; 中積 宏之; 川本 泰之; 原田 一顕; 村中 徹人; 畑中 一映; 曽我部 進; 中村 路夫; 武藤 理; 奥田 博介; 佐藤 温; 江藤 和範; 坂本 直哉; 坂田 優, 日本胃癌学会総会記事, 89回, 345, 345, 2017年03月
(一社)日本胃癌学会, 英語 - North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003).
Toshiaki Shichinohe; Satoshi Yuki; Norihiko Takahashi; Hiroshi Nakatsumi; Yasuyuki Kawamoto; Takaya Kusumi; Atsushi Ishiguro; Susumu Sogabe; Ichiro Iwanaga; Kazuteru Hatanaka; Kazuyoshi Oomori; Michio Nakamura; Naoto Senmaru; Kazuhiro Iwai; Masahiko Koike; Naoya Sakamoto; Akinobu Taketomi; Satoshi Hirano; Yoichi M. Ito; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 35, 4, 2017年02月
英語, 研究発表ペーパー・要旨(国際会議) - 切除不能進行・再発胃癌患者の二次治療例を対象としたnab-PTX/RAM療法の第II相試験
下平秀樹; 坂東英明; 藤谷和正; 高島淳生; 山口研成; 中山昇典; 高橋威洋; 沖英次; 東瑞智; 仁科智裕; 廣中秀一; 小松嘉人; 設樂紘平, 日本癌治療学会学術集会(Web), 55th, 2017年 - pStage III結腸癌に対するFOLFOXの第II相試験[NORTH/HGCSG1003]原発部位による解析
篠原敏樹; 結城敏志; 川本泰之; 川本泰之; 中積宏之; 中積宏之; 高橋典彦; 七戸俊明; 久須美貴哉; 中村文隆; 小林良充; 岩永一郎; 伊藤陽一; 坂本直哉; 武冨紹信; 平野聡; 小松嘉人; 小松嘉人, 日本癌治療学会学術集会(Web), 55th, ROMBUNNO.O29‐2 (WEB ONLY), 2017年
日本語 - 切除不能膵癌に対する化学療法の進歩と治療成績の関係の検討(単施設の後方視的検討)
川本泰之; 川本泰之; 結城敏志; 八木澤允貴; 八木澤允貴; 村中徹人; 村中徹人; 原田一顕; 原田一顕; 中積宏之; 中積宏之; 川久保和道; 桑谷将城; 小松嘉人; 坂本直哉, 日本臨床腫瘍学会学術集会(CD-ROM), 15th, ROMBUNNO.P1‐107, 2017年
日本語 - 切除不能大腸癌に対するmFOLFOX6/CapeOX+BmabとS‐1/CPT‐11+Bmabとの第3相試験:TRICOLORE試験
蒲生真紀夫; 沖田南都子; 傳田忠道; 岩永一郎; 小松嘉人; 下平秀樹; 中村将人; 山口達郎; 大堀久詔; 小林功治; 飛松和俊; 宮城島拓人; 馬場秀夫; 小竹優範; 嶋田顕; 佐藤温; 結城敏志; 森田智視; 高橋信; 石岡千加史, 日本臨床腫瘍学会学術集会(CD-ROM), 15th, ROMBUNNO.PS‐1, 2017年
日本語 - HGCSG1201:トラスツズマブを含む一次治療に不応のHER2陽性胃癌に対するトラスツズマブ/イリノテカン併用療法の第II相試験
畑中一映; 川本泰之; 川本泰之; 結城敏志; 目黒高志; 上林実; 阿部雅一; 中村路夫; 奥田博介; 坂田優; 小松嘉人, 日本臨床腫瘍学会学術集会(CD-ROM), 15th, ROMBUNNO.O3‐9‐3, 2017年
日本語 - 進行大腸癌化学療法臨床試験における北海道消化器癌化学療法研究会(HGCSG)の取り組み
小松嘉人; 結城敏志; 結城敏志; 中積宏之; 中積宏之; 川本泰之; 川本泰之; 村中徹人; 村中徹人; 八木澤充貴; 八木澤充貴; 畑中一映; 中村路夫; 小林良充; 岩永一郎; 原田一顕; 宮城島拓人; 太宰昌佳; 佐々木尚英; 目黒高志; 加藤貴司; 國枝保幸; 宮下憲暢; 舘山美樹; 坂田優, 日本臨床腫瘍学会学術集会(CD-ROM), 15th, ROMBUNNO.SY3‐4, 2017年
日本語 - Stage III結腸癌の術後補助化学療法としてのFOL‐FOX療法の第II相臨床試験:NORTH/HGCSG1003
小池雅彦; 結城敏志; 七戸俊明; 高橋典彦; 八木澤允貴; 村中徹人; 川本泰之; 中積宏之; 伊藤陽一; 坂本直哉; 平野聡; 武冨紹信; 小松嘉人, 大腸癌研究会プログラム・抄録集, 87th, 88, 2017年
日本語 - A targeted cancer clinical sequencing system based on a clinical biobank in Hokkaido University Hospital
H. Nishihara; H. Hayashi; S. Tanishima; R. Mori; I. Kinoshita; Y. Komatsu; H. Dosaka-Akita, ANNALS OF ONCOLOGY, 27, 2016年12月
英語, 研究発表ペーパー・要旨(国際会議) - Clinical sequencing system for pancreatic cancer as a laboratory examination
H. Hayashi; S. Tanishima; R. Mori; Y. Kawamoto; I. Kinoshita; Y. Komatsu; H. Dosaka-Akita; H. Nishihara, ANNALS OF ONCOLOGY, 27, 2016年12月
英語, 研究発表ペーパー・要旨(国際会議) - DCF療法で肺転移が消失し根治切除しえた食道がんの1切除例
村中徹人; 小松嘉人; 中積宏之; 川本泰之; 澤田憲太郎; 結城敏志; 清水勇一; 坂本直哉; 海老原裕麿; 倉島庸; 七戸俊明; 藤澤孝志; 三橋智子, 北海道医学雑誌, 91, 2, 93‐94, 2016年11月01日
日本語 - 当院で内視鏡治療を施行したT1a‐MM食道扁平上皮癌の長期予後
水島健; 清水勇一; 宮本秀一; 安孫子怜史; 津田桃子; 大野正芳; 村中徹人; 中積宏之; 坂本直哉; 高橋正和; 小野尚子; 中川学; 中川宗一; 小松嘉人, 北海道医学雑誌, 91, 2, 91, 2016年11月01日
日本語 - 切除不能進行・再発食道癌の二次化学療法におけるドセタキセル単剤およびパクリタキセル単剤療法の有効性・安全性の検討
中積宏之; 小松嘉人; 村中徹人; 川本泰之; 澤田憲太郎; 結城敏志; 坂本直哉, 北海道医学雑誌, 91, 2, 95, 2016年11月01日
日本語 - Updated report: A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402)
S. Yuki; Y. Komatsu; H. Satake; Y. Miyamoto; H. Tanioka; A. Tsuji; M. Asayama; T. Shiraishi; M. Kotaka; A. Makiyama; T. Kashiwada; N. Takeuchi; M. Shimokawa; H. Saeki; E. Oki; Y. Emi; H. Baba; Y. Maehara, ANNALS OF ONCOLOGY, 27, 2016年10月
英語, 研究発表ペーパー・要旨(国際会議) - Clinical significance of thymidine kinase 1 expression on TAS-102 treatment in RECOURSE phase III trial of TAS-102 versus placebo for metastatic colorectal cancer
K. Yamazaki; T. Yoshino; E. Shinozaki; Y. Komatsu; Y. Tsuji; T. Nishina; H. Baba; T. Denda; N. Sugimoto; A. Tsuji; K. Yamaguchi; T. Takayama; Y. Shimada; Y. Hamamoto; K. Muro; M. Gotoh; T. Tanase; A. Ohtsu, ANNALS OF ONCOLOGY, 27, 2016年10月
英語, 研究発表ペーパー・要旨(国際会議) - 切除不能転移性病変を有するステージIV大腸癌における原発巣切除の意義
市川 伸樹; 本間 重紀; 吉田 雅; 大野 陽介; 渋谷 一陽; 川村 秀樹; 川本 泰之; 村中 徹人; 原田 一顕; 中積 宏之; 結城 敏志; 小松 嘉人; 武冨 紹信, 日本大腸肛門病学会雑誌, 69, 抄録号, A279, A279, 2016年10月
(一社)日本大腸肛門病学会, 日本語 - 大腸 化学療法の進歩 その他 大腸癌レゴラフェニブ療法の疲労・倦怠感に対する経口ステロイドによる予防の検討
佐竹 悠良; 宮本 裕士; 谷岡 洋亮; 辻 晃仁; 朝山 雅子; 白石 猛; 結城 敏志; 小高 雅人; 牧山 明資; 小松 嘉人; 佐伯 浩司; 沖 英次; 江見 泰徳; 馬場 秀夫; 前原 喜彦, 日本癌治療学会学術集会抄録集, 54回, WS92, 5, 2016年10月
(一社)日本癌治療学会, 日本語 - 切除不能転移性病変を有するステージIV大腸癌における原発巣切除の意義
市川伸樹; 本間重紀; 吉田雅; 大野陽介; 渋谷一陽; 川村秀樹; 川本泰之; 村中徹人; 原田一顕; 中積宏之; 結城敏志; 小松嘉人; 武冨紹信, 日本大腸肛門病学会雑誌(Web), 69, A279, 2016年10月
日本語 - がん治療が変わる―免疫チェックポイント阻害剤の与えるインパクト―先行する癌腫における治療成績 悪性黒色腫に対する薬物療法の治療成績
石黒敦; 小松嘉人, 肝胆膵, 73, 3, 361‐367, 2016年09月28日
日本語 - 消化管がん薬物療法2016 切除不能・再発進行大腸がんの薬物療法アップデート―State‐of‐art―
結城敏志; 川本泰之; 中積宏之; 小松嘉人, Mebio, 33, 7, 39‐47, 47, 2016年07月10日
(株)メジカルビュー社, 日本語 - FOLFOX or XELOX as adjuvant therapy after curative resection of metastatic or relapsed colorectal cancer
Kentaro Sawada; Yoshito Komatsu; Satoshi Yuki; Hiroshi Nakatsumi; Yasuyuki Kawamoto; Tetsuhito Muranaka; Atsusi Ishiguro; Kazuteru Hatanaka; Naohide Sasaki; Takuto Miyagishima; Naoya Sakamoto, ANNALS OF ONCOLOGY, 27, 2016年07月
英語, 研究発表ペーパー・要旨(国際会議) - Retrospective comparison of efficacy and safety of docetaxel and weekly-paclitaxel as 2nd-line chemotherapy for patients with unresectable or recurrent esophageal cancer
H. Nakatsumi; Y. Komatsu; K. Sawada; T. Muranaka; Y. Kawamoto; S. Yuki; N. Sakamoto, ANNALS OF ONCOLOGY, 27, 50, 50, 2016年06月
英語, 研究発表ペーパー・要旨(国際会議) - Final survival results and onset of neutropenia as an indicator of therapeutic effect in phase 2 of TAS-102 vs placebo with metastatic colorectal cancer (J003-10040030)
T. Yoshino; E. Shinozaki; K. Yamazaki; T. Nishina; Y. Komatsu; H. Baba; A. Tsuji; K. Yamaguchi; K. Muro; N. Sugimoto; Y. Tsuji; T. Moriwaki; T. Esaki; C. Hamada; T. Tanase; A. Ohtsu, ANNALS OF ONCOLOGY, 27, 107, 107, 2016年06月
英語, 研究発表ペーパー・要旨(国際会議) - 固形がんに対する分子標的治療の進歩と精密医療の動向 大腸がんに対する新しい殺細胞性抗悪性腫瘍薬・分子標的治療薬の開発
結城敏志; 小松嘉人, 月刊腫瘍内科, 17, 5, 475‐479, 499, 2016年05月28日
科学評論社, 日本語 - Update analysis: Prospective observational study for the impact of short-term periodic steroid premedication for cancer chemotherapy on bone metabolism-ESPRESSO-01 study.
Michio Nakamura; Atsushi Ishiguro; Tetsuhito Muranaka; Satoshi Yuki; Taichi Murai; Chika Matsuda; Ayane Oba; Kazufumi Itaya; Taku Shigesawa; Yuta Koike; Yomo Fujita; Ayana Endo; Yoko Tsukuda; Yuji Ono; Takahiko Kudo; Atsushi Nagasaka; Shuji Nishikawa; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月
英語, 研究発表ペーパー・要旨(国際会議) - PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
Kei Muro; Hiroyuki Uetake; Katsuya Tsuchihara; Kohei Shitara; Kentaro Yamazaki; Eiji Oki; Takeo Sato; Takeshi Naitoh; Yoshito Komatsu; Takeshi Kato; Kouji Iwasaki; Junpei Soeda; Masamitsu Hihara; Takeharu Yamanaka; Atsushi Ochiai; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月
英語, 研究発表ペーパー・要旨(国際会議) - The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced non-colorectal (Non-CRC) gastrointestinal cancer
Atsuo Takashima; Wataru Okamoto; Shuichi Hironaka; Takeshi Kato; Yoshito Komatsu; Takeshi Kajiwara; Naoki Izawa; Taito Esaki; Hiroki Hara; Ryota Nakanishi; Yoshiyuki Yamamoto; Hiromichi Ebi; Shigenori Kadowaki; Takeshi Kuwata; Satoshi Fujii; Toshihiko Dol; Atsushi Ohtsu; Kohei Shitara; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月
英語, 研究発表ペーパー・要旨(国際会議) - Supportive treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer
Robert. J. Mayer; Eric Van Cutsem; Takayuki Yoshino; Alfredo Falcone; Rocio Garcia-Carbonero; Guillem Argiles; Alessandro Pastorino; Marc Peeters; Robert Winklert; Mona Wahba; Lukas Makris; Alberto Zaniboni; Yasuhiro Shimada; Kentaro Yamazaki; Yoshito Komatsu; Howard S. Hochster; Heinz-Josef Lenz; Ben Tran; Atsushi Ohtsu, JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月
英語, 研究発表ペーパー・要旨(国際会議) - Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial
Robert J. Mayer; Atsushi Ohtsu; Takayuki Yoshino; Alfredo Falcone; Rocio Garcia-Carbonero; Guillem Argiles; Azzurra Damiani; Marc Peeters; Lukas Makris; Alberto Zaniboni; Yasuhiro Shimada; Kentaro Yamazaki; Yoshito Komatsu; Howard S. Hochster; Heinz-Josef Lenz; Ben Tran; Robert Winkler; Paul Bebeau; Mona M. Wahba; Eric Van Cutsem, JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月
英語, 研究発表ペーパー・要旨(国際会議) - Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer.
Atsushi Ohtsu; Takayuki Yoshino; Alfredo Falcone; Rocio Garcia-Carbonero; Guillem Argiles; Alberto F. Sobrero; Marc Peeters; Lukas Makris; Fabio Benedetti; Alberto Zaniboni; Yasuhiro Shimada; Kentaro Yamazaki; Yoshito Komatsu; Howard S. Hochster; Heinz-Josef Lenz; Ben Tran; Mona Wahba; Kenichiro Yoshida; Eric Van Cutsem; Robert J. Mayer, JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月
英語, 研究発表ペーパー・要旨(国際会議) - A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410
Yasutoshi Kuboki; Tomohiro Nishina; Kensei Yamaguchi; Eiji Shinozaki; Yoshito Komatsu; Satoshi Yuki; Kentaro Yamazaki; Hiroki Hara; Miki Fukutani; Yasue Uchida; Natsuko Tsukahara; Hiromi Hasegawa; Seiko Matsuda; Wataru Okamoto; Masahito Yonemura; Shogo Nomura; Akihiro Sato; Atsushi Ohtsu; Takayuki Yoshino, JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月
英語, 研究発表ペーパー・要旨(国際会議) - Safety and efficacy of regorafenib in Japanese patients with metastatic colorectal cancer (mCRC) in clinical practice: Interim result from postmarketing surveillance (PMS).
Yoshito Komatsu; Kei Muro; Kensei Yamaguchi; Hiroyuki Uetake; Taroh Satoh; Takayuki Yoshino; Toshirou Nishida; Naoya Yamazaki; Hajime Takigawa; Yoko Hamada; Masayuki Chosa; Toshiyuki Sunaya; Yuka Yamamoto; Yuichiro Ito; Toshiaki Watanabe; Kenichi Sugihara, JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月
英語, 研究発表ペーパー・要旨(国際会議) - TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial.
Robert J. Mayer; Atsushi Ohtsu; Takayuki Yoshino; Alfredo Falcone; Rocio Garcia-Carbonero; Josep Tabernero; Alberto F. Sobrero; Marc Peeters; Fabio Benedetti; Lukas Makris; Hiroshi Ambe; Alberto Zaniboni; Yasuhiro Shimada; Kentaro Yamazaki; Yoshito Komatsu; Howard S. Hochster; Heinz-Josef Lenz; Ben Tran; Eric Van Cutsem, JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月
英語, 研究発表ペーパー・要旨(国際会議) - PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
Takayuki Yoshino; Hiroyuki Uetake; Katsuya Tsuchihara; Kohei Shitara; Kentaro Yamazaki; Eiji Oki; Takeo Sato; Takeshi Naitoh; Yoshito Komatsu; Takeshi Kato; Kouji Iwasaki; Junpei Soeda; Masamitsu Hihara; Takeharu Yamanaka; Atsushi Ochiai; Kei Muro, JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月
英語, 研究発表ペーパー・要旨(国際会議) - Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the GERCOR index.
Osamu Muto; Satoshi Yuki; Tetsuhito Muranaka; Takashi Kato; Takashi Meguro; Michio Nakamura; Atsushi Sato; Ichiro Iwanaga; Minoru Uebayashi; Miki Tateyama; Kazuteru Hatanaka; Kazunori Eto; Hiroyuki Okuda; Susumu Sogabe; Masakazu Abe; Kanji Kato; Sosuke Kato; Kencho Miyashita; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月
英語, 研究発表ペーパー・要旨(国際会議) - Phase III RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.
Atsushi Ohtsu; Takayuki Yoshino; Mona M. Wahba; Fabio M. Benedetti; Alfredo Falcone; Rocio Garcia-Carbonero; Josep Tabernero; Alberto F. Sobrero; Marc Peeters; Alberto Zaniboni; Yasuhiro Shimada; Kentaro Yamazaki; Yoshito Komatsu; Howard S. Hochster; Heinz-Josef Lenz; Ben Tran; Robert J. Mayer; Eric Van Cutsem, JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月
英語, 研究発表ペーパー・要旨(国際会議) - TAS-102 versus placebo (PBO) in patients (pts) >= 65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.
Eric Van Cutsem; Fabio M. Benedetti; Hirokazu Mizuguchi; Robert J. Mayer; Alfredo Falcone; Rocio Garcia-Carbonero; Josep Tabernero; Alberto F. Sobrero; Marc Peeters; Alberto Zaniboni; Takayuki Yoshino; Yasuhiro Shimada; Kentaro Yamazaki; Yoshito Komatsu; Howard S. Hochster; Heinz-Josef Lenz; Ben Tran; Atsushi Ohtsu, JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月
英語, 研究発表ペーパー・要旨(国際会議) - Phase II trial of bolus 5-FU/l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant unresectable gastric cancer (HGCSG1502).
Tetsuhito Muranaka; Satoshi Yuki; Kentaro Sawada; Yasuyuki Kawamoto; Hiroshi Nakatsumi; Masayoshi Dazai; Hideyuki Hayashi; Michio Nakamura; Atsushi Ishiguro; Susumu Sogabe; Yoshimitsu Kobayashi; Takuto Miyagishima; Ichiro Iwanaga; Miki Tateyama; Kazuteru Hatanaka; Takashi Kato; Naoya Sakamoto; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月
英語, 研究発表ペーパー・要旨(国際会議) - Prospective observational study for the impact of short-term periodic intravenous steroid premedication for gastrointestinal cancer chemotherapy on bone metabolism.
Atsushi Ishiguro; Michio Nakamura; Tetsuhito Muranaka; Satoshi Yuki; Taichi Murai; Chika Matsuda; Ayane Oba; Kazufumi Itaya; Taku Shigesawa; Yuta Koike; Yomo Fujita; Ayana Endo; Yoko Tsukuda; Yuji Ono; Takahiko Kudo; Atsushi Nagasaka; Shuji Nishikawa; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月
英語, 研究発表ペーパー・要旨(国際会議) - Updated analysis: Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802)-Sub-group analysis by KRAS Exon2 status.
Michio Nakamura; Satoshi Yuki; Kentaro Sawada; Ayane Oba; Atsushi Sato; Takashi Kato; Takashi Meguro; Nobuyuki Ehira; Miki Tateyama; Kazuteru Hatanaka; Kazunori Eto; Hiroyuki Okuda; Yoshimitsu Kobayashi; Osamu Muto; Masakazu Abe; Kanji Kato; Mineo Kudo; Kencho Miyashita; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月
英語, 研究発表ペーパー・要旨(国際会議) - Updated analysis of phase II trial of irinotecan/s-1/cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902-Comparison of administration interval in cetuximab treatment.
Tomohiro Kondo; Satoshi Yuki; Yasuyuki Kawamoto; Yasushi Tsuji; Ayumu Hosokawa; Michio Nakamura; Osamu Muto; Takashi Kato; Ichiro Iwanaga; Atsushi Sato; Kazunori Eto; Kouichi Furukawa; Hideyuki Hayashi; Miki Tateyama; Yasuo Takahashi; Susumu Sogabe; Takuya Honda; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月
英語, 研究発表ペーパー・要旨(国際会議) - 造影超音波検査を施行した悪性リンパ腫肝病変の1症例
岩井孝仁; 岩井孝仁; 西田睦; 西田睦; 佐藤恵美; 佐藤恵美; 工藤悠輔; 工藤悠輔; 表原里実; 表原里実; 藤田裕美; 真鍋徳子; 小松嘉人; 加畑馨; 清水力, 超音波医学, 43, 1, 115‐122 (J‐STAGE), 122, 2016年
症例は70歳代,女性.主訴は心窩部痛.ALT持続正常HCVキャリアで,前医にて経過観察中であった.1年半前の超音波検査(US)で,肝S4に均質的な低エコー域を認めていたが,明らかな腫瘤としては認識されず,同時期のCTでも異常所見は指摘されなかったため経過観察されていた.経過観察中のUSで低エコー域は明瞭化,サイズ増大し明らかな腫瘤性病変として認識された.CTにては肝腫瘤および胃食道接合部に肥厚を認め,胃食道接合部癌と転移性肝癌の疑いで,精査加療目的に当院紹介となった.当院USにて,肝S4を主座とする境界明瞭な最大径91 mmの充実性腫瘤を認めた.辺縁は低エコーで中心部は高エコーを呈していた.肝門部には境界明瞭で低エコーのリンパ節腫大を多数認めた.Sonazoid®造影超音波検査(CEUS)では,動脈相で辺縁から内部に流入する微細点状の造影効果を認め,主に辺縁は強く造影されたが,中心部の造影効果はみられなかった.門脈相で辺縁の造影効果は減弱し,後血管相で造影欠損像を呈した.CTでは,内部に変性ないし壊死を疑う低吸収域を伴う乏血性腫瘤の形態であった.また,肝門部の他,頸部と左腋窩にリンパ節腫大像を認めた.診断目的で肝腫瘍生検が施行され,病理組織学的診断は,びまん性大細胞型B細胞リンパ腫であり,悪性リンパ腫の肝浸潤と診断された.悪性リンパ腫の肝臓病変は,低エコーで均質な性状を呈する腫瘤性病変が多く,中心部が壊死を呈する症例の報告は少ない.今回,CEUSを施行した中心部に変性または壊死を疑う悪性リンパ腫肝浸潤の1症例を経験したので報告する., 一般社団法人 日本超音波医学会, 日本語 - 食道癌の二次化学療法におけるDocetaxelおよびPaclitaxelの有効性・安全性の検討
中積宏之; 小松嘉人; 村中徹人; 原田一顕; 川本泰之; 結城敏志; 坂本直哉, 日本癌治療学会学術集会(Web), 54th, ROMBUNNO.WS72‐6 (WEB ONLY), 2016年
日本語 - 切除不能胃癌に対するsalvage lineとしてのRPMI療法の安全性・有効性の検討
澤田憲太郎; 小松嘉人; 結城敏志; 中積宏之; 川本泰之; 村中徹人, 日本胃癌学会総会記事, 88th, 295, 2016年
日本語 - ベバシズマブ投与例(一次治療)におけるGlasgow Prognostic Scoreの有用性:HGCSG0802
高畑武功; 結城敏志; 中積宏之; 佐々木尚英; 中村路夫; 岩永一郎; 舘山美樹; 江藤和範; 畑中一映; 工藤峰生; 奥田博介; 加藤寛士; 曽我部進; 坂田優; 小松嘉人, 日本癌治療学会学術集会(Web), 54th, ROMBUNNO.WS50‐5 (WEB ONLY), 2016年
日本語 - 切除不能進行大腸癌に対するレゴラフェニブ療法の後方視的研究:HGCSG1401
結城敏志; 小松嘉人; 川本泰之; 辻靖; 曽我部進; 吉田俊太郎; 畑中一映; 奥田博介; 佐々木尚英; 太宰昌佳; 太田智之; 本田琢也; 石黒敦; 坂田優; 坂本直哉, 日本癌治療学会学術集会(Web), 54th, ROMBUNNO.MS33‐3 (WEB ONLY), 2016年
日本語 - セツキシマブ不応例に対するパニツムマブの有効性に関する第II相試験:HGCSG1101
辻靖; 結城敏志; 原田一顕; 安藤孝将; 細川歩; 畑中一映; 佐藤温; 小林良充; 宮城島拓人; 奥田博介; 加藤総介; 中村路夫; 久居弘幸; 坂田優; 小松嘉人, 日本癌治療学会学術集会(Web), 54th, ROMBUNNO.WS51‐1 (WEB ONLY), 2016年
日本語 - R0/1切除された転移性および再発結腸・直腸癌に対するOxaliplatinを含む術後補助化学療法の検討
澤田憲太郎; 小松嘉人; 結城敏志; 中積宏之; 川本泰之; 村中徹人; 石黒敦; 畑中一映; 佐々木尚英; 宮城島拓人; 坂本直哉, 日本臨床腫瘍学会学術集会(CD-ROM), 14th, ROMBUNNO.P2‐049, 2016年
日本語 - 消化器癌に対する全身化学療法施行時の定期的なステロイド前投薬の骨代謝系への影響を検討する前向き調査研究:ESPRESSO‐01試験
中村路夫; 石黒敦; 村中徹人; 結城敏志; 村井太一; 大場彩音; 板谷一史; 永坂敦; 西川秀司; 小松嘉人, 日本臨床腫瘍学会学術集会(CD-ROM), 14th, ROMBUNNO.O1‐17‐2, 2016年
日本語 - 進行胃癌化学療法時の成分栄養剤併用の有効性に関する探索的臨床試験:HGCSG1202
中村路夫; 結城敏志; 村中徹人; 小林良充; 畑中一映; 武藤理; 奥田博介; 福島拓; 佐藤温; 江藤和範; 紺野潤; 佐々木尚英; 加藤貴司; 坂田優; 小松嘉人, 日本癌治療学会学術集会(Web), 54th, ROMBUNNO.WS9‐2 (WEB ONLY), 2016年
日本語 - 消化器癌化学療法のステロイド前投薬による骨代謝系への影響を検討する前向き調査研究
中村路夫; 石黒敦; 村中徹人; 結城敏志; 村井太一; 松田千佳; 大場彩音; 板谷一史; 工藤俊彦; 永坂敦; 西川秀司; 大野浩太; 小松嘉人, 日本癌治療学会学術集会(Web), 54th, ROMBUNNO.WS92‐4 (WEB ONLY), 2016年
日本語 - Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) plus BV and oral FU/OX plus BV
Y. Komatsu; S. Yuki; H. Nakatsumi; K. Sawada; K. Hatanaka; T. Kato; T. Meguro; M. Nakamura; I. Iwanaga; M. Uebayashi; M. Tateyama; K. Eto; M. Kudo; K. Kato; H. Okuda; S. Sogabe; T. Miyagishima; K. Miyashita; N. Sakamoto; Y. Sakata, ANNALS OF ONCOLOGY, 26, 52, 53, 2015年12月
英語, 研究発表ペーパー・要旨(国際会議) - Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in phase II study (NORTH/HGCSG1003) - an analysis of surgeons vs oncologists
A. Ishiguro; S. Yuki; Y. Kawamoto; F. Nakamura; N. Takahashi; T. Shichinohe; T. Kusumi; S. Sogabe; K. Hatanaka; K. Misawa; M. Nenohi; H. Hayashi; H. Fukushima; M. Takahashi; T. Amano; Y. M. Ito; N. Sakamoto; A. Taketomi; S. Hirano; Y. Komatsu, ANNALS OF ONCOLOGY, 26, 50, 50, 2015年12月
英語, 研究発表ペーパー・要旨(国際会議) - Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy
S. Yuki; Y. Komatsu; H. Nakatsumi; T. Muranaka; Y. Kobayashi; T. Miyagishima; N. Ehira; I. Iwanaga; H. Okuda; M. Tateyama; Y. Tsuji; K. Hatanaka; M. Nakamura; M. Kudo; H. Fukushima; H. Hisai; R. Abe; N. Sakamoto; K. Oba; Y. Sakata, ANNALS OF ONCOLOGY, 26, 48, 48, 2015年12月
英語, 研究発表ペーパー・要旨(国際会議) - 食道癌術後/化学放射線療法後再発に対する化学放射線療法の成績
井上哲也; 原田慶一; 加藤徳雄; 清水伸一; 白土博樹; 中積宏之; 福島拓; 小松嘉人; 海老原裕磨; 七戸俊明, 北海道医学雑誌, 90, 2, 153‐154, 2015年11月01日
日本語 - 消化管がん(食道がん,胃がん,大腸がん等)の新しい標準的治療に対する考察 進行大腸がんKRAS wild typeに対する一次治療薬選択の考え方
小松嘉人; 川本泰之, 月刊腫瘍内科, 16, 4, 332, 338, 2015年10月28日
(有)科学評論社, 日本語 - オキサリプラチンによる血管痛発現における患者背景の調査
坂本和央; 久保田康生; 速水章一; 大江利治; 齋藤佳敬; 熊井正貴; 笠師久美子; 山田武宏; 小松嘉人; 柴山良彦; 小林正紀; 井関健; 井関健, 日本医療薬学会年会講演要旨集, 25th, 430, 2015年10月23日
日本語 - Randomized phase II study of S-1 plus oral leucovorin (SL) versus SL plus oxaliplatin (SOL) versus S-1 plus cisplatin (SP) in patients with advanced gastric cancer (AGC): Update data
Y. Komatsu; H. Shuichi; S. Naotoshi; Y. Kensei; M. Toshikazu; N. Tomohiro; T. Akihito; E. N. Takako; G. Masahiro; M. Nozomu; B. Hideaki; E. Taito; E. Yasunori; S. Takashi; M. Shigemi; B. Narikazu; B. Hideo; H. Ichinosuke, EUROPEAN JOURNAL OF CANCER, 51, S447, S447, 2015年09月
英語, 研究発表ペーパー・要旨(国際会議) - Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy
Y. Kobayashi; S. Yuki; Y. Kawamoto; K. Sawada; T. Miyagishima; N. Ehira; I. Iwanaga; H. Okuda; M. Tateyama; Y. Tsuji; K. Hatanaka; M. Nakamura; M. Kudo; H. Fukushima; T. Tagaki; H. Hisai; M. Koike; R. Abe; Y. Sakata; Y. Komatsu, EUROPEAN JOURNAL OF CANCER, 51, S359, S359, 2015年09月
英語, 研究発表ペーパー・要旨(国際会議) - Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902 updated analysis
M. Nakamura; S. Yuki; H. Nakatsumi; O. Muto; A. Hosokawa; T. Kato; I. Iwanaga; K. Hatanaka; Y. Tsuji; A. Sato; K. Eto; K. Furukawa; H. Okuda; M. Onodera; K. Fujikawa; M. Kudo; S. Yokoyama; T. Honda; Y. Sakata; Y. Komatsu, EUROPEAN JOURNAL OF CANCER, 51, S360, S360, 2015年09月
英語, 研究発表ペーパー・要旨(国際会議) - Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX) plus BV and oral FU/OX plus BV
H. Nakatsumi; S. Yuki; Y. Kawamoto; T. Muranaka; K. Hatanaka; T. Kato; T. Meguro; M. Nakamura; I. Iwanaga; M. Uebayashi; M. Tateyama; K. Eto; M. Kudo; S. Kato; H. Okuda; S. Sogabe; K. Miyashita; Y. Sakata; N. Sakamoto; Y. Komatsu, EUROPEAN JOURNAL OF CANCER, 51, S358, S359, 2015年09月
英語, 研究発表ペーパー・要旨(国際会議) - Association of morphologic response with overall survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: Updated analysis-HGCSG0802
M. Yagisawa; S. Yuki; T. Muranaka; K. Sawada; K. Hatanaka; T. Kato; T. Meguro; M. Nakamura; I. Iwanaga; K. Eto; A. Sato; H. Okuda; K. Kato; T. Miyagishima; O. Muto; S. Yabusaki; N. Miyamoto; K. Kudo; Y. Sakata; Y. Komatsu, EUROPEAN JOURNAL OF CANCER, 51, S361, S362, 2015年09月
英語, 研究発表ペーパー・要旨(国際会議) - 大腸 大腸がん分子標的薬の最新情報 レゴラフェニブ(スチバーガ錠)使用大腸癌患者に対する製造販売後調査 中間報告
小松 嘉人; 渡邉 聡明; 西田 俊朗; 植竹 宏之; 山口 研成; 佐藤 太郎; 吉野 孝之; 山崎 直也; 滝川 一; 濱田 葉子; 帖佐 雅幸; 山本 由佳; 伊藤 雄一郎; 室 圭; 杉原 健一; スチバーガ(レゴラフェニブ; 適正使用アドバイザリーボード, 日本癌治療学会誌, 50, 3, 1308, 1308, 2015年09月
(一社)日本癌治療学会, 英語 - Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in phase II study (NORTH/HGCSG1003) - an analysis of surgeons vs oncologists
I. Iwanaga; S. Yuki; H. Fukushima; N. Takahashi; T. Shichinohe; T. Kusumi; F. Nakamura; S. Sogabe; K. Hatanaka; K. Oomori; K. Misawa; N. Senmaru; K. Iwai; T. Shinohara; M. Koike; K. Miyashita; T. Amano; Y. M. Ito; N. Sakamoto; A. Taketomi; S. Hirano; Y. Komatsu, ANNALS OF ONCOLOGY, 26, 2015年06月
英語, 研究発表ペーパー・要旨(国際会議) - Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX) plus BV and oral FU/OX plus BV
Kazuteru Hatanaka; Satoshi Yuki; Hiroshi Nakatsumi; Hiraku Fukushima; Hirohito Naruse; Takashi Kato; Takashi Meguro; Michio Nakamura; Ichiro Iwanaga; Minoru Uebayashi; Miki Tateyama; Kazunori Eto; Mineo Kudo; Sosuke Kato; Hiroyuki Okuda; Susumu Sogabe; Kencho Miyashita; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 33, 3, 2015年01月
英語, 研究発表ペーパー・要旨(国際会議) - RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy-An age-group analysis
Kei Muro; Gyorgy Bodoky; Alvydas Cesas; Yee Chao; Philip Clingan; Shuichi Hironaka; Yoshito Komatsu; Galina Petrova Kurteva; Oleg N. Lipatov; Tomohiro Nishina; Sang Cheul Oh; Atsushi Ohtsu; Yasuhiro Shimada; Naotoshi Sugimoto; Eric Van Cutsem; Roberto Carlesi; Kumari Chandrawansa; Hansjochen Wilke, JOURNAL OF CLINICAL ONCOLOGY, 33, 3, 2015年01月
英語, 研究発表ペーパー・要旨(国際会議) - Comparison between neoadjuvant chemotherapy followed by surgery (NAC-S) and definitive chemoradiotherapy (CRT) in overall survival for patients with clinical stage II-III esophageal squamous cell carcinoma (ESCC) (JCOG1406-A)
Motoo Nomura; Ken Kato; Junki Mizusawa; Kozo Kataoka; Nobutoshi Ando; Kei Muro; Atsushi Ohtsu; Hiroyasu Igaki; Masayuki Shinoda; Hiroya Takeuchi; Hideaki Shimizu; Kazuhiko Hayashi; Hiroyuki Daiko; Masahiro Goto; Yoshito Komatsu; Kazuo Konishi; Yoshinori Miyata; Yuko Kitagawa, JOURNAL OF CLINICAL ONCOLOGY, 33, 3, 2015年01月
英語, 研究発表ペーパー・要旨(国際会議) - Analysis of the GERCOR index in KRAS Exon2 WT patients with mCRC treated with salvage-line cetuximab- based chemotherapy: HGCSG0901.
Ayumu Hosokawa; Satoshi Yuki; Hiroshi Nakatsumi; Kazuteru Hatanaka; Yasushi Tsuji; Hiroyuki Okuda; Yasuo Takahashi; Jun Konno; Kazunori Eto; Yasuyuki Kawamoto; Norikazu Sonoda; Yasushi Sato; Mayuko Saito; Takuto Miyagishima; Shinichiro Ikeda; Koji Yoshizaki; Takahide Sasaki; Soh Saitoh; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 33, 3, 2015年01月
英語, 研究発表ペーパー・要旨(国際会議) - Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by KRAS Exon2 status
Takenori Takahata; Satoshi Yuki; Hiroshi Nakatsumi; Kazuaki Harada; Hiraku Fukushima; Atsushi Sato; Takashi Kato; Takashi Meguro; Michio Nakamura; Nobuyuki Ehira; Ichiro Iwanaga; Miki Tateyama; Kazuteru Hatanaka; Kazunori Eto; Hiroyuki Okuda; Yoshimitsu Kobayashi; Osamu Muto; Masakazu Abe; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 33, 3, 2015年01月
英語, 研究発表ペーパー・要旨(国際会議) - Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in phase II study (NORTH/HGCSG1003): Detailed analysis of peripheral sensory neuropathy.
Susumu Sogabe; Satoshi Yuki; Hiraku Fukushima; Norihiko Takahashi; Toshiaki Shichinohe; Takaya Kusumi; Fumitaka Nakamura; Ichiro Iwanaga; Kazuteru Hatanaka; Kencho Miyashita; Jun Konno; Kazuhito Uemura; Masaaki Nenohi; Masaya Kina; Naoya Sakamoto; Akinobu Taketomi; Satoshi Hirano; Toraji Amano; Yoichi M. Ito; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 33, 3, 2015年01月
英語, 研究発表ペーパー・要旨(国際会議) - Phase II trial of irinotecan plus s-1 (IRIS) with cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS wild-type metastatic colorectal cancer (mCRC): HGCSG0902-Comparison of administration interval in cetuximab treatment.
Yoshito Komatsu; Satoshi Yuki; Hiroshi Nakatsumi; Ayumu Hosokawa; Michio Nakamura; Osamu Muto; Takashi Meguro; Ichiro Iwanaga; Kazuteru Hatanaka; Yasushi Tsuji; Atsushi Sato; Kazunori Eto; Kouichi Furukawa; Manabu Onodera; Miki Tateyama; Yasuo Takahashi; Masayoshi Dazai; Sachio Yokoyama; Takuya Honda; Yuh Sakata, JOURNAL OF CLINICAL ONCOLOGY, 33, 3, 2015年01月
英語, 研究発表ペーパー・要旨(国際会議) - がんの親をもつ子どものサポート“ことりカフェ”の実践報告
蛭田悠子; 藤井あけみ; 浜田公子; 田巻知宏; 小松嘉人, 日本緩和医療学会学術大会プログラム・抄録集, 20th, 232, 2015年
日本語 - ワンタキソテールにおけるアルコール不耐症患者への安全な投与管理の検討
三宅亜矢; 中野政子; 石岡明子; 小松嘉人, 日本臨床腫瘍学会学術集会(CD-ROM), 13th, ROMBUNNO.P2-6-58, 2015年
日本語 - 切除不能進行/再発胃癌における一次化学療法導入時のGlasgow Prognostic Score(GPS)の有用性の検討
結城敏志; 小松嘉人; 村中徹人; 林秀幸; 中積宏之; 福島拓; 坂本直哉, 日本胃癌学会総会記事, 87th, 439, 2015年
日本語 - HGCSG1401:切除不能進行大腸癌に対するRegorafenib療法の後方視的研究(第1報)
太宰昌佳; 結城敏志; 川本泰之; 辻靖; 吉田俊太郎; 畑中一映; 好崎浩司; 石黒敦; 武藤理; 佐藤温; 江藤和範; 小野寺馨; 中村路夫; 坂田優; 小松嘉人, 日本癌治療学会学術集会(Web), 53rd, P121‐2 (WEB ONLY), 2015年
日本語 - 当院における切除不能進行大腸癌に対するRegorafenib療法の安全性と有効性の検討
川本泰之; 小松嘉人; 結城敏志; 中積宏之; 福島拓; 林秀幸; 村中徹人; 澤田憲太郎; 本間理央; 中野政子; 三宅亜矢; 石岡明子; 坂本直哉, 日本癌治療学会学術集会(Web), 53rd, P121‐3 (WEB ONLY), 2015年
日本語 - 当院における切除不能進行大腸癌に対するTAS‐102療法の安全性と有効性の検討
結城敏志; 小松嘉人; 川本泰之; 中積宏之; 福島拓; 林秀幸; 村中徹人; 澤田憲太郎; 本間理央; 中野政子; 三宅亜矢; 石岡明子; 坂本直哉, 日本癌治療学会学術集会(Web), 53rd, P122‐6 (WEB ONLY), 2015年
日本語 - 切除不能大腸癌の一次治療におけるBevacizumab観察研究(HGCSG0802)/レジメン別の解析
中村路夫; 結城敏志; 中積宏之; 澤田憲太郎; 加藤貴司; 岩永一郎; 館山美樹; 江藤和範; 畑中一映; 佐藤温; 工藤峰生; 奥田博介; 加藤寛士; 坂田優; 小松嘉人, 日本癌治療学会学術集会(Web), 53rd, WS76‐3 (WEB ONLY), 2015年
日本語 - 3次治療におけるPanitumumabの皮膚障害に関する無作為化比較試験:J‐STEPP試験
近藤知大; 小林良充; 小林良充; 結城敏志; 川本泰之; 村中徹人; 辻靖; 岩永一郎; 奥田博介; 舘山美樹; 畑中一映; 中村路夫; 紺野潤; 江藤和範; 坂田優; 小松嘉人, 日本癌治療学会学術集会(Web), 53rd, 3, WS77‐3 (WEB ONLY), 1305, 2015年
(一社)日本癌治療学会, 日本語 - 進行食道癌と術前診断した,表面にHigh grade intraepithelial neoplasiaを伴う顆粒細胞腫の1例
村中徹人; 林秀幸; 中積宏之; 福島拓; 小松嘉人; 結城敏志; 清水勇一; 坂本直哉; 七戸俊明, 北海道外科雑誌, 59, 2, 202, 203, 2014年12月20日
日本語 - 局所進行食道癌に対する強度変調放射線治療を用いた放射線化学療法の経験
井上哲也; 加藤徳雄; 清水伸一; 白土博樹; 鈴木隆介; 佐々木尚英; 福島拓; 小松嘉人, 北海道外科雑誌, 59, 2, 206, 2014年12月20日
日本語 - 分子標的薬の皮膚障害対策の標準化 パニツムマブの皮膚障害予防に対する検討:J‐STEPP試験について
小松嘉人; 小林良充, Skin Cancer, 29, 2, 120, 122, 2014年11月15日
日本語 - Stage III結腸癌の術後補助化学療法としてのFOLFOX療法の第II相臨床試験:NORTH/HGCSG1003:安全性解析結果
久須美貴哉; 結城敏志; 中村文隆; 三澤一仁; 篠原敏樹; 小池雅彦; 福島剛; 中西喜嗣; 植村一仁; 子野日政昭; 高橋典彦; 七戸俊明; 武冨紹信; 平野聡; 小松嘉人, 日本臨床外科学会雑誌, 75, 増刊, 637, 637, 2014年10月20日
日本臨床外科学会, 日本語 - ANALYSIS OF GERCOR INDEX IN KRAS EXON2 WT PATIENTS WITH mCRC TREATED WITH SALVAGE-LINE CMAB-BASED REGIMEN: HGCSG0901
Soh Saitoh; Satoshi Yuki; Takahide Sasaki; Kazuteru Hatanaka; Hiroyuki Okuda; Yasushi Tsuji; Ayumu Hosokawa; Yasushi Sato; Yuh Sakata; Yoshito Komatsu, ANNALS OF ONCOLOGY, 25, 2014年10月
英語, 研究発表ペーパー・要旨(国際会議) - OBSERVATIONAL COHORT STUDY OF 1ST LINE BEVACIZUMAB COMBINED WITH CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER: HGCSG0802
Michio Nakamura; Satoshi Yuki; Kazuaki Harada; Yoshimitsu Kobayashi; Takashi Kato; Minoru Uebayashi; Norikazu Sonoda; Kazunori Eto; Takenori Takahata; Yoshito Komatsu, ANNALS OF ONCOLOGY, 25, 2014年10月
英語, 研究発表ペーパー・要旨(国際会議) - EGFR阻害剤を用いた食道扁平上皮癌幹細胞を標的とした新規治療法の開発(EGFR inhibitors suppress EMT and diminish cancer stem-like cells in esophageal squamous cell carcinoma)
佐藤 史幸; 夏井坂 光輝; 大橋 真也; 賀川 真吾; 桑谷 将城; 河上 洋; 大西 俊介; 小松 嘉人; 加藤 元嗣; 坂本 直哉, 日本癌学会総会記事, 73回, J, 1034, 2014年09月
日本癌学会, 英語 - SAFETY ANALYSIS OF FOLFOX AS ADJUVANT CHEMOTHERAPY FOR STAGE III COLON CANCER IN NORTH JAPAN MULTICENTER PHASE II STUDY (NORTH/HGCSG1003)
Takahashi Norihiko; Yuki Satoshi; Fukushima Hiraku; Shichinohe Toshiaki; Sasaki Takahide; Kusumi Takaya; Nakamura Fumitaka; Miyagishima Takuto; Iwanaga Ichiro; Hatanaka Kazuteru; Oomori Kazuyoshi; Misawa Kazuhito; Senmaru Naoto; Iwai Kazuhiro; Koike Masahiko; Shinohara Toshiki; Fukushima Tsuyoshi; Ohno Koichi; Tateyama Miki; Nishimoto Naoki; M. Ito Youichi; Komatsu Yoshito, ANNALS OF ONCOLOGY, 25, 2014年06月
英語, 研究発表ペーパー・要旨(国際会議) - ANALYSIS OF GLASGOW PROGNOSTIC SCORE(GPS) IN KRAS EXON2 WILD TYPE PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH SALVAGE-LINE CETUXIMAB-BASED REGIMEN: HGCSG0901
Yuki Satoshi; Komatsu Yoshito; Harada Kazuaki; Fukushima Hiraku; Sasaki Takahide; Kobayashi Yoshimitsu; Tsuji Yasushi; Naruse Hirohito; Okuda Hiroyuki; Takahashi Yasuo; Hosokawa Ayumu; Konno Jun; Eto Kazunori; Kudo Mineo; Kawamoto Yasuyuki; Sonoda Norikazu; Sato Yasushi; Uebayashi Minoru; Kato Takashi; Onodera Manabu; Ohta Tomoyuki; Sakata Yuh, ANNALS OF ONCOLOGY, 25, 2014年06月
英語, 研究発表ペーパー・要旨(国際会議) - 高リスクGISTに対する完全切除後の治療に関するレジストリ研究 病理診断の重要性
西田 俊朗; 長 晴彦; 尾阪 将人; 小松 嘉人; 黒川 幸典; 土井 俊彦; 平井 敏弘; 北川 雄光; 馬場 秀夫; 山田 康秀; 杉山 敏郎; 掛地 吉弘; 羽藤 慎二; 平島 詳典; 廣田 誠一, 日本癌治療学会誌, 49, 3, 1414, 1414, 2014年06月
(一社)日本癌治療学会, 日本語 - Safety, tolerability, and pharmacokinetics (PK) of rilotumumab (R) combined with cisplatin (C) and capecitabine (X) in Japanese patients (pts) with MET-positive metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
Toshihiko Doi; Kensei Yamaguchi; Yoshito Komatsu; Kei Muro; Tomohiro Nishina; Takako Eguchi Nakajima; Richard Lizambri; Elwyn Loh; Rui Tang; Yilong Zhang; Hirofumi Yasui, JOURNAL OF CLINICAL ONCOLOGY, 32, 15, 2014年05月
英語, 研究発表ペーパー・要旨(国際会議) - RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum-and fluoropyrimidine-containing combination therapy-Efficacy analysis in Japanese and Western patients.
Shuichi Hironaka; Yasuhiro Shimada; Naotoshi Sugimoto; Yoshito Komatsu; Tomohiro Nishina; Kensei Yamaguchi; Yoshihiko Segawa; Yasushi Omuro; Takao Tamura; Toshihiko Doi; Seigo Yukisawa; Hirofumi Yasui; Fumio Nagashima; Masahiro Gotoh; Taito Esaki; Michael Emig; Kumari Chandrawansa; Kei Muro; Hansjochen Wilke; Atsushi Ohtsu, JOURNAL OF CLINICAL ONCOLOGY, 32, 15, 2014年05月
英語, 研究発表ペーパー・要旨(国際会議) - Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/I-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).
Masato Nakamura; Yasuhide Yamada; Daisuke Takahari; Hiroshi Matsumoto; Hideo Baba; Kazuhiro Yoshida; Motoki Yoshida; Shigeyoshi Iwamoto; Ken Shimada; Yoshito Komatsu; Yasutsuna Sasaki; Taroh Satoh; Keiichi Takahashi; Hideyuki Mishima; Kei Muro; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Kenichi Sugihara, JOURNAL OF CLINICAL ONCOLOGY, 32, 15, 2014年05月
英語, 研究発表ペーパー・要旨(国際会議) - 大腸がん化学療法の最前線 殺細胞性抗がん剤の特徴と代表的なレジメン イリノテカンを用いたレジメン(イリノテカン単剤,FOLFIRI,IRIS,XELIRI)
福島拓; 小松嘉人, Mebio, 31, 3, 32, 39, 2014年03月10日
日本語 - OP-043-5 レゴラフェニブ(スチバーガ錠)使用大腸癌患者を対象とした製造販売後調査第1回中間報告(OP-043 大腸 化学療法-1,一般演題,第114回日本外科学会定期学術集会)
植竹 宏之; 吉野 孝之; 佐藤 太郎; 山口 研成; 小松 嘉人; 渡邉 聡明; 西田 俊朗; 山崎 直也; 滝川 一; 坂口 敏晃; 伊藤 雄一郎; 山田 敬; 室 圭; 杉原 健一, 日本外科学会雑誌, 115, 2, 391, 391, 2014年03月05日
一般社団法人日本外科学会, 日本語 - レゴラフェニブ(スチバーガ錠)使用大腸癌患者を対象とした製造販売後調査 第1回中間報告
植竹宏之; 吉野孝之; 佐藤太郎; 山口研成; 小松嘉人; 渡邉聡明; 西田俊朗; 山崎直也; 滝川一; 坂口敏晃; 伊藤雄一郎; 山田敬; 室圭; 杉原健一, 日本外科学会雑誌, 115, 391, 2014年03月05日
日本語 - 胃癌の治療戦略 化学療法 分子標的薬治療 切除不能進行・再発胃癌に対する分子標的治療薬併用の有用性と問題点
結城敏志; 小松嘉人; 佐々木尚英; 福島拓; 坂本直哉, 日本臨床, 72, 485, 490, 2014年01月20日
日本語 - 大腸癌化学療法のトピックス 米国臨床腫瘍学会(ASCO 2014)におけるトピックス
小松 嘉人, 大腸がんperspective : new perspectives in the treatment of colorectal cancer, 1, 2, 132, 135, 2014年
メディカルレビュー社, 日本語 - The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Including multivariate analysis of two phase II studies
Satoshi Yuki; Yoshito Komatsu; Hiraku Fukushima; Takahide Sasaki; Yoshimitsu Kobayashi; Kazuaki Harada; Toraji Amano; Michio Nakamura; Mineo Kudo; Miki Tateyama; Kazuteru Hatanaka; Soh Saitoh; Takuto Miyagishima; Takashi Kato; Yasuyuki Kawamoto; Tomofumi Takagi; Ichiro Iwanaga; Kencho Miyashita; Manabu Onodera; Yuh Sakata, JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月
英語, 研究発表ペーパー・要旨(国際会議) - Comparison of cetuximab (Cmab) with panitumumab (Pmab) monotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSG0901 and 1002.
Akira Ueda; Satoshi Yuki; Takahide Sasaki; Yoshimitsu Kobayashi; Ayumu Hosokawa; Ayako Doi; Yasushi Tsuji; Hiroyuki Okuda; Takashi Kato; Yutaka Watanabe; Takuto Miyagishima; Kazunori Eto; Tomoyuki Ohta; Takenori Takahata; Shinichiro Ikeda; Hiroshi Nakatsumi; Kazuhiro Iwai; Kanji Kato; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月
英語, 研究発表ペーパー・要旨(国際会議) - Comparison of adding cetuximab (Cmab) or panitumumab (Pmab) to irinotecan (IRI)-based chemotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSG0901 and 1002.
Koshi Fujikawa; Satoshi Yuki; Takahide Sasaki; Yasuo Takahashi; Ichiro Iwanaga; Minoru Uebayashi; Soh Saitoh; Masahiko Koike; Michio Nakamura; Yasushi Sato; Mineo Kudo; Miki Tateyama; Yasuyuki Kawamoto; Hiroyuki Hisai; Mayuko Saito; Manabu Onodera; Tomofumi Takagi; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月
英語, 研究発表ペーパー・要旨(国際会議) - Analysis of Kohne's prognostic index in KRAS wild-type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.
Ayako Doi; Satoshi Yuki; Yasushi Tsuji; Takahide Sasaki; Hiraku Fukushima; Kazuteru Hatanaka; Hirohito Naruse; Hiroyuki Okuda; Takaya Kusumi; Koshi Fujikawa; Yasuo Takahashi; Soh Saitoh; Shinya Kajiura; Ayumu Hosokawa; Yutaka Watanabe; Fumiyasu Yamamoto; Mineo Kudo; Nobuaki Akakura; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月
英語, 研究発表ペーパー・要旨(国際会議) - Exploratory randomized trial to evaluate the effect of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV)/acute-onset diarrhea induced by IRIS/FOLFIRI: HGCSG0704.
Sosuke Kato; Hiraku Fukushima; Kanji Kato; Satoshi Yuki; Kazuaki Harada; Yoshimitsu Kobayashi; Takahide Sasaki; Nobuyuki Ehira; Ichiro Iwanaga; Minoru Uebayashi; Masayoshi Dazai; Susumu Sogabe; Takuto Miyagishima; Mineo Kudo; Kazuteru Hatanaka; Hirohito Naruse; Miki Tateyama; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月
英語, 研究発表ペーパー・要旨(国際会議) - Phase II trial of S-1 plus split cisplatin (SSP) in patients with advanced gastric cancer (HGCSG0702): Final report.
Satoshi Yuki; Yoshito Komatsu; Hiraku Fukushima; Takahide Sasaki; Yoshimitsu Kobayashi; Kazuaki Harada; Masayoshi Dazai; Susumu Sogabe; Takuto Miyagishima; Atsushi Ishiguro; Takenori Takahata; Atsushi Sato; Mineo Kudo; Sosuke Kato; Kanji Kato; Ichiro Iwanaga; Nobuyuki Ehira; Minoru Uebayashi; Yuh Sakata, JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月
英語, 研究発表ペーパー・要旨(国際会議) - Evaluation of usefulness of Royal Marsden Hospital prognostic index in second-line chemotherapy of advanced gastric cancer.
Takahide Sasaki; Yoshito Komatsu; Satoshi Yuki; Kazuaki Harada; Yoshimitsu Kobayashi; Hiraku Fukushima; Naoya Sakamoto, JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月
英語, 研究発表ペーパー・要旨(国際会議) - Stage III結腸癌の術後補助化学療法としてのFOLFOX療法の第II相臨床試験:NORTH
中村路夫; 結城敏志; 福島拓; 高橋典彦; 七戸俊明; 三澤一仁; 久須美貴哉; 中村文隆; 宮城島拓人; 岩永一郎; 畑中一映; 大森一吉; 西本尚樹; 伊藤陽一; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 52nd, 増刊, ROMBUNNO.P48-1, 637, 2014年
日本臨床外科学会, 日本語 - 進行胃癌の二次化学療法におけるRoyal Marsden Hospital prognostic indexの有用性の検討
原田一顕; 結城敏志; 小林良充; 佐々木尚英; 福島拓; 小松嘉人; 坂本直哉, 日本胃癌学会総会記事, 86th, 282, 2014年
日本語 - 進行大腸癌の一次治療におけるベバシズマブ観察研究(HGCSG0802):レジメン別の解析
岩永一郎; 結城敏志; 林秀幸; 中積宏之; 福島拓; 加藤貴司; 中村路夫; 園田範和; 畑中一映; 工藤峰生; 加藤総介; 宮下憲暢; 阿部雅一; 坂田優; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 52nd, ROMBUNNO.O52-2, 2014年
日本語 - HER2陽性進行再発胃癌に対するS‐1+CDDP+Trastuzumab(SPT)療法第II相試験
小林研二; 杉本直俊; 三輪洋人; 下川敏雄; 黒川幸典; 辻仲利政; 小松嘉人; 蒲生真紀夫; 古河洋, 日本胃癌学会総会記事, 86th, 159, 2014年
日本語 - 大腸癌の一次治療におけるベバシズマブ観察研究(HGCSG0802):KRAS status別の解析
加藤貴司; 結城敏志; 村中徹人; 原田一顕; 小林良充; 目黒高志; 中村路夫; 江平宣起; 江藤和範; 高畑武功; 奥田博介; 曽我部進; 武藤理; 坂田優; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 52nd, ROMBUNNO.O52-1, 2014年
日本語 - 当院における切除不能進行・再発大腸癌に対するSOX+BVの使用経験
福島拓; 結城敏志; 原田一顕; 小林良充; 佐々木尚英; 坂本直哉; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 52nd, ROMBUNNO.P52-9, 2014年
日本語 - ベクティビックスの皮膚障害予防に対する検討~J‐STEPP試験について~
小松嘉人; 小林良充; 中積宏之; 林秀幸; 村中徹人; 福島拓; 結城敏志, 日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 30th, 80, 2014年
日本語 - Non‐AC MECによるCINVに対するPalonosetron+Dexamethason day1単回投与の有効性の検討
曽我部進; 結城敏志; 高橋康雄; 阿部雅一; 畑中一映; 磯部宏; 中村路夫; 佐々木高明; 大庭幸治; 小松嘉人, 日本臨床腫瘍学会学術集会(CD-ROM), 12th, ROMBUNNO.O1-3-1, 2014年
日本語 - 進行胃癌に対するS‐1+Cisplatin分割療法の第II相試験:HGCSG0702
加藤総介; 結城敏志; 福島拓; 佐々木尚英; 高畑武功; 佐藤温; 岩永一郎; 曽我部進; 宮城島拓人; 工藤峰生; 坂田優; 小松嘉人, 日本胃癌学会総会記事, 86th, 215, 2014年
日本語 - 三次治療以降のKRAS野生型Cetuximab投与例でのGlasgow Prognostic Score(GPS)の有用性
結城敏志; 小松嘉人; 原田一顕; 福島拓; 佐々木尚英; 小林良充; 辻靖; 成瀬宏仁; 奥田博介; 藤川幸司; 細川歩; 山本文泰; 工藤峰生; 坂田優; 坂本直哉, 日本癌治療学会学術集会(CD-ROM), 52nd, ROMBUNNO.O14-2, 2014年
日本語 - 大腸癌の最新治療 III.臨床研究 治療 分子標的治療 新規薬剤―大腸癌の新しい分子標的治療―
小松嘉人; 原田一顕; 福島拓; 結城敏志, 日本臨床, 72, 1, 120, 126, 2014年01月01日
日本語 - フッ化ピリミジン系+プラチナ系抗癌剤に不応となった切除不能進行・再発食道癌に対するドセタキセルの有効性,安全性の検討:retrospective staudy
佐々木尚英; 小林良充; 原田一顕; 福島拓; 小松嘉人; 結城敏志; 坂本直哉, 北海道外科雑誌, 58, 2, 109, 110, 2013年12月20日
日本語 - 局所進行食道癌に対する通常照射と強度変調放射線治療を組み合わせた放射線化学療法
井上哲也; 加藤徳雄; 清水伸一; 白土博樹; 鈴木隆介; 佐々木尚英; 福島拓; 小松嘉人, 北海道外科雑誌, 58, 2, 112, 2013年12月20日
日本語 - 癌薬物療法の副作用対策―支持療法と用量調整のポイント 6.アレルギーとインフュージョンリアクション
福島拓; 小松嘉人, コンセンサス癌治療, 12, 4, 197, 199, 2013年11月30日
日本語 - SAFETY AND EFFICACY OF REGORAFENIB IN JAPANESE PATIENTS WITH METASTATIC COLORECTAL CANCER: A SUBGROUP ANALYSIS OF THE PHASE III CORRECT TRIAL
Y. Yamada; T. Yoshino; Y. Komatsu; K. Yamazaki; A. Tsuji; T. Ura; A. Grothey; E. Van Cutsem; A. Wagner; A. Ohtsu, ANNALS OF ONCOLOGY, 24, 2013年11月
英語, 研究発表ペーパー・要旨(国際会議) - 食道扁平上皮癌におけるTGF-βおよびNotch1による癌幹細胞維持機構(TGF-β changes a switch of Notch1-mediated signaling to maintain tumor-initiating cells in esophageal SCC(ESCC))
夏井坂 光輝; 大橋 真也; 長沼 誠二; 大西 俊介; 桑谷 将城; 河上 洋; 中馬 誠; 小松 嘉人; 加藤 元嗣; 坂本 直哉, 日本癌学会総会記事, 72回, 137, 137, 2013年10月
日本癌学会, 英語 - 胃底部に認める多発白色扁平隆起病変の検討
大野正芳; 大森沙織; 鈴木美櫻; 高橋正和; 清水勇一; 小野尚子; 間部克裕; 加藤元嗣; 結城敏志; 小松嘉人; 山本純司; 中川学; 中川宗一; 坂本直哉, Gastroenterol Endosc, 55, Supplement 2, 2817, 2013年09月10日
日本語 - An open, multi-center, phase II clinical trial to evaluate efficacy and safety of S-1 plus split cisplatin in patients with advanced gastric cancer (AGC)-HGCSG0702 preliminary report
A. Ishiguro; S. Yuki; H. Fukushima; A. Sato; I. Iwanaga; T. Miyagishima; M. Kudo; K. Kato; Y. Sakata; Y. Komatsu, EUROPEAN JOURNAL OF CANCER, 49, S629, S629, 2013年09月
英語, 研究発表ペーパー・要旨(国際会議) - A randomized phase III trial of palonosetron plus dexamethasone (day 1) versus palonosetron plus dexamethasone (day 1-3) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy, not including a combination of anthracycline plus cyclophosphamide
K. Sasaki; K. Okita; S. Yuki; Y. Takahashi; M. Abe; K. Hatanaka; H. Isobe; S. Sogabe; K. Oba; Y. Komatsu, EUROPEAN JOURNAL OF CANCER, 49, S267, S268, 2013年09月
英語, 研究発表ペーパー・要旨(国際会議) - Non-AC MECによるCINVに対するPalonosetron+Dexamethason day1単回投与の有効性の検討
佐藤 康裕; 沖田 憲司; 結城 敏志; 福島 拓; 古畑 智久; 高橋 康雄; 益子 博幸; 畑中 一映; 磯部 宏; 曽我部 すすむ; 佐々木 一晃; 中村 路夫; 大崎 能伸; 大庭 幸治; 小松 嘉人, 日本癌治療学会誌, 48, 3, 1658, 1658, 2013年09月
(一社)日本癌治療学会, 日本語 - 分子標的治療薬の選び方,使い方 1.分子標的治療薬の選び方,使い方 24)ベバシズマブ
小松嘉人; 結城敏志; 福島拓, 臨床腫瘍プラクティス, 9, 3, 276, 277, 2013年08月10日
日本語 - 分子標的治療薬の選び方,1.分子の標的治療薬の選び方,使い方 26)レゴラフェニブ
小松嘉人; 結城敏志; 福島拓, 臨床腫瘍プラクティス, 9, 3, 280, 281, 2013年08月10日
日本語 - 分子標的治療薬の選び方,使い方 1.分子標的治療薬の選び,使い方 25)スニチニブ
小松嘉人; 結城敏志; 福島拓, 臨床腫瘍プラクティス, 9, 3, 278, 279, 2013年08月10日
日本語 - 薬の特徴から副作用がなぜ起こるかわかる!ケアポイントが整理できる!!消化器がんの化学療法のキードラッグ事典 6 ベバシズマブ
小松嘉人, 消化器外科Nursing, 18, 7, 618, 623, 2013年07月01日
日本語 - A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer: The SOFT study.
Daisuke Takahari; Yasuhide Yamada; Hiroshi Matsumoto; Hideo Baba; Kazuhiro Yoshida; Masato Nakamura; Motoki Yoshida; Shigeyoshi Iwamoto; Yasutaka Takinishi; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Yoshito Komatsu; Yasutsuna Sasaki; Taroh Satoh; Keiichi Takahashi; Hideyuki Mishima; Kei Muro; Masahiko Watanabe; Kenichi Sugihara, JOURNAL OF CLINICAL ONCOLOGY, 31, 15, 2013年05月
英語, 研究発表ペーパー・要旨(国際会議) - The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies
Satoshi Yuki; Hiraku Fukushima; Toraji Amano; Michio Nakamura; Mineo Kudo; Norikazu Sonoda; Miki Tateyama; Yasuyuki Kawamoto; Kazuteru Hatanaka; Susumu Sogabe; Takuto Miyagishima; Nobuaki Akakura; Takashi Kato; Tomofumi Takagi; Ichiro Iwanaga; Kencho Miyashita; Manabu Onodera; Soh Saitoh; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 31, 15, 2013年05月
英語, 研究発表ペーパー・要旨(国際会議) - A phase II study of new combination regimen with trastuzumab, S-1, and CDDP in HER2-positive advanced gastric cancer (HERBIS-1).
Keisuke Koeda; Naotoshi Sugimoto; Junji Tanaka; Masahiro Tsuda; Wataru Okamoto; Hiroyuki Okuda; Hiroshi Imamura; Jin Matsuyama; Toshio Shimokawa; Daisuke Sakai; Norimasa Fukushima; Yukinori Kurokawa; Yoshito Komatsu; Toshimasa Tsujinaka; Hiroshi Furukawa, JOURNAL OF CLINICAL ONCOLOGY, 31, 15, 2013年05月
英語, 研究発表ペーパー・要旨(国際会議) - 当院における大腸腫瘍に対するESDの切除成績,長期成績の検討
大野正芳; 石垣沙織; 鈴木美櫻; 高橋正和; 清水勇一; 小野尚子; 間部克裕; 加藤元嗣; 結城敏志; 小松嘉人; 山本純司; 中川学; 中川宗一; 坂本直哉, Gastroenterol Endosc, 55, Supplement 1, 1150, 2013年04月15日
日本語 - 切除不能進行/再発胃癌に対するS‐1+Cisplatin分割療法の第II相臨床試験:HGCSG0702―安全性の解析報告―
結城敏志; 小松嘉人; 坂本直哉, 日本消化器病学会雑誌, 110, A48, 2013年02月20日
日本語 - Retrospective cohort study on the safety and efficacy of panitumumab for patients with metastatic colorectal cancer: The HGCSG1002 study-Analysis of adverse events
Masayoshi Dazai; Hiraku Fukushima; Yasushi Sato; Satoshi Yuki; Hiroyuki Ohnuma; Hiroyuki Okuda; Yasushi Tsuji; Yasuyuki Kawamoto; Kazuteru Hatanaka; Ichiro Iwanaga; Masahiko Koike; Takashi Kato; Michio Nakamura; Susumu Sogabe; Koshi Fujikawa; Ayumu Hosokawa; Hiroyuki Hisai; Miki Tateyama; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 31, 4, 2013年02月
英語, 研究発表ペーパー・要旨(国際会議) - Retrospective cohort study on the safety and efficacy of panitumumab for patients with metastatic colorectal cancer: The HGCSG1002 study-Analysis of after cetuximab refractory
Yoshimitsu Kobayashi; Hiraku Fukushima; Takahide Sasaki; Satoshi Yuki; Hiroyuki Okuda; Takaya Kusumi; Ayako Doi; Yasushi Tsuji; Kazuteru Hatanaka; Minoru Uebayashi; Masahiko Koike; Takashi Kato; Michio Nakamura; Yasushi Sato; Tomoyuki Ohta; Mineo Kudo; Jun Konno; Kazuhiro Iwai; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 31, 4, 2013年02月
英語, 研究発表ペーパー・要旨(国際会議) - Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial-Comparison of the efficacy of KRAS status
Michio Nakamura; Satoshi Yuki; Masayoshi Dazai; Yoshimitsu Kobayashi; Takashi Kato; Hirohito Naruse; Mineo Kudo; Nobuaki Akakura; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 31, 4, 2013年02月
英語, 研究発表ペーパー・要旨(国際会議) - Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysis-Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial
Satoshi Yuki; Yoshito Komatsu; Hiraku Fukushima; Takahide Sasaki; Toraji Amano; Takuto Miyagishima; Kazuteru Hatanaka; Michio Nakamura; Miki Tateyama; Yuh Sakata, JOURNAL OF CLINICAL ONCOLOGY, 31, 4, 2013年02月
英語, 研究発表ペーパー・要旨(国際会議) - An open, multicenter, phase II clinical trial to evaluate efficacy and safety of S-1 split cisplatin in patients with advanced gastric cancer (AGC): HGCSG0702-Safety analysis
Ichiro Iwanaga; Satoshi Yuki; Hiraku Fukushima; Atsushi Ishiguro; Takenori Takahata; Takuto Miyagishima; Mineo Kudo; Yasuko Uehata; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 31, 4, 2013年02月
英語, 研究発表ペーパー・要旨(国際会議) - Retrospective cohort study on the safety and efficacy of panitumumab (Pmab) for patients with metastatic colorectal cancer (mCRC): The HGCSG1002 study-Analysis of clinical early predictor for the efficacy
Susumu Sogabe; Hiraku Fukushima; Satoshi Yuki; Yoshimitsu Kobayashi; Takuto Miyagishima; Hiroyuki Okuda; Takaya Kusumi; Ayako Doi; Yasushi Tsuji; Yasuyuki Kawamoto; Nobuyuki Ehira; Masahiko Koike; Takashi Meguro; Yasuo Takahashi; Koji Yoshizaki; Shuichi Muto; Atsushi Ishiguro; Sosuke Kato; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 31, 4, 2013年02月
英語, 研究発表ペーパー・要旨(国際会議) - KRAS野生型結腸直腸癌:サルベージラインにおける抗EGFR抗体単剤療法の比較
佐々木尚英; 結城敏志; 福島拓; 辻靖; 畑中一映; 奥田博介; 細川歩; 岩永一郎; 小池雅彦; 佐藤康史; 中村路夫; 工藤峰生; 園田範和; 坂田優; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 51st, ROMBUNNO.O132-4, 2013年
日本語 - 看護師が行う中心静脈ポート穿刺の検討―合併症を踏まえた判断―
中野政子; 尾形裕子; 日下部緑; 小野塚美香; 石岡明子; 福島拓; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 51st, ROMBUNNO.P32-3, 2013年
日本語 - KRAS遺伝子変異別の有効性解析:IRIS/Bevの第II相試験(HGCSG trial)
太宰昌佳; 結城敏志; 宮城島拓人; 佐々木尚英; 中村路夫; 西川秀司; 畑中一映; 成瀬宏仁; 斎藤聡; 工藤峰生; 加藤貴司; 赤倉伸亮; 舘山美樹; 坂田優; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 51st, ROMBUNNO.O91-1, 2013年
日本語 - IRIS・IRIS/Bevの有効性比較:2つの独立した第II相試験の比較検討:HGCSG
畑中一映; 結城敏志; 福島拓; 原田一顕; 中村路夫; 工藤峰生; 舘山美樹; 宮城島拓人; 加藤貴司; 岩永一郎; 赤倉伸亮; 高木智史; 宮下憲暢; 坂田優; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 51st, ROMBUNNO.O89-2, 2013年
日本語 - 三次治療以降のKRAS野生型Cetuximab投与例でのKoehne indexの有用性:HGCSG0901
結城敏志; 小松嘉人; 小林良充; 土井綾子; 辻靖; 畑中一映; 奥田博介; 藤川幸司; 細川歩; 渡邉豊; 山本文泰; 及能健一; 工藤峰生; 川本泰之; 坂田優, 日本癌治療学会学術集会(CD-ROM), 51st, ROMBUNNO.O122-2, 2013年
日本語 - 積極的な化学療法により3度にわたりDICから離脱しえた胃癌骨髄癌腫症の1例
中野真太郎; 小松嘉人; 原田一顕; 小林良充; 佐々木尚英; 福島拓; 結城敏志; 坂本直哉, 日本癌治療学会学術集会(CD-ROM), 51st, ROMBUNNO.P80-13, 2013年
日本語 - 進行胃癌に対するS‐1+Cisplatin分割療法の第II相試験:HGCSG0702:早期有効性報告
高畑武功; 結城敏志; 福島拓; 佐々木尚英; 小林良充; 原田一顕; 石黒敦; 佐藤温; 岩永一郎; 上林実; 宮城島拓人; 工藤峰生; 加藤寛士; 坂田優; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 51st, ROMBUNNO.O107-3, 2013年
日本語 - HER2陽性進行再発胃癌に対するTS‐1+CDDP+Trastuzumab併用療法の検討(HERBIS‐1)
松山仁; 三輪洋人; 杉本直俊; 津田政広; 仁科慎一; 奥田博介; 今村博司; 下川敏雄; 坂井大介; 黒川幸典; 小松嘉人; 加藤俊介; 辻仲利政; 古河洋, 日本癌治療学会学術集会(CD-ROM), 51st, ROMBUNNO.O107-4, 2013年
日本語 - KRAS野生型結腸直腸癌:サルベージラインの抗EGFR抗体+irinotecan併用療法の比較
藤川幸司; 結城敏志; 佐々木尚英; 原田一顕; 土井綾子; 成瀬宏仁; 奥田博介; 目黒高志; 佐藤温; 宮城島拓人; 江藤和範; 太田智之; 紺野潤; 坂田優; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 51st, ROMBUNNO.O132-3, 2013年
日本語 - インジセトロン錠のIrinotecan関連悪心/早発下痢に対する探索研究:HGCSG0704
福島拓; 小松嘉人; 結城敏志; 小林良充; 江平宣起; 岩永一郎; 上林実; 太宰昌佳; 宮城島拓人; 曽我部進; 工藤峰生; 畑中一映; 加藤総介; 園田範和; 坂田優, 日本癌治療学会学術集会(CD-ROM), 51st, ROMBUNNO.P102-6, 2013年
日本語 - 切除不能進行大腸癌におけるPanitumumabの有用性(HGCSG1002)早期効果予測因子の解析
岩永一郎; 福島拓; 小林良充; 奥田博介; 辻靖; 畑中一映; 小池雅彦; 加藤貴志; 中村路夫; 曽我部進; 佐藤康史; 藤川幸司; 太田智之; 坂田優; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 51st, ROMBUNNO.O122-3, 2013年
日本語 - 切除不能進行/再発胃癌に対する分割SP療法の第II相試験:HGCSG0702―安全性報告―
曽我部進; 結城敏志; 宮城島拓人; 福島拓; 石黒敦; 岩永一郎; 坂田優; 小松嘉人, 日本胃癌学会総会記事, 85th, 333, 2013年
日本語 - 国内臨床試験グループのネットワーク化 HGCSGの立場から
福島拓; 小松嘉人; 原田一顕; 小林良充; 佐々木尚英; 結城敏志, 日本臨床腫瘍学会学術集会(CD-ROM), 11th, ROMBUNNO.WS7-3, 2013年
日本語 - HER2陽性進行再発胃癌に対するS‐1+CDDP+Trastuzumab療法第II相試験(HERBIS‐1)
仁科慎一; 田中淳二; 杉本直俊; 下川敏雄; 坂井大介; 黒川幸典; 小松嘉人; 高畑武功; 辻仲利政; 古河洋, 日本臨床腫瘍学会学術集会(CD-ROM), 11th, ROMBUNNO.WS11-6, 2013年
日本語 - 胃癌2nd line化学療法における分子標的療法の試み(HGCSG1201)
小松嘉人; 結城敏志; 福島拓; 佐々木尚英; 太宰昌佳; 小林良充, 日本胃癌学会総会記事, 85th, 151, 2013年
日本語 - HER2陽性進行再発胃癌に対するS‐1+CDDP+Trastuzumab療法第II相試験
田中淳二; 杉本直俊; 津田政広; 岡本渉; 今村博司; 下川敏雄; 坂井大介; 黒川幸典; 奥田博介; 小松嘉人; 石岡千加史; 辻仲利政; 瀧内比呂也; 古河洋, 日本胃癌学会総会記事, 85th, 259, 2013年
日本語 - パクリタキセルを含むがん化学療法における末梢神経障害に対するプレガバリンの有用性についての検討
藤村 拓也; 久保田 康生; 今田 愛也; 相馬 まゆ子; 佐々木 洋一; 笠師 久美子; 山田 武宏; 小松 嘉人; 井関 健, 医療薬学, 39, 9, 546, 551, 2013年
Paclitaxel-induced peripheral neuropathy not only reduces patient quality of life but also significantly interferes with the completion of cancer chemotherapy. In this study, we investigated the benefits and adverse events in 31 patients who received pregabalin for the treatment of paclitaxel : induced peripheral neuropathy between October 2010 and February 2012. In 27 (87.1%) of 31 patients who received pregabalin for peripheral neuropathy induced by paclitaxel, the neuropathy did not worsen to Grade 3, and paclitaxel chemotherapy could be continued. Drowsiness was a common adverse event associated with pregabalin (41.9%). These results suggest that pregabalin administration might prevent paclitaxel-induced peripheral neuropathy from worsening and consequently lead to improved chemotherapy completion rates. Moreover, it seems that pharmacists should monitor the severity of peripheral neuropathy and actively participate in planning treatment that includes the management of adverse events associated with pregabalin., 一般社団法人日本医療薬学会, 日本語 - 治癒切除不能な進行再発結腸直腸癌治療におけるPanitumumabの有用性を検討する観察研究(HGCSG1002)―有害事象の解析―
小池雅彦; 福島拓; 結城敏志; 三野和宏; 久須美貴哉; 岩井和浩; 狭間一明; 小松嘉人, 日本臨床外科学会雑誌, 73, 748, 2012年10月20日
日本語 - UPDATED ANALYSIS: PHASE II TRIAL OF COMBINED CHEMOTHERAPY WITH IRINOTECAN, S-1, AND BEVACIZUMAB (IRIS/BEV) IN PATIENTS WITH METASTATIC COLORECTAL CANCER: HOKKAIDO GASTROINTESTINAL CANCER STUDY GROUP (HGCSG) TRIAL
S. Yuki; Y. Komatsu; H. Nakatsumi; Y. Kobayashi; S. Takeuchi; S. Sogabe; T. Miyagishima; T. Kato; K. Hatanaka; M. Nakamura; M. Kudo; N. Akakura; N. Sonoda; M. Munakata; Y. Sakata, ANNALS OF ONCOLOGY, 23, 82, 82, 2012年10月
英語, 研究発表ペーパー・要旨(国際会議) - SAFETY REPORT OF A PHASE II TRIAL OF IRINOTECAN PLUS S-1 (IRIS) WITH CETUXIMAB IN PRE-TREATED PATIENTS WITH KRAS WILD TYPE OF METASTATIC COLORECTAL CANCER: HGCSG0902
Y. Komatsu; S. Yuki; Y. Kawamoto; H. Hayashi; T. Kato; A. Hosokawa; I. Iwanaga; O. Muto; K. Hatanaka; M. Nakamura; Y. Tsuji; M. Tateyama; H. Fukushima; M. Kudo; Y. Sakata, ANNALS OF ONCOLOGY, 23, 87, 87, 2012年10月
英語, 研究発表ペーパー・要旨(国際会議) - 切除不能進行結腸直腸癌に対するセツキシマブ使用症例のレトロスペクティブ調査(HGCSG0901)―効果予測因子別の解析
結城敏志; 小松嘉人; 坂本直哉, 日本消化器病学会雑誌, 109, A697, 2012年09月15日
日本語 - PHASE II TRIAL OF COMBINED CHEMOTHERAPY WITH IRINOTECAN, S-1, AND BEVACIZUMAB (IRIS/BEV) IN PATIENTS WITH METASTATIC COLORECTAL CANCER -UPDATED ANALYSIS-. HOKKAIDO GASTROINTESTINAL CANCER STUDY GROUP (HGCSG) TRIAL
K. Hatanaka; S. Yuki; T. Miyagishima; T. Kato; M. Nakamura; M. Kudo; M. Tateyama; M. Asaka; Y. Sakata; Y. Komatsu, ANNALS OF ONCOLOGY, 23, 202, 202, 2012年09月
英語, 研究発表ペーパー・要旨(国際会議) - Q&Aで綴るレジデント・ノート―専門医がわかりやすく解説―No.34 オキサリプラチンによる「末梢神経障害」とは,具体的にどのような症状でしょうか?
小林良充; 小松嘉人, 大腸癌FRONTIER, 5, 2, 187, 189, 2012年06月20日
メディカルレビュー社, 日本語 - Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer: Update analysis-Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial
Satoshi Yuki; Yoshito Komatsu; Takuto Miyagishima; Takashi Kato; Kazuteru Hatanaka; Michio Nakamura; Mineo Kudo; Nobuaki Akakura; Miki Tateyama; Yuh Sakata, JOURNAL OF CLINICAL ONCOLOGY, 30, 15, 2012年05月
英語, 研究発表ペーパー・要旨(国際会議) - Safety report of a phase II trial of irinotecan plus S-1 (IRIS) with cetuximab in patients with KRAS wild type of metastatic colorectal cancer: HGCSG0902.
Yoshito Komatsu; Satoshi Yuki; Takashi Kato; Ayumu Hosokawa; Ichiro Iwanaga; Osamu Muto; Kazuteru Hatanaka; Michio Nakamura; Yasushi Tsuji; Yuh Sakata, JOURNAL OF CLINICAL ONCOLOGY, 30, 15, 2012年05月
英語, 研究発表ペーパー・要旨(国際会議) - 膵癌治療の新展開;タルセバ・ジェムザール・TS‐1 膵癌初承認 分子標的治療薬;タルセバ タルセバ臨床成績,特徴,副作用および処方の実際
小松嘉人; 林秀幸; 小林良充; 川本泰之; 中積宏之; 結城敏志, 肝胆膵, 64, 2, 187, 194, 2012年02月28日
(株)アークメディア, 日本語 - Regional differences in patient (pt) characteristics of AVAGAST: An exploratory comparison in chemotherapy plus placebo (PL) arm between Japanese (JPN) and the rest of the world (ROW) pts.
Tomohira Nishina; Akira Sawaki; Kensei Yamaguchi; Toshihiko Doi; Yasuhide Yamada; Keisho Chin; Taroh Satoh; Narikazu Boku; Yasushi Omuro; Yoshito Komatsu; Hiroya Takiuchi; Yasuo Hamamoto; Wasaburo Koizumi; Shigehira Saji; Manish A. Shah; Eric Van Cutsem; Yoon-Koo Kang; Atsushi Ohtsu, JOURNAL OF CLINICAL ONCOLOGY, 30, 4, 2012年02月
英語, 研究発表ペーパー・要旨(国際会議) - Validation study of a prognostic classification system in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Kentaro Yamazaki; Yoichi Naito; Satoshi Yuki; Yasuyuki Kawamoto; Hirofumi Yasui; Toshimi Takano; Yoshito Komatsu; Kei Muro, JOURNAL OF CLINICAL ONCOLOGY, 30, 4, 2012年02月
英語, 研究発表ペーパー・要旨(国際会議) - Retrospective cohort study on the safety and efficacy of cetuximab for metastatic colorectal cancer patients: The HGCSG0901 study-Analysis of cetuximab refractory.
Satoshi Yuki; Yoshito Komatsu; Yasuyuki Kawamoto; Yasushi Tsuji; Hirohito Naruse; Ayumu Hosokawa; Takaya Kusumi; Atsushi Ishiguro, JOURNAL OF CLINICAL ONCOLOGY, 30, 4, 2012年02月
英語, 研究発表ペーパー・要旨(国際会議) - 当科におけるImatinib耐性GISTに対するSunitinibの有効性、安全性についての検討
中積 宏之; 結城 敏志; 林 秀幸; 小林 良充; 川本 泰之; 加藤 元嗣; 小松 嘉人, 日本胃癌学会総会記事, 84回, 202, 202, 2012年02月
(一社)日本胃癌学会, 日本語 - 当科における切除不能進行・再発胃癌に対する二次化学療法の有効性の検討
林 秀幸; 結城 敏志; 小林 良充; 川本 泰之; 中積 宏之; 加藤 元嗣; 小松 嘉人, 日本胃癌学会総会記事, 84回, 343, 343, 2012年02月
(一社)日本胃癌学会, 日本語 - 治癒切除不能な進行再発結腸直腸癌治療におけるPanitumumabの有用性を検討する観察研究(HGCSG1002)―有害事象の解析―
小林良充; 結城敏志; 中積宏之; 奥田博介; 辻靖; 畑中一映; 田村元; 加藤貴司; 中村路夫; 宮城島拓人; 高橋康雄; 長佐古友和; 石黒敦; 加藤総介; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 10th, 172, 2012年
日本語 - 治癒切除不能な進行再発結腸直腸癌治療におけるPanitumumabの有用性を検討する観察研究(HGCSG1002)―Salvage lineの解析―
畑中一映; 小松嘉人; 小林良充; 川本泰之; 結城敏志; 細川正夫; 古川孝広; 成瀬宏仁; 小池雅彦; 堀田彰一; 佐藤康史; 好崎浩司; 武藤修一; 岩永一郎; 奥田博介, 日本臨床腫瘍学会学術集会プログラム・抄録集, 10th, 173, 2012年
日本語 - がん患者の呼吸困難に対するオキシコドンの有用性
桂有希; 敦賀健吉; 田中輝明; 竹田泰子; 熊井正貴; 田巻知宏; 小松嘉人, 日本緩和医療学会学術大会プログラム・抄録集, 17th, 413, 2012年
日本語 - 治癒切除不能な進行再発結腸直腸癌治療におけるPanitumumabの有用性を検討する観察研究(HGCSG1002)―Cetuximab不応後症例の解析
奥田博介; 小林良充; 結城敏志; 林秀幸; 澄川宗佑; 辻靖; 平山眞章; 畑中一映; 小池雅彦; 加藤貴司; 中村路夫; 曽我部進; 佐川保; 舘川美樹; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 10th, 172, 173, 2012年
日本語 - 全例登録調査(特定使用成績調査)を用いた消化管間質腫瘍(GIST)に対するスニチニブの安全性および有効性の検討
小松嘉人; 福山朋房; 上野直美; 朴沢博之; 植田英治; 西田俊朗, 日本臨床腫瘍学会学術集会プログラム・抄録集, 10th, 193, 2012年
日本語 - KRAS野生型結腸直腸癌に対する二次治療IRIS/Cet第II相試験:HGCSG0902―安全性解析―
岩永一郎; 結城敏志; 細川歩; 武藤理; 辻靖; 石黒敦; 佐藤康裕; 古川浩一; 畑中一映; 中村路夫; 加藤貴司; 奥田博介; 浅香正博; 坂田優; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 50th, ROMBUNNO.OS10-5, 2012年
日本語 - 切除不能進行結腸直腸癌におけるPanitumumabの観察研究(HGCSG1002):3次以降/IRI併用
佐々木尚英; 太宰昌佳; 奥田博介; 成瀬宏仁; 江平宣起; 中村路夫; 目黒高志; 佐藤康裕; 久居弘幸; 加藤総介; 辻靖; 小池雅彦; 紺野潤; 小林良充; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 50th, ROMBUNNO.PD11-10, 2012年
日本語 - 切除不能進行結腸直腸癌におけるPanitumumabの観察研究(HGCSG1002):Cmab不応例
石黒敦; 小林良充; 久須美貴哉; 土井綾子; 小池雅彦; 佐藤康史; 好崎浩司; 武藤修一; 岩井和浩; 畑中一映; 上林実; 曽我部進; 加藤貴司; 結城敏志; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 50th, ROMBUNNO.PD11-09, 2012年
日本語 - 切除不能進行結腸直腸癌におけるPanitumumabの観察研究(HGCSG1002):有害事象解析
植田亮; 福島拓; 辻靖; 川本泰之; 小池雅彦; 岩永一郎; 宮城島拓人; 大沼啓之; 藤川幸司; 奥田博介; 中村路夫; 工藤峰生; 舘山美樹; 結城敏志; 小松嘉人, 日本癌治療学会学術集会(CD-ROM), 50th, ROMBUNNO.PS2-194, 2012年
日本語 - がん治療医と緩和ケア医の治療の違い:北海道Team Oncology Meeting多施設共同調査
田巻知宏; 小松嘉人; 岩波悦勝; 成田吉明; 合田由紀子; 磯部宏; 中村路夫; 片山勝之; 高橋康雄; 尾崎鈴子; 鈴木康弘; 田中浩一; 熊谷章, 日本癌治療学会学術集会(CD-ROM), 50th, ROMBUNNO.PS1-624, 2012年
日本語 - 切除不能進行結腸直腸癌に対するIRIS/Bevの第II相試験:HGCSG trial:3年追跡結果報告
結城敏志; 小松嘉人; 福島拓; 太宰昌佳; 天野虎次; 曽我部進; 宮城島拓人; 加藤貴司; 畑中一映; 中村路夫; 工藤峰生; 赤倉伸亮; 園田範和; 浅香正博; 坂田優, 日本癌治療学会学術集会(CD-ROM), 50th, ROMBUNNO.OS09-2, 2012年
日本語 - 集学的治療により長期生存が得られた食道未分化癌の1例
福島拓; 小林良充; 中積宏之; 曽我部進; 結城敏志; 浅香正博; 小松嘉人; 井上哲也; 七戸俊明; 久保田佳奈子, 北海道外科雑誌, 56, 2, 172, 173, 2011年12月20日
日本語 - 食道癌IMRT(強度変調放射線治療)の初期経験
原田慶一; 井上哲也; 安田耕一; 加藤徳雄; 清水伸一; 白土博樹; BENGUA Gerard; 石川正純; 中積宏之; 結城敏志; 小松嘉人, 北海道外科雑誌, 56, 2, 176, 177, 2011年12月20日
北海道外科学会, 日本語 - PHASE II STUDY OF CHEMORADIOTHERAPY WITH 5-FLUOROURACIL AND CISPLATIN FOR STAGE II-III ESOPHAGEAL SQUAMOUS CELL CARCINOMA: JCOG TRIAL (JCOG 9906)
Ken Kato; Kei Muro; Keiko Minashi; Atsushi Ohtsu; Satoshi Ishikura; Narikazu Boku; Hiroya Takiuchi; Yoshito Komatsu; Yoshinori Miyata; Haruhiko Fukuda, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 3, 684, 690, 2011年11月
英語 - セツキシマブ使用症例のレトロスペクティブ調査(HGCSG0901)‐バイオマーカー別の解析
結城敏志; 小松嘉人; 川本泰之; 辻靖; 畑中一映; 細川歩; 高橋康雄; 中村路夫; 奥田博介; 石黒敦; 斉藤真由子; 佐藤康史; 斎藤聡; 橋野聡; 坂田優, 日本癌治療学会誌, 46, 2, 443, 2011年09月13日
日本語 - 標準治療無効な切除不能進行大腸癌患者対象のTAS‐102第II相試験(KRAS status層別解析)
馬場秀夫; 吉野孝之; 水沼信之; 山崎健太郎; 仁科智裕; 小松嘉人; 辻晃仁; 山口研成; 室圭; 杉本直俊; 大津敦, 日本癌治療学会誌, 46, 2, 402, 402, 2011年09月13日
(一社)日本癌治療学会, 日本語 - 切除不能大腸癌二次治療例に対するFOLFIRIとIRISの第III相試験(FIRIS study)最終報告
傳田忠道; 仁科智裕; 山口研成; 瀧内比呂也; 江崎泰斗; 徳永伸也; 桑野博行; 小松嘉人; 安井久晃; 島田安博; 朴成和; 渡邊昌彦; 兵頭一之介; 森田智視; 杉原健一, 日本癌治療学会誌, 46, 2, 472, 2011年09月13日
日本語 - セツキシマブ使用例のレトロスペクティブ調査(HGCSG0901)‐Cetuximab単剤使用例の解析
岩永一郎; 結城敏志; 上林実; 小林良充; 辻靖; 畑中一映; 藤川幸司; 久須美貴哉; 渡辺豊; 棟方正樹; 山内純; 池田慎一郎; 太田智之; 橋野聡; 小松嘉人, 日本癌治療学会誌, 46, 2, 521, 2011年09月13日
日本語 - XELOX+Bevacizumab療法により切除可能となった高度進行直腸癌の一例
下國達志; 本間重紀; 崎浜秀康; 林秀幸; 川本泰之; 小林良充; 中積宏之; 結城敏志; 高橋典彦; 片岡昭彦; 小松嘉人; 神山俊哉, 日本癌治療学会誌, 46, 2, 847, 847, 2011年09月13日
(一社)日本癌治療学会, 日本語 - セツキシマブ使用例のレトロスペクティブ調査(HGCSG0901)‐CPT‐11+Cetuximab例の解析
長佐古友和; 結城敏志; 工藤峰生; 中積宏之; 古川孝広; 成瀬宏仁; 細川歩; 久須美貴哉; 福島拓; 宮城島拓人; 月岡雄治; 舘山美樹; 棟方正樹; 加藤元嗣; 小松嘉人, 日本癌治療学会誌, 46, 2, 519, 2011年09月13日
日本語 - セツキシマブ使用例のレトロスペクティブ調査(HGCSG0901)‐FOLFIRI+Cmab使用例の解析
加藤貴司; 結城敏志; 目黒高志; 林秀幸; 古川孝広; 成瀬宏仁; 中村とき子; 紺野潤; 加藤寛士; 竹内啓; 横山仁; 腰山達美; 久能健一; 加藤元嗣; 小松嘉人, 日本癌治療学会誌, 46, 2, 520, 2011年09月13日
日本語 - The Value of Thymidine Kinase 1 (TK1) and Thymidine Phosphorylase (TP) Expression as Predictive Factors With the Treatment Efficacy of TAS-102, a Novel Antitumour Agent, in Patients (pts) With Metastatic Colorectal Cancer (mCRC)
Y. Komatsu; T. Yoshino; N. Mizunuma; K. Yamazaki; T. Nishina; H. Baba; A. Tsuji; K. Yamaguchi; K. Muro; A. Ohtsu, EUROPEAN JOURNAL OF CANCER, 47, S421, S421, 2011年09月
英語, 研究発表ペーパー・要旨(国際会議) - A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)
Y. Kuboki; T. Yoshino; K. Yamazaki; T. Nishina; Y. Komatsu; H. Baba; A. Tsuji; K. Yamaguchi; K. Muro; A. Ohtsu, EUROPEAN JOURNAL OF CANCER, 47, S392, S392, 2011年09月
英語, 研究発表ペーパー・要旨(国際会議) - 塩酸イリノテカンが原因と思われる一過性の構語障害を来した1例
曽我部進; 結城敏志; 高野博信; 小林良充; 中積宏之; 佐々木尚英; 川本泰之; 福島拓; 岩永一郎; 上畠寧子; 小松嘉人; 浅香正博, 癌と化学療法, 38, 8, 1375, 1377, 2011年08月15日
日本語 - 座談会 胃癌Board Meeting 進行胃癌に対する外来化学療法レジメン―ドセタキセツの役割について考える―
大津敦; 掛地吉弘; 小泉和三郎; 小寺泰弘; 小松嘉人; 笹子三津留; 瀧内比呂也; 竹内正弘; 藤井雅志; 藤谷和正; 吉田和弘, 外来癌化学療法, 2, 3, 62-69, 141, 2011年06月20日
メディカルレビュー社, 日本語, 機関テクニカルレポート,技術報告書,プレプリント等 - 消化器癌化学療法2011―最近の話題 3 胃癌に対する分子標的治療―エビデンスと実臨床への導入
小松嘉人; 結城敏志; 小林良充; 中積宏之; 福島拓; 曽我部進; 浅香正博, 臨床消化器内科, 26, 6, 645, 652, 2011年05月20日
日本語 - 大腸癌治療におけるQOL評価 大腸癌化学療法とQOL(外来化学療法の有用性と問題点)
中積宏之; 結城敏志; 小林良充; 小松嘉人, 日本臨床, 69, 585, 588, 2011年04月20日
日本語 - 国内第I/II相臨床試験(JO19380)―XELOX+BEV併用療法の成績と長期治療例の検討―
佐藤温; 土井俊彦; 朴成和; 加藤健; 小松嘉人; 山口研成; 室圭; 浜本康夫; 小泉和三郎; 水沼信之; 瀧内比呂也, 癌と化学療法, 38, 4, 561, 569, 2011年04月15日
日本語 - MACRO試験:大腸がん化学療法 ベバシズマブによる維持療法の非劣性に関する検討―ベバシズマブによる維持療法の意義は,有害事象の軽減のためだけなのか?
小松嘉人; 曽我部進; 福島拓, 臨床腫瘍プラクティス, 18, 22, 2011年03月10日
日本語 - S-1+CDDP療法開始前の血清クレアチニン値およびシスタチンC値と腎障害・有害事象に関する検討
曽我部 進; 結城 敏志; 小林 良充; 中積 宏之; 福島 拓; 浅香 正博; 小松 嘉人, 日本胃癌学会総会記事, 83回, 190, 190, 2011年03月
(一社)日本胃癌学会, 日本語 - 胃癌化学療法中の有害事象による緊急入院の背景因子
小林 良充; 結城 敏志; 中積 宏之; 曽我部 進; 福島 拓; 佐々木 尚英; 浅香 正博; 小松 嘉人, 日本胃癌学会総会記事, 83回, 191, 191, 2011年03月
(一社)日本胃癌学会, 日本語 - 当科における胃癌患者の血清AFP値の検討
佐々木 尚英; 結城 敏志; 小林 良充; 中積 宏之; 曽我部 進; 福島 拓; 浅香 正博; 小松 嘉人, 日本胃癌学会総会記事, 83回, 191, 191, 2011年03月
(一社)日本胃癌学会, 日本語 - The optimal dose period of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV) induced by mFOLFOX6: An exploratory trial HGCSG0703
S. Yuki; H. Nakatsumi; M. Tateyama; Y. Uehata; M. Kudo; K. Kato; T. Miyagishima; M. Uebayashi; M. Asaka; Y. Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 29, 4, 2011年02月
英語, 研究発表ペーパー・要旨(国際会議) - 大腸癌の化学療法(XELOX+BV)中に腸管穿通をきたした1例
小柳要; 片岡昭彦; 高橋典彦; 本間重紀; 崎浜秀康; 下國達志; 辻健志; 藤堂省; 福島拓; 結城敏志; 小松嘉人, 日本大腸こう門病学会雑誌, 64, 2, 99, 99, 2011年02月
(一社)日本大腸肛門病学会, 日本語 - Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
Takuji Okusaka; Junji Furuse; Akihiro Funakoshi; Tatsuya Ioka; Kenji Yamao; Shinichi Ohkawa; Narikazu Boku; Yoshito Komatsu; Shoji Nakamori; Haruo Iguchi; Tetsuhide Ito; Kazuhiko Nakagawa; Kohei Nakachi, CANCER SCIENCE, 102, 2, 425, 431, 2011年02月, [国際誌]
英語 - Randomized Phase II Study Comparing Dose Escalated Weekly Paclitaxel vs. Standard Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric Cancer
Kohei Shitara; Isao Oze; Ayako Mizota; Chihiro Kondo; Motoo Nomura; Tomoya Yokota; Daisuke Takahari; Takashi Ura; Satoshi Yuki; Yoshito Komatsu; Keitaro Matsuo; Kei Muro, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 41, 2, 287, 290, 2011年02月, [国際誌]
英語 - 切除不能進行結腸直腸癌に対するセツキシマブ使用症例のレトロスペクティブ調査(HGCSG0901)―効果予測因子別の解析
結城敏志; 小松嘉人; 川本泰之; 福島拓; 古川孝広; 畑中一映; 細川歩; 高橋康雄; 斎藤聡; 宮城島拓人; 園田範和; 中村路夫; 岩永一郎; 坂田優; 浅香正博, 日本臨床腫瘍学会学術集会プログラム・抄録集, 9th, 336, 2011年
日本語 - 切除不能進行結腸直腸癌に対するセツキシマブ使用例のレトロスペクティブ調査(HGCSG0901)―Cetuximab単剤使用例の解析
奥田博介; 結城敏志; 小林良充; 古川孝広; 辻靖; 畑中一映; 成瀬宏仁; 安藤孝将; 中村とき子; 堀川直樹; 國枝保幸; 好崎浩司; 棟方正樹; 浅香正博; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 9th, 338, 2011年
日本語 - 切除不能結腸直腸癌に対するBevacizumabのレトロスペクティブ調査:BBP(Bevacizumab継続使用例)の解析(HGCSG0801)
曽我部進; 結城敏志; 奥田博介; 紺野潤; 成瀬宏仁; 林秀幸; 目黒高志; 腰山達美; 上畠寧子; 武藤修一; 岩永一郎; 中村路夫; 高木智史; 小松嘉人; 浅香正博, 日本臨床腫瘍学会学術集会プログラム・抄録集, 9th, 340, 2011年
日本語 - 切除不能結腸直腸癌に対するBevacizumabの安全性及び有用性を検討するレトロスペクティブ調査(HGCSG0801)全症例のアップデート
小松嘉人; 結城敏志; 奥田博介; 畑中一映; 曽我部進; 宮城島拓人; 加藤貴司; 細川歩; 月岡雄治; 中村路夫; 高野眞寿; 内田多久實; 福島拓; 竹内啓; 浅香正博, 日本臨床腫瘍学会学術集会プログラム・抄録集, 9th, 303, 2011年
日本語 - 切除不能進行結腸直腸癌に対するセツキシマブ使用例のレトロスペクティブ調査(HGCSG0901)―FOLFIRI+Cetuximab使用例の解析
藤川幸司; 結城敏志; 林秀幸; 吉田真誠; 古川孝広; 辻靖; 畑中一映; 久須美貴哉; 紺野潤; 池田慎一郎; 内田多久實; 上畠寧子; 斉藤真由子; 浅香正博; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 9th, 336, 2011年
日本語 - 切除不能進行結腸直腸癌に対するセツキシマブ使用例のレトロスペクティブ調査(HGCSG0901)―Cetuximab不応後の生存解析
古川孝広; 結城敏志; 曽我部進; 畑中一映; 棟方正樹; 梶浦新也; 佐川保; 佐藤康史; 奥田博介; 高野眞寿; 石黒敦; 天野虎次; 大庭幸治; 浅香正博; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 9th, 276, 2011年
日本語 - 切除不能進行結腸直腸癌に対するセツキシマブ使用例のレトロスペクティブ調査(HGCSGO901)―CPT‐11+Cetuximab例の解析
畑中一映; 結城敏志; 中積宏之; 古川孝広; 辻靖; 小川浩平; 佐藤康裕; 久須美貴哉; 月岡雄治; 腰山達美; 加藤貴司; 竹内啓; 坂田優; 浅香正博; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 9th, 337, 2011年
日本語 - 胃癌化学療法における緊急入院のリスク因子についての検討
小林良充; 結城敏志; 中積宏之; 福島拓; 曽我部進; 大庭幸治; 浅香正博; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 9th, 334, 2011年
日本語 - 当院におけるT4食道癌に対する化学放射線療法の治療成績
岩永一郎; 小松嘉人; 高島雄太; 武田慧太郎; 佐々木尚英; 中積宏之; 曽我部進; 結城敏志; 浅香正博, 北海道外科雑誌, 55, 2, 195, 196, 2010年12月20日
日本語 - Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
Kuniaki Shirao; Toshirou Nishida; Toshihiko Doi; Yoshito Komatsu; Kei Muro; Yinhua Li; Eiji Ueda; Atsushi Ohtsu, INVESTIGATIONAL NEW DRUGS, 28, 6, 866, 875, 2010年12月
英語 - PHASE II STUDY OF FIRST-LINE SUNITINIB (SU) IN COMBINATION WITH IRINOTECAN, LEUCOVORIN, AND 5-FLUOROURACIL (5-FU) (FOLFIRI) IN JAPANESE PATIENTS (PTS) WITH UNRESECTABLE/METASTATIC COLORECTAL CANCER (MCRC)
A. Tsuji; T. Denda; Y. Tsuji; T. Satoh; M. Yoshida; Y. Nishina; M. Nagase; Y. Komatsu; T. Kato; K. Muro, ANNALS OF ONCOLOGY, 21, 199, 200, 2010年10月
英語, 研究発表ペーパー・要旨(国際会議) - PHASE II TRIAL OF COMBINED CHEMOTHERAPY WITH IRINOTECAN, S-1, AND BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER
Y. Komatsu; S. Yuki; S. Sogabe; M. Nakamura; K. Hatanaka; T. Miyagishima; M. Kudo; M. Munakata; Y. Sakata; M. Asaka, ANNALS OF ONCOLOGY, 21, 197, 197, 2010年10月
英語, 研究発表ペーパー・要旨(国際会議) - Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
Toshihiko Doi; Narikazu Boku; Ken Kato; Yoshito Komatsu; Kensei Yamaguchi; Kei Muro; Yasuo Hamamoto; Atsushi Sato; Wasaburo Koizumi; Nobuyuki Mizunuma; Hiroya Takiuchi, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 40, 10, 913, 920, 2010年10月, [国際誌]
英語 - 分子標的マーカーに基づいた臨床試験 EGFRを標的とした臨床試験の現状と今後の展望 2)大腸がん
福島拓; 結城敏志; 小松嘉人, 月刊腫瘍内科, 6, 3, 209, 218, 2010年09月28日
日本語 - 当院におけるがん診療に対する電子カルテの利用状況と将来展望
小松嘉人; 遠藤晃; 櫻木範明; 田巻知宏; 小野塚美香; 久保田康生; 初山貢; 結城敏志; 曽我部進; 福島拓; 中積宏之; 小林良充; 浅香正博, 日本癌治療学会誌, 45, 2, 429, 2010年09月21日
日本語 - セツキシマブ使用例のレトロスペクティブ調査(HGCSG0901)‐Cetuximab単剤使用例の解析
藤川幸司; 結城敏志; 小林良充; 辻靖; 畑中一映; 棟方正樹; 高橋康雄; 月岡雄治; 久能健一; 高野眞寿; 上林実; 太田智之; 浅香正博; 小松嘉人, 日本癌治療学会誌, 45, 2, 710, 2010年09月21日
日本語 - 切除不能大腸癌に対するBevacizumab使用に関する調査(HGCSG0801)全症例のアップデート
中村路夫; 結城敏志; 小林良充; 久須美貴哉; 細川正夫; 渡辺豊; 畑中一映; 上畠寧子; 武藤修一; 宮城島拓人; 西研; 細川歩; 加藤貴司; 浅香正博; 小松嘉人, 日本癌治療学会誌, 45, 2, 712, 2010年09月21日
日本語 - セツキシマブ使用症例のレトロスペクティブ調査(HGCSG0901)‐KRAS status別の解析
結城敏志; 小松嘉人; 福島拓; 辻靖; 畑中一映; 棟方正樹; 細川歩; 高橋康雄; 久須美貴哉; 斎藤聡; 舘山美樹; 横山仁; 浅香正博, 日本癌治療学会誌, 45, 2, 346, 2010年09月21日
日本語 - 切除不能大腸癌に対するBevacizumab使用に関する調査(HGCSG0801)継続使用例の解析
曽我部進; 結城敏志; 久須美貴哉; 細川正夫; 渡辺豊; 畑中一映; 中村路夫; 工藤峰生; 山内純; 宮城島拓人; 月岡雄治; 上林実; 福島拓; 浅香正博; 小松嘉人, 日本癌治療学会誌, 45, 2, 711, 2010年09月21日
日本語 - セツキシマブ使用例のレトロスペクティブ調査(HGCSG0901)‐CPT‐11+Cetuximab例の解析
石黒敦; 結城敏志; 曽我部進; 古川孝広; 畑中一映; 宮城島拓人; 武藤修一; 渡邊豊; 腰山達美; 加藤寛士; 奥田博介; 池田慎一郎; 棟方正樹; 浅香正博; 小松嘉人, 日本癌治療学会誌, 45, 2, 568, 2010年09月21日
日本語 - 切除不能結腸直腸癌に対するセツキシマブ使用例のレトロスペクティブ調査(HGCSG0901)
畑中一映; 結城敏志; 中積宏之; 辻靖; 成瀬宏仁; 棟方正樹; 小川浩平; 新谷直昭; 佐藤康史; 加藤貴司; 中村路夫; 伊東重豪; 竹内啓; 浅香正博; 小松嘉人, 日本癌治療学会誌, 45, 2, 507, 2010年09月21日
日本語 - mFOLFOX6療法時の悪心・嘔吐に対する塩酸インジセトロン錠の至適投与法(HGCSG0703)
中積宏之; 結城敏志; 曽我部進; 園田範和; 武藤修一; 高野眞寿; 工藤峰生; 加藤寛士; 小田寿; 宮城島拓人; 上林実; 目黒高志; 浅香正博; 小松嘉人, 日本癌治療学会誌, 45, 2, 499, 2010年09月21日
日本語 - KRAS野生型の大腸癌患者に対するBiweekly Cetuximab+Irinotecan併用療法の第II相試験
吉田元樹; 設楽紘平; 結城敏志; 高張大亮; 佐藤洋造; 宇都宮節夫; 田近正洋; 横田知哉; 稲葉吉隆; 山浦秀和; 加藤弥菜; 河合宏紀; 山崎健太郎; 小松嘉人; 室圭, 日本癌治療学会誌, 45, 2, 707, 2010年09月21日
日本語 - 切除不能大腸癌に対するBevacizumab使用に関する調査(HGCSG0801)年齢別の解析
小松嘉人; 結城敏志; 久須美貴哉; 細川正夫; 高木智史; 畑中一映; 成瀬宏仁; 中積宏之; 竹内啓; 加藤寛士; 横山仁; 細川歩; 目黒高志; 堀田彰一; 浅香正博, 日本癌治療学会誌, 45, 2, 712, 2010年09月21日
日本語 - 切除不能結腸直腸癌に対するBevacizumabの安全性および有用性を検討するレトロスペクティブ調査:レジメン別解析のアップデート報告(HGCSG0801)
宮城島拓人; 結城敏志; 小林良充; 久須美貴哉; 畑中一映; 渡邊豊; 加藤貴司; 小川浩平; 中村路夫; 武藤修一; 内田多久實; 山内純; 腰山達美; 加藤寛士; 浅香正博; 小松嘉人, 日本消化器病学会雑誌, 107, A840, 2010年09月15日
日本語 - 切除不能結腸直腸癌に対するBevacizumabの安全性および有用性を検討するレトロスペクティブ調査:全症例のアップデート報告(HGCSG0801)
曽我部進; 結城敏志; 小松嘉人, 日本消化器病学会雑誌, 107, A666, 2010年09月15日
日本語 - 切除不能進行結腸直腸癌に対するセツキシマブ使用症例のレトロスペクティブ調査(HGCSG0901)‐KRAS status別の解析
佐藤康史; 結城敏志; 中積宏之; 古川孝広; 成瀬宏仁; 棟方正樹; 梶浦新也; 高橋康雄; 久須美貴哉; 斎藤聡; 舘山美樹; 中村路夫; 伊東重豪; 加藤淳二; 浅香正博; 小松嘉人, 日本消化器病学会雑誌, 107, A841, 2010年09月15日
日本語 - 切除不能進行結腸直腸癌に対するセツキシマブ使用症例のレトロスペクティブ調査(HGCSG0901)
細川歩; 結城敏志; 小松嘉人, 日本消化器病学会雑誌, 107, A666, 2010年09月15日
日本語 - 無治療の進行・転移性胃癌患者を対象としたベバシズマブの第III相試験(AVAGAST試験)
澤木 明; 山田 康秀; 山口 研成; 土井 俊彦; 仁科 智裕; 佐藤 太郎; 陳 勁松; 朴 成和; 小室 泰司; 瀧内 比呂也; 小松 嘉人; 浜本 康夫; 小泉 和三郎; 佐治 重衡; 大津 敦, 日本癌治療学会誌, 45, 2, 512, 512, 2010年09月
(一社)日本癌治療学会, 日本語 - Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro; Narikazu Boku; Yasuhiro Shimada; Akihito Tsuji; Shinichi Sameshima; Hideo Baba; Taroh Satoh; Tadamichi Denda; Kenji Ina; Tomohiro Nishina; Kensei Yamaguchi; Hiroya Takiuchi; Taito Esaki; Shinya Tokunaga; Hiroyuki Kuwano; Yoshito Komatsu; Masahiko Watanabe; Ichinosuke Hyodo; Satoshi Morita; Kenichi Sugihara, LANCET ONCOLOGY, 11, 9, 853, 860, 2010年09月
英語 - 消化器癌の分子標的治療 治癒切除不能進行/再発結腸直腸癌におけるベバシズマブの有用性と安全性を検討するレトロスペクティブ調査(HGCSG0801)
結城敏志; 曽我部進; 小松嘉人; 浅香正博, 月刊消化器内科, 51, 1, 59, 68, 2010年07月28日
科学評論社, 日本語 - Phase 1/2 Clinical Study of Irinotecan and Oral S-1 (IRIS) in Patients with Advanced Gastric Cancer
Yoshito Komatsu; Satoshi Yuki; Nozomu Fuse; Takashi Kato; Takuto Miyagishima; Mineo Kudo; Yasuyuki Kunieda; Miki Tateyama; Osamu Wakahama; Takashi Meguro; Yuh Sakata; Masahiro Asaka, ADVANCES IN THERAPY, 27, 7, 483, 492, 2010年07月
英語 - Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-treated Metastatic Colorectal Cancer Harboring Wild-type KRAS
Kohei Shitara; Tomoya Yokota; Daisuke Takahari; Takashi Shibata; Takashi Ura; Yoshito Komatsu; Satoshi Yuki; Motoki Yoshida; Hiroya Takiuchi; Setsuo Utsunomiya; Yasushi Yatabe; Kei Muro, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 40, 7, 699, 701, 2010年07月, [国際誌]
英語 - 変わりゆく大腸がん化学療法―FOLFOX,FOLFIRI,そして次の10年 5.分子標的治療薬―導入後,治療はどう変わったか?3)パニツムマブへの期待と欧米での現状
結城敏志; 曽我部進; 小松嘉人, 臨床腫瘍プラクティス, 6, 2, 151, 157, 2010年05月10日
ヴァン・メディカル, 日本語 - Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)
W. Koizumi; H. Takiuchi; Y. Yamada; N. Boku; N. Fuse; K. Muro; Y. Komatsu; A. Tsuburaya, ANNALS OF ONCOLOGY, 21, 5, 1001, 1005, 2010年05月
英語 - Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)
W. Koizumi; H. Takiuchi; Y. Yamada; N. Boku; N. Fuse; K. Muro; Y. Komatsu; A. Tsuburaya, ANNALS OF ONCOLOGY, 21, 5, 1001, 1005, 2010年05月
英語 - Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
Toshihiko Doi; Kei Muro; Narikazu Boku; Yasuhide Yamada; Tomohiro Nishina; Hiroya Takiuchi; Yoshito Komatsu; Yasuo Hamamoto; Nobutsugu Ohno; Yoshie Fujita; Matthew Robson; Atsushi Ohtsu, JOURNAL OF CLINICAL ONCOLOGY, 28, 11, 1904, 1910, 2010年04月
英語 - Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer
Shouko Ono; Mototsugu Kato; Kikuko Takagi; Junichi Kodaira; Kanako Kubota; Yoshihiro Matsuno; Yoshito Komatsu; Masahiro Asaka, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 25, 4, 804, 809, 2010年04月
英語 - Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate
Akira Sawaki; Yasuhide Yamada; Yoshito Komatsu; Tatsuo Kanda; Toshihiko Doi; Masato Koseki; Hideo Baba; Yu-Nien Sun; Koji Murakami; Toshirou Nishida, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 65, 5, 961, 967, 2010年04月
英語 - 分子標的治療薬 スニチニブ(スーテント)
小松嘉人; 岩永一郎; 結城敏志; 曽我部進; 中積宏之; 佐々木尚英, Biotherapy (Tokyo), 24, 2, 172, 177, 2010年03月30日
日本語 - 癌性リンパ管症を伴ったS状結腸癌に対して分子標的薬を併用した治療が奏効した1例
曽我部進; 結城敏志; 高木智史; 宮崎拓自; 高野博信; 川本泰之; 中積宏之; 佐々木尚英; 岩永一郎; 上畠寧子; 浅香正博; 小松嘉人, 癌と化学療法, 37, 3, 535, 538, 2010年03月15日
(株)癌と化学療法社, 日本語 - 当科における化学療法施行中の進行胃癌の緊急入院について
佐々木 尚英; 結城 敏志; 中積 宏之; 曽我部 進; 岩永 一郎; 浅香 正博; 小松 嘉人, 日本胃癌学会総会記事, 82回, 255, 255, 2010年03月
(一社)日本胃癌学会, 日本語 - GIST診療の進歩 イマチニブ標準治療耐性GIST患者に対するイマチニブ増量療法の検討
小松嘉人; 中積宏之; 佐々木尚英, 月刊消化器内科, 50, 2, 140, 144, 2010年02月28日
科学評論社, 日本語 - Bevacizumabの有用性を検討するレトロスペクティブ調査(HGCSG0801)―1次治療例の検討
畑中一映; 結城敏志; 佐々木尚英; 宮城島拓人; 中村路夫; 梶浦新也; 久須美貴哉; 細川正夫; 碇修二; 上林実; 渡辺豊; 上畠寧子; 小林隆司; 浅香正博; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 8th, 158, 159, 2010年
日本語 - 切除不能進行結腸直腸癌に対するセツキシマブ使用症例のレトロスペクティブ調査(HGCSG0901)‐Irinotecan+Cetuximab併用例の解析
小松嘉人; 結城敏志; 中積宏之; 古川孝広; 辻靖; 片桐雅樹; 中村路夫; 上畠寧子; 高橋康雄; 久能健一; 上林実; 池田慎一郎; 渡辺豊; 坂田優; 浅香正博, 日本臨床腫瘍学会学術集会プログラム・抄録集, 8th, 240, 2010年
日本語 - 切除不能結腸直腸癌に対するBevacizumabの安全性及び有用性を検討するレトロスペクティブ調査(HGCSG0801)
曽我部進; 結城敏志; 岩永一郎; 成瀬宏仁; 宮城島拓人; 中村路夫; 工藤峰生; 細川歩; 久須美貴哉; 堀田彰一; 渡辺豊; 武藤修一; 月岡雄治; 浅香正博; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 8th, 158, 2010年
日本語 - Bevacizumabの有用性を検討するレトロスペクティブ調査(HGCSG0801)―2次治療例の検討
加藤貴司; 結城敏志; 中積宏之; 天野虎次; 林秀幸; 宮城島拓人; 久須美貴哉; 細川正夫; 小西康平; 腰山達美; 加藤総介; 川岸直樹; 高木智史; 浅香正博; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 8th, 159, 2010年
日本語 - 進行・再発大腸癌に対するIrinotecan+TS‐1+Bevacizumab(IRIS/Bev)併用臨床第II相試験―中間報告―
棟方正樹; 小松嘉人; 結城敏志; 中村路夫; 畑中一映; 宮城島拓人; 工藤峰生; 西研; 目黒高志; 舘山美樹; 坂田優; 浅香正博, 日本臨床腫瘍学会学術集会プログラム・抄録集, 8th, 157, 2010年
日本語 - 切除不能進行結腸癌に対するセツキシマブ使用症例のレトロスペクティブ調査(HGCSG0901)
結城敏志; 岩永一郎; 辻靖; 棟方正樹; 細川歩; 畑中一映; 渡辺豊; 久須美貴哉; 月岡雄治; 宮城島拓人; 高野眞寿; 古川滋; 加藤貴司; 浅香正博; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 8th, 249, 2010年
日本語 - 切除不能進行結腸直腸癌に対するセツキシマブ使用症例のレトロスペクティブ調査(HGCSG0901)‐KRAS status別の解析
古川孝広; 結城敏志; 曽我部進; 奥田博介; 佐藤康史; 竹内啓; 梶浦新也; 伊東重豪; 斎藤聡; 棟方正樹; 舘山美樹; 林秀幸; 松永明宏; 坂田優; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 8th, 248, 2010年
日本語 - CYFRA上昇は食道癌の予後不良因子である(当科における症例の検討)
曽我部進; 岩永一郎; 結城敏志; 佐々木尚英; 中積宏之; 浅香正博; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 8th, 220, 2010年
日本語 - 本邦の切除不能進行大腸癌患者に対するイリノテカンベースの化学療法における,UGT1A1*6と*28の遺伝子多型の意義
岩永一郎; 結城敏志; 佐々木尚英; 中積宏之; 曽我部進; 久須美貴哉; 細川正夫; 浅香正博; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 8th, 170, 2010年
日本語 - 切除不能進行結腸直腸癌に対するセツキシマブ使用症例のレトロスペクティブ調査(HGCSG0901)‐Cetuximab単剤使用例の解析
小川浩平; 結城敏志; 佐々木尚英; 古川孝広; 辻靖; 小川浩司; 棟方正樹; 細川正夫; 太田智之; 川畑修平; 宮下憲暢; 渡辺豊; 小林隆司; 坂田優; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 8th, 241, 2010年
日本語 - Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidi
INVESTIGATIONAL NEW DRUGS, 1, 2010年 - Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer Results of Phase I and II Studies
Satoshi Yuuki; Yoshito Komatsu; Nozomu Fuse; Takashi Kato; Takuto Miyagishima; Mineo Kudo; Masao Watanabe; Miki Tateyama; Yasuyuki Kunieda; Osamu Wakahama; Yu Sakata; Masahiro Asaka, CLINICAL DRUG INVESTIGATION, 30, 4, 243, 249, 2010年
英語 - 大腸がん化学療法のNEW STRATEGY〈切除不能進行・再発大腸がんに対する化学療法〉標準治療としてのFOLFOX/FOLFIRI療法を知る
小松嘉人; 結城敏志; 曽我部進; 岩永一郎; 中積宏之; 佐々木尚英; 浅香正博, Mebio, 26, 10, 48, 55, 2009年10月10日
日本語 - Metachronous gastric cancer following complete remission of gastric MALT lymphoma
S. Ono; M. Kato; K. Takagi; J. Kodaira; K. Kubota; Y. Matsuno; Y. Komatsu; M. Asaka, ANNALS OF ONCOLOGY, 20, 10, 1748, 1749, 2009年10月
英語, 速報,短報,研究ノート等(学術雑誌) - 治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ(BV)の有用性を検討するレトロスペクティブ調査(HGCSG0801)
結城敏志; 小松嘉人; 浅香正博, 日本消化器病学会雑誌, 106, A624, 2009年09月15日
日本語 - Bevacizumabの有用性を検討するレトロスペクティブ調査(HGCSG0801)‐2次治療例の検討
加藤総介; 結城敏志; 佐々木尚英; 中園綾乃; 畑中一映; 片桐雅樹; 上畠寧子; 武藤修一; 宮下憲暢; 内田多久實; 久須美貴哉; 細川歩; 渡辺豊; 浅香正博; 小松嘉人, 日本癌治療学会誌, 44, 2, 506, 2009年09月14日
日本語 - Bevacizumabの有用性を検討するレトロスペクティブ調査(HGCSG0801)‐3次治療以降の検討
中積宏之; 結城敏志; 加藤貴司; 目黒高志; 畑中一映; 山本義也; 高野眞寿; 工藤峰生; 小野雄司; 高木智史; 久須美貴哉; 月岡雄治; 渡辺豊; 浅香正博; 小松嘉人, 日本癌治療学会誌, 44, 2, 506, 2009年09月14日
日本語 - Bevacizumabの有用性を検討するレトロスペクティブ調査(HGCSG0801)―1次治療例の検討
細川歩; 結城敏志; 曽我部進; 梶浦新也; 腰山達美; 西研; 小田寿; 宮城島拓人; 久須美貴哉; 月岡雄治; 高野眞寿; 工藤峰生; 渡辺豊; 浅香正博; 小松嘉人, 日本癌治療学会誌, 44, 2, 422, 2009年09月14日
日本語 - ガイドラインにおいて推奨されていない肝機能異常値患者に対する化学療法の検討
小松嘉人; 岩永一郎; 結城敏志; 曽我部進; 佐々木尚英; 中積宏之; 浅香正博, 日本癌治療学会誌, 44, 2, 340, 2009年09月14日
日本語 - Bevacizumabの有用性を検討するレトロスペクティブ調査(HGCSG0801)―FOLFIRI+BVの解析
竹内啓; 結城敏志; 中積宏之; 天野虎次; 林秀幸; 畑中一映; 加藤貴司; 目黒高志; 上畠寧子; 武藤修一; 久須美貴哉; 月岡雄治; 渡辺豊; 浅香正博; 小松嘉人, 日本癌治療学会誌, 44, 2, 419, 2009年09月14日
日本語 - Bevacizumabの有用性を検討するレトロスペクティブ調査(HGCSG0801)
結城敏志; 小松嘉人; 岩永一郎; 久須美貴哉; 畑中一映; 成瀬宏仁; 梶浦新也; 細川歩; 加藤貴司; 目黒高志; 太宰昌佳; 宮城島拓人; 中村路夫; 渡辺豊; 浅香正博, 日本癌治療学会誌, 44, 2, 421, 2009年09月14日
日本語 - Bevacizumabの有用性を検討するレトロスペクティブ調査(HGCSG0801)―FOLFOX+BVの解析
中村路夫; 結城敏志; 岩永一郎; 西川秀司; 山内純; 畑中一映; 宮下憲暢; 藤永明; 加藤寛士; 國枝保幸; 久須美貴哉; 細川歩; 渡辺豊; 浅香正博; 小松嘉人, 日本癌治療学会誌, 44, 2, 544, 2009年09月14日
日本語 - Bevacizumabの有用性を検討するレトロスペクティブ調査(HGCSG0801)―年齢別の解析
小松嘉人; 結城敏志; 曽我部進; 大西俊介; 宮城島拓人; 畑中一映; 成瀬宏仁; 加藤貴司; 目黒高志; 鎌田豪; 上林実; 中村路夫; 細川歩; 久須美貴哉; 浅香正博, 日本癌治療学会誌, 44, 2, 422, 2009年09月14日
日本語 - 進行・再発大腸癌に対するIrinotecan+TS‐1+Bevacizumab(IRIS/Bev)併用臨床第II相試験
中村路夫; 小松嘉人; 結城敏志; 畑中一映; 宮城島拓人; 工藤峰生; 西研; 目黒高志; 舘山美樹; 棟方正樹; 坂田優; 浅香正博, 日本癌治療学会誌, 44, 2, 578, 2009年09月14日
日本語 - 国内におけるXELOX療法+ベバシズマブ(BV)療法の第I/II相臨床試験成績
浜本康夫; 小松嘉人; 山口研成; 土井俊彦; 加藤健; 関川高志; 佐藤温; 水沼信之; 小泉和三郎; 朴成和; 室圭; 瀧内比呂也; 兵頭一之介; 宮川国久; 坂田優, 日本癌治療学会誌, 44, 2, 252, 2009年09月14日
日本語 - 切除不能大腸癌二次治療例に対するFOLFIRIとIRISとの第III相臨床試験(FIRIS study)
辻晃仁; 仁科智裕; 山口研成; 瀧内比呂也; 江崎泰斗; 徳永伸也; 桑野博行; 小松嘉人; 安井久晃; 島田安博; 朴成和; 渡邊昌彦; 兵頭一之介; 森田智視; 杉原健一, 日本癌治療学会誌, 44, 2, 253, 253, 2009年09月14日
(一社)日本癌治療学会, 日本語 - Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab in patients with metastatic colorectal cancer
K. Hatanaka; Y. Komatsu; S. Yuki; M. Nakamura; T. Miyagishima; M. Kudo; M. Munakata; Y. Sakata; M. Asaka, EJC SUPPLEMENTS, 7, 2, 336, 336, 2009年09月
英語, 研究発表ペーパー・要旨(国際会議) - 前治療で増悪した進行性胃癌患者を対象としたRAD001の第2相臨床試験
仁科 智裕; 土井 俊彦; 室 圭; 朴 成和; 山田 康秀; 瀧内 比呂也; 小松 嘉人; 浜本 康夫; 大野 宣嗣; 藤田 芳江; Matthew Robson; 大津 敦, 日本癌治療学会誌, 44, 2, 652, 652, 2009年09月
(一社)日本癌治療学会, 日本語 - セカンドライン化学療法・分子標的治療の進歩 大腸癌のSecond‐Line化学療法―分子標的薬の進歩―
小松嘉人; 曽我部進; 川本泰之; 岩永一郎; 上畠寧子; 結城敏志; 浅香正博, 癌と化学療法, 36, 5, 721, 725, 2009年05月15日
(株)癌と化学療法社, 日本語 - Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene
Toshirou Nishida; Tsuyoshi Takahashi; Akiko Nishitani; Toshihiko Doi; Kuniaki Shirao; Yoshito Komatsu; Kiyokazu Nakajima; Seiichi Hirota, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 14, 2, 143, 149, 2009年04月, [国内誌]
英語 - 当科における消化管間質腫瘍(GIST)診療の検討―分子標的薬治療を中心に―
川本泰之; 浅香正博; 小松嘉人; 結城敏志; 浅香瑠美子; 曽我部進; 山本桂子; 岩永一郎; 上畠寧子; 加藤元嗣, 日本消化器病学会雑誌, 106, A326, 2009年03月20日
日本語 - 進行膵癌に対するIrinotecan+S‐1(IRIS)併用療法のpilot study
小松嘉人; 結城敏志; 設楽紘平; 棟方正樹; 武藤理; 川本泰之; 曽我部進; 上畠寧子; 岩永一郎; 河上洋; 坂田優; 浅香正博, 日本消化器病学会雑誌, 106, A160, 2009年03月20日
日本語 - 当院における消化管内分泌細胞癌の検討
畑中一映; 林秀幸; 中井正人; 井上弘行; 小川浩司; 山本文泰; 山本義也; 片桐雅樹; 成瀬宏仁; 小松嘉人; 浅香正博, 日本消化器病学会雑誌, 106, A356, 2009年03月20日
日本語 - 治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ(BV)の有用性を検討するレトロスペクティブ調査(HGCSG0801)~2次治療例の検討
工藤峰生; 結城敏志; 曽我部進; 久須美貴哉; 細川正夫; 畑中一映; 成瀬宏仁; 山内純; 加藤寛士; 高木智史; 宮下憲暢; 梶浦新也; 細川歩; 渡邊豊; 佐々木尚英; 宮城島拓人; 加藤貴司; 中村路夫; 浅香正博; 小松嘉人, 日本消化器病学会雑誌, 106, A299, 2009年03月20日
日本語 - 治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ(BV)の有用性を検討するレトロスペクティブ調査(HGCSG0801)~3次治療以降の検討
加藤貴司; 結城敏志; 川本泰之; 上畠寧子; 寺井潔; 渡邊豊; 畑中一映; 成瀬宏仁; 宮城島拓人; 目黒高志; 竹内啓; 羽田政平; 上林実; 渡辺雅男; 久須美貴哉; 高野眞寿; 工藤峰生; 舘山美樹; 浅香正博; 小松嘉人, 日本消化器病学会雑誌, 106, A300, 2009年03月20日
日本語 - 当科にて一次化学療法を導入したAFP上昇胃癌症例の検討
曽我部進; 結城敏志; 川本泰之; 岩永一郎; 西田麗; 上畠寧子; 吉田武史; 清水勇一; 浅香正博; 小松嘉人, 日本消化器病学会雑誌, 106, A337, 2009年03月20日
日本語 - 当科における重度肝障害患者におけるmFOLFOX6療法の検討
岩永一郎; 結城敏志; 川本泰之; 曽我部進; 上畠寧子; 中川学; 中川宗一; 浅香正博; 小松嘉人, 日本消化器病学会雑誌, 106, A410, 2009年03月20日
日本語 - 治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ(BV)の有用性を検討するレトロスペクティブ調査(HGCSG0801)~1次治療例の検討
宮城島拓人; 結城敏志; 岩永一郎; 久須美貴哉; 太宰昌佳; 中村路夫; 加藤総介; 小林秋人; 西研; 梶浦新也; 細川歩; 月岡雄治; 赤倉伸亮; 渡邊豊; 畑中一映; 片桐雅樹; 加藤貴司; 目黒高志; 浅香正博; 小松嘉人, 日本消化器病学会雑誌, 106, A299, 2009年03月20日
日本語 - 切除不能進行結腸直腸癌におけるFOLFOX療法failure後のFOLFIRI+Bevacizumab療法の治療成績
岩永一郎; 結城敏志; 川本泰之; 曽我部進; 上畠寧子; 今井亜希; 久須美貴哉; 細川正夫; 浅香正博; 小松嘉人, 日本消化器病学会雑誌, 106, A299, 2009年03月20日
日本語 - 当科における頚部食道癌に対する化学放射線療法の治療成績
岩永一郎; 結城敏志; 川本泰之; 曽我部進; 上畠寧子; 小野尚子; 浅香正博; 小松嘉人, 日本消化器病学会雑誌, 106, A185, 2009年03月20日
日本語 - 治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ(BV)の有用性を検討するレトロスペクティブ調査(HGCSG0801)
結城敏志; 小松嘉人; 浅香正博, 日本消化器病学会雑誌, 106, A133, 2009年03月20日
日本語 - 消化管がん薬物療法の最前線 各臓器がん(切除不能進行例)での標準治療と実地医療における注意点 4)GIST
結城敏志; 川本泰之; 浅香正博; 小松嘉人, 月刊腫瘍内科, 3, 2, 164, 170, 2009年02月28日
(有)科学評論社, 日本語 - What's going on FOLFOX療法とXELOX療法の効果が同等であることを示した論文[Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L 'Randomized phase 3 study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer']
結城 敏志; 小松 嘉人, Mebio oncology, 6, 1, 124, 127, 2009年02月
メジカルビュー社, 日本語 - Q&Aで綴るレジデント・ノート―専門医がわかりやすく解説―No.8 大腸癌補助化学療法について,治療にかかる期間や副作用について教えて下さい。
小松嘉人, 大腸癌FRONTIER, 1, 4, 351, 353, 2009年01月10日
日本語 - 治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ(BV)の有用性を検討するレトロスペクティブ調査(HGCSG0801)
畑中一映; 結城敏志; 岩永一郎; 久須美貴哉; 渡邊豊; 加藤貴司; 細川歩; 宮城島拓人; 月岡雄治; 中村路夫; 武藤一; 工藤峰生; 宮下憲暢; 浅香正博; 小松嘉人, 日本臨床腫瘍学会学術集会プログラム・抄録集, 7th, 228, 2009年
日本語 - 切除不能/術後再発結腸・直腸癌に対するCPT‐11+S‐1併用療法(IRIS療法)の第II相臨床試験(HGCSG0302):最終解析
結城敏志; 小松嘉人; 川本泰之; 曽我部進; 園田範和; 高木智史; 工藤峰生; 目黒高志; 古川滋; 上林実; 若浜理; 宮下憲暢; 竹内啓; 浅香正博; 坂田優, 日本臨床腫瘍学会学術集会プログラム・抄録集, 7th, 229, 2009年
日本語 - 当科における造影剤を用いた腋窩静脈穿刺法によるCVポート造設の経験
岩永一郎; 小松嘉人; 川本泰之; 曽我部進; 上畠寧子; 結城敏志; 浅香正博, 日本臨床腫瘍学会学術集会プログラム・抄録集, 7th, 264, 2009年
日本語 - FOLFOX4+Bevacizumab(BV)の進行・再発結腸・直腸癌を対象とした安全性確認試験~追跡調査
仁科智裕; 加藤健; 加藤俊介; 松本寛; 土井俊彦; 水沼信之; 奥野達哉; 馬場英司; 長島文夫; 小松嘉人; 植竹宏之; 大津敦, 日本臨床腫瘍学会学術集会プログラム・抄録集, 7th, 228, 2009年
日本語 - 当科における大腸癌の転移性肝腫瘍による重度の肝障害患者に対するmFOLFOX6療法の治療成績
岩永一郎; 小松嘉人; 川本泰之; 曽我部進; 上畠寧子; 結城敏志; 浅香正博, 日本臨床腫瘍学会学術集会プログラム・抄録集, 7th, 230, 2009年
日本語 - Second-line chemotherapy for colorectal cancer
Yoshito Komatsu; Susumu Sogabe; Yasuyuki Kawamoto; Ichiro Iwanaga; Yasuko Uehata; Satoshi Yuki; Masahiro Asaka, Japanese Journal of Cancer and Chemotherapy, 36, 5, 721, 725, 2009年
Japanese Journal of Cancer and Chemotherapy Publishers Inc., 日本語 - 当科における食道癌に対する根治的化学放射線療法の治療成績
岩永一郎; 小松嘉人; 川本泰之; 福島拓; 曽我部進; 上畠寧子; 小笹真理子; 町田望; 結城敏志; 浅香正博, 北海道外科雑誌, 53, 2, 243, 2008年12月20日
日本語 - Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines
Makoto Tahara; Kuniaki Shirao; Narikazu Boku; Kensei Yamaguchi; Yoshito Komatsu; Yoshitaka Inaba; Tatsuhiro Arai; Nobuyuki Mizunuma; Taroh Satoh; Hiroya Takiuchi; Tomohiro Nishina; Yuh Sakata, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 38, 11, 762, 769, 2008年11月, [国際誌]
英語 - HGCSG0501‐手術不能/術後再発大腸癌に対するmFOLFOX6療法のFeasibility Study:最終解析結果
中村路夫; 小松嘉人; 川本泰之; 上畠寧子; 結城敏志; 上林実; 若浜理; 西研; 工藤峰生; 浅香正博; 坂田優, 日本癌治療学会誌, 43, 2, 597, 2008年10月01日
日本語 - グリベック耐性の消化管間質腫瘍(GIST)患者を対象としたグリベック増量による有用性検討試験
小松嘉人; 岩永一郎; 結城敏志; 曽我部勉; 川本博; 上畠寧子; 浅香正博, 日本癌治療学会誌, 43, 2, 257, 2008年10月01日
日本語 - 北海道大学病院腫瘍センター化学療法部の試み
船木典子; 小松嘉人; 結城敏志; 木下一郎; 淺野恵子; 日下部緑; 白石則子; 久保田康生; 福田諭, 日本癌治療学会誌, 43, 2, 514, 2008年10月01日
日本語 - 進行・再発胃癌に対するtailored CPT‐11+TS‐1療法とTS‐1単独療法のランダム化比較第II相臨床試験(JFMC31‐0301:がん集学的治療研究財団)
木村豊; 小田寿; 田嶋勇介; 三木宏文; 櫻井丈; 若杉健弘; 建部茂; 小松嘉人; 北島政樹; 久保田哲朗; 坂本純一; 高橋豊; 佐治重豊, 日本癌治療学会誌, 43, 2, 552, 2008年10月01日
日本語 - CPT‐11+S‐1併用療法(IRIS)にて組織学的CRが得られた左鎖骨上窩及び縦隔,腹部大動脈周囲リンパ節転移陽性進行胃癌の一例
上林実; 村川力彦; 阿部容子; 三浦紗智子; 川畑修平; 工藤大樹; 鎌田豪; 渡邉雅男; 山本高正; 小出亨; 村上慶洋; 新関浩人; 北上英彦; 池田淳一; 須永道明; 新里順勝; 小松嘉人; 浅香正博, 日本癌治療学会誌, 43, 2, 917, 2008年10月01日
日本語 - 手術不能または術後再発大腸癌に対するCPT‐11+S‐1併用療法(IRIS療法)の第II相臨床試験(HGCSG0302):最終解析結果
結城敏志; 小松嘉人; 曽我部進; 岩永一郎; 中村路夫; 畑中一映; 加藤貴司; 舘山美樹; 工藤峰生; 宮城島拓人; 浅香正博; 坂田優, 日本癌治療学会誌, 43, 2, 604, 2008年10月01日
日本語 - 進行・再発大腸癌に対するIrinotecan+TS‐1+Bevacizumab(IRIS/Bev)併用臨床第II相試験
小松嘉人; 結城敏志; 中村路夫; 畑中一映; 棟方正樹; 武藤理; 加藤貴司; 宮城島拓人; 岩永一郎; 上畠寧子; 曽我部勉; 川本博; 坂田優; 浅香正博, 日本癌治療学会誌, 43, 2, 604, 2008年10月01日
日本語 - 化学療法未施行の進行・転移性結腸・直腸癌を対象としたXELOX療法+ベバシズマブ(BV)療法の第I/II相臨床試験(追加報告)
加藤健; 小松嘉人; 浜本康夫; 山口研成; 土井俊彦; 大津敦; 佐藤温; 水沼信之; 小泉和三郎; 朴成和; 室圭; 瀧内比呂也; 兵頭一之介; 宮川国久; 坂田優, 日本癌治療学会誌, 43, 2, 258, 2008年10月01日
日本語 - 小腸癌転移病変にIRISが奏効した1例
畑中一映; 林秀幸; 中井正人; 井上弘行; 小川浩司; 山本文泰; 山本義也; 片桐雅樹; 成瀬宏仁; 工藤和洋; 坂田幸雄; 辻龍一; 小松嘉人, 日本癌治療学会誌, 43, 2, 935, 935, 2008年10月01日
(一社)日本癌治療学会, 日本語 - 手術不能または術後再発大腸癌に対するCPT‐11+S‐1併用療法(IRIS療法)の第II相臨床試験(HGCSG0302):最終解析結果
結城敏志; 小松嘉人; 浅香正博, 日本消化器病学会雑誌, 105, A480, 2008年09月15日
日本語 - PHASE II CLINICAL STUDY OF COMBINATION THERAPY WITH IRINOTECAN AND S-1(IRIS) FOR INOPERABLE RECURRENT ADVANCED COLORECTAL CANCER: HOKKAIDO GASTROINTESTINAL CANCER STUDY GROUP STUDY HGCSG-0302). FINAL ANALYSIS
Y. Komatsu; S. Yuki; I. Iwanaga; T. Kato; M. Tateyama; M. Uebayashi; M. Kudo; Y. Sakata; M. Asaka, ANNALS OF ONCOLOGY, 19, 129, 129, 2008年09月
英語, 研究発表ペーパー・要旨(国際会議) - 各論:胃癌治療法―現状・動向・評価―併用療法CPT‐11との併用療法 CPT‐11+S‐1
結城敏志; 小松嘉人; 宮城島拓人; 工藤峰生; 浅香正博, 日本臨床, 66, 391, 394, 2008年07月28日
日本語 - Phase II study of combination with irinotecan and S-1(IRIS) for inoperable recurrent advanced colorectal cancer(HGCSG0302). Final analysis
S. Yuki; Y. Komatsu; I. Iwanaga; H. Fukushima; M. Kudo; M. Tateyama; T. Meguro; M. Watanabe; M. Asaka; Y. Sakata, JOURNAL OF CLINICAL ONCOLOGY, 26, 15, 2008年05月
英語, 研究発表ペーパー・要旨(国際会議) - 直腸病変に対する内視鏡的粘膜下層剥離術の検討
中川学; 小野尚子; 清水勇一; 加藤元嗣; 西田麗; 今井亜希; 吉田武史; 幡有; 高木貴久子; 廣田ジョージョ; 桂田武彦; 小松嘉人; 武田宏司; 浅香正博; 中川宗一, 日本大腸こう門病学会雑誌, 61, 5, 275, 2008年05月
日本語 - Bevacizumab(BV)+FOLFOX4療法の進行・再発結腸・直腸癌を対象とした安全性確認試験
松本寛; 加藤健; 白尾國昭; 加藤俊介; 土井俊彦; 大津敦; 水沼信之; 畠清彦; 田村孝雄; 仁科智裕; 長島文夫; 馬場英司; 小松嘉人; 植竹宏之; 杉原健一; 戸井雅和; 南博信; 西條長宏, 日本外科学会雑誌, 109, 臨増2, 205, 205, 2008年04月25日
(一社)日本外科学会, 日本語 - 進行・再発大腸癌の最適な化学療法 切除不能進行結腸直腸癌に対するイリノテカン+S‐1併用療法
結城敏志; 小松嘉人; 舘山美樹; 中村路夫; 浅香正博, 月刊消化器科, 46, 3, 291, 298, 2008年03月28日
日本語 - TS‐1+CPT‐11併用化学療法(IRIS療法)が奏効し治癒切除できた高度進行胃癌の1例
宮下憲暢; 内田多久實; 藤永明; 大島隆宏; 西川眞; 後藤田裕子; 村岡俊二; 小松嘉人; 浅香正博, 日本消化器病学会雑誌, 105, A353, 2008年03月20日
日本語 - 新しい大腸がん化学療法 1.大腸がん化学療法に用いられる投与スケジュール 2)塩酸イリノテカンを用いた投与スケジュールと,その選択基準は
小松嘉人; 岩永一郎; 浅香正博, 臨床腫瘍プラクティス, 4, 1, 17, 23, 2008年02月10日
ヴァン・メディカル, 日本語 - がんの腹膜播種に対する標準的治療の確立に関する研究 胃癌の腹膜播種に対する標準的治療の確立
小松嘉人, がんの腹膜播種に対する標準的治療の確立に関する研究 平成19年度 総括研究報告書, 3, 2008年
日本語 - 呼吸不全が急速に進行した多発筋炎の終末期にbilevel positive airway pressure(BiPAP)を導入し,本人と家族のコミュニケーションを継続できた一例
岩永一郎; 小松嘉人; 福島拓; 小笹真理子; 結城敏志; 町田望; 浅香正博, 日本緩和医療学会学術大会プログラム・抄録集, 13th, 220, 2008年
日本語 - XELOX療法+Bevacizumab(BV)併用の進行・転移性結腸・直腸癌を対象とした第I/II相臨床試験
小松嘉人; 浜本康夫; 山口研成; 土井俊彦; 大津敦; 加藤健; 佐藤温; 水沼信之; 小泉和三郎; 朴成和; 室圭; 瀧内比呂也; 兵頭一之介; 宮川国久; 坂田優, 日本臨床腫瘍学会学術集会プログラム・抄録集, 6th, 219, 2008年
日本語 - Bevacizumab(BV)の進行・再発結腸・直腸癌を対象とした安全性確認試験
加藤俊介; 吉岡孝志; 加藤健; 白尾國昭; 松本寛; 土井俊彦; 大津敦; 水沼信之; 畠清彦; 田村孝雄; 仁科智裕; 長島文夫; 馬場英司; 小松嘉人; 植竹宏之, 日本臨床腫瘍学会学術集会プログラム・抄録集, 6th, 194, 2008年
日本語 - DICを合併した大腸癌にmFOLFOX6が奏効した一例
森本真有; 小松嘉人; 藤田憲明; 塩谷曜子; 福島拓; 岩永一郎; 小笹真理子; 町田望; 結城敏志; 浅香正博, 日本臨床腫瘍学会学術集会プログラム・抄録集, 6th, 487, 2008年
日本語 - 進行膵癌に対するIrinotecan+S‐1併用療法(IRIS)のpilot study
設楽紘平; 小松嘉人; 結城敏志; 棟方正樹; 武藤理; 嶋谷泉; 浅香正博; 坂田優, 日本臨床腫瘍学会学術集会プログラム・抄録集, 6th, 221, 2008年
日本語 - 手術不能/術後再発大腸癌に対するmFOLFOX6療法のFeasibility Study:最終解析‐HGCSG0501
結城敏志; 小松嘉人; 福島拓; 岩永一郎; 町田望; 小笹真理子; 工藤峰生; 加藤貴司; 宮城島拓人; 西研; 坂田優; 浅香正博, 日本臨床腫瘍学会学術集会プログラム・抄録集, 6th, 393, 2008年
日本語 - Stage II,III進行食道癌に対する放射線化学療法の同時併用療法の第II相臨床試験(JCOG9906)
瀧内比呂也; 室圭; 大津敦; 加藤健; 石倉聡; 朴成和; 小松嘉人; 齋藤博; 宮田佳典; 金子和弘; 中村朗; 仁科智裕; 福田治彦, 日本臨床腫瘍学会学術集会プログラム・抄録集, 6th, 193, 2008年
日本語 - メチル酸イマチニブ投与中に病勢の進行又は再発が認められたGIST日本人患者に対するAMG706臨床第2相試験
西田俊朗; 澤木明; 山田康秀; 小松嘉人; 神戸達夫; 土井俊彦; 小関萬里; 馬場秀夫; 小林恵子; 浅見由美子; 大津智子, 日本臨床腫瘍学会学術集会プログラム・抄録集, 6th, 396, 2008年
日本語 - Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer
Kohei Shitara; Yoshito Komatsu; Satoshi Yuki; Masaki Munakata; Osamu Muto; Sen Shimaya; Yuh Sakata, ONCOLOGY, 75, 1-2, 67, 70, 2008年
英語 - 大腸がん化学療法の目まぐるしい進歩 2 Cytotoxic agentにおける進歩―経口フッ化ピリミジン製剤を中心に―
小松嘉人, Mebio Oncol, 4, 3, 16, 27, 2007年12月20日
メジカルビュー社, 日本語 - 根治切除不能結腸直腸癌に対するmFOLFOX6療法のFeasibility Study(HGCSG0501)
結城敏志; 小松嘉人; 岩永一郎; 小笹真理子; 工藤峰生; 目黒高志; 宮城島拓人; 西研; 浅香正博; 坂田優, 日本癌治療学会誌, 42, 2, 575, 2007年09月20日
日本語 - EGFR陽性の治癒切除不能進行・再発大腸癌に対するcetuximab・CPT‐11併用第II相試験
吉野孝之; 田原信; 山口研成; 小松嘉人; 新井達広; 稲葉吉隆; 朴成和; 白尾国昭; 坂田優, 日本癌治療学会誌, 42, 2, 285, 285, 2007年09月20日
(一社)日本癌治療学会, 日本語 - 悪性腹膜中皮腫の3例
畑中一映; 中井正人; 小松康之; 江藤和範; 小川浩司; 山本文泰; 山本義也; 片桐雅樹; 成瀬宏仁; 下山則彦; 小松嘉人, 日本癌治療学会誌, 42, 2, 827, 2007年09月20日
日本語 - 根治切除不能大腸癌に対するCPT‐11+S‐1併用療法の第II相臨床試験(HGCSG0302)
福島拓; 小松嘉人; 結城敏志; 町田望; 舘山美樹; 高木智史; 若浜理; 渡辺雅男; 浅香正博; 坂田優, 日本癌治療学会誌, 42, 2, 285, 2007年09月20日
日本語 - イマチニブ(IM)耐性又は不忍容GIST患者に対するスニチニブ(SU)の第I/II相試験
小松嘉人; 白尾国昭; 西田俊朗; 土井俊彦; 島田安博; 柴山千秋; BAUM C. M; 大津敦, 日本癌治療学会誌, 42, 2, 283, 2007年09月20日
日本語 - Phase II study of combination with irinotecan and S-1 (IRIS) for inoperable recurrent advanced colorectal cancer (HGCSG0302). Safety analysis
S. Yuki; Y. Komatsu; N. Machida; M. Ozasa; K. Nishi; T. Miyagishima; T. Kato; M. Nakamura; M. Asaka; Y. Sakata, EJC SUPPLEMENTS, 5, 4, 252, 252, 2007年09月
英語, 研究発表ペーパー・要旨(国際会議) - 胃癌治療の新しいエビデンスを求めて―臨床試験の取り組み―HGCSG(北海道消化器癌化学療法研究会)での取り組みと現状
小松嘉人; 結城敏志; 浅香正博, 外科治療, 97, 2, 188, 192, 2007年08月01日
永井書店, 日本語 - 早期胃癌の内視鏡的粘膜下層剥離術例における非治癒切除例の検討
中川学; 加藤元嗣; 浅香正博; 中川宗一; 清水勇一; 小野尚子; 小野雄司; 廣田ジョージョ; 高木貴久子; 幡有; 今井亜希; 吉田武史; 結城敏史; 布施望; 小松嘉人; 武田宏司; 鎌田豪, Gastroenterol Endosc, 49, Supplement 1, 925, 2007年04月05日
日本語 - Safeness and usefulness of endoscopic submucosal dissection (ESD) versus conventional EMR for superficial gastric lesions
Manabu Nakagawa; Mototsugu Kato; Shuko Ono; Yuichi Shmizu; Aki Imai; Takeshi Yoshida; Tamotso Hata; Jojo Hirota; Yuji Ono; Kikuno Tagaki; Go Kamada; Yoshito Komatsu; Hiroshi Takeda; Masahiro Asaka; Souichi Nakagawa, GASTROINTESTINAL ENDOSCOPY, 65, 5, AB181, AB181, 2007年04月
英語, 研究発表ペーパー・要旨(国際会議) - 内視鏡的粘膜下層剥離術導入を目的とした直腸病変へのアプローチ
中川学; 加藤元嗣; 中川宗一; 清水勇一; 小松嘉人; 吉田武史; 廣田ジョージョ; 今井亜希; 小野雄司; 小野尚子; 幡有; 武田宏司; 浅香正博; 鎌田剛, 日本大腸こう門病学会雑誌, 60, 4, 242, 243, 2007年04月
日本語 - 切除不能進行結腸直腸癌に対するIrinotecan+S‐1併用療法(IRIS療法)のEvidence構築への道―HGCSG0302:Phase II studyの結果を中心に―
結城敏志; 小松嘉人; 浅香正博, 日本消化器病学会雑誌, 104, A61, 2007年03月20日
日本語 - 当科における手術不能進行・再発胃癌患者に対する化学療法の変遷と入院期間の短縮
岩永一郎; 小松嘉人; 林秀幸; 曽我部進; 福島拓; 結城敏志; 布施望; 浅香正博, 日本緩和医療学会総会プログラム・講演抄録集, 12th, 246, 2007年
日本語 - Bevacizumab(BV)の進行・再発結腸・直腸癌を対象とした安全性確認試験
濱口哲弥; 白尾國昭; 土井俊彦; 大津敦; 水沼信之; 畠清彦; 小松嘉人; 吉岡孝志; 山本亘; 松本寛; 植竹宏之; 田村孝雄; 仁科智裕; 中野修治; 西條長宏, 日本臨床腫瘍学会学術集会プログラム・抄録集, 5th, 199, 2007年
日本語 - 悪性腹膜中皮腫の3例
日本癌治療学会誌, 827, 2007年 - [Progress of chemotherapy in colorectal cancer]
Yoshito Komatsu, Gan To Kagaku Ryoho., 34, 11, 1771, 6, 2007年, [国内誌]
日本語 - [Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas]
Yoshito Komatsu, Gan To Kagaku Ryoho., 34, 5, 799, 807, 2007年, [国内誌]
Chemotherapy that targets metastatic colorectal cancer originally developed in Europe and the US, and was introduced to Japan in April, 2005, where it has since headed toward full scale clinical applications. This event created an opportunity to re-evaluate the role of postoperative adjuvant chemotherapy in Japan. In Europe and the US, adjuvant therapy has centered on the intravenous administration of leucovorin/fluorouracil, while in Japan, it has been long-term continuous administration of oral fluoropyrimidine preparations. Despite this difference in historical background,guidelines created in 2005 recommend both LV/5-FU and LV/UFT regimens and there has been increased application of evidence-based adjuvant chemotherapy. The benefits of postoperative adjuvant chemotherapy in stage II and III (high risk of recurrence) colorectal cancer patients have also come to be recognized. Examination of a new survey of 100 medical specialists on the current state of adjuvant chemotherapy for colorectal cancer in Japanese clinical settings revealed that for stage III patients, there is a tendency to choose treatment based on evidence gathered from both home and abroad. In contrast, a solid majority (60%) of stage II patients are treated exclusively with oral fluoropyrimidine despite a lack of, or limited evidence of efficacy. At the same time, half of the physicians who treated stage II patients with adjuvant chemotherapy initially attempted to identify those with a high risk of cancer recurrence and treat them accordingly; which was a breakthrough in the clinical treatment approach. While ongoing comparative Japanese clinical studies that use adjuvant chemotherapy for the treatment of colorectal cancer were noted, consideration was also given to the desired future direction clinical research should take., 日本語 - Eradication of Helicobacter pylori for primary gastric cancer and secondary gastric cancer after endoscopic mucosal resection
Motosugu Kato; Masahiro Asaka; Shouko Ono; Manabu Nakagawa; Souichi Nakagawa; Yuichi Shimizu; Makoto Chuma; Hiroshi Kawakami; Yoshito Komatsu; Shuhei Hige; Hiroshi Takeda, JOURNAL OF GASTROENTEROLOGY, 42, 16, 20, 2007年01月
英語 - 切除不能進行食道癌に対する化学療法―HGCSG0305切除不能進行食道癌に対するDocetaxel+CDDP+5‐FU(TPF)併用療法の第I/II相臨床試験を中心に―
結城敏志; 小松嘉人; 布施望; 岩永一郎; 加藤貴司; 宮城島拓人; 舘山美樹; 工藤峰生; 目黒高志; 小笹茂; 渡辺雅男; 武田宏司; 浅香正博; 坂田優, 日本消化器病学会雑誌, 103, A771, 2006年09月10日
日本語 - 手術不能進行大腸癌患者に対する新規抗癌剤併用化学療法による通院化学療法とQOLの検討
小松嘉人; 結城敏志; 浅香正博; 浅香正広, 日本消化器病学会雑誌, 103, A419, 2006年09月10日
日本語 - Phase II clinical study of combination therapy with irinotecan and S-1(IRIS) for inoperable recurrent advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group study HGCSG-0302).
Y. Komatsu; S. Yuki; H. Akita; M. Kudo; M. Tateyama; T. Saga; T. Megro; G. Suzuki; Y. Sakata; M. Asaka, JOURNAL OF CLINICAL ONCOLOGY, 24, 18, 168S, 168S, 2006年06月
英語, 研究発表ペーパー・要旨(国際会議) - Phase I/II study of docetaxel and S-I in patients with advanced gastric cancer
K. Yamaguchi; T. Shimamura; I. Hyodo; W. Koizumi; T. Doi; H. Narahara; Y. Komatsu; T. Kato; S. Saitoh; T. Akiya; M. Munakata; Y. Miyata; Y. Maeda; H. Takiuchi; S. Nakano; T. Esaki; F. Kinjo; Y. Sakata, BRITISH JOURNAL OF CANCER, 94, 12, 1803, 1808, 2006年06月
英語 - 手術不能進行結腸・直腸癌に対するmFOLFOX6(l‐OHP+l‐LV+5‐FU)療法のFeasibility Study〈HGCSG0501〉‐Hokkaido Gastrointestinal Cancer Study Group‐
宮城島拓人; 小松嘉人; 結城敏志; 布施望; 天野虎次; 上畠寧子; 中村路夫; 国枝保幸; よし内史朗; 西川秀司; 大原行雄; 常松泉; 西研; 小田寿; 加藤貴司; 佐々木清貴; 川村直之; 工藤峰夫; 浅香正博; 坂田優, 日本消化器病学会雑誌, 103, A240, 2006年03月20日
日本語 - 大腸癌遠隔臓器転移に対する化学療法:Hokkaido Gastrointestinal Cancer Study Group(HGCSG)のCPT‐11+S‐1(IRIS)とmFOLFOX6の臨床試験を通じて
小松嘉人; 結城敏志; 浅香正博; 天野虎次; 布施望; 小笠真理子; 国枝保幸; 大原行雄; 渡辺豊; 西川秀司; 渡辺雅男; 内田多久実; 舘山美樹; 若浜理; 鈴木岳; 西研; 目黒高志; 宮城島拓人; 工藤峰生; 坂田優, 日本消化器病学会雑誌, 103, A240, 2006年03月20日
日本語 - 手術不能または術後再発大腸癌に対するCPT‐11+S‐1併用療法(IRIS)の臨床第II相試験〈HGCSG0302〉‐Hokkaido Gastrointestinal Cancer Study Group‐
結城敏志; 小松嘉人; 布施望; 小笹真理子; 加藤総介; 加藤寛士; 目黒高志; 渡辺雅男; 内田多久実; 小笹茂; 若浜理; 古川滋; 岸本篤人; 鈴木岳; 小西茂; 舘山美樹; 加藤元嗣; 武田宏司; 浅香正博; 坂田優, 日本消化器病学会雑誌, 103, A240, 2006年03月20日
日本語 - Phase I-II study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancer
Kensei Yamaguchi; Tomotaka Shimamura; Yoshito Komatsu; Akinori Takagane; Takashi Yoshioka; Soh Saitoh; Masaki Munakata; Yu Sakata; Tsukasa Sato; Tatsuhiro Arai; Hiroshi Saitoh, Gastric Cancer, 9, 1, 36, 43, 2006年02月
英語 - What's going on 消化器癌 Phase 1/2 study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. Cancer and Leukemia Group B 89901; Ryan DP, Niedzwiecki D, Hollis D, Mediema BE, Wadler S, Tepper JE, Goldberg RM, Mayer RJ. J Clin Oncol. 2006; 24: 2557-62. PMID: 16636336. 局所進行直腸癌に対する術前オキサリプラチン、フルオロウラシル、放射線治療による第1/2相試験:CALGB89901
布施 望; 結城 敏志; 小松 嘉人, Mebio oncology, 3, 4, 84, 87, 2006年
メジカルビュー社, 日本語 - What's going on 消化器癌 Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin Improves survival for patients with metastatic colorectal cancer. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. J Clin Oncol. 2005; 23: 3706-12. PMID: 15867200.--転移性大腸癌患者に対するLV+5-FU療法のベバシズマブの上乗せによる生存期間改善効果の検討
小松 嘉人, Mebio oncology, 3, 1, 102, 105, 2006年
メジカルビュー社, 日本語 - 手術不能進行結腸・直腸癌に対するmFOLFOX6(l‐OHP+l‐LV+5‐FU)療法のFeasibility Study―HGCSG0501―
結城敏志; 小松嘉人; 布施望; 町田望; 小笹真理子; 天野虎次; 上畠寧子; 中村路夫; 常松泉; 宮城島拓人; 目黒高志; 工藤峰生; 秋田弘俊; 浅香正博; 坂田優, 日本臨床腫瘍学会学術集会プログラム・抄録集, 4th, 207, 2006年
日本語 - 手術不能・術後再発大腸癌に対するCPT‐11+S‐1併用療法(IRIS)の臨床第II相試験―HGCSG0302―
小松嘉人; 結城敏志; 加藤総介; 加藤寛士; 加藤貴司; 上林実; 宮下憲暢; 西研; 若浜理; 古川滋; 鈴木岳; 舘山美樹; 秋田弘俊; 浅香正博; 坂田優, 日本臨床腫瘍学会学術集会プログラム・抄録集, 4th, 211, 2006年
日本語 - 微小血管吻合を付加した門脈圧こう進症合併食道癌手術の経験
菊地健司; 奥芝俊一; 北城秀司; 川原田陽; 七戸俊明; 山本有平; 小松嘉人; 森川利昭; 加藤紘之; 近藤哲, 日本消化器外科学会雑誌, 39, 2, 158, 163, 2006年
Japanese Society of Gastroenterological Surgery, 日本語 - Phase II multi center study of combination therapy with irinotecan and S-1 for metastatic colorectal cancer
Y. Komatsu; S. Yuki; K. Kato; S. Kato; M. Nakamura; M. Tateyarna; M. Kudo; H. Akita; Y. Sakata; M. Asaka, EJC SUPPLEMENTS, 3, 2, 199, 199, 2005年10月
英語, 研究発表ペーパー・要旨(国際会議) - Phase I study of docetaxel, cisplatin and 5-fluorouracil(TPF) as first-line chemotherapy in patients with advanced esophageal cancer. -Hokkaido Gastrointestinal Cancer Study Group (HGCSG) study-
S. Yuki; Y. Komatsu; N. Machida; M. Ozasa; N. Fuse; T. Amano; T. Kato; M. Kudo; M. Asaka; Y. Sakata, EJC SUPPLEMENTS, 3, 2, 220, 221, 2005年10月
英語, 研究発表ペーパー・要旨(国際会議) - 手術不能進行・術後再発進行食道癌に対するDocetaxel+CDDP+5‐FU併用療法(TPF療法)の臨床第I/II相試験―HGCSG0305―
結城敏志; 小松嘉人; 小笹真理子; 加藤寛士; 加藤総介; 中村路夫; 上畠寧子; 加藤貴司; 宮城島拓人; 舘山美樹; 工藤峰生; 若浜理; 小笹茂; 渡辺雅男; 秋田弘俊; 浅香正博; 坂田優, 日本癌治療学会誌, 40, 2, 428, 2005年09月22日
日本語 - 癌化学療法の個別化医療の実現にむけて Tailored dose化学療法による投与量の個別化―薬理動態からみた根拠と臨床試験(JFMC31)の実際―
高橋豊; 木村豊; 小田寿; 嘉悦勉; 三木宏文; 木村正之; 舟橋整; 近藤亮; 小松嘉人; 高橋昌宏; 北島政樹; 佐治重豊, 日本癌治療学会誌, 40, 2, 222, 2005年09月22日
日本語 - 上大静脈症候群を呈した食道癌術後再発の一例
小笹真理子; 小松嘉人; 上畠寧子; 結城敏志; 加藤寛士; 加藤総介; 中村路夫; 天野虎次; 七戸俊明; 奥芝俊一; 鈴木昭; 外丸詩野; 伊藤智雄; 山本純司; 清水勇一; 小林隆彦; 加藤元嗣; 武田宏司; 秋田弘俊; 浅香正博, 日本癌治療学会誌, 40, 2, 552, 2005年09月22日
日本語 - 胃癌におけるF‐18‐FDG‐PETの検出能の検討
小松嘉人; 結城敏志; 加藤寛二; 中村路夫; 加藤総介; 上畠寧子; 加藤元嗣; 武田宏司; 浅香正博; 玉木長良, 日本消化器病学会雑誌, 102, A741, 2005年09月10日
日本語 - Gastrointestinal Stromal Tumor(GIST)の基礎と臨床 GISTに対するイマチニブのFDG‐PETによる効果予測
小松嘉人; 結城敏志; 浅香正博, 月刊消化器科, 40, 6, 633, 638, 2005年06月28日
日本語 - Phase II study of S-1 in combination with irinotecan in patients with advanced colorectal cancer (CRC)
Y Komatsu; S Yuuki; T Amano; N Machida; M Ozasa; T Kato; S Furukawa; H Akita; M Asaka; Y Sakata, JOURNAL OF CLINICAL ONCOLOGY, 23, 16, 297S, 297S, 2005年06月
英語, 研究発表ペーパー・要旨(国際会議) - Phase I study of docetaxel, cisplatin and 5-fluorouracil (TPF) as first-line chemotherapy in patients with advanced esophageal cancer. Hokkaido Gastrointestinal Cancer Study Group (HGCSG) study.
S Yuki; Y Komatsu; N Machida; M Ozasa; K Miyashita; T Kato; S Furukawa; M Kudo; H Akita; M Asaka; Y Sakata, JOURNAL OF CLINICAL ONCOLOGY, 23, 16, 353S, 353S, 2005年06月
英語, 研究発表ペーパー・要旨(国際会議) - がん治療における分子標的薬Q&A がん治療における分子標的薬を理解する イマチニブ(グリベック) 用法・用量などを含めた実際の薬物療法について教えてください
小松嘉人; 浅香正博, 薬局, 56, 4, 1728, 1731, 2005年04月05日
日本語 - がん治療における分子標的薬Q&A がん治療における分子標的薬を理解する イマチニブ(グリベック) どのような疾患に適応できるのですか? また,そのメカニズムを教えてください
小松嘉人; 浅香正博, 薬局, 56, 4, 1726, 1727, 2005年04月05日
日本語 - Usefulness of endoscopic submucosal dissection (esd) versus conventional EMR for superficial gastric lesions
M Nakagawa; S Nakagawa; Y Shimizu; N Kato; Y Ono; T Katsurada; S Ono; Y Miura; Y Mori; J Yamamoto; T Hayakawa; Y Komatsu; H Takeda; M Asaka, GASTROINTESTINAL ENDOSCOPY, 61, 5, AB234, AB234, 2005年04月
英語, 研究発表ペーパー・要旨(国際会議) - 安全性の向上を目的とした内視鏡的粘膜下層剥離術(ESD)における治療手技の標準化
中川 学; 浅香 正博; 加藤 元嗣; 桂田 武彦; 小野 雄司; 小野 尚子; 山本 純司; 三浦 洋輔; 森 康明; 早川 敏文; 小松 嘉人; 武田 宏司; 中川 宗一; 清水 勇一, Gastroenterological Endoscopy, 47, Suppl.1, 803, 803, 2005年04月
(一社)日本消化器内視鏡学会, 日本語 - 既治療食道癌に対するDocetaxel+Cisplatin+5‐FU併用療法(TPF療法)の第I/II相臨床試験~HGCSG0305‐2~
小笹真理子; 小松嘉人; 町田望; 結城敏志; 天野虎次; 竹内啓; 加藤貴司; 宮城島拓人; 舘山美樹, 日本消化器病学会雑誌, 102, A219, 2005年03月20日
日本語 - 切除不能進行および術後再発すい癌に対するGemcitabine+S‐1併用療法(GEM+S‐1療法)のパイロット試験
河上洋; 小松嘉人; 上林実; 小西康平; 小笹真理子; 町田望; 結城敏志; 宮下憲暢; 信田亜一郎, 日本消化器病学会雑誌, 102, A312, 2005年03月20日
日本語 - Helicobacter pylori非侵襲的診断法の実際―診療現場の最前線より―学会ガイドラインによるHelicobacter pylori非侵襲う的診断法の選択
加藤元嗣; 中川宗一; 清水勇一; RINAN Z; 中井義仁; 小西康平; 三浦洋輔; 斉藤永仁; 小松嘉人, Helicobacter Res, 9, 1, 8, 12, 2005年02月01日
日本語 - Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302. Jpn J Clin Oncol. 2005 Feb;35(2):88-9. Komatsu Y, Yuuki S, Fuse N, Takei M, Kato T, Miyagishima T, Kudo M, ・・・
Y Komatsu; S Yuuki; N Fuse; M Takei; T Kato; T Miyagishima; M Kudo; Y Kunieda; M Tateyama; O Wakahama; T Meguro; H Ohizumi; M Watanabe; H Akita; Y Sakata; M Asaka, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 35, 2, 88, 89, 2005年02月
英語 - Komatsu Y, Takei M, Yuki S, Fuse N, Furukawa S, Kato T, Takeda H, Kato M, Asaka M. Treatment of a Gilbert's syndrome patient with irinotecan, leucovorin and 5-fluorouracil. J Chemother. 2005 Feb;17(1):111-4.*
2005年 - 放射線化学療法中に縦隔炎を併発した食道癌に対して,サルページ手術として縦隔鏡下食道切除術を施行した1例
七戸俊明; 奥芝俊一; 川原田陽; 真名瀬博人; 近藤哲; 加藤紘之; 小松嘉人; 関堂充; 山本有平, 北海道外科雑誌, 49, 2, 215, 216, 2004年12月20日
日本語 - 進行食道癌に対する根治的放射線化学療法中に食道穿孔による縦隔炎を発症した1例
布旋望; 古川滋; 小松嘉人; 秋田弘俊; 清水勇一; 加藤元嗣; 奥芝俊一; 白土博樹; 宮坂和夫, 北海道外科雑誌, 49, 2, 215, 2004年12月20日
日本語 - 食道 1 既治療食道癌に対するDocetaxel+Cisplatin+5‐FU併用療法(TPF療法)の臨床第I/II相試験~Hokkaido Gastrointestinal Cancer Study Group(HGCSG)~
町田望; 小松嘉人; 加藤貴司; 宮城島拓人; 舘山美樹; 工藤峰生; 大泉弘子; 渡辺雅男; 加藤元嗣, 日本癌治療学会誌, 39, 2, 656, 2004年09月29日
日本語 - 大腸癌化学療法の実際 進行再発大腸癌に対する治療戦略‐新規抗癌剤併用療法CPT‐11+TS‐1の第2相臨床試験(第一報)を中心に
小松嘉人; 結城敏志; 浅香正博; 町田望; 小笹真理子; 武居正明; 宮下憲暢; 加藤元嗣; 坂田優, 日本癌治療学会誌, 39, 2, 283, 2004年09月29日
日本語 - 難治性癌に対する化学療法の工夫(食道) 手術不能進行・術後再発食道癌に対するDocetaxel+Cisplatin+5‐FU併用療法(TPF療法)の臨床第I/II相試験~Hokkaido Gastrointestinal Cancer Study Group(HGCSG)~
結城敏志; 小松嘉人; 浅香正博, 日本癌治療学会誌, 39, 2, 361, 2004年09月29日
日本語 - 胃 19 胃癌患者に対するPaclitaxelとCisplatinの隔週併用化学療法の臨床試験(中間報告):東日本胃癌化学療法研究会
斎藤聡; 坂田優; 山口研成; 小松嘉人; 高金明典; 吉岡孝志; 金丸龍之介; 新井達広; 佐藤司, 日本癌治療学会誌, 39, 2, 800, 2004年09月29日
日本語 - 難治性癌に対する化学療法の工夫(食道) Clinical Stage II,III食道癌に対する放射線化学療法の第II相臨床試験(JCOG9906)‐中間報告‐
室 圭; 大津敦; 石倉聡; 滝内比呂也; 宮田佳典; 斎藤博; 金子和弘; 小松嘉人; 石塚直樹, 日本癌治療学会誌, 39, 2, 361, 361, 2004年09月29日
日本語 - 胃 31 進行胃がんに対する骨髄非破壊的造血幹細胞移植の一例
小林寿美子; 小松嘉人; 結城敏志; 布施望; 宮下憲暢; 高畑むつみ; 藤沢文絵; 近藤健; 橋野聡, 日本癌治療学会誌, 39, 2, 926, 2004年09月29日
日本語 - 放射線化学療法施行中に食道穿孔を来たした食道癌の1例
結城敏志; 小松嘉人; 布施望; 中川宗一; 清水勇一; 七戸俊明; 川原田陽; 白土博樹; 宮坂和男, 日本消化器病学会雑誌, 101, A680, 2004年09月20日
日本語 - 金マーカーの埋め込みを上部消化管内視鏡下に行ったReal-time Tumor Tracking Radiotherapy
森 康明; 小野 雄司; 桂田 武彦; 小野 尚子; 山本 純司; 中川 学; 三浦 洋輔; 工藤 真弓; 結城 敏志; 武居 正明; 宮下 憲暢; 小松 嘉人; 浅香 正博; 中川 宗一; 清水 勇一; 加藤 元嗣; 橋本 孝之; 白土 博樹, Gastroenterological Endoscopy, 46, Suppl.2, 1895, 1895, 2004年09月
(一社)日本消化器内視鏡学会, 日本語 - Phase I/II study of CPT-11 plus S-1 in patients with advanced gastric cancer.
Y Komatsu; S Yuuki; N Fuse; M Takei; T Miyagishima; M Kudo; S Hashino; M Asaka; Y Sakata, JOURNAL OF CLINICAL ONCOLOGY, 22, 14, 361S, 361S, 2004年07月
英語, 研究発表ペーパー・要旨(国際会議) - 小腸原発形質細胞腫の1例
馬場基; 財津雅昭; 藤好真人; 本間重紀; 皆川のぞみ; 前田好章; 近藤正男; 小松嘉人; 森康明, 北海道外科雑誌, 49, 1, 62, 63, 2004年06月20日
北海道外科学会, 日本語 - Takahashi Y, Komatsu Y, Toge T, Saji S.et al:A randomized phase * clinical of tailored CPT-11 + S-1 vs S-1 in patients with advanced of recurrent gastric carcinoma as the first line chemotherapy.",Jpn J Clin Oncol.(6):342-5(2004)*
Y Takahashi; J Sakamoto; T Takeuchi; M Mai; T Kubota; M Kitajima; Y Tanigawara; Y Komatsu; T Toge; S Saji, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 34, 6, 342, 345, 2004年06月
英語 - TS‐1/CPT‐11併用療法が奏功し治癒切除が可能となった2例
川村直之; 桂田武彦; 露口雅子; 大泉弘子; 斎藤雅雄; 小松嘉人; 浅香正博, 日本消化器病学会雑誌, 101, A350, 2004年03月20日
日本語 - 眼こうへの転移を契機に診断された進行胃癌の一例
結城敏志; 小松嘉人; 曽我部進; 布施望; 森康明; 中川宗一; 清水勇一; 加藤元嗣; 舘山美樹, 日本消化器病学会雑誌, 101, A349, 2004年03月20日
日本語 - GIST分子標的治療薬イマチニブの治療成績とGISTの外科治療の今後
西田俊朗; 西谷暁子; 遠藤俊治; 生島裕文; 樋口一郎; 杉山敏郎; 小松嘉人; 打越史洋; 北川透, 日本外科学会雑誌, 105, 128, 128, 2004年03月15日
一般社団法人日本外科学会, 日本語 - "【逆流性食道炎をめぐる新たな知見】「内視鏡陰性逆流性食道炎に対する拡大内視鏡観察の有用性」
『消化器科』, 38巻, 2号, 172, 176, 2004年 - Shimizu Y, Komatsu Y, Asaka M.et al :"Endoscopic clip application for closure of esophageal perforations caused by EMR.",Gastrointest Endosc, 60(4):636-9.(2004)*
2004年 - 根治的放射線化学療法が著効したStage III頚部食道癌の1例
武居正明; 小松嘉人; 中村路夫; 小平純一; 長佐古友和; 武藤修一; 大川原辰也; 清水勇一; 武田宏司, 北海道外科雑誌, 48, 2, 229, 230, 2003年12月20日
日本語 - 切除不能・術後再発進行GISTに対するSTI571のFDG‐PETによる抗腫よう効果予測の可能性について
小松嘉人; 武居正明; 杉山敏郎, 日本消化器病学会雑誌, 100, A492, 2003年09月20日
日本語 - 胃癌患者に対するPaclitaxelとCisplatinの併用化学療法のPhase I study 第2報 〔東日本胃癌化学療法研究会〕
山口研成; 島村智崇; 坂田優; 棟方正樹; 小松嘉人; 斎藤聡; 高金明典; 吉岡孝志; 斎藤博, 日本癌治療学会誌, 38, 2, 330, 2003年09月16日
日本語 - 塩酸イリノテカン(CPT‐11)を含む治療に耐性の進行結腸・直腸癌に対するFOLFOX(Oxaliplatin(l‐OHP)+LV+5FU)療法変法のpilot study
小松嘉人; 武居正明; 布施望; 結城敏志; 加藤元嗣; 浅香正博, 日本癌治療学会誌, 38, 2, 553, 2003年09月16日
日本語 - 転移性大腸癌に対する血縁者間同種末梢血幹細胞移植
小林寿美子; 小松嘉人; 武居正明; 結城敏志; 布施望; 小野沢真弘; 泉山康; 加藤元嗣; 浅香正博, 日本癌治療学会誌, 38, 2, 625, 2003年09月16日
日本語 - 切除不能・術後再発進行大腸癌に対するCPT‐11+I‐LV+5‐FU併用療法の臨床後期第II相試験
武居正明; 小松嘉人; 布施望; 小平純一; 清水勇一; 武田宏司; 加藤元嗣; 杉山敏郎; 浅香正博, 日本癌治療学会誌, 38, 2, 382, 2003年09月16日
日本語 - 手術不能進行胃癌患者に対するTS‐1の至適投与法,併用療法のベストパートナーは何か?‐TS‐1+CPT11併用第二相試験,各種TS‐1関連報告を通じて‐
小松嘉人; 武居正明; 布施望; 結城敏志; 加藤元嗣; 浅香正博, 日本癌治療学会誌, 38, 2, 520, 2003年09月16日
日本語 - 腹水を伴うGIST多発性肝転移にSTI571が奏効した一例
武居正明; 小松嘉人; 布施望; 小平純一; 清水勇一; 武田宏司; 加藤元嗣; 杉山敏郎; 浅香正博, 日本癌治療学会誌, 38, 2, 741, 2003年09月16日
日本語 - エンドキサン内服療法にて低蛋白血症の改善を認めたIPSIDの一例
武居正明; 小松嘉人; 中村路夫; 小平純一; 清水勇一; 武田宏司; 加藤元嗣; 杉山敏郎; 浅香正博, Gastroenterol Endosc, 45, Supplement 2, 1768, 2003年09月10日
日本語 - 根治的放射線化学療法が著効したStage III頚部食道癌の一例
武居正明; 小松嘉人; 中村路夫; 小平純一; 長佐古友和; 清水勇一; 加藤元嗣; 杉山敏郎; 浅香正博, Gastroenterol Endosc, 45, Supplement 2, 1727, 2003年09月10日
日本語 - 13C酢酸呼気試験を用いた胃排出能の検討
中川学; 山本純司; 小平純一; 中川宗一; 小松嘉人; 武田宏司; 清水勇一; 柳沢克之; 小池隆夫, Gastroenterol Endosc, 45, Supplement 1, 695, 2003年04月10日
日本語 - 化学療法が奏効した同時性胃壁内転移をきたした下行結腸癌の一例
武居正明; 小松嘉人; 中村路夫; 長佐古友和; 武藤修一; 大川原辰也; 清水勇一; 伊藤智雄; 長嶋和郎, Gastroenterol Endosc, 45, Supplement 1, 624, 2003年04月10日
日本語 - 食道表在癌の治療戦略 食道m3・sm1癌の治療成績からみたEMR後の再発対策 放射線化学療法は必要か
清水勇一; 加藤元嗣; 山本純司; 中川学; 塚越洋元; 細川正夫; 藤田昌宏; 小松嘉人; 浅香正博, 消化器内視鏡, 15, 3, 397, 400, 2003年03月25日
日本語 - Severe CPT‐11 toxicityが認められたGilbert’s syndrome患者の一例
武居正明; 小松嘉人; 中村路夫; 長佐古友和; 武藤修一; 大川原辰也; 武田宏司; 加藤元嗣; 浅香正博, 日本消化器病学会雑誌, 100, A301, 2003年03月20日
The Japanese Society of Gastroenterology, 日本語 - Ohkawara T, Kato M, Nakagawa S, Nakamura M, Takei M, Komatsu Y, Shimizu Y, Takeda H, Sugiyama T, Asaka M. Spontaneous resolution of cap polyposis: case report. Gastrointest Endosc. 2003 Apr;57(4):599-602.*
2003年 - Kato M, Shimizu Y, Kobayashi T, Komatsu Y, Takeda H, Sugiyama T, Asaka M. Rapid urease test Nippon Rinsho. 2003 Jan;61(1):72-8.*
2003年 - 外来治療も考慮した手術不能進行大腸癌に対するCPT11+l‐LV+5FU併用療法の検討 第I相臨床試験
小松嘉人; 武居正明; 清水勇一; 加藤元嗣; 宮城島拓人; 内田多久実; 目黒高志; 加藤貴司; 坂田優, 日本消化器病学会雑誌, 99, A638, 2002年09月20日
日本語 - 手術不能進行大腸癌に対するCPT11+l‐LV+5FU併用療法の第I/II相臨床試験
小松嘉人; 中村路夫; 武居正明; 武田広司; 浅香正博; 宮城島拓人; 目黒高志; 加藤貴司; 坂田優, 日本癌治療学会誌, 37, 2, 320, 2002年09月10日
日本語 - 胃癌患者に対するPaclitaxelとCisplatinの併用化学療法のPhase I study
山口研成; 島村智崇; 坂田優; 棟方正樹; 小松嘉人; 斎藤聡; 高金明典; 吉岡孝志; 斎藤博, 日本癌治療学会誌, 37, 2, 312, 2002年09月10日
日本語 - 進行胃癌に対するCPT11+S‐1併用療法の第I/II相臨床試験
小松嘉人; 武居正明; 中村路夫; 浅香正博; 宮城島拓人; 舘山美樹; 大泉弘子; 若浜理; 坂田優, 日本癌治療学会誌, 37, 2, 310, 2002年09月10日
日本語 - MALTリンパ腫の治療 胃MALTリンパ腫の治療方針
武居正明; 小松嘉人; 加藤貴司; 加藤元嗣; 杉山敏郎; 浅香正博, モダンフィジシャン, 22, 6, 772, 775, 2002年06月15日
日本語 - Evaluation of a new 13CO2 infrared analyzer (UBiT-IR300) for 13C-urea breath test.
M Kato; M Asaka; T Sugiyama; H Takeda; Y Shimizu; Y Komatsu, GASTROENTEROLOGY, 122, 4, A208, A208, 2002年04月
英語, 研究発表ペーパー・要旨(国際会議) - 頚部リンパ節腫大を契機に発見された上行結腸癌の一例
佐々木彩美; 近藤正男; 津田一郎; 山下健一郎; 清水隆文; 横田健太郎; 藤堂省; 小松嘉人; 加藤元嗣, 日本大腸こう門病学会雑誌, 55, 4, 221, 2002年04月
日本語 - 結腸全摘後に関節炎が出現した潰よう性大腸炎の一症例
古川滋; 大川原辰也; 小松嘉人; 武田宏司; 浅香正博; 中川宗一; 河原崎暢; 加藤元嗣, 日本大腸こう門病学会雑誌, 55, 4, 218, 2002年04月
日本語 - 食品に含まれる抗Helicobacter pylori活性物質 ウシ初乳抗Helicobacter pylori抗体
加藤元嗣; 清水勇一; 小松嘉人; 小林隆彦; 浅香正博; 島岡達郎; 関口潔; 平山文博; 池田敬史, Helicobacter Res, 6, 2, 128, 131, 2002年04月01日
日本語 - 大腸腫ように対するFDG‐PETの有用性の検討
加藤貴司; 小松嘉人; 武居正明; 山本文康; 塚本江利子; 中川宗一; 加藤元嗣; 玉木長良; 浅香正博, 日本消化器病学会雑誌, 99, A154, 2002年03月20日
日本語 - 進行大腸癌術後再発に対しCPT11+LV+5FU併用化学療法が奏効した1例
小松嘉人; 武居正明; 浅香正博; 小平純一; 加藤元嗣; 水嶋琢二; 宮城島拓人; 横山朗子; 坂田優, 日本消化器病学会雑誌, 99, A275, 2002年03月20日
日本語 - 胃・食道疾患の最新情報 Helicobacter pylori除菌時代の知見を中心に 除菌後の問題点 除菌後の長期予後
小松嘉人; 加藤元嗣; 武田宏司; 杉山敏郎; 浅香正博, 内科, 89, 3, 465, 470, 2002年03月01日
日本語 - 胃・食道疾患の最新情報 Helicobacter pylori除菌時代の知見を中心に Helicobacter pyloriの診断法 新しいHelicobacter pylori診断法とその位置付け
加藤元嗣; 清水勇一; 小松嘉人; 小林隆彦; 杉山敏郎; 浅香正博, 内科, 89, 3, 442, 446, 2002年03月01日
日本語 - H.pylori時代の消化性潰よう学 H.pylori発見20周年を記念して X H.pylori除菌療法 我が国におけるH.pylori除菌治療のガイドライン
加藤元嗣; 清水勇一; 小松嘉人; 武田宏司; 杉山敏郎; 浅香正博, 日本臨床, 60, 397, 402, 2002年02月28日
日本語 - 血清抗H.pylori(HP)空胞化サイトトキシン(VacA)抗体の臨床的意義 とくに胃癌との関連
小松嘉人; 杉山敏郎; 小松琢弥; 大川原辰也; 水嶋琢二; 武田宏司; 加藤元嗣; 浅香正博, 日本内科学会雑誌, 91, 181, 2002年02月20日
日本語 - ヘリコバクター・ピロリのcagA,vacAs1,babA2遺伝子のGenotypeと臨床病態との関連
水嶋琢二; 長佐古友和; 中川宗一; 大川原辰也; 河原崎暢; 小松嘉人; 加藤元嗣; 杉山敏郎; 浅香正博, 日本内科学会雑誌, 91, 181, 2002年02月20日
日本語 - 高齢者における進行食道癌放射線化学療法著効例の1例
小松嘉人; 武居正明; 浅香正博; 河原崎暢; 中川宗一; 加藤元嗣; 西岡井子; 西岡健; 宮坂和男, 日本老年医学会雑誌, 39, 1, 122, 123, 2002年01月25日
日本語 - 高齢者のH.pylori除菌後における血清ペプシノーゲン値の推移
中川宗一; 加藤元嗣; 水嶋琢二; 小松嘉人; 武田宏司; 杉山敏郎; 浅香正博, 日本老年医学会雑誌, 39, 1, 122, 2002年01月25日
日本語 - Phase I/II study of irinotecan (CPT-11) combined with 1-leucovorin (I-LV) and 5FU in patients with advanced colorectal cancer
Y Komatsu; M Takei; T Kato; T Miyagishima; Y Kunieda; M Tateyama; O Wakahama; H Takeda; M Kato; T Sugiyama; M Asaka; Y Sakata, INTERNATIONAL JOURNAL OF CANCER, 437, 437, 2002年
英語, 研究発表ペーパー・要旨(国際会議) - Phase I study of irinotecan (CPT-11) combined with S-1 in patients with advanced gastric cancer(AGC)
Y Komatsu; M Takei; T Kato; T Miyagishima; Y Kunieda; M Tateyama; O Wakahama; H Takeda; M Kato; T Sugiyama; M Asaka; Y Sakata, INTERNATIONAL JOURNAL OF CANCER, 253, 254, 2002年
英語, 研究発表ペーパー・要旨(国際会議) - Ohkawara T, Kato M, Nakagawa S, Nakamura M, Takei M, Komatsu Y, Shimizu Y, Takeda H, Sugiyama T, Asaka M. Spontaneous resolution of cap polyposis: case report. Gastrointest Endosc. 2003 Apr;57(4):599-602.2002
2002年 - Kato T, Komatsu Y, Tsukamoto E, Takei M, Takei T, Yamamoto F, Kuge Y, Asaka M, Tamaki N. Intense F-18 FDG accumulation in the stomach in a patient with Menetrier's disease. Clin Nucl Med. 2002 May;27(5):376-7.2002
2002年 - Komatsu Y. Clinical significance of serum antibodies against Helicobacter pylori VacA protein Hokkaido Igaku Zasshi. 2002 Mar;77(2):185-92.2002*
2002年 - Perez Aldana L, Kato M, Nakagawa S, Kawarasaki M, Nagasako T, Mizushima T, Oda H, Kodaira J, Shimizu Y, Komatsu Y, Zheng R, Takeda H, Sugiyama T, Asaka M. Related Articles, Links,The relationship between consumption of antimicrobial agents and the prev・・・
2002年
Perez Aldana L, Kato M, Nakagawa S, Kawarasaki M, Nagasako T, Mizushima T, Oda H, Kodaira J, Shimizu Y, Komatsu Y, Zheng R, Takeda H, Sugiyama T, Asaka M. Related Articles, Links,The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance.Helicobacter. 2002 Oct;7(5):306-9.2002* - Kato M, Shimizu Y, Nakagawa S, Kodaira J, Takei M, Furukawa S, Yamamoto F, Takano M, Nagasako T, Nakaya H, Kato T, Oda H, Okawara T, Mizushima T, Komatsu Y, Takeda H, Sugiyama T, Asaka M. Analysis of H. pylori eradicated patients during more-than-5-ye・・・
2002年
Kato M, Shimizu Y, Nakagawa S, Kodaira J, Takei M, Furukawa S, Yamamoto F, Takano M, Nagasako T, Nakaya H, Kato T, Oda H, Okawara T, Mizushima T, Komatsu Y, Takeda H, Sugiyama T, Asaka M.
Analysis of H. pylori eradicated patients during more-than-5-year follow-up
Nippon Rinsho. 2002 Feb;60 Suppl 2:491-6.2002 - Kato M, Shimizu Y, Komatsu Y, Takeda H, Sugiyama T, Asaka M. Guidelines for the management of Helicobacter pylori infection in Japan] Nippon Rinsho. 2002 Feb;60 Suppl 2:397-402.2002
2002年 - Mizushima T, Sugiyama T, Kobayashi T, Komatsu Y, Ishizuka J, Kato M, Asaka M. Decreased adherence of cagG-deleted Helicobacter pylori to gastric epithelial cells in Japanese clinical isolates. Helicobacter. 2002 Feb;7(1):22-9.2002*
2002年 - Helicobacter pylori感染診断における日本人株を使用したELISAキット「Eプレート‘栄研’H.ピロリ抗体」の有用性の検討
小松嘉人; 杉山敏郎; 浅香正博, 臨床検査機器・試薬, 24, 5, 331, 335, 2001年10月10日
日本語 - 高齢者進行食道癌に対する放射線同時併用化学療法著効例(CR)の二例
小松嘉人; 武居正明; 浅香正博; 中川宗一; 河原崎暢; 加藤元嗣; 西岡井子; 西岡健; 宮坂和男, 日本消化器病学会雑誌, 98, A458, 2001年09月20日
日本語 - H.pylori除菌におけるsucralfateの意義
露口雅子; 幡有; 斎藤雅雄; 小平純; 中川宗一; 加藤元嗣; 小松嘉人; 武田宏司; 浅香正博, 日本消化器病学会雑誌, 98, A483, 2001年09月20日
日本語 - 高齢者の消化性潰よう 高齢者の消化性潰ようの原因 H.pyloriとNSAIDs
武田宏司; 小松嘉人; 杉山敏郎; 浅香正博; 清水勇一; 加藤元嗣, Geriatr Med, 39, 8, 1221, 1227, 2001年08月01日
日本語 - 直腸転移を来たした悪性黒色腫の1例
古川滋; 加藤元嗣; 中川宗一; 大川原辰也; 河原崎暢; 小松嘉人; 鈴木岳; 八百坂透; 浅香正博, 日本大腸こう門病学会雑誌, 54, 6, 397, 401, 2001年06月
顔面に原発し,切除後6年5カ月の経過を経て直腸転移が認められた悪性黒色腫の―例を経験した.症例は51歳男性.主訴は血便と下腹部痛.昭和63年に近医で皮下腫瘤の切除術を受け,悪性黒色腫と診断された.平成7年5月頃より便に血液が付着し,下腹部痛も見られたため7月6日当科を受診した.下部内視鏡で直腸に粘膜下腫瘍様の隆起性病変が認められ,生検で悪性黒色腫が疑われた.既往から悪性黒色腫の直腸転移と診断し,当院第一外科で直腸切除術を施行した.悪性黒色腫は消化管転移を起こしやすい事が知られているが,消化管転移に対して積極的に外科的処置が施行され,症状の改善をみたとする報告が多い.しかし,手術例の報告の多くは小腸への転移であり,直腸転移に対し外科的切除を施行した報告は,本邦においてはみられない., The Japan Society of Coloproctology, 日本語 - Diagnosis of histological gastritis using magnifying endoscopy
S Nakagawa; M Kato; K Hokari; M Kawarasaki; K Oohira; J Ishizuka; T Mizushima; Y Komatsu; H Kagaya; T Sugiyama; M Asaka, GASTROINTESTINAL ENDOSCOPY, 53, 5, AB127, AB127, 2001年04月
英語, 研究発表ペーパー・要旨(国際会議) - H. pylori eradication for the prevention of metachronous gastric cancer after endoscopic resection of early gastric cancer
M Kato; K Hokari; J Ishizuka; T Mizushima; Y Komatsu; S Nakagawa; H Kagaya; T Sugiyama; M Asaka, GASTROENTEROLOGY, 120, 5, A744, A744, 2001年04月
英語, 研究発表ペーパー・要旨(国際会議) - H.pylori除菌成功後の血清ペプシノーゲン値の長期推移
中川宗一; 加藤元嗣; 穂刈格; 河原崎暢; 小田寿; 熊谷彩恵; 水嶋琢二; 小松嘉人; 浅香正博, 日本消化器病学会雑誌, 98, A284, 2001年03月20日
日本語 - Turner症候群の経過中にCrohn病を合併した一例
大石正枝; 大川原辰也; 横山仁; 石塚淳; 小松嘉人; 中川宗一; 河原崎暢; 穂刈格; 加藤元嗣, 日本消化器病学会雑誌, 98, A289, 2001年03月20日
日本語 - Helicobacter pylori除菌後の長期予後 Helicobacter pylori除菌後に再発する消化性潰ようの現状とその対策
西川恵子; 杉山敏郎; 石塚淳; 小松嘉人; 加賀谷英俊; 穂刈格; 加藤元嗣; 浅香正博, Helicobacter Res, 5, 1, 37, 41, 2001年02月01日
日本語 - Mizushima T, Sugiyama T, Komatsu Y, Ishizuka J, Kato M, Asaka M. Clinical Relevance of the babA2 Genotype of Helicobacter pylori in Japanese Clinical Isolates.J Clin Microbiol. 2001 Jul;39(7):2463-5.*
2001年 - Helicobacter pylori感染診断における日本人株を使用したELISAキット 「Eプレート栄研H.pylori抗体」の有用性の検討 <2001、10月>
機器・試薬, 24, 5, 331, 335, 2001年 - Sugiyama T, Nishikawa K, Komatsu Y, Ishizuka J, Mizushima T, Kumagai A, Kato M, Saito N, Takeda H,Asaka M, Freston JW. Attributable risk of H. pylori in peptic ulcer disease: does declining prevalence ofinfection in general population explain increasi・・・
2001年
Sugiyama T, Nishikawa K, Komatsu Y, Ishizuka J, Mizushima T, Kumagai A, Kato
M, Saito N, Takeda H,Asaka M, Freston JW. Attributable risk of H. pylori in
peptic ulcer disease: does declining prevalence ofinfection in general
population explain increasing frequency of non-H. pylori ulcers? Dig Dis
Sci. 2001 Feb;46(2):307-10.* - 血清抗Helicobacter pylori空胞化サイトトキシン抗体の臨床的意義
北海道医学雑誌, 2001年 - 実践・がん化学療法
篠原出版新社, 2001年 - 食道癌に対する大照射野化学放射線同時併用療法
橋本井子; 影井兼司; 宮坂和男; 小松嘉人; 穂刈格; 加藤元嗣; 浅香正博; 浜本康夫; 伴紀宏, 北海道外科雑誌, 45, 2, 108, 109, 2000年12月20日
日本語 - 感染症 変貌する治療 Helicobacter pylori感染の治療
穂刈格; 加藤元嗣; 西川恵子; 石塚淳; 小田寿; 水嶋琢二; 小松嘉人; 助川真; 浅香正博, 月刊臨床と研究, 77, 10, 1865, 1867, 2000年10月20日
日本語 - 日本ヘリコバクター学会ガイドライン 2000 ガイドラインによるHelicobacter pylori診断・治療の実際
加藤元嗣; 穂刈格; 小田寿; 熊谷彩恵; 水嶋琢也; 小松嘉人; 武田宏司; 杉山敏郎; 浅香正博, Helicobacter Res, 4, 5, 417, 423, 2000年10月01日
日本語 - H.pylori感染の基礎と臨床の進歩 H.pylori除菌治療の長期予後
加藤元嗣; 穂刈格; 片桐雅樹; 水嶋琢也; 小松嘉人; 石塚淳; 助川真; 加賀谷英俊; 浅香正博, 月刊消化器科, 31, 3, 273, 277, 2000年09月28日
日本語 - 進行食道癌の放射線併用化学療法CR例の粘膜癌再発に対しEMRにて完全切除でき良好な経過を示した1例
小松嘉人; 穂刈格; 小田寿; 仲屋裕樹; 加藤貴司; 中川宗一; 河原崎暢; 加藤元嗣; 浅香正博, 日本消化器病学会雑誌, 97, A550, 2000年09月20日
日本語 - Helicobacter pyloriにおけるbabA2遺伝子およびcagA遺伝子の有無による胃上皮細胞への接着能の評価
水島琢二; 杉山敏郎; 小田寿; 熊谷彩恵; 大河原辰也; 石塚淳; 小松嘉人; 加藤元嗣; 浅香正博, 日本消化器病学会雑誌, 97, A567, 2000年09月20日
日本語 - 内視鏡治療の最前線
加藤 元嗣; 穂刈 格; 中川 宗一; 仲屋 裕樹; 小田 寿; 加藤 貴司; 大川原 辰也; 神島 雄一郎; 水嶋 琢也; 小松 嘉人; 石塚 淳; 佐藤 富士夫; 河原崎 暢; 助川 真; 加賀谷 英俊; 武田 宏司; 杉山 敏郎; 浅香 正博, 北海道醫學雜誌 = Acta medica Hokkaidonensia, 75, 4, 223, 227, 2000年07月01日
日本語 - Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population
K Nishikawa; T Sugiyama; M Kato; J Ishizuka; Y Komatsu; H Kagaya; M Katagiri; S Nishikawa; K Hokari; H Takeda; M Asaka, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 12, 6, 635, 640, 2000年06月
英語 - 胃MALTリンパ腫のH.pylori除菌治療後の経過と臨床的特徴
穂刈格; 加藤元嗣; 清水道生; 加賀谷英俊; 小松嘉人; 石塚淳; 助川真; 杉山敏郎; 浅香正博, Gastroenterological Endoscopy, 42, Supplement 1, 690, 2000年04月10日
日本語 - H.pylori除菌治療後に発見された胃癌症例の検討
加賀谷英俊; 穂刈格; 加藤元嗣; 石塚淳; 小松嘉人; 助川真; 西川恵子; 杉山敏郎; 浅香正博, Gastroenterological Endoscopy, 42, Supplement 1, 689, 2000年04月10日
日本語 - Cag PAI have the function related to adhesion to the cells than other adhesion related genes, paA and babA2, in Japanese clinuical isolates.
T Mizushima; T Sugiyama; A Kumagai; Y Kamishima; J Ishizuka; Y Komatsu; M Sukegawa; H Kagaya; K Hokari; M Kato; H Takeda; M Asaka, GASTROENTEROLOGY, 118, 4, A1277, A1277, 2000年04月
英語, 研究発表ペーパー・要旨(国際会議) - Cag PAI have a function related with adhesion to the gastric epithelial cells.
T Mizushima; T Sugiyama; A Kumagai; Y Kamishima; J Ishizuka; Y Komatsu; M Sukegawa; H Kagaya; K Hokari; M Kato; H Takeda; M Asaka, GASTROENTEROLOGY, 118, 4, A1277, A1277, 2000年04月
英語, 研究発表ペーパー・要旨(国際会議) - Assessment of Helicobacter pylori eradication using a urine-based ELISA of anti-Helicobacter pylori antibody.
M Kato; K Hokari; J Ishizuka; T Mizushima; M Sukegawa; Y Komatsu; H Kagaya; K Nishikawa; H Takeda; T Sugiyama; M Asaka, GASTROENTEROLOGY, 118, 4, A505, A505, 2000年04月
英語, 研究発表ペーパー・要旨(国際会議) - Helicobacter pyloriのcag pathogenicity islandとbabA2および疾患との関連
水嶋琢二; 杉山敏郎; 熊谷彩恵; 神島雄一郎; 石塚淳; 小松嘉人; 加賀谷英俊; 穂苅格; 浅香正博, 日本消化器病学会雑誌, 97, A307, 2000年03月20日
日本語 - 内視鏡の読み方 異所性胃粘膜から発生した食道腺癌
穂刈格; 加賀谷英俊; 小川浩司; 小松嘉人; 石塚淳; 片桐雅樹; 助川真; 武田宏司; 浅香正博, 臨床消化器内科, 15, 1, 101, 103, 2000年01月
日本語 - 内視鏡の読み方 尿管S状結腸吻合術後にS状結腸癌を生じた1例
穂刈格; 助川真; 加藤元嗣; 加賀谷英俊; 片桐雅樹; 石塚淳; 小松嘉人; 杉山敏郎; 浅香正博, 臨床消化器内科, 14, 13, 1777, 1780, 1999年12月
日本語 - Helicobacter pylori研究のピットホール II. 診断 I. 13C‐尿素呼気試験のみで診断は万全か?
加藤元嗣; 穂刈格; 小松嘉人; 石塚淳; 佐藤富士夫; 助川真; 武田宏司; 杉山敏郎; 浅香正博, Helicobacter Res, 3, 6, 475, 481, 1999年12月01日
日本語 - 便中抗原測定キットによるHelicobacter pylori診断および除菌判定の試み
石塚淳; 杉山敏郎; 大川原辰也; 神島雄一郎; 片桐雅樹; 小松嘉人; 佐藤富士夫; 水嶋琢二; 浅香正博, 日本消化器病学会雑誌, 96, 10, 1196, 1196, 1999年10月05日
The Japanese Society of Gastroenterology, 日本語 - Clinical significance of anti-catalase antibodies in sera of H-pylori infected patients
Y Kamishima; T Sugiyama; K Nishikawa; T Mizushima; J Ishizuka; Y Komatsu; K Hokari; M Kato; M Asaka, GASTROENTEROLOGY, 116, 4, A204, A204, 1999年04月
英語, 研究発表ペーパー・要旨(国際会議) - Frequency of non-Helicobacter pylori and non-NSAIDs peptic ulcers in Japanese population
K Nishikawa; T Sugiyama; J Ishizuka; Y Komatsu; F Sato; T Mizushima; M Katagiri; M Sukegawa; H Kagaya; K Hokari; M Kato; M Asaka, GASTROENTEROLOGY, 116, 4, A268, A268, 1999年04月
英語, 研究発表ペーパー・要旨(国際会議) - Loss of IL-8 induction from gastric epithelial cells in cag-G natural deleted-strains in Japanese H.pylori
T Mizushima; T Sugiyama; Y Kamishima; J Ishizuka; K Nishikawa; Y Komatsu; K Hokari; M Kato; H Takeda; M Asaka, GASTROENTEROLOGY, 116, 4, A257, A257, 1999年04月
英語, 研究発表ペーパー・要旨(国際会議) - 食道疾患研究の新しい展開 食道疾患とHelicobacter pylori
水嶋琢二; 杉山敏郎; 加藤元嗣; 穂刈格; 西川恵子; 小林隆彦; 助川真; 小松嘉人; 浅香正博, GI Res, 6, 6, 475, 481, 1998年12月
日本語 - Helicobacter pyloriのすべて H.pyloriの診断と除菌判定
加藤元嗣; 目良清美; 石塚淳; 神島雄一郎; 小松嘉人; 助川真; 小林隆彦; 加賀谷英俊; 浅香正博, 消化器内視鏡, 10, 8, 957, 964, 1998年08月
日本語 - 胃炎 Sydney SystemとHelicobacter pylori 胃炎におけるHelicobacter pylori除菌前後の内視鏡像の変化 長期経過例
加藤元嗣; 穂刈格; 石塚淳; 片桐雅樹; 小松嘉人; 佐藤富士夫; 小林隆彦; 助川真; 浅香正博, 胃と腸, 33, 8, 1123, 1130, 1998年07月
日本語 - H.pylori除菌前後の問題点を探る 除菌療法の現状と除菌後の病変 7. H.pylori除菌療法後の十二指腸びらん
加藤元嗣; 小松嘉人; 石塚淳; 片桐雅樹; 佐藤富士夫; 助川真; 小林隆彦; 西川恵子; 浅香正博, Prog Med, 18, 6, 1247, 1250, 1998年06月
日本語 - Dyspepsiaの診療 H.pylori除菌後のGERDの発生とその対策
加藤元嗣; 小松嘉人; 石塚淳; 片桐雅樹; 小林隆彦; 助川真; 西川恵子; 穂刈格; 浅香正博, 綜合臨床, 47, 5, 947, 951, 1998年05月
日本語 - H.pylori除菌後の消化性潰よう H.pylori除菌後に生じる上部消化管疾患
加藤元嗣; 小松嘉人; 石塚淳; 片桐雅樹; 佐藤富士夫; 助川真; 小林隆彦; 西川恵子; 浅香正博, 月刊消化器科, 26, 5, 502, 508, 1998年05月
日本語 - Examination on acute gastric erosion, duodenal erosion and reflux esophagitis after eradication of Helicobacter pylori.
Y Komatsu; M Kato; T Kudo; J Ishizuka; M Katagiri; F Sato; M Sukegawa; T Kobayashi; K Nishikawa; H Kagaya; K Hokari; H Takeda; T Sugiyama; M Asaka, GASTROENTEROLOGY, 114, 4, A184, A184, 1998年04月
英語, 研究発表ペーパー・要旨(国際会議) - Study on the effect of a new anti-ulcer agent, Ecabet sodium, on the dual therapy for eradication of Helicobacter pylori in randomized patients.
H Kagaya; M Kato; T Kobayashi; J Ishizuka; K Nishikawa; Y Komatsu; M Sukegawa; H Takeda; T Sugiyama; M Asaka, GASTROENTEROLOGY, 114, 4, A164, A164, 1998年04月
英語, 研究発表ペーパー・要旨(国際会議) - A new combined therapeutic method for esophageal varices; Endoscopic variceal ligation followed by mucosa-fibrosing with microwave
K Hokari; M Kato; M Katagiri; Y Komatsu; F Sato; M Sukegawa; H Kagaya; K Nishikawa; H Takeda; T Sugiyama; M Asaka, GASTROENTEROLOGY, 114, 4, A1257, A1257, 1998年04月
英語, 研究発表ペーパー・要旨(国際会議) - Recurrence of peptic ulcer after successful eradication of Helicobacter pylori infection in the Japanese population: A prospective follow-up study.
K Nishikawa; M Kato; T Kudo; Y Komatsu; F Sato; M Katagiri; T Kobayashi; H Sukegawa; H Kagaya; T Sugiyama; M Asaka, GASTROENTEROLOGY, 114, 4, A244, A244, 1998年04月
英語, 研究発表ペーパー・要旨(国際会議) - 成人病治療への挑戦 消化器 Helicobacter pyloriの完ぺきな治療を目指して
加藤元嗣; 石塚淳; 小松嘉人; 小林隆彦; 助川真; 穂刈格; 杉山敏郎; 浅香正博, 臨床成人病, 28, 2, 181, 185, 1998年02月
日本語 - Helicobacter pylori除菌に伴う問題点 耐性菌の出現とその対策
加藤元嗣; 石塚淳; 工藤俊彦; 片桐雅樹; 小林隆彦; 小松嘉人; 佐藤富士夫; 助川真; 浅香正博, Helicobacter Res, 1, 5, 459, 465, 1997年12月
日本語 - Helicobacter pyloriと胃悪性腫よう Helicobacter pylori感染と未分化型胃癌
杉山敏郎; 小松嘉人; 片桐雅樹; 加藤元嗣; 西川恵子; 工藤俊彦; 佐藤富士夫; 助川真; 浅香正博, GI Res, 5, 5, 562, 567, 1997年10月
日本語 - Helicobacter pyloriと酸分泌 Helicobacter pylori除菌療法における酸分泌抑制の意義
武田宏司; 工藤俊彦; 片桐雅樹; 佐藤富士夫; 小松嘉人; 西川恵子; 工藤峰生; 加藤元嗣; 浅香正博, Helicobacter Res, 1, 3, 266, 273, 1997年08月
日本語 - H.pylori感染診断における新しい迅速ウレアーゼテスト(MRウレアS)の有用性の検討 CLOテスト,培養,13C‐尿素呼気試験との比較検討
西川恵子; 加藤元嗣; 工藤俊彦; 小松嘉人; 佐藤富士夫; 助川真; 片桐雅樹; 佐々木由理; 浅香正博, 月刊臨床と研究, 74, 7, 1879, 1881, 1997年07月
日本語 - Helicobacter pyloriと上部消化管疾患
加藤元嗣; 工藤俊彦; 片桐雅樹; 佐藤富士夫; 小松嘉人; 助川真; 西川恵子; 工藤峰生; 浅香正博, 最新医学, 52, June, 1254, 1264, 1997年06月
日本語 - Helicobacter pylori除菌時代における防御因子製剤の意義 その役割と評価法 防御因子製剤を用いたH.pylori除菌療法 Rebamipideの臨床効果
加藤元嗣; 助川真; 工藤俊彦; 小松嘉人; 片桐雅樹; 西川恵子; 佐藤富士夫; 工藤峰生; 浅香正博, Prog Med, 17, 6, 1594, 1599, 1997年06月
日本語 - H.pyloriと胃疾患 H.pylori感染の疫学
工藤峰生; 片桐雅樹; 小松嘉人; 助川真; 西川恵子; 加藤元嗣; 武田宏司; 浅香正博, 臨床科学, 33, 5, 525, 532, 1997年05月
日本語 - A new approach of Helicobacter pylori eradication therapy: Effects of rebamipide in combination with lansoprazole and amoxicillin
K Nishikawa; M Kato; T Kudo; F Sato; Y Komatsu; M Katagiri; M Sukegawa; H Kagaya; M Kudo; K Hokari; H Takeda; M Asaka, GASTROENTEROLOGY, 112, 4, A238, A238, 1997年04月
英語, 研究発表ペーパー・要旨(国際会議) - Helicobacter pyloriの除菌療法の現状と問題点 Helicobacter pylori除菌の判定基準
加藤元嗣; 工藤俊彦; 片桐雅樹; 小松嘉人; 佐藤富士夫; 助川真; 西川恵子; 工藤峰生; 浅香正博, Helicobacter Res, 1, 1, 15, 22, 1997年04月
日本語 - H.pyloriと胃癌 H.pylori感染症と酸分泌および消化管ホルモンの動態
武田宏司; 工藤俊彦; 小松嘉人; 佐藤富士夫; 助川真; 片桐雅樹; 西川恵子; 工藤峰生; 浅香正博, 月刊消化器科, 24, 3, 255, 262, 1997年03月
日本語 - 成人病と食事療法〔疾患別の食事指導の実際〕 消化管疾患
武田宏司; 工藤俊彦; 小松嘉人; 佐藤富士夫; 助川真; 片桐雅樹; 西川恵子; 工藤峰生; 浅香正博, 臨床成人病, 27, 3, 389, 392, 1997年03月
日本語 - Helicobacter pylori Helicobacter pylori感染の疫学
片桐雅樹; 加藤元嗣; 工藤俊彦; 小松嘉人; 佐藤富士夫; 助川真; 加賀谷英俊; 武田宏司; 浅香正博, 臨床検査, 41, 2, 127, 135, 1997年02月
日本語 - Helicobacter pyloriを学ぶ Helicobacter pyloriと消化性潰よう
加藤元嗣; 片桐雅樹; 佐藤富士夫; 小松嘉人; 大原行雄; 西川恵子; 工藤峰生; 武田宏司; 浅香正博, 消化器外科, 19, 13, 1957, 1962, 1996年12月
日本語 - 感染 ヘリコバクター・ピロリ感染と消化性潰よう・胃癌
加藤元嗣; 工藤俊彦; 片桐雅樹; 佐藤富士夫; 小松嘉人; 助川真; 西川恵子; 工藤峰生; 浅香正博, 感染・炎症・免疫, 26, 4, 188, 195, 1996年12月
日本語 - Helicobacter pylori研究の最前線 H.pylori除菌 天然成分によるHelicobacter pyloriに対する除菌効果
野田岳; 加藤勝; 小松嘉人; 斉藤大三, Prog Med, 16, 6, 1597, 1600, 1996年06月
日本語 - SunphenonのHelicobacter pylori排菌効果の検討
小松嘉人; 斉藤大三; 平山敦; 佃博; 木場崇剛; 近藤仁; 吉田茂昭; 加藤勝; 増田光治, Prog Dig Endosc, 47, 136, 137, 1995年12月
日本語 - 多発胃癌をどう取り扱うか 内視鏡からみた多発早期胃癌の実態 もう一つの胃癌を見逃さないために
清水靖仁; 近藤仁; 小松嘉人; 斉藤大三; 白尾国昭; 山口肇; 横田敏弘; 佃博; 吉田茂昭, 消化器内視鏡, 7, 7, 929, 934, 1995年07月
日本語 - 0型胃癌のみなおし IIb型早期胃癌の内視鏡診断 見直しによりどこまで診断が可能か
小松嘉人; 近藤仁; 多賀康浩; 平山敦; 清水靖仁; 松本政雄; 佃博; 斉藤大三; 吉田茂昭, 消化器内視鏡, 7, 5, 647, 653, 1995年05月
日本語
- Gastrointestinal Stromal Tumor
小松 嘉人
2019年02月, [編者(編著者)] - Chapter 8. Gastrointestinal Stromal Tumor Adjuvant Chemotherapy: Current Practices, Efficacy and Future Directions
小松 嘉人
2018年09月, [単著] - 「胃がん・大腸がんを薬で抑えましょう」と言われた時 : これから薬物療法を受ける患者さん、患者さんに説明する全ての医療スタッフのために
小松 嘉人; 北海道消化器癌化学療法研究会
ヴァンメディカル, 2011年, 9784860920982, 131p, 日本語 - GIST診療ハンドブック
ヴァンメディカル, 2010年 - 「胃がん・大腸がんを薬で抑えましょう」と言われた時 ―
小松 嘉人
ヴァンメディカル, 2008年09月 - 病名の告知とQOLを踏まえたインフォームドコンセントの行い方
ヴァンメディカル, 2007年 - 大腸がん診療に関するQ&A
ヴァンメディカル, 2007年 - 治療方針の決定
ヴァンメディカル, 2007年 - 消化管間質腫瘍
株式会社 南江道, 2006年
- 医学総論, 2024年, 博士後期課程, 医学研究科
- 基本医学研究, 2024年, 修士課程, 医学院
- 基本医学総論, 2024年, 修士課程, 医学院
- 医学総論, 2024年, 博士後期課程, 医学院
- 基盤医学研究, 2024年, 博士後期課程, 医学院
- 臨床医学研究, 2024年, 博士後期課程, 医学院
- 日本緩和医療学会
- 日本胃癌学会
- 米国臨床腫瘍学会
- 日本大腸肛門病学会
- 日本消化器病学会
- 日本癌学会
- 食道癌研究会
- GIST研究会
- 欧州臨床腫瘍学会
- 日本内科学会
- 日本消化器学会
- 北海道食道癌研究会
- 北海道消化器癌化学療法研究会
- American Society of Clinical Oncology
- European Society for Medical Oncology
- 日本がん予防学会
- 日本消化器内視鏡学会
- 日本消化管学会
- 北海道癌治療研究会
■ 共同研究・競争的資金等の研究課題
- KRAS変異を標的とした膵管癌に対する新規腫瘍免疫療法の開発
科学研究費助成事業
2026年04月01日 - 2029年03月31日
小松 嘉人; 桑谷 将城; 川久保 和道
日本学術振興会, 基盤研究(C), 北海道大学, 26K10204 - 肝癌幹細胞におけるPARP阻害剤耐性メカニズムの解明およびその克服
科学研究費助成事業
2022年04月01日 - 2025年03月31日
小松 嘉人; 川久保 和道; 須田 剛生
日本学術振興会, 基盤研究(C), 北海道大学, 22K08023 - 食道癌三次元培養モデルを用いた癌幹細胞ニッチの解析
科学研究費助成事業 基盤研究(C)
2014年04月01日 - 2017年03月31日
小松 嘉人; 夏井坂 光輝
本研究では食道3次元培養モデルを用いて食道扁平上皮癌(ESCC)の癌幹細胞ニッチ解析を行った。ESCCにおいては腫瘍浸潤部において癌幹細胞ニッチが形成されており、上皮間葉転換(EMT)が癌幹細胞の維持において重要な役割を有していた。間質の線維芽細胞より放出されるEGFはEMTを誘導し、腫瘍浸潤部において癌幹細胞を増幅した。EGFR阻害剤を用いることで、癌幹細胞ニッチの形成が阻害され、癌幹細胞が抑制されることを3次元培養モデルを用いて示した。
日本学術振興会, 基盤研究(C), 北海道大学, 26460933 - RNA結合蛋白を介した上皮間葉転換制御による抗癌剤耐性克服療法の開発
科学研究費助成事業 基盤研究(C)
2013年04月01日 - 2016年03月31日
小林 隆彦; 小松 嘉人
上皮間葉転換(EMT)は癌細胞の浸潤能亢進などに関連している。本研究では、RNA結合蛋白であるRBM5がEMTを介して抗癌剤感受性に与える影響を検討した。癌細胞においてRBM5をノックダウンさせるとEMT転写因子Snailの発現量が増加した。一方でRBM5を発現誘導するとSnailの発現量は減少した。5FU耐性癌細胞ではRBM5の発現量は減少しSnailの発現量は亢進していた。またRBM5をノックダウンさせると5FU感受性を低下させ、RBM5を発現誘導すると5FUに対する感受性を亢進させた。これらよりRBM5はSnailの発現制御を介して薬剤感受性に影響を与えていることが示唆された。
日本学術振興会, 基盤研究(C), 北海道大学, 25460921 - 消化器癌の化学療法 固形癌の化学療法
競争的資金 - GI oncology Cancer Chemotherapy Clinical Study
競争的資金
